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ABSTRACT 
Transmission of HIV among men who have sex with men (MSM) in the UK is ongoing. Among HIV-
diagnosed MSM, condomless sex (CLS) with HIV-serodifferent partners (CLS-D) was considered the main 
HIV transmission risk before evidence of the favourable impact of antiretroviral treatment (ART).  
 
Using data on HIV-diagnosed MSM from the ASTRA study (2011-2012), this thesis assessed: (i) 
prevalence of different types of CLS, including CLS-D with appreciable risk of HIV transmission 
(accounting for ART/viral load); (ii) associated co-factors (socio-demographic, lifestyle, psychological, 
HIV-related); (iii) prevalence and factors associated with other sexually transmitted infections (STIs), and 
subsequent risk of hepatitis C virus (HCV) co-infection.  
 
Among 2189 HIV-diagnosed MSM, 38% had recent CLS; 16% had CLS-D; only 4% had CLS-D with 
appreciable HIV transmission risk. These CLS measures tended to be associated with younger age, more 
recent HIV diagnosis, and not being on ART, and were strongly associated with recreational drug and 
polydrug use (which were prevalent). When classifying MSM into mutually exclusive categories, 36% did 
not have sex in the past three months; 25% had condom-protected sex only; 22% had CLS with HIV-
seroconcordant partners only (‘CLS-C without CLS-D’, which may indicate HIV-serosorting); 16% had CLS-
D. Chemsex-associated drug use and disclosure of HIV-status to new sex partners were more common 
among MSM who had ‘CLS-C without CLS-D’ compared to CLS-D. Over 10% of MSM had recent STI co-
infections. Recreational and injection drug use, CLS, and multiple partners were associated with pre-
existing STIs, with initial evidence of association with incident HCV.  
 
Consideration of different types of CLS among HIV-diagnosed MSM demonstrated differing implications 
for prevention of HIV versus other STI transmission. Expansion of ART use should further impact 
favourably on HIV transmission risk. There is a need for focus on harm reduction in recreational drug use 
and prevention of STI co-infections among HIV-diagnosed MSM. 
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1 Introduction 
1.1 Thesis aims  
In order better inform HIV prevention strategies and clinical care in the current era of effective 
antiretroviral therapy (ART), there is a need for greater understanding of the sexual behaviour of HIV-
diagnosed men who have sex with men (MSM), as well as the factors associated with sex that may pose 
a risk of transmission of human immunodeficiency virus (HIV) or other sexually transmitted infections 
(STIs). This thesis aims to ascertain the prevalence of specific sexual behaviours in HIV-diagnosed MSM 
in the United Kingdom (UK), with a particular focus on measures of condomless sex, including 
condomless sex with appreciable risk of transmission of HIV. The thesis aims to investigate factors 
associated with different types of condomless sex, including socio-demographic, psychological, HIV-
related, and lifestyle factors. Prevalence of non-disclosure of HIV-serostatus to the social circle and to 
sexual partners is also investigated; the association of sexual non-disclosure with condomless sex is 
additionally examined. This thesis also aims to investigate the prevalence of, and factors associated 
with, other STIs (including hepatitis C virus, HCV) and the subsequent risk of incident HCV co-infection 
among HIV-diagnosed MSM. To address these aims, data from the Antiretrovirals, Sexual Transmission 
Risk and Attitudes (ASTRA) study is used, a cross-sectional UK study of HIV-diagnosed individuals 
attending HIV clinics (2011-2012), with an additional longitudinal component. 
1.2 Thesis overview  
Chapter 1 states the thesis aims and provides a background on HIV treatment and transmission. 
Evidence relating to HIV transmission risk is reviewed and an overview of the HIV epidemic in the UK is 
presented, with a focus on MSM. 
Chapter 2 provides a literature review of studies examining the prevalence and correlates of 
condomless sex among HIV-diagnosed MSM since the introduction of widespread ART (1995-2016) in 
high-income countries. 
Chapter 3 describes the methodology of the ASTRA study, on which thesis analyses are based, as well as 
the main statistical methods used. The characteristics of HIV-diagnosed MSM participating in ASTRA are 
described in detail and compared to the HIV-diagnosed population under care in the UK during 2011-
2012. 
Chapter 4 defines the main measures of sexual behaviour used in the thesis for HIV-diagnosed MSM 
from ASTRA (including different measures of condomless sex), and assesses their prevalence, inter-
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relationships, and cross-sectional associations with socio-demographic, psychological, HIV- and ART-
related factors. 
Chapter 5 explores definitions of higher HIV risk condomless sex with HIV-serodifferent partners (CLS-D) 
by incorporating clinical criteria that could affect HIV infectiousness. The resulting prevalence of higher 
HIV risk CLS-D is assessed among ASTRA MSM. 
Chapter 6 investigates the prevalence and co-factors associated with of recreational drug use and 
polydrug use among HIV-diagnosed MSM in ASTRA. The association of recreational drug use with 
condomless sex and other measures of sexual behaviour is examined. 
Chapter 7 examines the prevalence of HIV serostatus non-disclosure within the social context, to a 
stable partner, and to new sexual partners among HIV-diagnosed MSM in ASTRA. Cross-sectional 
associations of non-disclosure with socio-demographic, psychological, and HIV-related factors are 
determined. The association of non-disclosure with measures of sexual behaviour is also evaluated.  
Chapter 8 assesses the prevalence and factors associated with self-reported STI co-infections. In the 
subgroup of HIV-diagnosed MSM with clinical data linked to the ASTRA questionnaire, prevalence and 
incidence of hepatitis C virus (HCV) is examined. Cross-sectional and prospective associations of sexual 
behaviour and other factors with prevalent and incident HCV are assessed.  
The literature review presented in chapter 2 provides background to the thesis aims, and in particular 
serves as a review for results chapter 4. Results chapters 5 to 8 each include additional literature 
reviews relevant to the objectives of the specific chapter, and end with a discussion of results in the 
context of other literature. 
Chapter 9 summarises the findings and conclusions from each chapter and discusses limitations and 
implications of these findings. 
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1.3  Background 
Since the beginning of the HIV epidemic in 1981, a total of 78 million individuals (95%CI 71-87 million) 
have acquired HIV, and 39 million (35-43) have died of AIDS-related diseases.
1
 Thirty-five years after the 
isolation of HIV, antiretroviral therapy (ART), technological and research advances in the understanding 
of transmission dynamics and determinants have transformed HIV from a ‘death sentence’ to a 
treatable chronic condition.
2
 The life expectancy of people living with HIV in the UK has dramatically 
increased since the introduction of effective ART, increasing by about 10 years during the ART era. 
Modelling studies now show that the life expectancy of HIV-positive MSM in high-income countries with 
extensive access to ART and HIV care is 75 years.
3,4
  
 
HIV circulates in body fluids of an HIV-positive person not on suppressive ART, including blood, 
cerebrospinal fluid, semen, rectal and cervical/vaginal fluids, and breastmilk. Therefore, transmission of 
HIV may occur through anal or vaginal sex, from a mother to child during pregnancy, birth, or 
breastfeeding, by sharing needles, syringes, or receiving blood transfusions/products contaminated with 
HIV, and by occupational exposure to HIV (needlestick injuries in healthcare workers).
41
 The virus is not 
spread by casual or social contact (sharing utensils, toilets, air space, swimming pools) with HIV-positive 
people). Risk of transmission varies by mode of exposure and is dependent upon the concentration of 
HIV in body fluids.
2,8,42
A detailed overview of the origins, biology, and natural history of HIV is provided 
in Appendix V. The following sections (1.3.1-1.3.5) provide a historical background to the use of ART for 
treatment and prevention of HIV.  
 Aims of antiretroviral therapy (ART) 1.3.1
The principal aim of life-long continuous ART is to prevent mortality and morbidity associated with 
chronic HIV infection. This is attained by achieving and maintaining continuous suppression of HIV viral 
replication, referred to as ‘undetectable viral load’ (VL), meaning a lack of HIV-1 RNA detection below 
the lower limit, usually <50c/mL. This allows recovery of immune function, measured by the number of 
CD4 T-cells in a cubic millimetre of blood (CD4 count). Normal CD4 count ranges between 500 and 
1200cells/mm
3
, and opportunistic infections most prevalent below 200cells/mm
3
. Recent evidence from 
cohort studies in the UK
5
  and the USA
6
 shows that individuals who started ART during 2008–2010 with 
CD4 counts above 350cells/mm
3 
one year after ART initiation have estimated life expectancy 
approaching that of the general population.
6
 
 
A further aim of ART is the prevention of onward sexual transmission of HIV through the reduction of 
plasma HIV-RNA (viral load) levels, referred to as Treatment as Prevention (TasP). Longitudinal studies 
and randomised controlled trials (RCTs) have estimated the risk of transmission to be extremely low 
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among heterosexual
7,8
, and more recently, among MSM
9,10
 serodifferent couples (in which one partner 
is HIV-positive and the other is HIV-negative) when the HIV-positive partner is on effective ART. In 
addition, HIV-negative partners can use antiretroviral drugs in order to prevent acquisition of HIV either 
before exposure to the virus (pre-exposure prophylaxis, PrEP) or after (post-exposure prophylaxis, PEP).  
 Initiation of ART for clinical benefit  1.3.2
The correct timing of start of ART for a person diagnosed with HIV has been a major point of debate. The 
clinical decision of when to initiate ART in people who have not undergone previous ART (were ART-
naïve) has traditionally been guided by CD4 count levels, with recommended CD4 thresholds tending to 
increase as new guidelines were introduced over time.  
 
From 2008, the British HIV Association (BHIVA) recommended that individuals with chronic HIV infection 
start ART at or below CD4 count of 350cells/mm
3
.
11
 This guideline was based on evidence from large-
scale cohort studies carried out in the mid to late 2000’s, demonstrating the higher risk of progression to 
AIDS and death among those who delayed ART initiation until their CD4 was below 350 cells/mm
3
, 
compared to those who started ART at CD4 count above 350cells/mm
3
.
12–14
 In early 2015, the Tempano 
ANRS trial (2008-2015) disseminated results; a total of 2056 HIV-diagnosed people in the Ivory Coast 
were randomised to either immediate ART (provided CD4 count was below 800cells/mm
3
) or deferred 
ART according to WHO criteria.
15
 During the course of the study, WHO guidelines for ART initiation 
changed the CD4 count criteria multiple times, from 200cells/mm
3
 in 2008-2009, to 350 in 2009-2012, 
and to 500 from 2012-2014. Tempano found that early initiation of ART at CD4 counts above 
500cells/mm
3
 independently resulted in a 44% reduction of severe HIV-related illnesses and 35% 
reduction in risk of death, compared to deferred ART.
15
 The comparator group for much of the follow-up 
time, however, was the group deferred to ART initiation at or below 200cells/mm
3
 as a limited number 
of people were randomised after the WHO raised the CD4 count criteria to 350cells/mm
3
. The median 
CD4 count in the comparator group was thus much lower than the 2008 BHIVA guidelines.  
 
In May 2015, interim results from the multi-national START randomised trial (2009-2013) offered 
definitive proof that initiation of ART at CD4 count higher than 500cells/mm
3
 provided 57% reduced risk 
of developing AIDS, other serious non-AIDS event, or death over three years, when compared to 
deferring ART until CD4 count decreased to 350cells/mm
3
.
16
As a result, treatment guidelines worldwide 
were amended to recommend ART initiation regardless of CD4 count, proposing the absolute risk be 
considered in individual decisions.
17
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 Initiation of ART for prevention of HIV transmission: Evidence among 1.3.3
heterosexual men and women 
In the mid-2000’s, longitudinal studies of heterosexual serodifferent couples estimated a reduction of 
80% in risk of HIV transmission attributed to use of ART.
18,19
 A meta-analysis of longitudinal studies on 
HIV transmission according to use of ART found that among 11 cohorts and 5021 heterosexual 
serodifferent couples the rate of overall transmission from the HIV-positive partner on ART was 0.46  
per 100 person-years (95%CI 0.19-1.09) based on five seroconversions; there were no observed 
transmissions from individuals on treatment and with VL below 400c/mL.
20
  
 
By 2011, robust evidence from RCTs indicated that ART could be beneficial in reducing HIV transmission 
if initiated immediately, irrespective of CD4 count.
7,21
 The multinational HIV Prevention Trials Network 
(HPTN) RCT (2007-2010) demonstrated a benefit of early versus deferred ART initiation (at baseline with 
CD4 count ≥350cells/mm
3 
or after two consecutive CD4 counts of ≤250cells/mm
3
, respectively) in the 
reduction of sexual transmission of HIV.
7
 Among 1763 serodifferent heterosexual couples in HPTN052, 
28 genetically-linked HIV transmissions occurred, only one of which was in the early ART initiation arm. 
This represents a relative reduction in the risk of HIV transmission of 96%.
7
As the CD4 count threshold in 
the deferred arm was substantially lower than that in the 2008 BHIVA guidelines, it was considered that 
HPTN052 may overestimate the benefit of immediate treatment compared to initiation at CD4 count 
below 350cells/mm
3
.  
 
The risk of HIV transmission is greater for anal sex than for vaginal sex (further discussed in section 
1.4.5).
22
 Hence, the degree to which these results apply to anal sex (among MSM or heterosexuals) was 
uncertain. In addition, prevalence of condom use was high in HPTN-052, with 5% of HIV-diagnosed 
participants reporting condomless sex in the past week.
7
 
 Initiation of ART for prevention of HIV transmission: Evidence among men 1.3.4
who have sex with men  
The best available evidence for use of ART to prevent transmission of HIV among MSM derives from two 
cohort studies, PARTNER phase 1 (2010-2014) and Opposites Attract (2012-2015). PARTNER is an 
international study of serodifferent couples who report condomless anal sex and the HIV-positive 
partner is on ART.
23
 The study aims to assess the risk of transmission from the HIV-positive partner on 
ART with when viral load (VL) is below 200c/mL.
9
 At baseline and every six months, both partners 
complete questionnaires on sexual risk behaviour, the HIV-negative partner is tested for HIV, and the 
HIV-positive partner’s VL is measured. By 2016, phase 1 of PARTNER had recruited 1166 couples, of 
whom 888 (38% MSM couples) contributed a total of 1238 couple-years follow-up (CYFU).
24
 The interim 
results reported no phylogenetically linked transmissions of HIV, despite 22,000 CLS acts among MSM 
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and 36,000 vaginal or anal CLS acts among heterosexuals. PARTNER gave a rate of within-couple HIV 
transmission of 0/100 CYFU (95%CI 0.00-0.30). For MSM, the upper confidence limit of the estimated 
transmission risk for all sex was 0.84/100 CYFU; for anal CLS, the upper bound was 0.71/100 CYFU 
(combining heterosexual and MSM data) and 2.70/100 CYFU for MSM who had receptive anal CLS with 
ejaculation.
9
 These results were extremely important, but included fewer receptive anal CLS acts 
compared to all other sex acts (approximately 7750 for receptive CLS vs 11700 for insertive CLS). For this 
reason, phase 2 of PARTNER (2014-2017) continues follow-up of MSM couples in order to accrue a 
larger sample size and increase precision for the estimate of transmission risk for receptive anal sex, 
especially with ejaculation. Opposites Attract is a prospective cohort study of serodifferent MSM 
partnerships in Australia, Thailand, and Brazil, who report regular condomless anal sex and the HIV-
positive partner has VL< 200c/mL.
25
 Unlike the PARTNER study, which required all HIV-positive partners 
to be on ART, 82.4% were on ART in Opposites Attract. Preliminary results (late 2014) among 88 MSM 
couples reporting condomless anal sex with 91 CYFU showed no linked HIV transmissions.
26
 The upper 
bound of the 95%CI for the rate of transmission was 4.06/100 CYFU for all CLS, and 6.46/100 CYFU for 
receptive CLS. The study reported much higher upper risk bounds compared to PARTNER, likely because 
of less cumulative total person time at risk accrued. Data from both PARTNER and Opposites Attract has 
added substantial evidence that the rate of HIV transmission among MSM is extremely low when the 
HIV-positive partner is on ART with suppressed viral load (<200c/mL). Ongoing follow-up will be 
important in better defining the risk of transmission according to type of condomless anal sex.  
 Initiation of ART for prevention of HIV acquisition 1.3.5
The short-term use of antiretroviral drugs by HIV-negative individuals following high-risk exposure to 
HIV (post-exposure prophylaxis) has been recommended since 1990. Randomised trials of antiretroviral 
drug use prior to sexual exposure to HIV (pre-exposure prophylaxis) have recently demonstrated the 
protective effect against HIV acquisition.  
1.3.5.1 Post-exposure Prophylaxis (PEP) 
Post-exposure prophylaxis (PEP) is now accepted as a standard of care for both occupational and non-
occupational exposures (via condomless sex or sharing of needles).
27
 This is based on limited evidence 
from one case-control study of healthcare workers, which demonstrated that ART can prevent chronic 
HIV infection if administered within a short time following exposure to the virus.
28
 The WHO 
recommends PEP initiation with a three-drug ART regimen within 72 hours of exposure, for a period of 
28 days.
29
  
1.3.5.2 Pre-Exposure Prophylaxis (PrEP)  
The provision of antiretroviral drugs to HIV-negative individuals before exposure to HIV (pre-exposure 
prophylaxis, PrEP) has been shown to reduce the risk of acquiring HIV. A number of trials of PrEP have 
been conducted, with differing strategies, including: oral PrEP taken before sex as a pill, topical PrEP as a 
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vaginal gel or ring or rectal gel impregnated with ART, or long-acting injection PrEP. Randomised trials 
carried out in sub-Saharan Africa in the late 2000’s showed that topical PrEP has a small protective 
effect (from 6-39%) against HIV acquisition. The modest benefit shown is likely due in part to low 
adherence but may also be due to other biological factors.
30–33
 Five large RCTs have provided evidence 
for the substantial protective effect conferred by oral PrEP and are summarised in Figure 1.1.
34–37
 On the 
basis of these studies, the WHO and the US Centers for Disease Control and Prevention approved the 
use of Truvada (emtricitabine/tenofovir) among “high risk” groups in July 2012.
38
 The PROUD trial (2012-
2016) randomised HIV-negative MSM attending sexual health clinics in England to immediate versus 
deferred Truvada (at enrolment versus after 12 months). Early results showing high efficacy of 
immediate PrEP (86%, 95%CI 64-96%) lead to early discontinuation of the trial  in 2014, and participants 
in the deferred arm were offered immediate PrEP.
36
 Coupled with similar efficacy reported in the French 
IPERGAY trial (86%) which used intermittent as opposed to continuous dosing in PROUD, these results 
supported early access to PrEP among those at high risk of acquiring HIV.
37
 
 
A recent modelling study estimated that the provision of PrEP along with expanded testing coverage 
among HIV-negative MSM in the UK could prevent more than 7000 new HIV infections before 2020.
39
 
Ongoing randomised trials, such as the PREP-5 in Canada and EPIC-NSW in Australia, will explore 
implementation of PrEP in real-world settings among MSM, with relation to its effectiveness, 
acceptability, and impact on STIs. Further strategies for PrEP, including daily versus intermittent use, are 
examined in ongoing randomised trials, such as IPERGAY in France and AMPrEP in the Netherlands.
40
 A 
summary of the current status of PrEP in the UK is provided in section 1.5.4.1. 
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Figure 1.1: Summary of oral PrEP efficacy (95%CI) from randomised trials of among 
populations including MSM.34–37 
CDC: Centers for Disease Control; TDF/FTC: Emtricitabine/tenofovir 
 
1.4 Sexual transmission of HIV  
HIV transmission by sexual intercourse accounts for nearly 90% of infections worldwide.
43
 A discussion 
of other modes of HIV transmission is provided in Appendix V. The probability of infection through sex 
depends on a multitude of biological and behavioural factors.
8,44–49
 These are discussed below and 
include (in addition to use of ART discussed in sections 1.3.2-1.3.5): stage of HIV infection and associated 
viremia, physiological susceptibility to HIV, presence of ulcerative STIs in both HIV-negative and HIV-
positive partners, whether condoms are used, type of sex act and positioning. 
 Effect of HIV-RNA on transmission 1.4.1
 Viral load (VL) is the strongest predictor of the risk of HIV transmission. The first evidence to emerge on 
the role of VL was in the landmark Rakai Project cohort study (1994-1999), which followed 415 
serodifferent heterosexual couples for 30 months; the couples were not on ART (ART-naïve) and none 
reported consistent condom use during vaginal sex (none of the partners reported anal sex during 
follow-up).
8
 The incidence of HIV infection in the HIV-negative partners (seroconversion) was 11.8 per 
100 person-years based on 90 new infections and did not differ by gender of the index partner (male-to-
female or female-to-male transmission).
8
 HIV-positive participants whose partners seroconverted were 
found to have higher serum VL compared to those whose partners did not seroconvert. A dose-response 
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relationship was also found between higher VL (≥1500c/mL) and increased risk of transmission.
8
 
Although transmissions in this study were not genetically confirmed, the data presented were crucial in 
assessing transmission risk by VL concentration.
50
 Subsequent studies further corroborated these 
findings among serodifferent heterosexual ART-naïve couples in Africa.
51,52
 The Partners in Prevention 
Transmission Study (2004-2008) modelled the relationship of plasma VL and risk of heterosexual 
transmission in genetically-linked transmission events.
52
 This study found the incidence of HIV to be 2.3 
per 100 person-years based on 108 genetically linked seroconversions. In addition, a linear relationship 
was observed between log risk of HIV transmission and log10 plasma HIV RNA concentrations (log-linear 
relationship); an average decrease in plasma VL of 0.74log10c/mL (95%CI 0.60-0.97 log10c/mL) was 
associated with a reduction in heterosexual transmission risk by 50%. 
52
 
 Effect of stage of HIV infection on transmission 1.4.2
Primary HIV infection (PHI) is the first stage of HIV disease, characterised by active viral replication and 
CD4 cell depletion; it is a major driver of the HIV epidemic, estimated to cause a large proportion of new 
infections.
53,54
 AIDS refers to the point in disease progression when CD4 counts decline to critical levels 
(<200 cells/mm
3
) resulting in opportunistic infections and clinical immunodeficiency. The risk of sexual 
transmission of HIV is highest during PHI and AIDS, as sustained viral replication and ensuing high-level 
viremia boost the host’s infectiousness.
55
 As most HIV infections are not diagnosed during the acute 
stage, the HIV-positive person, being unaware of their seropositive status, may continue to have 
condomless sex. This may result in clusters of HIV transmissions, especially if there is high level of 
concurrent sexual partnerships.
56
  
 
A stochastic modelling study from the UK found that in 2010 a median of 48% (90%CI 34-62%) of new 
infections among MSM were derived from MSM with undiagnosed PHI and 34% (22-46%) from MSM 
with undiagnosed asymptomatic infection (clinical latency).
57
 Later studies among MSM from 
Switzerland and Denmark also reported similar findings.
4,58
  
 Effect of host susceptibility on transmission 1.4.3
Langerhans cells express CD4 co-receptors on their membrane, and have thus been identified as a 
primary target for HIV infection during sexual transmission. These cells are accumulated in mucous 
membranes (cervix, sperm and seminal plasma, as well as the foreskin and frenulum of the penis
44,59
) 
which allow contact with free virus from secretions, rather than requiring HIV to cross epithelia to infect 
them.
60
 The host’s degree of infectivity depends on immune system activation, which may increase the 
number and receptivity of susceptible Langerhans cells, or affect viral replication within infected cells.
44
  
Male circumcision also substantially reduces the risk of acquiring HIV, by up to 53%,
61–63
 due to removal 
of foreskin tissue on the penis, which is rich in Langerhans cells.  
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 Effect of other sexually transmitted infections on transmission (STIs) 1.4.4
A detailed review and discussion of the role of STIs in increasing the risk of HIV transmission is provided 
in Chapter 8. Briefly, STIs increase the risk of both HIV acquisition (in HIV-negative individuals) and 
transmission (from ART-naïve HIV-positive individuals) through a number of biological mechanisms 
(discussed in section 8.2). Much of the evidence on STI/HIV co-infection comes from studies performed 
prior to the era of widespread ART. It remains unclear whether co-infection with HIV and other STIs 
carries higher risk of HIV transmission if the HIV-positive partner is on virally suppressive ART.
64,65
  
 
Hepatitis C virus (HCV) remains of particular concern for HIV-positive individuals. HCV is most efficiently 
transmitted through blood contact, primarily by injection drug use (IDU) (section 8.2.7.1). However, 
sexual transmission of HCV is ongoing among HIV-positive MSM (not reporting IDU) in North America 
and Europe.
66,67
 The reasons for this increase are multifactorial (further discussed in Chapter 8) and 
most likely associated with sexual practices which lead to mucosal trauma and bleeding.
68
 The effect of 
HCV co-infection on onwards transmission of HIV remains unclear, particularly in the context of HIV 
suppression.  
 Effect of type of sex on transmission 1.4.5
The risk of HIV transmission varies according to the type of sex (anal or vaginal), position during sex 
(insertive versus receptive partner), and specific sexual practices.  
 
Consistent condom use is recognised as one of the safest, most cost-effective, and readily available 
methods of reducing the risk of HIV transmission.
69,70
 This section refers to condomless anal or vaginal 
sex (CLS), in other words sex during which condoms are not used. Anal CLS is associated with a greater 
risk of HIV transmission compared to vaginal CLS (1.69% per act versus 0.18% respectively).
71
 This 
difference is due to greater susceptibility of rectal mucosal membranes to HIV as well as to traumatic 
abrasions when compared to cervicovaginal membranes.
22
 Oropharyngeal membranes are considerably 
less susceptible to HIV infection compared to cervicovaginal or rectal membranes (due to thicker 
epithelial layers and low CD4 cell concentrations); no HIV transmissions have been recorded via oral CLS 
to date.
72
 For this reason, oral CLS is not discussed in this thesis (and was not a part of the ASTRA study 
questionnaire).  
 
Partner positioning during condomless anal sex is also associated with risk of HIV transmission. 
Receptive anal sex (when the HIV-negative partner is in receptive or ‘bottom’ position and the HIV-
positive partner is in the insertive or ‘top’ position) carries a greater risk of HIV acquisition compared to 
insertive anal sex (when the HIV-positive partner is in bottom position and the HIV-negative partner is 
the top position). Pooled meta-analysis data from 16 studies shows that the risk of HIV acquisition is 
highest during CLS when the HIV-negative partner is receptive rather than insertive, among 
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heterosexuals and MSM alike. Specifically, the per-partner transmission probability for receptive CLS has 
been estimated to be 40.4% (95%CI 6.0-74.9%) compared to 21.7%(0.2-43.3) for insertive CLS.
22
 In 
addition, risk of transmission is increased when the HIV-positive partner is in insertive position and 
ejaculates inside the receptive HIV-negative partner.
73
  
 
In addition to anal CLS, other sexual practices may also facilitate transmission of HIV; those associated 
with mucosal trauma, such as the manual insertion of digits in the rectum (‘fisting’) or use of sex toys, 
may lead to bleeding, which can increase risk of transmission of HIV and other STIs. In addition, 
frequency and duration of sex acts as well as high number of sexual partners are associated with greater 
transmission risk, although the relative contribution of each factor remains unclear.
43
  
 
1.5 HIV epidemiology  
 The global HIV epidemic 1.5.1
A total of 36.7 million (95%CI 34.0-39.8 million) people were living with HIV globally in 2015, of whom 
46% (43-50%) had access to ART.
74
 New infections have decreased by 38% since 2001, with 2.1 million 
(1.8-2.4 million) people becoming newly infected with HIV in 2015. Since 2010, there have been no 
declines in the number of new HIV infections among adults. AIDS-related deaths have also decreased by 
45% since the peak in 2005. In western and central Europe and North America there were 2.4 million 
people (2.2-2.7 million) living with HIV, and 91,000 (89,000-97,000) new infections in 2015.  
 The UK HIV epidemic (until 2015) 1.5.2
The number of people living with HIV in the UK had been steadily increasing between 2010 and 2015. 
This was due to effective ART leading to longer life expectancy of people living with HIV, together with 
ongoing HIV transmission. In 2015, there were an estimated 101,200 (95%CI 97,500-105,700) people 
living with HIV in the UK, with an overall HIV prevalence of 1.6 per 1000 population (and 2.1 per 1000 
among people aged 15 to 74 years).
75
 Among people living with HIV, 47,000 men (44,200-50,900) had 
acquired HIV through sex with other men, 19,600 men (18,600-21,500) and 29,900 women (28,900-
31,000) had acquired HIV through heterosexual sex. The majority of HIV-positive heterosexuals (60%) 
were of black African ethnicity, while the majority of MSM (86%) are white. These estimates include 
individuals who are unaware of their HIV infection (are undiagnosed) and are thus at risk of unknowingly 
transmitting HIV. Through a multi-parameter statistical model fitted to unlinked anonymous sero-
surveillance and behavioural survey data, Public Health England estimates the proportion of 
undiagnosed individuals to be 13% (10-17%) in 2015, a decline from 25% (19-31%) in 2010.
76
 As HIV 
develops into a chronic condition, the age of people accessing care for HIV has been increasing, with 
almost 17% now aged 50 years or over. 
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HIV treatment coverage in the UK is high and in line with the UNAIDS “90-90-90” goals,
77
 whose target is 
that 90% of people living with HIV know their HIV status, 90% of diagnosed are on ART, and 90% of 
those on ART are virally suppressed by 2020. In 2015, among all people living with diagnosed HIV, 96% 
were on ART, of whom 94% were virally suppressed (VL<200c/mL).
75
  
 
The overall trend of new HIV diagnoses in the UK declined between 2005 and 2010, and has since 
stabilised at around 6,000 newly diagnosed individuals annually.
78
 This corresponds to a new diagnosis 
rate of 0.10 per 1,000 population. (Figure 1.2) The number of new diagnoses among heterosexuals has 
declined by almost half since 2005; among MSM, the number of new diagnoses increased from 2006 
until 2014 and has remained high in 2015. During 2015, 6,095 people were newly diagnosed with HIV in 
the UK; 3,320 men acquired HIV through sex with other men and 2,360 men and women acquired HIV 
through heterosexual contact. Among newly diagnosed individuals, the prevalence of a late stage HIV 
diagnosis (with CD4 count <350 cells/mm
3 
within three months of diagnosis) has steadily declined from 
56% in 2005 to 29% in 2015. Late stage HIV is associated with ten-fold higher risk of death within a year 
of diagnosis,
79
 making timely diagnosis critical in ART initiation and prevention of onward HIV 
transmission. 
 
Figure 1.2: Number of new HIV infections by exposure category, sex, and year of diagnosis 
Adapted from 80  
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 The UK HIV epidemic among men who have sex with men (until 2015) 1.5.3
The HIV epidemic in the UK remains concentrated among gay, bisexual, and other men who have sex 
with men. As effective ART has led to a reduction in premature deaths from HIV and transmission of HIV 
is ongoing among MSM, the number of MSM living with HIV had been increasing from 38,400 (34,300-
43,800) in 2010 to 47,040 (44,219-50,860) in 2015.
75
 HIV prevalence was one in 17 among MSM aged 
15-44 years in 2015, a rate of 58.7 (51.2-68.0) per 1,000. Prevalence differs substantially by UK region, 
being higher in London compared to the rest of England and Wales (one in seven vs one in 25 
respectively).
76
 In 2015, 12% (7-19%) of MSM living with HIV were undiagnosed.
81
 Although the 
prevalence of undiagnosed HIV infection among MSM has followed a decreasing trend since 2010, there 
was no evidence of a significant decline between 2013 and 2015.  
 
Linkage and retention to HIV care following diagnosis is high among MSM in the UK, who accounted for 
45% (n=38,432) of all individuals accessing HIV care in 2014.
78
 Over 94% of all MSM living with HIV were 
receiving ART. Among MSM accessing care, almost 89% were receiving ART and 77% of those had an 
undetectable viral load. The median age at diagnosis among MSM was 33 years in 2015; over 80% of 
MSM newly diagnosed were of white ethnicity, 4% of black African or Caribbean ethnicity and 60% were 
born in the UK. 
 
Despite high rates of HIV testing coverage in STI clinics and high prevalence of effective ART for HIV-
diagnosed MSM, HIV transmission remained ongoing among MSM. The trend of new HIV diagnoses 
among MSM in the UK increased steadily from 1999 to 2015.(Figure 1.2) Even though the proportion of 
MSM newly diagnosed with late stage HIV has declined in the past decade, from 42% (n/N=948/2,255) 
in 2005 to 30% (777/2,628) in 2015, this remains high.
80
 Similarly, almost 4% (121/3,055) of new 
diagnoses observed among MSM were reported as first AIDS diagnoses, and 7% (209/3,055) were 
reported among MSM who died.
81
 Timely diagnosis of HIV infection among MSM thus remains a major 
challenge. 
  
Individuals newly diagnosed with HIV may also receive blood testing by Recent Infection Testing 
Algorithm (RITA), which distinguishes between recent or established infection. Among 2,823 individuals 
tested by RITA in 2015, 1,589 were MSM, of whom, 429 (27%; 95%CI 25-29%) had been recently 
infected.
78
 The high proportion of recently infected MSM may be attributable to more frequent HIV 
testing patterns compared to heterosexuals,
82
 however, findings from RITA further highlight the issue of 
ongoing HIV transmission among MSM in the UK.  
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 Changing epidemiology of HIV among MSM in the UK (2016 onwards)  1.5.4
1.5.4.1 Reduction in HIV diagnoses among MSM  
In late 2016, five HIV clinics in London (‘steep fall’ clinics) observed a substantial fall in the number of 
new HIV diagnoses among MSM. (Figure 1.2)
85
 In parallel, in London, there has been an extensive 
increase in the number of HIV tests conducted among both individuals attending for a new test as well 
as those attending for a repeat test at the at the same clinic in the last two years. The downturn in new 
HIV diagnoses among repeat testers also has an impact on the number of new diagnoses among new 
testers in these five HIV clinics. In other London clinics and in the rest of England, smaller declines in the 
number of HIV diagnoses have been observed. This may be due to the smaller scale of HIV testing 
conducted in these clinics, which is still not as effective in reducing the number of new HIV diagnoses, 
despite increases in HIV testing overall. By October 2017, an 18% decline in new HIV diagnoses was 
documented in the UK (between 2015 and 2016).
86
 This decrease was concentrated among MSM and 
particularly in London, and was driven both by increased HIV testing and increased uptake of early ART.  
 
Figure 1.3: New HIV diagnoses among MSM attending GUM clinics in England (2013-2016). 
From ‘Towards Elimination of HIV amongst gay and bisexual men in the United Kingdom’85 
 
GUM: Genitourinary Medicine clinic; Steep fall clinics: >20% decrease in HIV diagnoses between October 
2014 to September 2015 and October 2015 to September 2016, and >40 diagnoses during this period. 
 
1.5.4.2 PrEP  
In March 2016, NHS England announced that it would not commission PrEP for HIV prevention, 
considering “local authorities as the responsible commissioner for HIV prevention services”. The 
National AIDS Trust (NAT) challenged the legality of this decision in the High Court and the Court of 
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Appeal, arguing that there is no legal impediment to NHS England funding PrEP. In November 2016 the 
Court of Appeal ruled in favour of NAT, confirming that NHS is obliged to give due consideration to 
commissioning PrEP. As a result, NHS England announced funding for a clinical trial evaluating real-world 
PrEP implementation among 10,000 participants at “high risk of HIV” across 70 GenitoUrinary Medicine 
(GUM) clinics over three years. The IMPACT trial began enrolment in October 2017 among eligible 
groups: HIV-negative individuals who report condomless sex, a recent STI, and/or use of recreational 
drugs and HIV-negative partners of an HIV-diagnosed person not virally suppressed. The trial aims to 
measure PrEP eligibility, uptake, and use among eligible GUM attendees, and to assess the impact of 
PrEP on new HIV diagnoses and STIs. Results are expected from 2020 onwards. 
 
During this period, Scotland was making headway in provision of PrEP. In October 2016 an expert group 
of clinicians, public health practitioners, community representatives, and academics produced a report 
recommending PrEP to the Scottish Medicines Consortium (SMC), responsible for evaluating the cost-
effectiveness of new licensed medications and advising NHS Boards accordingly.
83
 In April 2017 the SMC 
licensed use of PrEP, making Scotland the first UK country to offer full PrEP provision through the NHS. 
An estimated 1700 individuals are eligible for PrEP in Scotland, of whom 58% are expected to present 
for use. 
 
In April 2017, the All Wales Medicines Strategy Group advised the Welsh government against funding 
PrEP on the grounds of cost-effectiveness. Nevertheless, the Welsh government approved PrEP 
provision through the NHS, as part of a three year trial.
84
 The PrEPARE trial aims to begin enrolling 
participants in all six GUM clinics in Wales by 2018. 
 
1.6 Conclusion 
This thesis uses data from the Antiretrovirals Sexual Transmission Risk and Attitudes (ASTRA) study, 
which was planned and conducted during a period of ongoing HIV transmission among MSM and 
changing HIV prevention messages (2008 onwards). The study was completed in 2012, prior to 
emergence of results from PARTNER, PrEP trials, the change in guidelines on ART initiation, and the first 
observed decline in HIV diagnoses in MSM in 2016. Nevertheless, the extent to which these advances in 
HIV treatment and prevention affect sexual behaviours of HIV-diagnosed MSM in the UK remains 
unclear. Findings from the ASTRA study (and this thesis) are important informing HIV clinical care and 
prevention effors and in planning and conducting future epidemiological research of sexual behaviours 
among HIV-diagnosed MSM. 
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2 Literature review of sexual behaviour among HIV-diagnosed 
men who have sex with men  
2.1 Chapter aims 
This chapter provides a context to the evolving concept of ‘high risk sex’ for HIV transmission among 
MSM living with HIV since the introduction of antiretroviral therapy (ART) in 1995. The overall aim is to 
review quantitative studies of sexual behaviour among HIV-diagnosed MSM in high income countries. A 
historical overview is first provided on the trends in prevalence of condomless sex (CLS) in the context of 
widespread ART use and the 2008 Swiss Statement. A literature review is then undertaken of studies 
carried out from 1995 to 2016 that have assessed the prevalence of and factors associated with 
condomless sex (including with HIV-serodifferent and HIV-seroconcordant partners) among MSM living 
with HIV in high income countries. Evidence is summarised according to study recruitment location; 
firstly, from studies of HIV-diagnosed clinic attendees (with a laboratory-confirmed positive HIV 
diagnosis), and secondly, from convenience samples including both HIV-diagnosed and/or HIV-positive 
MSM (either self-reported HIV-positive or tested HIV-positive as part of the study but were 
undiagnosed/unaware of their serostatus).  
2.2 Terminology used 
Condomless anal sex (CLS) has been the key indicator of HIV transmission risk in HIV behavioural 
research and surveillance, and as such, is considered a ‘risky’ sexual practice often referred to as 
‘unprotected intercourse’ (UAI) in the literature.
87
 Among people living with HIV the definition of ‘high 
risk sex’ is usually restricted to condomless anal or vaginal sex with an individual who does not have HIV 
(HIV-negative) or does not know their HIV status (CLS with an HIV-serodifferent partner, CLS-D). 
However, over recent years evidence has accumulated on the extremely low risk of HIV transmission 
during CLS-D when the HIV-positive partner is on ART with an undetectable HIV viral load (VL).
8,88
 There 
is now understanding that condom use is not the only method of ‘protection’ against transmission of 
HIV infection, and that referring to condomless sex as ‘unprotected’ may be inappropriate. Hence, this 
thesis uses the more specific term CLS instead of UAI.  
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2.3 Condomless sex – historical overview of an evolving concept of 
transmission risk behaviour 
 Rationale 2.3.1
HIV incidence is driven by patterns of sexual risk behaviour between HIV-diagnosed, HIV-undiagnosed, 
and HIV-negative MSM.
89
 Given the increase in uptake of HIV testing and ART use in the past decade, 
sustained HIV incidence among MSM points to increasing sexual risk behaviours during this period.
90
 
While the majority of HIV transmissions among MSM in the UK derive from HIV-undiagnosed 
MSM,
57,91,92
 a sizeable proportion of transmissions is estimated to originate from HIV-diagnosed 
individuals; modelling studies have estimated the this to be up to 18% in the UK
57
 and up to 29% in the 
Netherlands.
4
 The prevalence of CLS may be continuously evolving in response to changes in HIV 
treatment and prevention. A number of important co-factors may also impact on levels of CLS (with HIV-
negative/unknown and other HIV-positive partners) among HIV-diagnosed MSM: sociodemographic 
factors (for example, level of educational attainment, employment, financial status), lifestyle 
characteristics (use of recreational drugs and alcohol), HIV-related factors (time since HIV diagnosis, use 
of ART, beliefs regarding infectiousness), mental health issues (symptoms of depression and anxiety), 
and sexual partner characteristics. Understanding the drivers of various types of CLS among HIV-
diagnosed MSM is important for targeting and informing prevention strategies and thus warrants 
further study. 
 Trends in prevalence of condomless sex in the context of introduction of 2.3.2
combination ART (1996-2008) 
The introduction of ART in 1995/1996 was accompanied by reported increases in prevalence of ‘high-
risk sexual behaviours’ (such as CLS) among all MSM (HIV-negative and HIV-diagnosed or HIV-positive) in 
Europe and North America.
93–97
 This raised concern about a possible causal effect, whereby HIV 
optimism among MSM (raised hope or optimism about HIV being readily treatable due to ART), may 
prompt complacency around ‘safe sex’ practices, and thus lead to increases in ‘risky’ sexual 
behaviours.
98
 While a number of cross-sectional studies showed an association between HIV optimism 
(assessed using attitudinal questions on a questionnaire) and ‘high-risk’ sexual behaviours (defined as 
CLS) among HIV-negative and HIV-diagnosed MSM at the time,
95,99–101
 they were unable to establish 
causality, or examine longitudinal trends. In the ‘London Gyms’ study of 455 HIV-positive (and 1776 HIV-
negative) MSM surveyed annually in gyms and HIV outpatient clinics (1998-2001), there was evidence of 
a substantial increase, among HIV-diagnosed MSM, in prevalence of CLS and CLS-D.
98
 (Further discussed 
in section 2.5.1) This increase, however, was unlikely to be explained by increases in HIV optimism, as 
there were no differences in prevalence of CLS between those reporting and those not reporting HIV 
optimism.
98
 In addition, no interaction was found between year, HIV optimism, and CLS. The authors 
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hypothesize that other factors may account for the increasing trend in CLS, such as widespread access to 
the internet and sex-on-premises venues, and ‘habituation to the risk of HIV’ after two decades since 
the first AIDS reports. Levels of HIV optimism also remained stable despite the increasing evidence of 
the benefits of ART, which appears to indicate the absence of a causal dose-response relationship 
between HIV optimism and ‘high-risk’.
102
 During the early 2000’s, evidence from studies of HIV-
outpatients in Western Europe and USA found either no association between HIV optimism, ART use, 
and sexual risk behaviours,
98,103–107
 or found that MSM on ART had lower prevalence of sexual risk 
behaviours compared to MSM not on ART.
108–110
 
 Use of ART and condomless sex among HIV-diagnosed MSM  2.3.3
With the introduction and widespread use of combination ART for treatment of HIV, many studies 
aimed to investigate whether ART use impacted on levels of CLS among people diagnosed with HIV. 
These studies showed that MSM on ART had lower prevalence of sexual risk behaviours compared to 
MSM not on ART.
100,103,104,108–116
 A meta-analysis of 25 studies of HIV-diagnosed people recruited from 
HIV clinical settings in Western Europe, North America, and Australia (1996-2003) reported that the 
prevalence of CLS was not higher among HIV-positive people receiving ART (versus not receiving ART) or 
among HIV-positive people with an undetectable VL on ART (versus with detectable VL on ART).
117
 
Coupled with evidence from this meta-analytic review, results from the Strategies for Management of 
Antiretroviral Therapy (SMART) study (2002-2006) also showed no support for the hypothesis that 
receiving ART or having undetectable VL leads to ‘risky’ sexual behaviours (such as CLS and CLS-D) 
among MSM. The SMART trial was the first of its kind to compare continuous versus intermittent CD4-
guided ART.
79
 A USA sub-study of 875 HIV-diagnosed SMART participants (heterosexuals and MSM) 
found that those on ART at baseline had 30% lower odds of having CLS-D in the past two months 
compared to those not on ART.
112
 Over two years of follow-up, the proportion of SMART participants 
reporting CLS and CLS-D in the past two months was similar in the two study arms, at about 13% and 5% 
respectively, and did not differ by gender or sexual orientation.
112
  
 Prevalence of condomless sex in the era following the Swiss Statement (2008 2.3.4
onwards) 
Following the evidence that ART use was not associated with sexual behaviours with ‘higher risk’ of HIV 
transmission, the late 2000’s saw fundamental changes in the awareness and understanding of HIV 
transmission risk.
118
 Evidence continued to accumulate on the profound protective effect of virological 
suppression on ART on reducing an individual’s HIV infectiousness, mostly from observational studies of 
heterosexual HIV-serodifferent couples.
8,19,119
(Section 1.3) In 2008 an internationally renowned panel of 
Swiss HIV clinicians and scientists from the National HIV/AIDS Commission convened to summarise this 
information by issuing the “Swiss statement”, which states that condom use can be discontinued in a 
stable HIV-serodifferent partnership if the following three conditions are met: (i.) the HIV-positive 
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partner is receiving ART with excellent adherence, (ii.) plasma HIV VL has been undetectable(<40 
copies/mL) for six months or longer, and (iii.) both partners do not have another STI.
120
 An HIV-
diagnosed person who met these conditions was deemed “not sexually infectious (i.e. cannot transmit 
HIV through sexual contact.)”
121
 The statement referred to monogamous heterosexual HIV-serodifferent 
partners having vaginal CLS. It attracted worldwide attention and was initially extremely controversial 
and not unanimously accepted by experts and health professionals, due to lack of evidence from 
randomised trials and concern about the potential impact on sexual behaviour among people with 
HIV.
122,123
 Debate arose on whether condom use was necessary to prevent transmission of HIV if HIV 
replication was suppressed. It was hypothesized that the prevalence and patterns of ‘risky’ sexual 
behaviours among HIV-positive people (vaginal or anal CLS-D) could change as a result of raised 
awareness of the Swiss statement.
124
 The only study finding evidence of the impact of the “Swiss 
statement” on changes in prevalence of CLS among HIV-diagnosed people is the Swiss HIV Cohort study 
(SHCS), which has enrolled HIV-diagnosed clinic attendees since 1988.
125
 Retrospective analyses of over 
2000 MSM in the SHCS indicate an increase in prevalence of CLS-D with stable and occasional partners 
(comparing periods 2000-2007 and 2008-2013).
124,126
 In addition, among MSM with stable HIV-negative 
or HIV-unknown status partners, there was a significant association between having undetectable VL on 
ART and reporting higher prevalence of CLS-D. This indicates that HIV-diagnosed MSM may have 
adopted the belief that ART can be used to prevent sexual transmission of HIV. The “Swiss statement” 
may have elicited changes in the acceptability of CLS in Switzerland by making MSM more aware of the 
conditions for lower infectiousness. However, the increase in CLS-D prevalence may have also been due 
to a real change in sexual behaviours and liberalisation of attitudes towards CLS; hence it is difficult to 
disentangle whether the increase in CLS after the introduction of ART or after the “Swiss Statement” 
may have been a period or a cohort effect, or a mixture of both. 
127
  
 
In this context, the ASTRA study (discussed in Chapter 3) was designed as part of a program of research 
aiming to investigate whether a policy of early ART for all HIV-diagnosed people in the UK would be 
associated with a decline in HIV transmissions through a reduction in infectiousness of HIV-diagnosed 
people.(Section 1.3) There was concern that increased awareness of the protective effect of 
undetectable VL on HIV infectiousness may adversely impact on levels of CLS among MSM with HIV, and 
that increases in CLS may compromise or undermine the full potential impact of early treatment in 
reducing transmission. The ASTRA study aimed to understand the association between use of ART, 
perceived (self-reported) VL suppression, and sexual behaviours, in order to inform assessment of the 
public health impact of a possible strategy of early ART initiation.
89
  
2.4 Literature review methods 
The aim of this literature review was to locate peer-reviewed research on the prevalence of and/or 
factors associated with CLS (any CLS, CLS with HIV-serodifferent or HIV-seroconcordant partners) among 
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MSM living with HIV in high-income countries. A search on MEDLINE and EMBASE (OvidSP version) was 
conducted in December 2014 and repeated in September 2016. (Search strategy shown in Appendix II 
and search results in Appendix III.) Specific inclusion criteria for this review were (Figure 2.1):  
 Original research studies (cross-sectional, cohort, case-control studies, and randomised 
controlled trials),  
 Reporting on the prevalence of and/or factors associated with CLS among MSM who are living 
with HIV,  
 Conducted in North America (United States and Canada), Western Europe (including the United 
Kingdom), or Australia,  
 Conducted between 1996 and 2016 (recruitment to have commenced no earlier than 1996), 
 Have at least 100 HIV-diagnosed participants, 
 Written in English  
Exclusion criteria were: published systematic reviews and studies that only included: heterosexual 
individuals or transgender men living with HIV, HIV-negative or HIV-unknown status MSM, prison, sex 
worker, or paediatric/adolescent populations (under 18 years). A sequential search was conducted using 
thesaurus searching (medical subject headings, MeSH, and all items indexed with that heading) and 
textword searching (in titles, abstracts, article bodies, and keywords).(Figure 2.1) A manual assessment 
of retrieved publications (by reading the abstract or if needed, the full paper) was then conducted using 
inclusion and exclusion criteria.(Details in Appendix III) The methodological quality of each paper was 
assessed with regards to research design, study sample (response rate, representativeness of the study 
population), data collection (ascertainment of the dependent and independent variables), sources of 
bias (respondent bias, confounders), and data analysis. While a formal assessment of study quality was 
not conducted, studies were excluded if they did not meet eligibility and/or quality assessment criteria 
(and the reasoning was provided for each study in Table of Appendix III). An additional search was 
carried out on the Sigma Research website (http://sigmaresearch.org.uk/) in order to identify relevant 
reports which may not be published in peer-reviewed journals. Following this search strategy, a total of 
82 papers (representing approximately 40 unique studies) were identified as relevant and included in 
the literature review.  
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Figure 2.1: Literature review diagram 
 
See Appendices II and III for detailed search term strategy and results 
 
2.5 Overview of evidence on prevalence of condomless sex among HIV-
diagnosed MSM  
 Studies of HIV-outpatient clinics 2.5.1
Table 2.1 summarises evidence from 10 studies which have recruited HIV-diagnosed MSM in clinical 
settings (attending for HIV care in hospitals, clinics, or enrolled in clinical trials) in Western Europe or the 
USA since 1996, and have assessed the prevalence of various types of CLS.  
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The ‘London Gyms’ study (1998-2008) was one of the first to examine trends in sexual behaviour of HIV-
diagnosed MSM in the UK.
128
 This annual questionnaire survey of gym-attending MSM in London  was 
part of a behavioural surveillance programme enrolling over 6000 MSM, of whom 16.5% were HIV-
diagnosed and recruited from HIV outpatient clinics (remaining 63.8% were HIV-negative and 19.7% 
never tested, not discussed here).
129–131
 Over the study period, there was a significant increase in 
prevalence of any CLS in the previous three months among 1001 HIV-diagnosed MSM in the clinic 
sample, however this masked more complex underlying trends; as shown in Figure 2.2, the prevalence 
of CLS-D (with HIV-negative of HIV-unknown status partners) in the past three months increased rapidly 
between 1998 and 2002 (p<0.001), and declined between 2003 and 2005 (p<0.05) returning to the level 
reported in 1998.
131
 Other UK clinic-based questionnaire studies of HIV-diagnosed MSM that have 
incorporated measures of CLS-D include the ‘Internet and HIV’ and ‘East London’ studies, which found 
the prevalence of CLS-D in the previous three months to be 18.0% and 20.2% respectively.(Table 
2.1)
103,132
 A smaller cross-sectional study from HIV-outpatient clinics in London and South East England 
(‘Switching study’, 2005) examined the association between ART switching and psychological, clinical 
variables, and CLS;  among 451 HIV-diagnosed MSM, 15% reported having CLS with a partner of 
unknown HIV-serostatus in the previous three months.
133
  
 
During the late 2000’s evidence from cross-sectional studies and probability samples from HIV-
diagnosed MSM in the clinic setting in high-income countries suggested a plateau in the prevalence of 
CLS-D and an increase in the prevalence of condomless sex with other HIV-positive partners (CLS-
C).
73,90,128,134–137
(Table 2.2) In the ‘London Gyms’ study, for example, the prevalence of CLS-C in the 
previous three months (CLS only with other HIV-positive partners and not with HIV-serodifferent 
partners) doubled significantly over the study period.
131
(Figure 2.2) Point estimates for prevalence of 
CLS-C in the past three months were similar among HIV-diagnosed MSM in the clinic samples of the 
‘Internet and HIV’ and ‘East London’ studies (15% and 14% respectively).
103,138,139
  
 
These trends were further observed in a systematic review of 30 cross-sectional studies conducted 
between 2000 and 2007 of over 18,000 HIV-diagnosed MSM recruited from HIV clinics and gay social 
venues in the USA.
111
 There was marked heterogeneity of CLS prevalence estimates across study 
recruitment settings and time periods, sampling methods, and sexual behaviour recall windows (from 
last sex to the past 12 months). The aggregate estimates (with any recall window) were: CLS 43% (95%CI 
37-48%), CLS-C 30% (25-36%), and CLS-D 26% (21-30%).
111
 No significant difference was observed by the 
length of the recall window; the prevalence of CLS-D in the previous three months ranged from 25% to 
68%. In addition, CLS with HIV-unknown status partners was found to be more prevalent than CLS with 
HIV-negative partners (16 vs 13% respectively). As the review was based on studies conducted in the 
USA, however, results could not be extrapolated to HIV-diagnosed MSM in the UK.  
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 Studies of HIV-positive or HIV-diagnosed MSM from convenience samples  2.5.2
Results from studies using convenience sampling of HIV-diagnosed MSM (attending social or community 
venues, using specific websites) during the same period in the UK and the USA show diverse trends in 
the prevalence of CLS.(Table 2.2) The UK behavioural surveillance system was an annual survey of MSM 
recruited from gay venues and GUM clinics between 1996 and 2004, with oral fluid HIV antibody 
tests.
97,105,140,141
 During the study period, approximately 5.3% of MSM recruited were HIV-diagnosed 
(aware of their serostatus) and within this group levels of CLS in the past 12 months remained stable 
(between 31.1% and 43.9%).
97,105,140,141
 However, there was evidence of a significant increase in the 
overall prevalence of CLS in the past twelve months between 2005 and 2013 among over 1500 HIV-
diagnosed MSM participating in the London and Scotland Gay Men’s Sexual Health Surveys 
(GMSHS).
142,143
 This was also observed in the US National HIV Behavioural Surveillance (NHBS) of 1586 
HIV-positive MSM recruited from venue-based, time-space sampling between 2011 and 2014 (Table 
2.2).
136
 However, no statistically significant increase in CLS was observed in the UK Gay Men’s Sex Survey 
(GMSS) of 243 internet-recruited HIV-positive MSM in England between 2001 and 2008.
134,144
  
 
Prevalence of CLS-C increased significantly between 2000 and 2014, as evidenced in the GMSS, London 
GMSHS, and the NHBS studies.
134,136,143,144
 (Table 2.2) While CLS-C (when HIV-seropositive status is 
known with certainty) poses no risk of HIV transmission it contributes to transmission of other sexually 
transmitted infections (STIs). The rise in prevalence of CLS-C in the UK mirrors the trend of increasing 
diagnoses of STIs observed in the past decade (further discussed in Chapter 8).
145–147
 These epidemics 
are overlapping and disproportionately affect HIV-diagnosed MSM in the UK, suggesting that CLS-C may 
play a key role in continued transmission of other STIs.
148,149
 The prevalence of, and factors associated 
with CLS with HIV-seroconcordant versus HIV-serodifferent partners, are not well studied among HIV-
diagnosed MSM in the UK.  
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Table 2.1: Summary of studies recruiting HIV-diagnosed MSM from clinical settings in high-income countries (1996-2016) 
Study / Data collection 
period / Country 
Recruitment,  study type Sample  On ART 
(%) 
CLS 
recall 
window  
Type of 
partner  
CLS overall 
(%) 
CLS-D (%)  CLS-C (%) Notes on definitions 
London 
Gyms 
128,131,150
 
 
 
1998-
2008 
 
UK 
Cross-sectional annual self-
completed questionnaire 
study of HIV-negative and 
HIV-positive MSM using gyms 
in central London and of HIV-
diagnosed MSM attending 
for HIV care in NHS hospitals. 
Here showing data for HIV-
diagnosed MSM only.  
• N total =6064 
• N HIV-diagnosed 
MSM from 
clinics=1001 
(16.5%) 
Not 
shown 
Past 3 
months  
Stable, 
casual, 
combine
d  
1998: 
31.4% 
2008: 
51.4% 
(p<0.001)
‡ 
 
(see Figure 
2.2 for full 
details) 
1998: 19.5% 
2008: 27.0% 
(p=0.65)
‡
 
1998: 
11.9% 
2008: 
24.3% 
(p<0.001)
‡
 
CLS-D: CLS with HIV-negative 
or HIV-unknown status 
partners.  
CLS-C: CLS with other HIV-
positive partners only (CLS-D 
and CLS-C are mutually 
exclusive categories)  
Internet and 
HIV 
132,151
 
 
2002-
2003 
 
UK 
Cross-sectional self-
completed questionnaire 
study of HIV-diagnosed MSM 
receiving HIV care at a 
London NHS hospital. (Not 
shown here: additional 
samples of HIV-positive and 
HIV-negative MSM from gay 
website, GUM clinic, gyms)  
• N total= 4015 
• N HIV-diagnosed 
MSM from clinics= 
506 (12.6%) 
66% Past 3 
months  
Casual   Not shown 18.0% 15.0% CLS-D: CLS with HIV-negative 
or HIV-unknown status 
partners. 
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Study / Data collection 
period / Country 
Recruitment,  study type Sample  On ART 
(%) 
CLS 
recall 
window  
Type of 
partner  
CLS overall 
(%) 
CLS-D (%)  CLS-C (%) Notes on definitions 
Southern 
California 
Acute 
Infection and 
Early Disease 
Research 
Program 
152
 
2002-
2006 
 
USA 
Cohort study of recently HIV-
diagnosed individuals (≤12 
months) with self-interview 
questionnaires on sex 
behaviours at baseline 
(enrolment) and every 3 
months during in 1st year 
enrolled. Here showing data 
for HIV-diagnosed MSM only. 
• N HIV-diagnosed 
MSM at baseline: 
225 
• N HIV-diagnosed 
MSM with ≥1 
follow-up visit: 193 
32% • at 
baseline
: last sex  
• at 
follow-
up: past 
3 
months  
Last 
partner 
47.5% At baseline: 
42% 
At follow-up 
(month 12): 
50% 
At 
baseline: 
78.6% 
At follow-
up: 73.3% 
CLS-D: CLS with HIV-negative 
or HIV-unknown last partner 
Positive 
STEPS 
113
 
2004 
 
USA 
Baseline questionnaire of a 
behavioural intervention 
among randomly selected 
HIV-diagnosed men and 
women attending for care in 
7 clinics. Results here are 
from MSM HIV-diagnosed for 
≥6 months, either planning 
on or already receiving care 
in clinic, and reporting any 
anal sex or IDU in past 3 
months.  
• N total=1050 
• N HIV-diagnosed 
MSM=496 (47.0%) 
69% Past 3 
months  
Not 
shown 
Not shown • Total: 
23.0% 
• with HIV-
negative 
partners: 
14.5% 
• with HIV-
unknown 
partners: 
12.7% 
35.8% CLS-D includes HIV-negative 
and unknown status partners 
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Study / Data collection 
period / Country 
Recruitment,  study type Sample  On ART 
(%) 
CLS 
recall 
window  
Type of 
partner  
CLS overall 
(%) 
CLS-D (%)  CLS-C (%) Notes on definitions 
East London 
103,153
 
 
2004-
2005 
 
UK 
Cross-sectional self-
completed questionnaire 
study of HIV-diagnosed men 
and women attending for 
HIV care in six East London 
NHS hospitals. Results here 
for HIV-diagnosed MSM only.  
• N total =1687 
• N HIV-diagnosed 
MSM=758 (44.9%) 
71% Past 3 
months  
Any 
(stable or 
casual) 
37.8% • Total: 
20.2% 
• with HIV-
negative 
partners: 
3.8% 
• with HIV-
unknown 
partners:  
16.4% 
14.0% Hierarchical classification 
(mutually exclusive): 1.CLS-C 
only, 2.CLS-D (with ≥1 HIV-
negative partner), 3.CLS with 
HIV-unknown partner (not 
with HIV-negative: incl. MSM 
with HIV-unknown and HIV-
positive partners)  
Switching 
Study 
114,154
 
2005-
2006 
 
UK  
Cross-sectional self-
completed questionnaire 
study in 5 HIV outpatient 
clinics in London and 
Brighton. Here showing 
results for HIV-diagnosed 
MSM only.  
• N total = 666 
• N HIV-diagnosed 
MSM=451 (67.7%) 
68%  Past 3 
months  
Any Not shown 15.30% Not 
shown 
CLS-D includes HIV-negative 
and unknown status partners 
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Study / Data collection 
period / Country 
Recruitment,  study type Sample  On ART 
(%) 
CLS 
recall 
window  
Type of 
partner  
CLS overall 
(%) 
CLS-D (%)  CLS-C (%) Notes on definitions 
ANRS-
VESPA1 and 
VESPA2 
155
 
2003 and 
2011 
 
France 
National cross-sectional, 
interviewer-administered 
surveys. Random location-
stratified sample of HIV-
diagnosed people attending 
for HIV care in 102 hospitals, 
diagnosed for ≥6 months. 
Showing results for MSM 
only. 
VESPA1: 
• N total=2932 
• N HIV-diagnosed 
MSM=1117 (35.6%) 
VESPA2: 
• N total=3022 
• N HIV-diagnosed 
MSM=1337 (39.1%) 
>80% Past 12 
months 
and 
most 
recent 
partner 
Stable 
and 
Casual  
Most 
recent 
casual 
partner: 
2003: 
22.9% 
2011: 
17.5% 
(p=0.07)† 
Stable 
partner:  
2003: 22.9% 
2011: 25.1% 
(p=0.64)† 
Not 
shown 
CLS-D with stable partner: CLS 
with a HIV-negative or HIV-
unknown status stable 
partner. 
 
Most recent CLS: no condom 
use at last sex with a casual 
partner.   
START trial 
(baseline) 
156
 
2009-
2013 
 
Internatio
nal 
RCT of HIV-diagnosed people 
allocated to early or deferred 
ART initiation. Results from 
ART-naïve HIV-diagnosed 
MSM on sexual behaviour 
questionnaire at baseline 
(prior to randomisation) from 
Europe/Israel only  
• N total=4601 
• N HIV-diagnosed 
MSM= 2559 
(55.6%) 
Europe/Israel:  
• N total = 1518 
• N HIV-diagnosed 
MSM=1173 (77.2%) 
0%  Past 2 
months 
Not 
shown 
Not shown • Overall 
MSM in 
Europe/Israel
: 15.1%  
• MSM 
diagnosed ≥3 
months ago: 
13.7% 
• MSM 
diagnosed <3 
months ago: 
25.4%  
Not 
shown 
CLS-D defined as CLS with 
HIV-negative or HIV-unknown 
status partners  
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Study / Data collection 
period / Country 
Recruitment,  study type Sample  On ART 
(%) 
CLS 
recall 
window  
Type of 
partner  
CLS overall 
(%) 
CLS-D (%)  CLS-C (%) Notes on definitions 
Medical 
Monitoring 
Project 
(MMP) 
157,158
   
2009-
2010 
 
USA 
HIV surveillance system 
producing nationally 
representative estimates of 
behavioural and clinical 
characteristics of HIV-
diagnosed adults receiving 
care. Cross-sectional random 
sample survey (face-to-face 
interviews) of black or white 
non-Hispanic HIV-diagnosed 
MSM reporting sex with a 
man in past 12 months, with 
≥1 medical visit.  
• N total = 4217 
• N HIV-diagnosed 
MSM=1010 (23.9%) 
>80% Past 12 
months  
Not 
shown 
Not shown 20.0% (95%CI 
17.0-23.0%) 
Not 
shown 
CLS-D:  'unprotected anal sex' 
with a male partner of HIV-
negative or HIV-unknown 
status  
Adolescent  
Medicine  
Trials  
Network  for 
HIV/AIDS  
Intervention
s 
(ATN070)
159
  
2011 
 
USA 
Cross-sectional questionnaire 
survey of young (16-24) HIV-
diagnosed MSM receiving 
care in clinics in 14 US cities. 
Restricted to those who 
reported ≥1 episode of anal 
sex with a male partner in 
past 12 months.  
• N HIV-diagnosed 
MSM= 200 (100%) 
47% Past 3 
months  
Not 
shown 
43.0% • 20.5% 
insertive  
• 22.5% 
receptive  
• 21.5% 
insertive 
CLS-C 
• 21.0% 
receptive 
CLS-C 
CLS-D: CLS with HIV-negative 
or unknown status partners 
95%CI: confidence interval; ‡: test for trend p-value for period shown; †: p-value for difference between two periods shown; ART: Antiretroviral Therapy; NHS: National Health 
Service; CLS: condomless sex; CLS-D: condomless sex with HIV-serodifferent partners; CLS-C: condomless sex with HIV-seroconcordant (HIV-positive) partners; GUM: Genito-Urinary 
Medicine (sexual health clinic); IDU: injection drug use; RCT: randomised controlled trial; START: Strategic Timing of AntiRetroviral Treatment trial; ‘Not shown’: study did not provide 
relevant information. 
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Figure 2.2: Prevalence of condomless sex (CLS) in the previous three months among HIV-
diagnosed MSM recruited from HIV outpatient clinics in the London Gyms study (1998-
2008)131 
 
‡ N HIV-diagnosed MSM surveyed each respective year  
No data for 2006 and 2007 as survey was carried out annually between 1998 and 2005 and again in 2008.  
* p-value<0.05 for trend for period 1998-2008 (2006-2007 data imputed). 
 HIV transmission risk reduction during condomless sex with HIV-serodifferent 2.5.3
partners (CLS-D)  
HIV-risk reduction strategies in the context of CLS-D include sexual positioning and withdrawal before 
ejaculation.(section 1.4.5) Insertive anal sex (when the HIV-positive partner is in the insertive or ‘top’ 
position and the HIV-negative partner is in receptive or ‘bottom’ position) with ejaculation inside the 
HIV-negative partner carries a greater risk of HIV transmission compared to receptive anal sex (when the 
HIV-positive partner is in receptive position).
22,73
 HIV-positive MSM may have developed understanding 
of the relative risks of insertive versus receptive CLS-D, and thus adopted the receptive position as a risk 
reduction measure. However, there have been few studies examining trends in seropositioning and 
withdrawal before ejaculation among HIV-diagnosed MSM in Europe.  
 
31.4 
51.4 
19.5 
27.0 
15.3 
18.9 
4.2 
8.1 
11.9 
24.3 
6.8 
14.2 
5.1 
10.1 
0%
10%
20%
30%
40%
50%
60%
70%
1998 1999 2000 2001 2002 2003 2004 2005 2008
Any CLS
Any CLS-D
CLS-D (casual)
CLS-D (main)
Any CLS-C
CLS-C (casual)
CLS-C (main)
* 
N‡ :       118      101      120       116       121       78         120       79        148 
* 
* 
* 
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The earliest evidence of patterns in sexual positioning based on partner’s HIV-serostatus emerged from 
ten cross-sectional surveys of MSM recruited from gay community and sexual health settings in Sydney 
between 1996 and 2000.
160
 Among 2695 HIV-positive MSM recruited, , the vast majority were the 
receptive partner only in the past 6 months (69.0%), and a minority reported CLS with ejaculation inside 
their HIV-serodifferent stable partner (2.7%). 
 
Conversely, results from HIV-positive MSM recruited from community-based venues in New York City 
and San Francisco in 2000-2001 showed that while some men in San Francisco were more likely to 
report being the receptive than the insertive partner (with HIV-unknown and HIV-negative partners), 
this pattern was not observed among men in New York.
73
 A meta-analysis of 30 cross-sectional USA 
studies (2000-2007), found that a higher proportion of HIV-diagnosed MSM reported taking the 
receptive rather than the insertive position during CLS with HIV-negative partners (9% vs 5%).
111
 While 
differences in patterns of CLS according to partners’ HIV-serostatus were found, this meta-analysis could 
not ascertain whether these behaviours were intentional strategies to reduce the risk of HIV 
transmission or merely sexual preferences.  
 
Since then, some studies from HIV-diagnosed MSM in the USA and Australia have suggested an increase 
in the prevalence of receptive CLS-D
26,136,161
 but no such evidence has been observed in the UK GMSS 
surveys.
134
 There is evidence of HIV risk compensation during CLS-D from interim analyses of the 
PARTNER and Opposites Attract studies, as HIV-negative partners in both studies reported being the 
insertive partner more often than being the receptive partner.
9,161
 In addition, when the HIV-negative 
partner was receptive, withdrawal before ejaculation by the HIV-positive partner was also more 
prevalent than ejaculation inside. It remains unclear how extensively these risk reduction approaches 
have been adopted in the UK among HIV-diagnosed MSM who may or may not have a stable 
serodifferent partner. Accrual of longer-term follow-up from these two cohorts will provide more 
precise estimates of HIV transmission risk and may in turn impact on trends of CLS-D.  
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Table 2.2: Summary of studies recruiting HIV-positive or HIV-diagnosed MSM from convenience samples in high-income countries (1996-2016) 
Study / Data 
collection period 
Recruitment, location, study type Sample 
On 
ART 
(%) 
CLS 
recall 
window 
Partner 
type 
CLS overall (%) CLS-D (%) CLS-C (%) 
Notes on 
definitions 
Active 
behavioural 
surveillance 
system 
97,105,140,141
 
 
1996-
2004 
 
UK  
Self-completed, cross-sectional 
annual behavioural surveys of MSM 
recruited from gay venues (bar, club, 
sauna) and GUM clinics in the UK with 
HIV antibody testing (unlinked 
anonymous survey). Here showing 
data for HIV-positive only.  
• N total= 
14,193 
• N tested 
HIV-
positive=567 
(4.0%) 
Not 
shown 
Previou
s 12 
months  
Casual  1996: 31.1% 
2004: 43.9%  
1996: 16.7% 
2004: 30.6% 
~19.0% CLS-D: CLS with HIV-
negative or HIV-
unknown partners.  
 
CLS-C: CLS with 
partners of the 
same HIV-
serostatus only.  
Gay men in 
Sydney 
160,162,163
 
 
 
1996-
2006 
 
Austra
lia 
10 biannual cross-sectional surveys 
of MSM from gay community, social, 
sex-on-premises, and sexual health 
clinic. Data shown here are for self-
reported HIV-positive MSM. 
• N=14,165 
• N HIV-
positive: 2695 
(19.6%) 
Not 
shown 
Previou
s 6 
months  
Main 
and 
casual  
• 30.1% (of 462 
with regular 
partner) 
• 41.6% (of 
2146 with 
casual 
partners) 
• 48.6% (of 146 with regular 
serodifferent partner)  
• 56.6% (of 881 had CLS 
with casual partner) 
Not shown CLS-D: with 
"serodiscordant" 
partner(s) 
Seropositive 
Urban Men's 
Intervention 
Trial 
(SUMIT)
73,164
 
2000-
2001  
 
USA 
Baseline assessment of RCT on single 
or six-session intervention designed 
to reduce HIV transmission risk and 
promote serostatus disclosure. Self-
identified HIV-positive MSM 
reporting sex with ≥1 HIV-
serodifferent partner in past year 
recruited from community-based 
venues in NYC and San Francisco 
• N HIV-
positive=1168 
75.1% Previou
s 3 
months 
Casual 
or 
main 
Not shown CLS-D with casual partners  
• 17.8% with HIV-negative   
• 34.0% with HIV-unknown 
 • Combined: 47.3% 
CLS-D with main partner: 
• 15.0% with HIV-negative  
• 6.3% with HIV-unknown  
• Combined: 21.3 
24.5% Combined CLS-D: 
CLS with HIV-
negative and HIV-
unknown status 
casual or main 
partners  
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Study / Data 
collection period 
Recruitment, location, study type Sample 
On 
ART 
(%) 
CLS 
recall 
window 
Partner 
type 
CLS overall (%) CLS-D (%) CLS-C (%) 
Notes on 
definitions 
Gay Men's 
Sex Survey 
(GMSS) 
134,144
 
 
 
2001 
and 
2008 
 
UK 
Annual community-based sexual 
health needs assessment 
questionnaire survey of MSM 
recruited from gay venues and online 
in England. Data shown are for 
internet-recruited self-reported HIV-
positive participants only.  
• N total= 
4953 
• N HIV-
positive=243 
(4.9%) 
Not 
shown 
Previou
s 12 
months 
Not 
shown 
2001: 73.7% 
2008: 82.1% 
(p>0.05)
‡
 
• CLS with HIV-negative:  
2001: 19.7% 
2008: 17.9% (p>0.05)
‡
 
• CLS with HIV-unknown 
status partner:  
2001: 44.9% 
2008: 49.6% (p>0.05)
‡
 
2001: 
49.6% 
2008: 
52.0% 
(p>0.05)
‡
 
- 
London Gay 
Men's Sexual 
Health 
Survey 
(London 
GMSHS) 
143
 
 
 
2000-
2013 
  
UK 
10 serial cross-sectional surveys of 
MSM (≥16 years) in London gay 
social venues (bars, clubs, saunas) 
using self-completed questionnaires 
and oral HIV antibody testing. Here 
showing results for HIV-diagnosed 
MSM only (excluding undiagnosed 
HIV-positive) 
• N=11,876 
• N HIV-
diagnosed 
MSM= 981 
(8.3%) 
Not 
shown 
Previou
s 12 
months  
New 
or 
casual 
2000: 49% 
2013: 64% 
(p=0.002)
‡
 
• CLS with HIV-negative 
main partner: 15.0% 
2000: 22% 
2013: 30% 
(p=0.06)
‡
 
CLS-D: CLS with new 
or casual partners 
and not exclusively 
serosorting  
 
CLS-C: 'exclusively 
serosorted' 
Internet-
recruited 
HIV-positive 
MSM
165
 
 
 
2008 
 
USA 
Cross-sectional behavioural survey of 
adult MSM recruited through MSM-
oriented sexual networking website. 
Survey was part of an RCT evaluating 
dramatic video-based interventions. 
This analysis on self-reported HIV-
positive MSM. 
• N 
total=8472 
• N HIV-
positive= 
1010 (24.0%) 
73.7% 3 most 
recent 
partners 
in the 
past 60 
days  
Any 50.3% 31.6% 29.0% CLS-D: with HIV-
negative and/or 
unknown status 
partners  
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Study / Data 
collection period 
Recruitment, location, study type Sample 
On 
ART 
(%) 
CLS 
recall 
window 
Partner 
type 
CLS overall (%) CLS-D (%) CLS-C (%) 
Notes on 
definitions 
National HIV 
Behavioural 
Surveillance 
(NHBS) 
136
 
 
2011-
2014 
 
USA 
Serial cross sectional survey 
(collected every 3 years) of MSM 
recruited for interviews and HIV 
testing through venue-based, time-
space sampling. This analysis 
restricted to self-reported HIV-
positive MSM who had sex in past 12 
months.  
• N at every 
cycle 11,000* 
• N HIV-
positive at 
every cycle 
1340* 
90% 
(2014) 
At last 
sex  
Any  2005: 34.2% 
2014: 44.5% 
(p<0.001)◊ 
2005: 15.0% 
2014: 19.0% (p<0.001)◊ 
2005: 
19.0% 
2014: 
25.4% 
(p<0.001)◊ 
CLS-D: CLS with a 
partner of 
'discordant' or 
unknown HIV 
status. 
The Gay 
Community 
Periodic 
Surveys 
(GCPS) 
166
 
 
2013 
 
Austr
alia 
Repeated (annual/biannual) cross-
sectional questionnaire surveys of 
MSM recruited from gay social 
events, sex-on-premises venues, and 
clinics. Self-completed questionnaire. 
Data here on 2013 cycle from self-
reported HIV positive MSM. 
• N 
total=6161 
• N HIV-
positive= 573 
(9.3%) 
>70% Previou
s 6 
months 
Casual  46.6% 21.0% "strategic 
positioning" (see notes) 
55.4% CLS-D not specified, 
"strategic 
positioning" as 
proxy: HIV-positive 
men in receptive 
role and HIV-
negative or HIV-
unknown men in 
insertive role during 
CLS. 
 
CLS-C: matching HIV 
status before CLS 
("serosorting") 
ART: Antiretroviral Therapy; CLS: condomless sex; CLS-D: condomless sex with HIV-serodifferent partners; CLS-C: condomless sex with HIV-seroconcordant partners; GUM: 
GenitoUrinary Medicine (sexual health clinic); NS: not specified; ‡ p-value for difference in prevalence estimates between years shown; * Average number of participants at every 
three-year cycle (2005, 2008, 2011, 2014); ◊ p-value for test of linear trend; Not shown: study did not provide relevant information 
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 Higher HIV risk condomless sex with HIV-serodifferent partners  2.5.4
Up until publication of results from HPTN052 and PARTNER, showing extremely low risk of HIV 
transmission from HIV-positive partners on effective ART, 
7,9,26,161
 CLS-D was considered the main marker 
of HIV transmission risk sex for surveillance and epidemiological research. The vast majority of published 
literature still defines ‘higher risk sex’ as CLS-D only. Certain studies have adapted to include HIV risk 
reduction sexual behaviours adopted by some HIV-diagnosed MSM, such as insertive CLS-D.
143,167
 
However, in the current stage of the HIV epidemic these measures do not fully capture the complexity 
of sexual behaviours nor the actual estimated per-contact probability of HIV transmission.
87
 Chapter 5 
provides a literature review of studies that have defined sex with higher risk of HIV transmission, and 
examines various definitions of ‘higher risk’ CLS-D for HIV transmission in ASTRA MSM, incorporating VL, 
ART status, and other factors which could potentially affect VL suppression.  
2.6 Overview of evidence on factors associated with condomless sex 
among HIV-diagnosed MSM 
This section summarises literature incorporating individual-level factors (socio-demographic, HIV-
related, psychological health, and sexual partner characteristics) which may be associated with higher 
prevalence of various types of CLS among HIV-diagnosed MSM. Lifestyle factors, such as recreational 
drug use and alcohol consumption, and their associations to CLS are reviewed and discussed separately 
in Chapter 6.  
 Socio-demographic characteristics 2.6.1
2.6.1.1 Participant’s age 
Evidence on the association between a participant’s age and prevalence of CLS is mixed. Of the 15 
studies that assessed this, eight have found no association between participant’s age and CLS-
D.
113,115,165,167–171
 This includes the HIV-diagnosed MSM sample from the ‘Internet and HIV’ study, 
although the sample size was small.
151
 Three studies showed that younger HIV-diagnosed MSM tend to 
report higher prevalence of CLS-D compared to their older counterparts.
143,156,172
Among over 2500 ART-
naïve HIV-diagnosed MSM in the START trial, a significant negative trend with age was observed at 
baseline; older men (≥50 years) were 70% less likely to report CLS-D in the past two months compared 
to younger men (<30 years).
156
 A similar significant finding was reported among 259 HIV-diagnosed 
MSM in the London GMSHS, (Table 2.2) where the odds of reporting CLS-D in the past year were more 
than twice as high among those aged 16-24 years compared to those over 45 years.
143
  
 
The association between age and CLS-C is less well studied. For example, among 280 self-reported HIV-
positive MSM from a US online HIV prevention study (2010-11), older men (≥40 years) were more likely 
to report CLS-C in the past six months compared to younger MSM.
173
 Conversely, HIV-diagnosed MSM 
from the ‘Internet and HIV’ study who had CLS-C were significantly younger than those who did not have 
CLS-C.
151
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2.6.1.2 Ethnicity/race 
There is, to date, little evidence on ethnic/racial differences in prevalence of CLS among HIV-diagnosed 
MSM in the UK.
151
 A 2009 meta-analysis of 30 cross-sectional US studies found the prevalence of any 
CLS to be significantly lower in study samples that were majority HIV-diagnosed MSM of non-white 
ethnicities (versus majority white ethnicities).
111
 Since then, no consistent association has been found 
between ethnicity/race and CLS or CLS-D among MSM living with HIV in a number of studies from the 
USA.
157,165,169–172
 In the GMSHS, although the majority of HIV-diagnosed MSM were of white ethnic 
origin, non-white (black, Asian, mixed/other) HIV-diagnosed MSM were significantly more likely to 
report CLS-D compared to white MSM; the effect was most pronounced for black MSM (12% reported 
CLS-D in the past year compared to 4% of white MSM, p<0.001).
143
  
2.6.1.3 Other socio-demographic characteristics 
Markers of socio-economic status have not been found to exhibit a consistent association with CLS or 
CLS-D across the studies in which the association has been examined. Level of education has been 
shown to not have significant associations with CLS or CLS-D in a number of US and UK studies of HIV-
diagnosed MSM.
103,156,165,171,174
 In two other diverse studies, lower education was associated with higher 
prevalence of CLS-D with a stable partner; the US SAFE study (1997-2000) included 674 HIV-diagnosed 
MSM outpatients with a steady HIV-serodifferent partner (prevalence of CLS-D in the past year was 
21%), among whom low educational levels (up to high school or less) were significantly associated with 
higher prevalence of CLS-D.
169
 A similar association was also reported in the French ANRS PRIMO study 
(2000-2009, Table 2.1) of 670 HIV-diagnosed ART-naïve MSM with primary HIV infection (prevalence of 
CLS-D with stable partner since last visit was 10.3%).
115
 Conversely, in the London GMSHS, HIV-
diagnosed MSM who were more educated were significantly more likely to report CLS-D in the past year 
compared to those less educated (≥2 years education after age 16 versus none or up to age 16).
143
  
 
Evidence from HIV-diagnosed MSM in the USA
110,113,175,176
 and the UK
103,151
 suggests that employment 
status is also not significantly associated with CLS. The literature review in this chapter yielded only one 
study in which unemployment was strongly associated with CLS-D; the USA ATN study(Table 2.1) of 688 
young HIV-diagnosed MSM (65% were under 20 years) with detectable VL found that current 
unemployment was associated with 24% higher odds of CLS-D in the past three months.
177
 However, 
ATN participants were of majority black race, had high levels of unemployment, history of incarceration, 
and low levels of ART coverage, and so are not representative of adult HIV-diagnosed MSM on effective 
ART with lower levels of overall deprivation.  
 HIV-related factors 2.6.2
2.6.2.1 Time living with diagnosed HIV   
Various associations have been found between length of time since HIV diagnosis and CLS. Earlier results 
(prior to 2009) from cross-sectional studies suggested that the prevalence of CLS-D did not differ 
significantly by the length of time diagnosed, remaining stable at around 20-30% over 6 to 10 years since 
HIV diagnosis.
103,110,111,113,167,175
 However, adjustment for participant’s age was conducted in only three 
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of these studies,
103,113,167
 while the remaining showed non-significant associations in unadjusted 
analyses only.
110,175,178
 In START
156
, as well as in four other USA studies,
135,165,179
 a significant trend 
association was observed for HIV-diagnosed MSM, with prevalence of CLS-D in the past two months 
decreasing as the length of time since diagnosis increased. Among these studies, only START 
156
and 
Fenway Health
180
 adjusted for participants age. 
 
A recent case-control study from Seattle, USA (2016) showed that HIV-diagnosed MSM modify their 
sexual behaviour soon after HIV diagnosis and sustain these changes for many years following
181
; 186 
newly HIV-diagnosed MSM who had previously tested HIV-negative (retrospective seroconversion 
cohort) were frequency-matched to 1000 HIV-negative controls, and results showed that the prevalence 
of CLS with HIV-negative partners declined by 61% from pre- to post-HIV diagnosis (p<0.001) and did not 
significantly change for up to four years after diagnosis.
181
 At the same time, the prevalence of CLS only 
with other HIV-positive partners increased by 56% after diagnosis and remained stable for the next four 
years. These findings show that the association between time since HIV diagnosis and CLS may be 
particularly dependent on whether participants who are recently diagnosed are excluded from analyses. 
This exclusion criterion ensures that participants are not reporting sexual behaviours occurring prior to 
HIV diagnosis. More research is needed to elucidate the role of length of time since HIV diagnosis on 
prevalence of various types of CLS, adjusting for the respondent’s age.  
2.6.2.2 Antiretroviral therapy status and viral load (VL) 
As discussed in section 2.3.3, prevalence of CLS among HIV-diagnosed MSM has not been found to be 
significantly higher among those receiving ART (versus those not) or those with undetectable VL on ART 
(versus detectable VL on ART).
117
 
 
It is hypothesized that individuals on treatment may modify their sexual behaviour according 
perceptions of personal virological status (perceived VL).
182
 This measure is important, as inaccurately 
perceiving one’s VL as suppressed (when it is detectable) may impact on HIV transmission. Findings from 
the Amsterdam Cohort study (n=57 HIV-diagnosed MSM outpatients, 2000-03) showed that perceived 
suppressed VL, rather than actual HIV RNA levels, was associated with almost six-fold higher prevalence 
of CLS-D with steady partners in the past six months.
183
 These findings do not agree with those from 
Australia (n=536 HIV-positive MSM from the Positive Health and Sydney Gay Community Periodic 
Surveys, 2001-07), where men who perceived their VL as detectable were no more likely to have CLS-D 
with their stable partner than those who perceived their VL as undetectable.
184
 Prior to the ASTRA study 
there were no studies that examined associations between perceived VL and CLS among HIV-diagnosed 
people in the UK.  
2.6.2.3 Adherence to antiretroviral therapy  
Studies on the relationship of ART adherence and measures of sexual risk behaviour have focused on 
heterosexual HIV-positive men and women and have not found a significant association.
154,185–188
 Among 
HIV-positive MSM, a 2009 meta-analysis showed that reporting more than 90% adherence was not 
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associated with any CLS, although findings were based on a small subset of studies with available 
adherence information.
111
 Few studies have since examined the relationship between ART adherence 
and CLS among MSM, and none from the UK. In a diverse sample of people living with HIV in the US 
recruited via community venues, no association was found between non-adherence (measured using an 
electronic medication monitor) and CLS among 156 HIV-positive MSM.
189
 
 Psychological well being 2.6.3
2.6.3.1 Symptoms of depression and anxiety 
The directionality of the association between negative affects, such as symptoms of depression and 
anxiety, and CLS is unclear among people living with HIV. Psychological symptoms may promote sexual 
risk-taking, but CLS may also promote anxiety, depression, or other negative emotional states. A meta-
analysis of 13 studies of people living with HIV (1990-1999) found limited evidence that depression or 
anxiety are associated with sexual risk behaviours (CLS, multiple sex partners, or other composite 
measures); the average weighted correlation for the overall association among men and women living 
with HIV was 0.7 (95%CI -0.30, 0.44), but no results were available from MSM. 
190
 Later studies from the 
UK and the USA have corroborated this finding among heterosexual HIV-diagnosed men and 
women.
113,151,175,191
 
 
The association between depression, anxiety and CLS may not be linear, either. Early research 
hypothesized that negative affects, may disrupt a HIV-diagnosed person’s ability to self-regulate 
emotions and perceive risk, thus leading to ‘risky’ sexual behaviours.
190
 On the other hand, depression 
may also promote low libido and lack of interest in pleasurable activities, which may lead to lower levels 
of sexual activity.  
 
At the individual level, there is some evidence that within-person associations do exist between 
depression and CLS. A USA study of 106 racially diverse HIV-positive MSM recruited via community 
venues (2007-09) conducted bi-weekly repeated online assessments and showed that when participants 
reported more symptoms of depression, episodes of CLS were more likely to occur.
192
  
2.6.3.2 Perceived social support  
Functional social support refers to the perception that supportive resources, such as emotional care and 
companionship as well as financial help, are available from one’s social network if needed. There is very 
limited evidence that lack of perceived social support from partners, family members, and friends is 
associated with CLS among HIV-diagnosed MSM. Three small studies (<50 HIV-positive MSM) from the 
pre-ART era in the USA showed that lower social support (measured in various constructs) was 
associated with a lower prevalence of CLS.
193
 
 Partner-related factors 2.6.4
The literature review in the preceding section (2.5) has shown that CLS is interrelated to partners’ HIV-
serostatus and type of relationship (casual, main, or other type of partner).
194
 A number of studies of 
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clinic and convenience samples have shown that among HIV-diagnosed MSM the prevalence of CLS with 
other HIV-positive partners is higher than with HIV-negative or HIV-unknown status 
partners.
113,134,136,143,152,166,195,196
 However, evidence from the three UK HIV-clinic studies of HIV-
diagnosed MSM (‘London Gyms’, ‘East London’, ‘Internet and HIV’) shows that the prevalence of CLS 
with HIV-seroconcordant partners in the past three months was lower than that for HIV-serodifferent 
partners.
128,131,139,150,151,197
(Table 2.1) In addition, there is some evidence to suggest that HIV-diagnosed 
(or HIV-positive) MSM report higher prevalence of CLS with HIV-unknown than with HIV-negative 
partners,
73,134,151,164,191,197,198
 but this is not the case in all studies that have examined CLS by partner’s 
HIV-serostatus.
113,165
 There are a multitude of reasons for which mixed results have been found on 
prevalence of CLS according to partners’ HIV-serostatus. A number of studies reviewed in this chapter 
restricted eligibility for study participation to MSM who reported any CLS (or specifically with at least 
one HIV-serodifferent partner).
113,136,157,159,164,199
 This may have led to overestimation of CLS prevalence 
estimates. In addition, most community studies of MSM used a 12 month recall period for CLS, which is 
not ideal for studies of HIV-diagnosed MSM; evidence suggests that sexual behaviour may change soon 
after diagnosis and in relation to factors such as starting ART and achieving VL suppression.
93
 A shorter 
recall period (such as in the previous three months) is more appropriate for studies of HIV-diagnosed 
MSM and is particularly relevant when asking about CLS according to partners’ HIV-serostatus. 
 
Furthermore, evidence remains mixed on the association between type of relationship with a partner 
(casual or main/stable) and prevalence of CLS among HIV-diagnosed MSM. An earlier systematic review 
of 61 studies from high-income countries (1980-2001) found that CLS overall was no more likely to occur 
with stable than with casual partners.
193
 However, this is not consistent with findings from HIV-
diagnosed MSM in the ‘London Gyms’ study, in which any CLS with casual partners was more prevalent 
than with stable partners.(Figure 2.2) Among HIV-diagnosed MSM who have HIV-serodifferent sexual 
partners, results are not uniform across type of partner, either. Prevalence of CLS with casual partners 
has been shown to be lower than,
195,198,200
 higher than,
98,103,131,150,196,201,202
 and equal to
176,203
 the 
prevalence of CLS with stable partners. The associations of partner type and partner HIV-serostatus with 
various types of CLS among HIV-diagnosed MSM thus remain unclear. 
2.7 Conclusion 
Studies of HIV-diagnosed MSM recruited from clinical settings in high-income countries since the 
introduction of effective ART in 1995 have reported broad ranges of estimates for CLS in the past three 
months overall (43-51%), CLS with HIV-serodifferent partners (15-27%), and CLS with HIV-
seroconcordant partners (14-24%).
103,113,114,131,150–152,156,157,159
 There is some indication of an increase in 
the prevalence of CLS over calendar time. Varying underlying trends are observed, with a suggestion of 
reduction in the prevalence of CLS with HIV-serodifferent partners concurrent with an increase in the 
prevalence of condomless sex with other HIV-positive partners.
94,99,115,126,140
 Research also suggests that 
differences exist in sexual positioning according to a partner’s HIV serostatus (insertive or receptive) 
among HIV-diagnosed MSM.
134,156,170,200,204
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A number of co-factors have been identified in the literature as related to CLS, but results vary according 
to study type, recruitment location, definition of co-factors, measurement of different types of ‘risky 
sex’, varying recall periods, adjustment for confounders, and sample sizes. There is now more consistent 
evidence that the use of ART is not associated with a higher prevalence of any CLS. As effective ART has 
led to a dramatic increase in life expectancy, the joint effects of ageing and living with HIV for longer on 
the prevalence of CLS are yet to be fully understood. Evidence on modification of sexual behaviours 
according to personal perceptions of virological status is scarce. There is also limited support for a 
positive association between symptoms of depression and anxiety and higher prevalence of CLS, 
although this has not been studied over calendar time. Condomless sex is linked to a partner’s HIV 
serostatus (HIV-negative, positive, or unknown) and the type of relationship (casual or stable). 
 
Hence, understanding the factors that contribute to different types of condomless sex among HIV-
diagnosed MSM remains important for HIV and STI prevention.  
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3 Data and Methodology 
3.1 Introduction 
Analyses presented in chapters  4, 5, 6, 7, and 8 of this thesis have been undertaken using data from the 
‘Antiretrovirals, Sexual Transmission Risk and Attitudes’ (ASTRA) study,  an observational, cross-sectional 
self-administered questionnaire study of HIV outpatients attending one of eight UK NHS clinics from 
February 2011 to December 2012. The study also included an additional longitudinal component based 
on routine linked clinic data, with follow-up until July 2014. The current chapter describes the ASTRA 
study design, data collection and management, summarises the key questionnaire factors, and discusses 
the representativeness of the ASTRA sample in relation to the HIV-diagnosed population in the UK. An 
overview of the main statistical methods used for analyses in this thesis is also presented.  
 
The ASTRA study was planned prior to this thesis being undertaken, and the recruitment period of 
ASTRA was ending at the start of my period of study for the PhD. I had no involvement in the study 
design and recruitment (presented in sections 3.3, 3.5) but did have responsibility for data management 
and cleaning procedures (section 3.8.1) and undertook all analyses presented in this thesis. The 
methodology of the ASTRA study has been published previously.
89
 
3.2 ASTRA questionnaire study 
The ASTRA study was designed to investigate sexual risk behaviours among HIV-diagnosed men and 
women in the UK. The primary aims of ASTRA were to: (i.) investigate the association of antiretroviral 
therapy (ART) use and self-reported viral suppression, with condomless sex with HIV-serodifferent 
status partners (CLS-D), (ii) assess beliefs about virological suppression and HIV transmission risk, and 
(iii) assess attitudes to early ART initiation among ART-naïve individuals. The secondary aims of ASTRA 
included investigating sexual behaviour and attitudes among key demographic subgroups and examining 
the association of a range of factors (socio-demographic, HIV, ART, and health-related, lifestyle) with 
specific sexual behaviour measures.
205
 This thesis makes a contribution to these secondary aims (also 
covering the first primary aim stated above), and considers men who have sex with men (MSM) only. 
3.3 Study design and population   
Clinical centres were chosen to participate in ASTRA on the basis of previously successful research 
collaborations and on the expectation that they could provide a sufficient sample size of HIV-diagnosed 
patients, including key demographic subgroups (MSM and black African individuals). Eight NHS clinics 
participated in the study, five of which were located in London (Royal Free Hospital, Mortimer Market 
Clinic, Homerton University Hospital, Newham University Hospital, and Whipps Cross University 
Hospital) and three were located outside London (Brighton and Sussex University Hospital, Eastbourne 
Sexual Health Clinic, North Manchester General Hospital). Eligibility criteria for study participation were: 
lab-confirmed HIV-positive diagnosis, aged ≥18 years, attending for care. Participants were excluded if 
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they were unable to complete the questionnaire due to language or cognitive difficulties or if they were 
too ill or distressed. 
3.4 Sample size estimation 
Sample size estimation used the endpoint of CLS-D in the previous three months, based on the main 
objective of detecting a difference in the prevalence of CLS-D between participants on ART and those 
not on ART. Based on previous UK studies on HIV-outpatients, the overall prevalence of CLS-D in the 
previous three months was estimated to be 15%.
103,139,154
 The calculation was based on 80% power, 5% 
two-sided significance level for this comparison, and assumed that 75% of participants would be on ART 
(based on national UK data on ART use in 2010
206
) and 15% would report CLS-D in the previous three 
months.
103–105,133
 Thus it was estimated that a total of 3349 participants were required to detect a 
difference of 4% in the prevalence of CLS-D in the previous three months between those on ART and 
those not on ART (so that 16% of participants on ART would report CLS-D compared to 12% of those not 
on ART.) In line with previous UK HIV-clinic studies,
133
 a 75% response rate was assumed and it was 
estimated that 3,825 individuals would participate in ASTRA, a sample size large enough to provide 
adequate power to answer the main objectives. 
3.5 Recruitment procedures 
Within each participating HIV outpatient clinic, during specific periods of recruitment to the study, 
patients attending the clinic were invited to participate by study nurses or HIV consultants while waiting 
for (or after) their outpatient appointments.  Clinics were encouraged to select specific clinical sessions 
each week for study recruitment and to attempt to approach consecutive patients attending within 
these sessions. It was emphasised that sessions selected for recruitment should be those for which a 
diverse range of clinic patients would be expected to attend (for example recruitment should not 
restricted to specialist clinical sessions, or always occur on the same day of the week). A private area 
within each clinic was made available for completion of questionnaires, if desired.  
 Information sheet 3.5.1
A study information sheet was provided, which described the aims of the study, the requirement to fill 
out a questionnaire that included personal questions on health and sexual lifestyle (among others), and 
the option to withdraw consent to the study at any time. (Appendix I) The information sheet also stated 
that if agreeing to participate in the study, the participant’s latest viral load (VL) and CD4 count would be 
recorded as part of the study data. A detailed explanation on anonymity was also on the information 
sheet. This explained that clinic staff would not open or read the completed questionnaires, or record 
any answers in the patient’s clinic notes, and that anonymised responses would be presented in 
aggregate form in medical journals and conferences, with no individual participant identified in any way. 
The information sheet also explained that the participant would also be asked if they would provide 
additional consent to have their routine HIV clinical data (from the specific recruiting HIV clinic only) 
linked to their respective questionnaire answers. It was explained that this linkage would be performed 
on a number of occasions over the next few years; the required clinical information was detailed 
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(laboratory test results, HIV treatment, other routine HIV care information). The linkage was described 
as standard procedure for research studies, and it was explained that linkage would be performed in 
such a way that questionnaire responses would remain confidential and would never be linked to the 
participant’s name or clinic number. Participants were further told that consent to this clinical linkage 
was optional and did not prevent them from study participation. The ASTRA study website and details of 
the study coordination department and funding were also made available on the same sheet. 
 Consent form  3.5.2
A separate consent form was provided to all those who, after reading the information sheet, agreed to 
participate in the study. (Appendix I) This included statements with accompanying fields for the 
participants’ initials (to indicate agreement): confirming they have read and understood the information 
sheet, agree to take part in the study, and understand that participation is voluntary and can be 
withdrawn at any time without explanation. An additional statement asked whether participants 
consented or not with linkage of their questionnaire responses to their routine clinical data. The 
participant printed their name, dated, and signed the consent form, as did the person taking consent 
(study nurse or consultant). Once complete, two additional copies were made (one for the participant 
and one for the researcher site file) and the original consent form was kept in the patient notes.  
 Study log 3.5.3
The study log was a record (Excel spreadsheet) of each person approached for the study and asked to 
participate, regardless of whether they agreed to participate or not. The information collected is shown 
in Table 3.1. The study log supplied a unique anonymised study identifier (ID) for each successive 
individual approached and was the only document linking the patient’s clinic number with their 
questionnaire study ID. The clinic number for each person approached was thus only recorded in the 
study log and never transferred to the research team at UCL. The study log was confidential to the study 
sites and securely stored on an encrypted hard drive. At each site, study nurses completed the required 
fields on the study log for each participant. All study log information except for the participant’s clinic 
number was exported and emailed to the study data manager weekly, via secure NHSmail service. 
Clinics used a pre-designed programme that automatically removed clinic numbers from the log prior to 
export. The study log contained the latest VL and CD4 count for each participant; it was specified that 
these were the latest values that had been communicated to the participant. 
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Table 3.1: Study log fields 
Field Purpose / Description Characteristics 
Study ID Anonymised identifier Pre-assigned and non-editable. 
Consists of a letter identifying the 
study site and a 4 digit sequence 
number  
Clinic ID Clinic Number Specific to each study site. Not to 
be transferred outside the clinic 
Date patient attended   
CONSENT 1: Agreed to 
participate? 
Consent to take part in the 
questionnaire study and supply 
latest CD4 counts and VL values 
Yes/No 
If Yes, signed Consent Form must 
exist with 1
st
 of 3 options initialled 
The following fields were only completed if a signed Consent Form existed 
CONSENT 2: Agreed to 
use of past/future clinic 
data? 
See information sheet and section 
3.6 for details of clinic data to be 
collected based on this consent 
Yes/No 
If Yes, signed Consent Form must 
exist with 4
th
 “clinical linkage” Yes 
box initialled 
Gender  Male/Female 
Type of questionnaire What questionnaire versions were 
completed 
Laptop, Paper or Both 
Paper questionnaire 
taken off-site? 
 Yes/No 
Optional contact details e.g. email address  
Only if questionnaire taken off-site 
Used only to follow up on missing 
paper questionnaires 
Comments Any notes for the attention of the 
study researchers 
 
Latest viral load Latest value known to patient To be supplied for ALL patients 
who signed a Consent Form (does 
not matter if the 4
th
 “clinical 
linkage” option is Yes or No). 
These should be the last results 
given to the patient (even if there 
is a more recent result the patient 
is not yet aware of). 
Date for latest viral load  
Latest CD4 count Latest value known to patient 
Date for latest CD4 count  
 Questionnaire administration 3.5.4
The ASTRA questionnaire was self-administered, as a printed A5 booklet available in versions for males 
(blue) and females (pink). (Appendix I.) French translations of both questionnaire versions were also 
available. Study nurses completed the pre-assigned study ID (from the study log) and the date on the 
front of the questionnaire. Therefore, questionnaires only contained the study number and no other 
identifying information, such as name or person’s clinic number. In order to ensure high response rates, 
participants were encouraged to complete the confidential questionnaire on the same day, in the clinic, 
placing it in a pre-supplied sealed envelope within a study-assigned box in the clinic. If this was not 
possible or desired, participants could complete the questionnaire at a later time, when most 
convenient, and post it to the research team in the pre-paid envelope. Study nurses ensured that sealed, 
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completed questionnaires were placed in the study-assigned box in the clinic; at the end of the day they 
collected all paper questionnaires from the box and stored them securely. Every month, study nurses 
ensured that completed questionnaires were collected and transferred to the core research team at 
UCL. 
3.6 ASTRA linked clinical data  
For consenting participants, linkage of ASTRA questionnaire responses with routine clinical data was 
completed within each study centre using the study log as a record of participants who completed the 
questionnaire. The clinical data was stored as encrypted, password protected excel spreadsheets and 
transferred by File Transfer Protocol (FTP) method to the study data manager at UCL, only including the 
study number, and no other identifying information; FTP is a standard network protocol for transferring 
files between clinics and main servers, which requires user authentication via username and password. 
Routine clinic data fields included, among others: date of first known positive HIV antibody test, date of 
first HIV attendance at the centre; results of laboratory test results: all HIV VL test results (in copies/mL) 
with dates; type of HIV RNA VL assay used for each test; all ART regimens prescribed with dates started 
and stopped; hepatitis laboratory test results with dates (including hepatitis C antibody and virus 
PCR/bDNA). The linked clinical data gives information on HIV history prior to the questionnaire and also 
allows for prospective analyses of specific virological or clinical outcomes, using the questionnaire as a 
baseline. Linked data were collated at the end of the data collection period (2012), and on several 
subsequent occasions up to 2016, from five of the eight NHS centres (Royal Free, Mortimer Market, 
Homerton, Brighton, Eastbourne, and Newham). All but one of these centres (Eastbourne) had existing 
established clinic databases (UKCHIC)
207
 with which the ASTRA questionnaire was linked.  
3.7 Ethical considerations 
 Ethical approval  3.7.1
Prior to study initiation, the study protocol, information sheet, consent form, and study questionnaires 
(men and women’s versions) were submitted for ethical review. All amendments to the study protocol 
were also submitted and the study was approved by the North West London REC 2 research ethics 
committee (ref 10/H0720/70), receiving permission for clinical research at all participating NHS sites. 
 Confidentiality 3.7.2
The information sheet stated that the questionnaire included personal questions on sexual lifestyle, 
stating that if the questionnaire raised any issues or concerns to the participant, they could ask the 
nurse to arrange for them to discuss this with an appropriate healthcare professional (e.g. HIV clinic 
counsellor). Confidentiality was ensured at all stages: private areas were made available for 
questionnaire completion in clinic, the questionnaires contained no identifying information, sealed 
envelopes were provided, and participants were informed that their responses would not be seen by 
clinic staff or recorded in clinical notes. Linkage of clinical data, for those providing consent to linkage, 
was done within the clinical centre, ensuring that each participant’s clinic number was removed before 
data were transferred to the UCL research department.  
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 Data security  3.7.3
Data from paper questionnaires was double-entered into an electronic data entry package by a data 
company. Paper forms (including questionnaires and copies of the study log) were securely stored in 
locked cabinets at the UCL research department. The complete ASTRA questionnaires were scanned and 
along with the complete data set and clinical data, they were stored on a secure electronic encrypted PC 
or laptop drive (Truecrypt), protected by password and only accessible to the data manager, the primary 
investigator, and me. No patient names or clinic numbers were recorded in any of the study data sets 
held in the research department (including the clinical datasets transferred from each clinic to the 
research department). All information was treated as strictly confidential and no individual patient could 
be identified in any results presented or published. 
3.8 The ASTRA questionnaire  
 Questionnaire data management and derivation of variables  3.8.1
The male questionnaire is shown in its entirety in Appendix I.  It had approximately 60 questions and 
took between 15 and 30 minutes to complete. My involvement in the study started after ASTRA was 
designed and data was collated, in the form of extensive data management. I imported all raw 
questionnaire data from Excel into Stata software, cleaned, and prepared it for analysis. I coded 
responses to questions with optional free text responses (such as number of new sexual partners in the 
past year) into numerical categories; and also used free text responses to create variables that could be 
comparable to standardised measures (e.g. see education variable below). I performed range checks for 
each variable and assessed the extent of missing data. I also compared questionnaire variables with 
each other, where relevant, to ensure consistency between related questions and within subsections of 
questions, (an example of an inconsistent response would be reporting no anal sex in the previous three 
months but completing the section on CLS during the same period). I assessed the appropriate order of 
dates (e.g. date of HIV diagnosis must precede date of ART initiation). For each participant, I examined 
the scanned copy of the completed questionnaire (stored on encrypted hard drives) to resolve data 
queries and discrepancies. These were used to check for errors in the data entry process, and to check 
whether the participant had made additional indication or text comment that might clarify any missing 
or inconsistent response. In addition, where applicable, I completed missing information on the 
questionnaire using information from linked clinical records (e.g. age, time since HIV diagnosis, ART 
status). I also resolved any discrepancies between questionnaire and linked clinical data on a case-by-
case basis.  
 Key socio-demographic, mental health, lifestyle variables defined  3.8.2
Throughout this thesis, a set of key socio-demographic, psychological, HIV-related, and lifestyle factors 
are used. I derived these from the questionnaire raw data as shown below. A discussion of the handling 
of missing data for each variable is also given as a proportion of the final dataset comprised of 2248 
MSM (the ASTRA sample is described in section 3.10). 
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 Men who have sex with men (MSM): male participant who had either identified himself as ‘gay’ or 
‘bisexual’, or had sex with another man in the previous three months.  A total of 35 men had 
missing sexual orientation status and were assigned a category according to other available 
relevant information, such as transmission route indicated as sex with an HIV-positive man from 
the questionnaire or from available routine linked clinical data. There were no missing values for 
this variable. 
 Age in years at the time of recruitment was derived from self-reported date of birth. Month of 
birth was missing for 972 MSM on the questionnaire and imputed to June; year of birth was 
missing for 78 MSM and was completed from dates of birth provided in the routine linked clinical 
data. An additional 7 inconsistencies between questionnaire and clinic date of birth were resolved. 
A total of 23 MSM (1.0% of all MSM in the final data set) remained with missing data for date of 
birth (and thus age), as these could not be reconciled (7 reported their clinic attendance date 
instead of their date of birth and the remaining 16 did not provide date of birth on the 
questionnaire and also did not consent to linkage with routine clinical data).  
 Ethnicity was based on the UK Census ethnic groups as per below (“Which ethnic group best 
describes you?”).  
A. White : white British, white Irish, or white other  
B. Black or black British: black African, black Caribbean, or black other 
C. Asian or Asian British: Indian, Pakistani, Bangladeshi, or other 
D. Mixed: white and black African, white and black Caribbean, white and Asian, mixed other 
E. Chinese or other ethnic group: Chinese, or any other ethnic group  
For those who indicated more than one ethnic category (n=15), ethnicity classification was made 
on individual basis and considering country of birth. Missing values for ethnicity (n=44) were re-
coded either according to self-reported country of birth (for participants with non-UK country of 
birth) or according to clinic-recorded ethnicity (for those who consented to linkage with routine 
clinical data). A dichotomous variable was derived: ‘white’ (category A) and ‘all other’ 
(incorporating all in categories B through E). No missing values remained for this variable.   
 Employment: of 10 possible response options to the question “What is your current work 
situation?”, a three-category variable was derived: 
1. Employed (incorporating ‘employed’ or ‘self-employed’ full or part-time) 
2. Unemployed (incorporating ‘unemployed and registered with benefits’ or ‘unemployed, not 
registered for benefits’) 
3. Other (incorporating ‘full time student/education/training’, ‘permanently sick/disabled (for 3 
months or more)’, ‘temporarily sick/disabled (for less than 3 months)’, ‘looking after 
home/family/dependants full-time’, ‘retired’, and ‘other’ free text option). 
A total of 37 MSM (1.7%) did not provide information on employment and were classified as 
missing. 
 Education was ascertained by the question “At what level did you complete your education?” with 
five options. These were reclassified into a binary variable: 
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1. No qualifications, or up to A levels, or equivalent of 12 years of education (including ‘finished 
education with no qualifications’, ‘O levels/GCSEs or equivalent qualifications at age 16’, ‘A 
levels or equivalent qualifications at age 18’) 
2. University degree or higher 
In addition, I coded participants’ free text responses (‘other, please specify’) according to 
attainment level and country where this was achieved. For example, the lowest level of ‘National 
Vocational Qualifications’ was equivalent to three GCSE exams and thus classified the participant 
as category 1 (no qualifications/or up to 12 years of education). A total of 39 MSM did not provide 
an answer to educational status and a further 4 ticked multiple (discordant) categories; this 
resulted in 43 (1.9%) missing values for this variable. 
 Financial hardship was ascertained by the question “Do you have money to cover your basic needs 
(e.g. food, heating)?” with categorical answers, 1:‘all the time’, 2:‘most of the time’, 3:‘some of the 
time’, and 4:‘no’. Where two or more consecutive answers were ticked, the lowest category (lower 
hardship) was selected; where two or more non-consecutive categories were selected, the middle 
category was used. There remained 33 participants with missing values (1.5% of all MSM), of 
whom 28 left the question blank and five ticked three or more categories.  
 Depression symptoms were defined using the standardised Patient Health Questionnaire-9 (PHQ-
9) questionnaire, which has high diagnostic validity.
208
 This instrument is used for screening and 
diagnosing the severity of depression. Responders rate the frequency of specific symptoms over 
the past two weeks (“How often have you been bothered by any of the following problems?”), 
which included nine statements such as ‘feeling down, depressed or hopeless’ and ‘thoughts that 
you would be better off dead, or of hurting yourself in some way’. Each of the nine symptoms was 
rated in frequency: 0 (‘not at all’), 1 (‘several days’), 2(‘more than half the days’), or 3 (‘nearly every 
day’); the total was summed, producing a scale ranging from 0 to 27. Missing values for individual 
symptoms on PHQ-9 were coded as absence of symptoms (assigned score 0), as the most common 
response pattern was to tick only those symptoms that the participant experienced. As a result, 
there were no missing values for this variable. I derived a binary variable from this scale according 
to standard definitions
208
: 
1. No depression symptoms (a score of <10 on the PHQ-9, which indicates no, minimal, or mild 
depression, or a missing value.) 
2. Presence of depression symptoms (a score of ≥10 on the PHQ-9, indicating moderate, 
moderately severe, or severe depression.) 
A cut-off of ≥10 was used as this is the standard score-based definition and has been shown to 
have sensitivity of 76% and specificity of 88% for major depression among HIV-diagnosed 
individuals.
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 Anxiety symptoms were defined using the standardised Generalized Anxiety Disorder 7 item scale 
(GAD-7), a valid tool for screening and diagnosing the severity of anxiety.
210
 GAD-7 uses the same 
normative scoring system as the PHQ-9. Responses for symptoms in the past two weeks (including 
‘feeling nervous, anxious, or on edge’ and ‘trouble relaxing’) were coded in the same way as 
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depression, from 0 to 3, and summed to produce a scale ranging from 0 to 21. Missing values for 
individual symptoms were treated as absence of that symptom (score 0). I derived a binary variable 
from this scale:  
1. No anxiety symptoms (a score of <10 on the GAD-7, which indicates no or mild anxiety, or a 
missing value.) 
2. Presence of anxiety symptoms (a score of ≥10 on the GAD-7, indicating moderate or severe 
anxiety symptoms) 
The cut-off of ≥10 was used as it is the standard definition and has been shown to have sensitivity 
of 89% and specificity of 82% for diagnosing generalised anxiety disorder.
210
  
 Low social support was measured using a validated five-item version of the Duke-UNC Functional 
Social Support Questionnaire (FSSQ), designed to measure perceived social support.
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Participants were asked to rate each of the following statements on a five-point Likert scale 
ranging from 1 (‘much less than I would like’) to 5 (‘as much as I would like’): ‘I have people who 
care what happens to me’; ‘I get love and affection’; ‘I get chances to talk to someone I trust about 
my personal problems’; ‘I get invitations to go out and do things with other people’; and ‘I get help 
when I am sick in bed’. The sum of scores from each question was used to create three categories 
of social support: 21-25 high, 13-20 medium, and 0-12 low. The mean individual score across all 
social support items ranged from 1 to 5 (rounded) and was used to reconcile discrepancies in 
scoring; where multiple consecutive responses were scored per question, the mean value was used 
(or the more extreme value if they were consecutive). A total of 20 MSM (0.9%) left all five FSSQ 
questions blank and the three-category variable of social support was coded as missing. 
 Higher alcohol consumption was measured using an abbreviated version of the Alcohol Use 
Disorders Identification Test-Consumption (AUDIT-C), which was developed by the WHO as a 
screening method for excessive alcohol drinking, and for identifying people with drinking patterns 
described as hazardous (increasing the risk of harmful consequences to the user or others) and 
harmful (that result in consequences to physical and mental health).
213
 Two of the original three 
AUDIT-C questions were used, which have been shown to have high internal consistency and 
validity.
214
  
1. “How often do you have a drink that contains alcohol?”, scored from 0 to 4 (0:‘never’, 
1:’monthly or less’, 2:’two to four times a month’, 3: ‘two to three times a week’, and 4:‘ 4 or 
more times a week’)  
2. “How many units of alcohol do you drink a typical day when you are drinking? (one unit being 
half a pint of beer/cider or a small glass of wine or a single measure of spirits)”, with five 
options scored from 0 to 4 (0: ‘1 or 2 units’, 1: ’3 or 4’, 2: ‘5 or 6’, 3: ‘7 to 9’, and 4:’10 or 
more’) 
There were 4 MSM (0.2%) who left both above questions blank; these missing values were recoded 
to the lowest categories (‘never’ and ‘1 or 2 units’ respectively). To generate a binary variable 
classifying participants as having evidence of harmful or hazardous consumption, the frequency 
and units of alcohol consumed were summed on the two questions above and a score of ≥6 out of 
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8 was considered “higher alcohol consumption”; this cut-off has been shown to have sensitivity of 
73% and specificity of 91% on the three-item AUDIT-C.
215
  
 Alcohol dependency was assessed using the CAGE questionnaire
216
, a screening instrument for 
alcoholism, comprised of four questions: “Have you ever…” 
1. Felt the need to cut down your drinking? 
2. Felt annoyed by criticism of your drinking? 
3. Had guilty feelings about drinking? 
4. Taken a morning eye opener? 
Each question was scored as 0 (no) or 1 (yes), and the sum of four questions ranged from 0 to 4. 
The recommended cut-off for CAGE is a total score of ≥2 as evidence of alcohol dependency.
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This cut-off has been shown to have high sensitivity and specificity (both >75%) across a range of 
populations.  
 Recreational drug use in the previous three months is discussed in detail in Chapter 6.  
 Stable partner status was ascertained by the question “Are you currently in an ongoing 
relationship with a partner (wife/husband or civil partner or girlfriend/boyfriend)?” Stable 
partner’s HIV serostatus was ascertained by the question “Does your partner have HIV?” with 
possible answers: ‘Yes’, ‘No’, or ‘Don’t know’. A categorical variable was derived:  
1. No stable partner  
2. HIV-positive stable partner 
3. HIV-negative or HIV-unknown status stable partner (includes those who answered 
‘don’t know’ and those who did not specify their stable partner’s HIV-serostatus)  
As the latter category (3) includes those who did not specify their partner’s serostatus, there were 
no missing answers for this variable. Participants were also asked whether they were co-habiting 
with their stable partner. The length of time in the specific long term relationship was estimated 
from months and/or years reported. 
 Key HIV-related variables defined 3.8.3
The main variables I derived relating to HIV diagnosis, treatment, and attitudes to HIV seropositivity are 
outlined in this section.  
 Time since HIV diagnosis was calculated from self-reported month and year that the participant 
first found out they were HIV positive. When only year of diagnosis was reported (in 559 cases, 
24.9% of all MSM), the month was imputed as June. Where dates of first diagnosis were unlikely 
(e.g. prior to licensing of the first ELISA test in 1985), inconsistent in comparison to the ART start 
date, or were missing, these were checked against the date of first known positive HIV antibody 
test from the linked routine clinical data, if available. Following this process, 12 MSM (0.5%) 
remained with missing values for time since HIV diagnosis. Years between HIV diagnosis and date 
of ASTRA questionnaire completion were calculated, and further grouped into categorical variables 
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according to analysis needs. This variable was used to flag and exclude MSM who were diagnosed 
with HIV for ≤3 months prior to ASTRA questionnaire completion (see section 3.9.1). 
 Disclosure of HIV serostatus is discussed in detail in Chapter 7.  
 ART status was ascertained by a positive answer to the question “Are you currently taking HIV 
treatment?” Missing answers on this question were reconciled with routine linked clinical data, 
where available; if there was a record of ART regimen prescribed at or near the date of the 
participant’s questionnaire completion then this was taken to indicate that the participant was on 
ART. There remained 11 MSM (0.5% of all) with missing values for ART status.  
 Self-reported CD4 count was ascertained by the question “At your last test what was your CD4 
count?” with five categories in cells/mm
3
: <200, 200-350, 351-500, >500, and ‘don’t know/can’t 
remember’. Where a participant indicated last CD4 count in two consecutive categories, the lowest 
one was selected; for those who indicated two non-consecutive categories (e.g. <200 and >500) or 
who included ‘don’t know’ in their response, these were re-coded into the ‘don’t known/can’t 
remember’ category. The question was left blank by 46 MSM (2.0%). 
 Self-reported viral load (VL) was ascertained by the question “What was your viral load the last 
time you got your test results?” with three options: ’50 copies/mL or less (‘undetectable’ or 
‘suppressed’)’; ‘more than 50 copies/mL (‘detectable’ or ‘raised’)’; and ‘don’t know’. A total of 343 
MSM (15.3%) did not answer this question and so these were considered missing values. Using the 
ART status variable above, a new variable was derived also incorporating self-reported VL, with the 
following categories; 
1. On ART, reports undetectable VL  
2. On ART, does not report undetectable VL (includes responses to self-reported VL ‘more than 
50copies/mL’ and ‘don’t know’) 
3. Not on ART 
 Non-adherence to ART (among participants on ART only) was measured using the following 
questions:  
1. Frequency of ART regimen (once a day, twice a day, or other) 
2. Number of ART doses missed in the last two weeks (none, 1, 2, 3, 4 to 6, 7 to 9, or 10 or 
more). Thus once a day ART equalled 14 doses in two weeks and twice a day ART equalled 28 
doses in two weeks and so on.  
3. Whether reported missing ART for two or more consecutive days in the previous three 
months (yes, no, or ‘don’t know/can’t remember’). The number of occasions this (3) occurred 
(once, two or three times, or more than three times) in the past three months was also 
specified.  
Using questions 1 and 3 above, the following dichotomous variable was derived (among MSM on 
ART only):  
(i.) Adherent to ART (either not missed any consecutive days of ART in the past three months, or 
missed ≥2 consecutive days of ART only once in the previous three months) 
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(ii.) Non-adherent to ART (missed ≥2 consecutive days of ART on ≥2 occasions in the past three 
months) 
 Transmission risk beliefs were series of statements on HIV transmission risk and infectiousness 
in relation to undetectable VL, to which participants indicate agreement on a 5-level Likert 
scale (‘strongly agree’, ‘tend to agree’, ’undecided/no opinion’, ’tend to disagree’, and 
’strongly disagree’). A transmission risk belief score was derived from the following 
statements: (A) “An undetectable HIV viral load makes someone less infectious to a sexual 
partner than if they had a high viral load” and (B) “When viral load is undetectable, a condom 
is not needed to prevent HIV transmission.” The score thus classified people according to how 
‘conservative’ (or risk-averse) their views on HIV transmission were: 
1. Least conservative (’strongly’ or ’tend to’ agree to statement A and ‘strongly’ or ‘tend 
to’ agree to statement B) 
2. Moderately conservative (‘strongly’ or ‘tend to’ agree to statement A and ’strongly’ or 
’tend to’ disagree or ‘undecided’ on statement B; or ‘strongly’ or ‘tend to’ disagree, or 
‘undecided’ to statement A and ‘strongly’ or ‘tend to’ agree to statement B) 
3. Most conservative (‘strongly’ or ‘tend to’ disagree or ‘undecided’ on statement A and 
`strongly’ or ‘tend to’ disagree or ‘undecided’ on statement B) 
Where participants indicated two consecutive levels of agreement for a single statement, the more 
extreme level was selected, (indicating least conservative transmission risk beliefs); if two non-
consecutive agreement levels were selected (e.g. ‘strongly agree’ and ‘undecided’), the average 
score was used. If participants selected inconsistent levels of agreement on the two statements 
(e.g. disagree to statement A and agree to statement B), they were classified as 2:’moderately 
conservative’. In the case of missing values in one of the two statements, the missing response was 
coded as ‘undecided/no opinion’. A total of 44 (2.0%) of missing values could not be reconciled as 
the section was left blank.  
 Sexual behaviour questionnaire section   3.8.4
This section outlines the main derived sexual behaviour variables, throughout this thesis (detailed in 
Chapter 4). The questionnaire sexual behaviour section was prefaced with a statement reiterating that 
any information about recent sex life is completely confidential, that the participant’s name or clinic is 
not written on the questionnaire, and that answers would never be seen by the clinic staff. (Appendix I) 
Two sub-sections were made available on the male questionnaire, one on sex with women and one on 
sex with other men. Specifically, vaginal sex was explained to be “a man’s penis in a woman’s vagina” 
and anal sex as “a man’s penis in a partner’s anus (rectum or back passage)”. The questionnaire did not 
inquire about oral sex. Almost all questions in this section related to sex in the past three months. The 
main derived variables were: 
 Sex in the past three months, ascertained as a positive answer to either of the following two 
questions: “In the past three months, have you had sex (vaginal or anal sex) with a woman?” 
and “In the past three months, have you had anal sex with a man?”   
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 Condomless sex (CLS) refers to sex with a man and/or a woman without a condom. This was 
defined by a positive answer to either of the following questions:  “In the past three months, 
have you had sex (vaginal or anal) with a woman without a condom?” or “In the past three 
months, have you had anal sex with a man without a condom?” 
 Condomless sex with HIV-serodifferent partners (CLS-D) was ascertained by a positive answer 
to either of: “In the past three months, have you had sex (vaginal or anal sex) without a 
condom with a woman who did not have HIV or whose HIV-status you did not know?” or “In 
the past three months, have you had anal sex without a condom with a man who did not have 
HIV or whose HIV-status you didn’t know?”  
 Condomless sex with HIV-seroconcordant partners (CLS-C) was defined as a positive answer to 
either of: “In the past three months, have you had sex (vaginal or anal sex) without a condom 
with a woman who you knew also had HIV?” or “In the past three months, have you had anal 
sex without a condom with a man who you knew also had HIV?” 
The variables on CLS with HIV-serodifferent (CLS-D) and with HIV-seroconcordant (CLS-C) partners are 
not mutually exclusive, meaning that those who had CLS-C may have also reported CLS-D in the same 
time period. Section 4.3.2 details derivation of variables examining exclusive CLS-C.  
 
For all CLS variables, all participants were assigned to a category (variables were derived with no missing 
values); absence of information on a specific CLS measure was taken to indicate negative response, with 
the exception of response patterns detailed below.  Consistency was ensured between responses for 
CLS, CLS-C, and CLS-D. If participants left the question on sex in the past three months blank (or selected 
‘no’), but had a positive answer in one or more  of the questions on CLS, CLS-D, or CLS-C, I then re-
classified them as having had sex in the past three months. Similarly, if no or a negative answer was 
given to the question on CLS, but positive answers were selected for one or more of the questions on 
CLS-D or CLS-C, then I re-classified participants as having had CLS in the past three months. Additional 
sexual behaviour variables were considered on an individual basis if it was unclear whether the 
participant reported having CLS-D or CLS-C. For example, in certain cases a positive answer was given for 
CLS in the past three months, but both questions on CLS-D and CLS-C were either left blank or were 
negative, and the participant indicated either CLS-C or CLS-D “with only one sexual partner, my long 
term partner”. In this case, I used the stable partner’s reported HIV-serostatus to assign whether CLS-C 
or CLS-D had occurred, on a case by case basis. For a minority of individuals who indicated having CLS 
but did not indicate either CLS-C or CLS-D, it was not possible to impute their partners’ HIV-serostatus, 
as either they did not have a stable partner, or they indicated sex with more than one partner. These 
individuals were classified as ‘CLS-unspecified’ (discussed in detail in section 4.4.7). Participants with 
missing information and those with insufficient information to classify as CLS were categorised as not 
having CLS. 
 Total number of sexual partners in the past three months was derived from combining the 
number of women and men the participant reported having had sex with; whether any of 
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these was the participant’s stable partner was also ascertained (only among those who 
reported being in a stable relationship). Participants were also asked how many HIV-
serodifferent men and/or women they had sex with without a condom (number of CLS-D 
partners) as well as how many HIV-positive men and/or women they had sex with without a 
condom (number of CLS-C partners) in the previous three months; and whether any of these 
CLS-D or CLS-C partners was the participant’s stable partner. If the total number of male or 
female sex partners in the past three months was lower than the sum of the number of CLS-D 
and CLS-C partners reported, then the total number of partners was replaced with the sum of 
CLS-D and CLS-C partners. A small number of participants indicated having more than one 
sexual partner in the past three months, but did not specify an exact number; where free text 
options were used to indicate a high number of partners, the number of partners was 
reconciled on an individual basis to either be closest to the number reported (e.g. “Hundreds” 
would be classified as ‘≥100 partners’) or the 75
th
 percentile of each variable (e.g. “Too many, 
lost count” would be the 75
th
 percentile for the mean of total number of new partners for 
MSM). 
 Types of condomless sex with HIV-serodifferent partners (CLS-D) were examined. Ejaculation 
inside a partner (male or female) was considered (only among those who reported CLS-D in 
the previous three months) either ‘some or all of the times’ or ‘no-none of the times’. 
Positioning during sex refers to the act of choosing a different sexual position (the 
receptive/“bottom” or the insertive/“top” position) during anal CLS with other men depending 
on the partner’s HIV-serostatus. Participants were asked which partner they were when they 
had CLS with HIV-serodifferent male partners in the past three months, choosing from three 
options: (i) ‘always the insertive partner (your penis was inside your partner)’, (ii) always the 
receptive partner (‘your partner’s penis was inside you’), and (iii) sometimes the insertive 
partner and sometimes the receptive partner. A hierarchical variable was created, reflecting 
decreasing HIV transmission risk reduction measures taken during anal CLS-D: 
1. Always the receptive partner  
2. Sometimes or always insertive but no ejaculation 
3. Sometimes or always insertive with ejaculation  
Only participants who reported having CLS-D were included in this variable; I recoded the 
remaining to missing.  
 Group sex was referred to as “sex with more than one other person on the same occasion in 
the past three months”. A total of 51 (2.3%) MSM did not answer this question and were 
recoded to missing values. 
 Participants were also asked whether they had “been diagnosed with a sexually transmitted 
infection (not including HIV) in the past three months”, further selecting one or more of the 
following if applicable: syphilis, gonorrhoea, chlamydia, LGV, new hepatitis B or C, new or 
recurrent genital herpes or warts, trichomonas, NSU (Non Specific Urethritis)/NGU (Non 
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Gonococcal Urethritis), or other. Those who specified other STIs were re-classified in the 
above categories if possible (details in section 8.3.1). There were 31 missing values (1.8%) for 
MSM who left this question blank. The questionnaire also included inquiry on “ever being told 
by a doctor that you have hepatitis C”, which was considered separately from other STIs as 
lifetime hepatitis C diagnosis.  A total of 44 MSM (2.0%) did not answer this question. 
 Total number of new sexual partners in the past 12 months was ascertained by the question 
“In the past 12 months, how many new sexual partners have you had? (this means people you 
have not had sex with before)”. Two choices were given: ‘none’ or ‘one or more’ with a free 
text option for the approximate number. A binary variable was created based on whether or 
not ≥10 new partners in the past year were reported: 
1. Yes (reported ≥10 new partners) 
2. No or missing answer (reported either: (i) <10 new partners in the past year, (ii) no 
new partners, (iii) >1 new partner but not the exact number, or (iv) did not complete 
this question and also did not provide the number of partners in the past three 
months from which to extrapolate number of new partners-see below.)  
There were 87 (4.0% of all) MSM who did not answer both questions on number of partners (in the past 
3 months and new partners in the past year); I incorporated them in the ‘no or missing answer’ category 
of this variable (category 2 above). For participants reporting one or more new partners but not the 
exact number, I extrapolated this from the total number of partners (or of the number of CLS-D or CLS-C 
partners) in the past three months: if participants reported having more than one (male or female) 
partner in the past three months (but did not say how many were new in the past year), then I 
calculated the number of new partners in the past year to be twice the number of partners in the past 
three months, subtracting one if sex with the participant’s stable partner was indicated. For example, if 
a participant reported four partners in the past three months, one of whom was their stable partner, 
and also reported more than one new partner in the past year but not the exact number, I imputed this 
to be six new sexual partners in the past year.  
3.9 Statistical analysis 
This section provides an overview of the main statistical methods I used to analyse data throughout this 
thesis. Details of specific eligibility criteria for analyses and additional statistical methods used are 
presented in detail in the methods section of each respective chapter, and summarised in Table 3.2. 
Stata 13 was used for statistical analysis.
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 Exclusion of recently diagnosed participants 3.9.1
MSM who were diagnosed with HIV up to three months prior to questionnaire completion may have 
reported condomless sex (CLS) and other sexual behaviours that took place prior to their positive HIV 
diagnosis. As this thesis explores the sexual behaviours associated with HIV-seropositivity, those 
participants who reported being diagnosed with HIV for three or fewer months were excluded from the 
sample for all analyses (see Table 3.2). A detailed discussion of the characteristics of this group is 
provided in section 4.4.1. 
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 Summary statistics 3.9.2
Summary statistics were used to describe the population under study, and to assist in data error 
checking prior to statistical analysis. The total number of patients (denoted by N) and the row or column 
percentage (%) in each category was reported. For continuous variables the mean and standard 
deviation (SD) were presented if the data was normally distributed; the median and interquartile range 
(IQR) was presented for skewed data.   
 Univariable analyses  3.9.3
This section describes the methods used to examine whether associations between the distribution of 
individuals among categories of one variable is independent of their distribution among the categories 
of another. The Pearson chi-squared test was used for binary independent variables with a binary 
dependent variable. When the expected numbers were too small, chi-squared tests were not considered 
a good approximation; in this case Fisher’s exact test was used, particularly when the overall total of a 
contingency table was <20 or was between 20 and 40 and the smallest expected value was <5.
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 For 
ordered categorical independent variables with a binary dependent variable, the chi-squared test for 
trend was used. In this case, approximation of chi-squared tests is valid if less than 20% of the expected 
numbers in a contingency table are <5 and none are <1; if this occurred, categorical variables were 
further collapsed or treated as continuous (if numerical). To evaluate the difference between means for 
a continuous dependent variable, t-tests were used if comparing two groups (binary independent 
variable) and analysis of variance (ANOVA) when comparing more than two groups.  
 
All statistical tests performed were two-sided and a p-value of less than 0.05 was considered statistically 
significant. The 5% threshold was interpreted as being small enough to justify rejection of the null 
hypothesis of no difference between groups. In interpreting results, patterns of association, the 
magnitude of association and width and limits of confidence intervals, and the sample size were also 
considered.  
 
Table 3.2: Summary of datasets, eligibility criteria, and statistical methods used in this thesis 
    Regression methods used  
Chapter/Title Dataset Eligibility 
criteria 
N MSM 
included 
Modified 
Poisson  
Multinomial 
Logistic  
Cox 
proportional  
hazards 
4 Condomless sex 
among HIV-
diagnosed MSM 
ASTRA 
 
MSM 
diagnosed with 
HIV for ≥3 
months prior 
to ASTRA 
questionnaire 
completion 
 
2189 
 
 
5 Characterising 
higher HIV risk 
CLS-D  
2189 
descriptive statistics only  
6 Recreational 
drug use and 
condomless sex  
2189 
 
 
7 Non-disclosure 
of HIV-
serostatus and 
condomless sex 
2189 
 
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8 Hepatitis C, 
other STI co-
infections, and 
condomless sex 
ASTRA 
with 
linked 
clinical 
data 
MSM 
diagnosed with 
HIV for ≥3 
months prior 
to ASTRA 
questionnaire 
completion 
and consenting 
to linkage of 
routine clinical 
data, with 
available 
hepatitis C test 
results 
1810 

 

 Multivariable analyses 3.9.4
Statistical models were used to quantify the associations between variables of interest, while controlling 
for other factors. This section provides an overview of the main multivariable models used in this thesis. 
3.9.4.1 Logistic regression 
Logistic regression models the association of a binary dependent variable and one or more independent 
variables in terms of odds ratios (ORs). In this context, data can be represented as in Table 3.3  
 
Table 3.3: Notation for contingency table of binary outcome (dependent) variable with two 
exposure groups (independent variable) 
 Outcome (dependent variable)  
Exposure (independent variable) Experienced outcome Did not experience outcome Total 
Exposed 𝑑1  ℎ1  𝑛1 
Unexposed 𝑑0  ℎ0 𝑛0 
Total 𝒅 𝒉 𝒏 
 
The odds are estimated by the number of individuals who experience the outcome (𝑑) divided by the 
number who do not experience the outcome (ℎ):  
𝑂𝑑𝑑𝑠 =
𝑝
1 − 𝑝
=
𝑑
𝑛
1 − (
𝑑
𝑛)
=
𝑑
𝑛
ℎ
𝑛
=
𝑑
ℎ
 
Where 𝑝 refers to the probability or risk that the outcome is experienced. Consequently, the odds ratio 
(OR) is estimated by: 
𝑂𝑅 =
𝑜𝑑𝑑𝑠 𝑖𝑛 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
𝑜𝑑𝑑𝑠 𝑖𝑛 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
=
𝑑1
ℎ1
𝑑0
ℎ0
=
𝑑1 ×  ℎ0
𝑑0 × ℎ1
 
Logistic regression derives its name from the logit function, which describes the transformation of 𝑝, the 
probability or risk of the outcome occurring, into log odds of 𝑝.(Equation 3.1) Thus logistic regression fits 
models on a log scale; log odds are not constrained and can take any value between -∞ and ∞, as 
opposed to probabilities, which must lie between 0 and 1.
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Equation 3.1: The logit function 
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𝐿𝑜𝑔𝑖𝑡(𝑝) =
log (𝑝)
log (1 − 𝑝)
 
The two parameters in the logistic regression model are the baseline odds (in the unexposed group, with 
the independent variable) and the exposure odds ratio (odds in the exposed/odds in the unexposed 
group), which are multiplied together on the log scale as: log (odds) = log (baseline odds) + log (exposure 
odds ratio). This takes the form shown in Equation 3.2, where 𝛽𝑝 refers to the estimated linear 
regression coefficients and 𝑥𝑝 refers to the exposure variables. 
Equation 3.2: The logistic regression model  
log 𝑜𝑑𝑑𝑠 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 = 𝛽0 + 𝛽1𝑥1 + 𝛽2 𝑥2 + 𝛽3𝑥3 + ⋯ + 𝛽𝑝𝑥𝑝 
The regression coefficients thus describe the effect of each independent variable on the dependent 
variable, adjusted for other independent variables. For example if the dependent variable is whether or 
not the participant reported having condomless sex and one of the independent variables is ART status 
(on ART or not on ART), then the odds of reporting condomless sex could be said to be higher or lower 
for those on ART compared to those not on ART.   
 
A likelihood-ratio test is used to derive p-values for each variable in the model. This is done by 
estimating two nested models; one model is considered nested within the other if the first model can be 
generated by imposing restrictions on the parameters of the second. In this case, the restriction is that 
the parameter is equal to zero (meaning that the parameter, or independent variable, is removed from 
the model). The log likelihood of the two models is compared (the fit of the nested model is compared 
to the fit of the first model) and if the difference is statistically significant then the first model is said to 
fit the data significantly better than the nested model; this implies that including the independent 
variable that was removed creates a statistically significant improvement in the fit of the model. 
3.9.4.2 Multinomial logistic regression (MNL) 
Logistic regression can be extended to model a dependent variable that has more than two categories 
(categorical variable). In this case, the model estimates the effect of one or more independent variables 
on the probability that the dependent variable is in a particular category. MNL assumes that the 
dependent variable categories are independent of each other, meaning that being in one category is not 
related to being in another category. It also assumes non-perfect separation of the dependent variable 
categories (if they are perfectly separated by the independent variable then unrealistic coefficients will 
be estimated and effect sizes can be exaggerated).
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 For example, Chapter 4 will examine, among MSM 
who report sex in the past three months, risk factors for three categories of sexual behaviour (condom-
protected sex only, condomless sex with HIV-seroconcordant partners, and condomless sex with HIV-
serodifferent partners). The outcome level ‘condom-protected sex’ is chosen as the reference group 
(comparison level) and (𝑛 − 1) regression coefficients (or odds ratios if exponentiated) corresponding 
to the other two categories of condomless sex are estimated for each exposure variable in the 
regression model (e.g. age, drug use etc.).  
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3.9.4.3 Comparison of odds and risk ratios 
The logistic regression model was initially adapted for case-control studies, for which the appropriate 
measure of association is the odds ratio (OR).
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 The OR is a common measure in epidemiological 
literature, but can be commonly misinterpreted as if it were a risk ratio. Risk ratios are measures of 
effect that describe the ratio of the proportion with the dependent variable in the exposed group (𝑝1, 
with the independent variable) to the proportion with the dependent variable in the unexposed group 
(𝑝0). Using notation from Table 3.3, the risk ratio (RR) is estimated by: 
 
𝑅𝑅 =
𝑟𝑖𝑠𝑘 𝑖𝑛 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
𝑟𝑖𝑠𝑘 𝑖𝑛 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
=
𝑝1
𝑝0
=
𝑑1
𝑛1
𝑑0
𝑛0
 
In cross sectional studies, such as ASTRA, the risk ratio is referred to as a prevalence ratio (PR), as it 
describes the ratio of the prevalence of the dependent variable in those exposed (with the independent 
variable) divided by the prevalence in the unexposed. When the outcome of interest is rare in the 
population (baseline risk <0.1, i.e. prevalence of <10%), the odds ratio approximates the prevalence 
ratio. (Figure 3.1) When the outcome is not rare, the odds ratio is numerically discrepant to the 
prevalence ratio by orders of magnitude. As shown in Figure 3.1, when the PR>1, the OR will always be 
greater than the PR, and when the PR<1, the OR will always be smaller. When the rare event assumption 
is not considered, ORs are often misinterpreted as PRs, which may lead to inaccurate conclusions.
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 For 
example, if the baseline risk is 0.5 (50% prevalence) then an OR of 2.0 is equivalent to a PR of 1.3, 
meaning that the OR of 2 mustn’t be interpreted as ‘double the risk’ of the outcome. As discussed in 
section 3.9.4.1, while odds can take any value between 0 and ∞, the risk (or prevalence in the 
unexposed group, 𝑝0) remains constrained between 0 and 1.
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 For this reason, this thesis estimates 
prevalence ratios using modified Poisson regression as an alternative to logistic regression (discussed in 
section 3.9.4.6). In addition, as unadjusted associations are usually presented in terms of percentages, 
presenting adjusted associations as prevalence ratios is the natural extension to this. 
 
Odds ratios have one advantage over prevalence ratios, particularly when comparing the magnitude of 
an association between a single independent variable with many dependent binary variables of varying 
prevalence (for example, recreational drug use and various types of condomless sex, CLS, as in Chapter 
6). Comparing the prevalence ratios between different models (e.g. drug use and CLS-D versus drugs use 
and CLS-C) would not be appropriate due to different prevalence in the reference group; comparison of 
odds ratios would be preferable in this case. (This has been done as sensitivity analyses in sections 
6.3.3.5 and 7.3.6). 
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Figure 3.1: Relationship between odds ratio and relative risk according to baseline risk. 
Adapted from 223 
  
3.9.4.4 Rate ratios 
The rate of occurrence of an outcome event measures the number of new events that occur per person 
per unit time (denoted by𝜆): 
𝑅𝑎𝑡𝑒, 𝜆 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 
𝑡𝑜𝑡𝑎𝑙 𝑝𝑒𝑟𝑠𝑜𝑛 − 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛
=
𝑑
𝑇
 
To compare rates of an outcome in two exposure groups (exposed denoted by 0 and unexposed by 1), 
the rate ratio (RR) is used: 
𝑅𝑅 =
𝑟𝑎𝑡𝑒 𝑖𝑛 𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝑟𝑎𝑡𝑒 𝑖𝑛 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
=  
𝜆1
𝜆0
=
𝑑1
𝑇1
𝑑0
𝑇0
=
𝑑1 ×  𝑇0
𝑑0  × 𝑇1
 
3.9.4.5 Poisson regression  
Poisson regression estimates rate ratios in the same way that logistic regression estimates odds ratios 
between different exposure groups. The Poisson distribution describes the number of times an event 𝑑 
occurs (counts) over a period of time, provided that the events occur independently of each other and 
at random.
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 The distribution depends on a single parameter, the mean number of occurrences (𝜇) per 
interval (during periods of time with the same duration). This is specified by:  
Equation 3.3: The Poisson distribution function 
𝑷𝒓𝒐𝒃𝒂𝒃𝒊𝒍𝒊𝒕𝒚(𝒅) =
𝒆−𝝁 × 𝝁𝒅
𝒅!
 
Where 𝑑! = 1, 2, 3 … and so on, indicating the number of times the outcome occurred.  
 
Figure 3.2 shows the predicted probabilities for different values of the Poisson distribution mean, 𝜇. 
When the mean is small, the distribution is skewed towards a probability of zero events occurring. 
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Conversely, the distribution is symmetrical for larger means and approximates the normal distribution 
when 𝜇 ≥ 10. One of the main assumptions of the Poisson distribution is that the mean (𝜇) is equal to 
the variance (the square of the standard deviation,𝜎2), referred to as equidispersion. Poisson is thus 
appropriate for analysis of rare outcomes when individuals are followed up for a variable length of 
time.
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Figure 3.2: Shape of the Poisson distribution at various values of the mean (μ).Adapted from 
219,225 
 
Poisson regression models are fitted on a log scale and results are exponentiated to derive rate ratios 
and confidence intervals. The two model parameters are the baseline rate (in the unexposed group) and 
the exposure rate ratio (rate in the exposed group/rate in the unexposed group), which, as with logistic 
regression, are summarised in the form: 
Equation 3.4: The Poisson regression model 
log 𝑟𝑎𝑡𝑒 = 𝛽0 + 𝛽1𝑥1 + 𝛽2 𝑥2 + 𝛽3𝑥3 + ⋯ + 𝛽𝑝𝑥𝑝 
Where 𝛽𝑝 refers to the regression coefficient associated with the p exposure variables 𝑥1 to𝑥𝑝.  
The equivalent model on the ratio scale is then:  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 =  𝑒𝛽0 × 𝑒(𝛽1𝑥1)  
This is also referred to as an incidence rate (IR).  
3.9.4.6 Modified Poisson regression 
So far Poisson regression has been discussed in the context of estimating rate ratios applied using count 
data. To examine the effect of an independent variable to the log of the risk of a binary dependent 
variable (rather than the log of the odds), generalised linear models can be used for a range of 
dependent variable distributions and link functions. Equation 3.1 shows that logistic regression assumes 
a binomial distribution for the dependent variable and thus uses a logit link function. To model the 
effect of independent variables as relative risks (instead of odds ratios), a log link function can be used 
(as in Equation 3.4), which specifies the log risk of the outcome occurring, log(𝑝).226 Hence, the log link 
allows the log risk to not be constrained and Poisson regression can be applied to a binomial distribution 
(rather than a Poisson distribution) to model the effect of an exposure variable as a prevalence ratio.
219
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.0 2.0 4.0 6.0 8.0 10.0 12.0
P
ro
b
ab
ili
ty
  
Number of events (d) 
μ=1 
μ=2 
μ=3 
80 
 
In this case, the outcome distribution is still binomial, the mean is still equal to the variance, and the 
model has the same form as Equation 3.4.  
 
An issue that arises from the application of Poisson to binomial data, is that the error for the prevalence 
ratios are overestimated and the confidence intervals become too wide.
224
 To counteract this, a robust 
error variance procedure is used, called ‘sandwich estimation’; when Poisson regression is used on 
binomial data with a log link function and sandwich estimation, it is henceforth referred to as ‘modified’ 
Poisson regression. Modified Poisson has been extensively used and validated, and is regarded as 
reliable even with small sample sizes.
221,225
 In this thesis, when the outcome of interest (dependent 
variable) is not rare (≥10% prevalence) modified Poisson is used to derive prevalence ratios.  
 Multivariable model strategy  3.9.5
Throughout analyses in Chapters 4, 6, 7, and 8, multivariable models were developed in order to assess 
the independent associations of a number of exposures with a particular dependent variable. Two 
adjustment strategies were used for each analysis. Firstly, each factor (exposure or independent 
variable) was adjusted in separate models for a set of ‘core’ factors; age (<30, 30-39, 40-49, 50-59, ≥60 
years, or <40, ≥40 in underpowered analyses), ethnicity (white, all other), time since HIV diagnosis (≤2, 
2-5, 5-10, 10-15, ≥15 years or <5, 5-10, >10 years in underpowered analyses), ART status (on ART, off 
ART), and stable partner status (HIV-positive, HIV-negative or unknown status, no stable partner). This 
strategy (referred to as ‘Models 1’ in relevant tables) included variables of known importance or 
relevance to CLS among HIV-diagnosed MSM, regardless of their statistical significance. Secondly, a 
stepwise adjustment strategy was used, so that any factor with p<0.10 at unadjusted analysis was a 
candidate for inclusion in a single multivariable model in addition to clinic (referred to as ‘Model 2’); 
variables that were correlated or which incorporated the same factors were examined critically in terms 
of their importance and relevance and excluded accordingly (detailed for each analysis in relevant 
sections).   
3.10 ASTRA sample description 
 Methods  3.10.1
3.10.1.1 Recruitment and patient populations 
For each participating clinic, the following proportions of patients (men and women) were calculated; 
invited to participate (approached), consented to participate, completed the questionnaire 
(respondents), consented to participate but did not return/complete the questionnaire (non-
respondents), and consented to linkage of the questionnaire with routine clinical data.  
3.10.1.2 Comparison of ASTRA participants by response status  
Study log-recorded gender, VL, and CD4 count were compared between ASTRA respondents and non-
respondents using chi-squared tests.  
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3.10.1.3 Characteristics of ASTRA MSM participants 
The distribution of main socio-demographic, psychological, and HIV-related derived variables (defined in 
sections 3.8.2 and 3.8.3) was examined by gender/sexuality of ASTRA respondents (MSM versus 
heterosexual men and women) and compared by chi-squared tests or Fisher’s exact test. Results are 
shown for heterosexual men and women in this chapter only to provide context, and are not discussed 
in detail; instead, the focus of this thesis is MSM who participated in ASTRA only. In addition, the 
distributions of the main sexual behaviour variables defined in section 3.8.4 are presented in Chapter 4.  
3.10.1.4 Comparison of ASTRA MSM by consent to clinical linkage 
MSM who did not consent to linkage of their questionnaire data with routine HIV clinical data were 
compared to those who consented to linkage, on key socio-demographic and HIV-related factors, using 
chi-squared tests. 
3.10.1.5 Comparison of ASTRA sample to UK HIV-diagnosed population 
To assess the generalisability of the ASTRA sample with the population of HIV-diagnosed men and 
women living in the UK as of the end of recruitment (2012), ASTRA respondents were compared to the 
individuals included in the Survey of Prevalent HIV Infections Diagnosed (SOPHID) in 2011 and 2012. 
SOPHID is a cross-sectional survey of all HIV-diagnosed individuals attending for HIV care at NHS sites in 
England, Wales, Northern Ireland, and incorporates Scottish data from Health Protection Scotland to 
produce UK totals.
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 Public Health England collects information bi-annually in London and annually 
outside London via aggregated data in SOPHID, including: the number of individuals living with 
diagnosed HIV at UK and regional level, by age, sex, probable route of HIV transmission (exposure 
group), ART status, CD4 count, and last measured VL. SOPHID therefore constitutes a reliable measure 
of the annual prevalence of diagnosed HIV. 
 Results 3.10.2
3.10.2.1 Recruitment and patient populations 
Table 3.4 describes the response rates of men and women approached to participate to the ASTRA study 
in eight clinics during 2011-2012. A total of 5112 HIV-diagnosed individuals met eligibility criteria and 
were approached and asked to participate in the study. Of those approached, 4200 (82.2%) consented 
to participate in the study, and 912 (17.8%) did not consent. (Table 3.4) A total of 3258 HIV-diagnosed 
individuals completed the ASTRA questionnaire, resulting in a total response rate of 63.7% across all 
clinics. Consent to clinical linkage of ASTRA questionnaire with routine clinical data was very high 
(>90%). Among 3258 ASTRA participants, 2248 (69.0%) were MSM.  
3.10.2.2 Comparison of consenting participants by response status 
Among 4200 men and women who provided written consent, 942 did not complete/return the 
questionnaire.(Table 3.5) There were no significant differences between those who completed the 
questionnaire (respondents) and those who did not (non-respondents) in terms of gender, VL, or CD4 
count.  
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3.10.2.3 Characteristics of ASTRA MSM participants: Socio-demographic, 
psychological, and lifestyle factors 
Table 3.6 shows the distribution of main socio-demographic, psychological, and lifestyle factors 
(described in section 3.8.2) among 3258 ASTRA participants, by gender/sexual orientation. There were 
significant differences between MSM and heterosexual men and women on almost all variables. Results 
are discussed in the context of the 2248 MSM, who are the focus of this thesis. The mean age of MSM 
was 45.5 years (SD 9.5), the majority identified as white (British, Irish, or other), and as not belonging to 
any particular religion. Over 70% were either born in the UK or had been living in the UK for five or more 
years if not UK-born. A minority were unemployed (14.6%) and over 55% had had been educated up to 
the equivalent of A levels. Prevalence of financial hardship was relatively low, with 52.0% of MSM 
reporting always having money for basic needs. Symptoms of depression and anxiety were evidenced in 
27.1% and 20.9% of MSM respectively. Over 59% reported having a high level of social support. Higher 
alcohol consumption was evident in 16.7% of MSM, and over half of MSM reported using recreational 
drugs in the previous three months (both discussed further in Chapter 6).  
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Table 3.4: Recruitment and consent to the ASTRA study clinical centres during 2011-2012 
  
Eligible 
patients  
approached 
Did not consent 
to study 
participation (% 
of approached) 
Consented to 
study 
participation 
(% of 
approached = 
consent rate) 
Completed 
questionnaire- 
respondents (% 
of approached 
= response 
rate) 
Consented to 
clinical linkage (% 
of respondents) 
Gender/sexual orientation 
of those completed 
questionnaire  
(% of respondents) 
MSM 
Heterosexual 
men and 
women 
All sites 
N 
(%) 
5,112 
- 
912 
(17.8) 
4200 
(82.2) 
3258 
(63.7) 
2983 
(91.6) 
2248 
(69.0) 
1010 
(31.0) 
Royal Sussex County 
Hospital Brighton 
n 
(%) 
787 
- 
69 
(8.8) 
718 
(91.2) 
523 
(66.5) 
484 
(92.5) 
451 
(86.2) 
72 
(13.8) 
Eastbourne Sexual 
Health Clinic 
n 
(%) 
104 
- 
22 
(21.2) 
82 
(78.8) 
61 
(58.7) 
60 
(98.4) 
35 
(57.4) 
26 
(42.6) 
Homerton University 
Hospital 
n 
(%) 
465 
- 
91 
(19.6) 
374 
(80.4) 
269 
(57.8) 
233 
(86.6) 
73 
(27.1) 
196 
(72.9) 
Mortimer Market 
Clinic 
n 
(%) 
1,317 
- 
185 
(14.0) 
1,132 
(86.0) 
907 
(68.9) 
842 
(92.8) 
743 
(81.9) 
164 
(18.1) 
Newham University 
Hospital 
n 
(%) 
276 
- 
80 
(29.0) 
196 
(71.0) 
179 
(64.9) 
147 
(82.1) 
37 
(20.7) 
142 
(79.3) 
North Manchester 
General Hospital 
n 
(%) 
732 
- 
209 
(28.6) 
523 
(71.4) 
355 
(48.5) 
345 
(97.2) 
235 
(66.2) 
120 
(33.8) 
Royal Free Hospital 
n 
(%) 
1,336 
- 
249 
(18.6) 
1,087 
(81.4) 
899 
(67.3) 
809 
(90.0) 
651 
(72.4) 
248 
(27.6) 
Whipps Cross 
University Hospital 
n 
(%) 
95 
- 
7 
(7.4) 
88 
(92.6) 
65 
(68.4) 
63 
(96.9) 
23 
(35.4) 
42 
(64.6) 
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Table 3.5: Comparison of 4200 HIV-diagnosed men and women consenting to ASTRA 
participation according to questionnaire completion status  
  Respondents (n=3258) Non-respondents (n=942)   
  n (row %) n (row %) p-value 
Gender (N=4200)           
Male 2621 (78.0) 739 (22.0)   
Female 637 (75.8) 203 (24.2) 0.177 
Viral load (c/mL) (N=4124)           
≤50 1788 (76.9) 536 (23.1)   
>50 1424 (79.1) 376 (20.9) 0.095 
CD4 count (cells/mm
3
) (N=4130) 
    
  
≤350 598 (75.4) 195 (24.6)   
>350 2619 (78.5) 718 (21.5) 0.061 
p-value by chi-squared test; study-log recorded latest VL and CD4 count communicated to the 
participant 
3.10.2.4 Characteristics of ASTRA MSM participants: HIV-related factors 
Over 73% of MSM had been diagnosed with HIV for more than five years (Table 3.7); 59 MSM (2.6%) 
were recently diagnosed (within ≤3 months of ASTRA completion) and were excluded from analyses 
which included inquiry on sexual behaviour in the past three months, as they may have been describing 
behaviour that occurred prior to their positive HIV diagnosis (section 3.9.1). A small minority (5.0%) of 
MSM had not disclosed their HIV-serostatus to anyone in their social circle, which is further discussed in 
Chapter 7. Prevalence of ART use at the time of the questionnaire was high (85.1% on ART), with 53.0% 
of MSM being on ART for five years or longer. Over 6% of MSM did not know their personal CD4 count 
and 7.7% did not know their VL. A total of 83.8% of MSM had a study log-recorded CD4 count of >350 
cells/mm
3
, and 76.0% had suppressed VL (≤50c/mL). For MSM on ART, VL was suppressed for 88.1% 
(n/N=1654/1878). Adherence to ART was overall high (76.9%). Only 4.7% reported least conservative 
transmission risk beliefs (see sections 3.8.2 and 3.8.3 for detailed definitions of all variables).  
3.10.2.5 Comparison of respondents by consent to clinical linkage 
Comparison of all ASTRA participants who provided consent to clinical linkage (n=2983) with those who 
did not (n=275) showed no significant differences in terms of age, education, employment, time since 
HIV diagnosis, ART status, and study log-recorded VL distributions (p>0.05, results not shown). When 
examining MSM separately, there were no significant differences between those who did and did not 
provide consent to linkage, in terms of age, education, employment, time since HIV diagnosis, ART 
status, and study log-recorded VL or CD4 count. (Table 3.8) Over 20% of MSM who did not consent were 
of non-white ethnicities as compared to 10.1% of MSM who gave consent to linkage (p<0.001). Similarly, 
MSM who were not born in the UK were more likely to not provide consent to linkage with clinical data 
as compared to UK-born MSM (p<0.001). By December 2016, four of the eight participating clinics had 
provided linked clinical data for 1811 MSM.  
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Table 3.6: Socio-demographic, mental health, and lifestyle characteristics among 3258 ASTRA 
participants according to gender/sexual orientation 
  
MSM (N=2248) 
Heterosexual men 
and women (N=1010) 
   n (%) n (%) p-value  
Age at recruitment (N=3114), years 
     <30 107 (4.9) 59 (6.4) 
 30-39 496 (22.6) 230 (24.9) 
 40-49 935 (42.7) 403 (43.7) 
 50-59 504 (23.0) 173 (18.8) 
 ≥60 150 (6.8) 57 (6.2) 0.037 
Mean [SD] age years 45.5 [9.5] 44.5 [9.7] 0.004 (T) 
Ethnic group (N=3174) 
     White 1974 (89.3) 242 (25.1) 
 Black African 23 (1.0) 583 (60.5) 
 Black Caribbean or other 53 (2.4) 69 (7.2) 
 Asian or Asian British 32 (1.4) 19 (2.0) 
 Mixed or other 129 (5.8) 50 (5.2) <0.001 
Religious (N=3204) 
     Yes 947 (42.8) 848 (85.4) 
 No 1264 (57.2) 145 (14.6) <0.001 
Born in UK/time lived in UK (N=3258) 
    Born in the UK 1540 (68.5) 209 (20.7) 
 Non-UK born lived in UK<5yrs 88 (3.9) 72 (7.1) 
 Non-UK born lived in UK>5yrs 537 (23.9) 651 (64.5) 
 Non-UK born (time not specified) 83 (3.7) 78 (7.7) <0.001 
Education (N=3144) 
     University degree or above 983 (44.6) 333 (35.5) 
 No qualifications or up to A levels 1222 (55.4) 606 (64.5) <0.001 
Employment status (N=3139) 
     Employed 1357 (61.8) 449 (47.7) 
 Unemployed 320 (14.6) 261 (27.7) 
 Other 520 (23.7) 232 (24.6) <0.001 
Financial hardship (money for basic needs) (N=3186) 
    Always 1151 (52.0) 238 (24.5) 
 Mostly/sometimes 886 (40.0) 511 (52.6) 
 No 178 (8.0) 222 (22.9) <0.001 (T) 
Depression symptoms (N=3258) 
     No/missing 1639 (72.9) 735 (72.8) 
 Yes 609 (27.1) 275 (27.2) 0.935 
Anxiety symptoms (N=3258) 
     No/missing 1778 (79.1) 771 (76.3) 
 Yes 470 (20.9) 239 (23.7) 0.078 
Social support (N=3196) 
     High 1330 (59.7) 549 (56.7) 
 Medium 678 (30.4) 310 (32.0) 
 Low 220 (9.9) 109 (11.3) 0.093 (T) 
Harmful/hazardous alcohol consumption (N=3258) 
    No/missing 1872 (83.3) 954 (94.5) 
 Possible 376 (16.7) 56 (5.5) <0.001 
Recreational drug use in past 3 months (N=3258) 
    No/missing 1110 (49.4) 906 (89.7) 
 Yes 1138 (50.6) 104 (10.3) <0.001 
p-values by chi-squared test or chi-squared test for trend (T); All factors defined in sections 3.8.2 and 3.8.3 
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Table 3.7: HIV-related characteristics among 3258 ASTRA participants by gender/sexual 
orientation 
  
MSM (N=2248) 
Heterosexual men and 
women (N=1010)   
  n (%) n (%) p-value  
Time since HIV diagnosis (N=3,226) 
   
  
≤3 months 59 (2.6) 20 (2.0)   
3 months-2 years 189 (8.5) 112 (11.3)   
2-5 years 340 (15.2) 165 (16.6)   
5-15 years 1,004 (44.9) 520 (52.4)   
>15 years 642 (28.7) 175 (17.6) <0.001 (T) 
Disclosure of HIV-serostatus (N=3,233) 
  
  
Disclosed to at least one person 2,128 (95.0) 834 (84.0)   
Not disclosed to anyone 112 (5.0) 159 (16.0) <0.001 
ART status (N=3,232) 
    
  
On ART 1,904 (85.1) 886 (89.0)   
Not on ART 333 (14.9) 109 (11.0) 0.003 
Self-reported CD4 count, cells/mm
3
 (N=3,158) 
  
  
<200 177 (8.0) 116 (12.1)   
200-350 308 (14.0) 139 (14.5)   
351-500 571 (25.9) 203 (21.2)   
>500 996 (45.2) 311 (32.5)   
"Don’t know" 150 (6.8) 187 (19.6) <0.001 
Study log CD4 count, cells/mm
3
 (N=3,217) 
   
  
≤350  359 (16.2) 254 (25.4)   
>350  1,859 (83.8) 745 (74.6) <0.001 
Self-reported viral load, c/mL (N=2,766) 
  
  
≤50 1,571 (82.5) 587 (68.2)   
>50 188 (9.9) 86 (10.0)   
"Don’t know" 146 (7.7) 188 (21.8) <0.001 
Study log viral load, c/mL (N=3,212) 
   
  
≤50 1,682 (76.0) 768 (77.0)   
>50  532 (24.0) 230 (23.0) 0.545 
Adherence to ART (N=2,790 on ART) 
   
  
Adherent 1,721 (76.9) 761 (76.5)   
Non-adherent 183 (8.2) 125 (12.6) <0.001 
HIV transmission risk beliefs (N=3,145) 
  
  
Most conservative 1,052 (47.7) 512 (54.4)   
Moderately conservative 1,049 (47.6) 347 (36.9)   
Least conservative 103 (4.7) 82 (8.7) 0.261 (T) 
p-values by chi-squared test or chi-squared test for trend (T);All factors defined in section 3.8.3 
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Table 3.8: Comparison of 2,248 MSM respondents according to status of consent to linkage 
with clinical data  
  
MSM consenting to 
linkage with clinical 
data (N=2,117) 
MSM not consenting 
to linkage with 
clinical data (N=131)     
  n (%) n (%) p-value 
Age group, years (N=2,224) 
    
  
<30 107 (5.1) 3 (2.5)   
30-39 465 (22.1) 38 (31.4)   
40-49 895 (42.6) 53 (43.8)   
50-59 488 (23.2) 21 (17.4)   
≥60 148 (7.0) 6 (5.0) 0.118 (T) 
Ethnicity (N=2,211)           
White 1872 (89.9) 102 (79.7)   
Black of black British 67 (3.2) 9 (7.0)   
Asian or Asian British 39 (1.9) 6 (4.7)   
Mixed 81 (3.9) 6 (4.7)   
Other ethnic group  24 (1.2) 5 (3.9) 0.002 (F) 
Born in the UK  (N=2,248)           
No 646 (30.5) 62 (47.3)   
Yes 1471 (69.5) 69 (52.7) <0.001 
Education (N=2,205)           
University degree or above 922 (44.4) 61 (47.7)   
No qualifications or up to A levels 1155 (55.6) 67 (52.3) 0.471 
Employment status (N=2,197)           
Employed 1276 (61.6) 81 (64.3)   
Unemployed 298 (14.4) 22 (17.5)   
Other 497 (24.0) 23 (18.3) 0.278 
Time since HIV diagnosis (N=2,234)           
≤3 months 57 (2.7) 2 (1.6)   
3 months-2 years 175 (8.3) 14 (11.1)   
2-5 years 319 (15.1) 21 (16.7)   
5-15 years 948 (45.0) 56 (44.4)   
>15 years 609 (28.9) 33 (26.2) 0.479 (T) 
ART status (N=2,237)           
On ART 1797 (85.3) 107 (82.3)   
Not on ART 310 (14.7) 23 (17.7) 0.354 
Study log VL, c/mL (N=2,214)           
≤50 1069 (51.2) 66 (52.4)   
>50 1019 (48.8) 60 (47.6) 0.796 
Study log CD4 count, cells/mm
3
 (N=2,218)           
≤350 322 (15.4) 26 (20.6)   
>350 1770 (84.6) 100 (79.4) 0.116 
p-values by chi-squared test, chi-squared test for trend (T), or Fisher's exact test (F); All factors defined in 
sections 3.8.2 and 3.8.3 
 
3.10.2.6 Comparison to the UK HIV-diagnosed MSM population  
Comparison of key characteristics of SOPHID (section 3.10.1.5) to ASTRA data during the same period 
(2011-2012) allows assessment of how similar the ASTRA MSM study population is to the UK HIV-
diagnosed MSM population accessing NHS care for HIV.(Table 3.9.) Overall, the distribution of HIV 
exposure categories varied, with ASTRA having higher prevalence of HIV acquisition through sex 
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between men compared to the general HIV-diagnosed population, where the prevalence through 
heterosexual contact is higher than in ASTRA.  
 
Focussing further on MSM, ASTRA had a higher estimate of men recruited from London compared to the 
rest of the UK (five of the eight participating clinics were located in London.(Table 3.9) As ASTRA was 
conducted in England, there were no MSM recruited in Wales, Northern Ireland, or Scotland, which 
account for 8.1% of all HIV-diagnosed MSM accessing care in the UK in 2011-2012. As a result, ASTRA 
MSM represented the following proportions of HIV-diagnosed MSM accessing care by region: up to 7.6% 
in all of England (specifically up to 10.2% in London, up to 12.9% in South East England, up to 6.8% in 
North West England) but 0% in the remaining regions of England.  
 
 
The age distribution differed between ASTRA and SOPHID MSM, with a lower proportion of men being 
in the younger age groups (15-34 years) in the former. Specifically, HIV-diagnosed MSM aged 15-24 
years made up less than 1% of the ASTRA MSM sample, as compared to almost 3% of SOPHID MSM. The 
distribution of age followed a similar pattern for MSM aged between 35 to 64 in ASTRA and SOPHID. 
MSM who were over 65 years tended to be represented more in SOPHID than in ASTRA (2.6% vs 3.6% 
respectively). Overall, ASTRA MSM represented up to 1.8% of SOPHID MSM under 24 years accessing 
HIV care in 2011-2012, up to 7% of SOPHID MSM between 25 and 64 years, and up to 5.5% of MSM over 
65 years.   
 
The distribution of ethnicity among MSM in ASTRA closely followed that of SOPHID, with the majority of 
HIV-diagnosed MSM in ASTRA being of white ethnicity (<87% for both populations). There was higher 
prevalence of black ethnicities (black Caribbean, black African, and black other/unspecified) in SOPHID 
MSM compared to ASTRA MSM, but higher prevalence of mixed ethnicities in ASTRA compared to 
SOPHID MSM. In addition, the ASTRA sample was comprised of less than 0.8% Indian, Pakistani, 
Bangladeshi, or other Asian ethnicities/nationalities, as compared to up to 1.8% in SOPHID MSM. The 
highest proportions of MSM in ASTRA represented in SOPHID according to ethnicity were other/mixed 
(up to 7.7%) and white (up to 7%), and the lowest was black other/unspecified (3.0-3.2%).  
 
The vast majority of HIV-diagnosed MSM in both SOPHID and ASTRA were on ART (>83% in both) and 
had a high CD4 counts. The ASTRA study is representative of up to 7.1% of HIV-diagnosed SOPHID MSM 
on ART and 6.6% of MSM with a CD4 count >350cells/mm
3
. 
 
Hence, the 2248 MSM who participated in ASTRA represented between up to 7.0% of the HIV-diagnosed 
MSM SOPHID accessing NHS care in 2011 and 2012.  
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Table 3.9: Comparison of HIV-diagnosed MSM receiving HIV care in the UK (SOPHID) in 2011 
and 2012 to MSM participating in the ASTRA study (2011-12)  
  
SOPHID MSM 
2011 
(N=32,204) 
SOPHID MSM 
2012 
(N=34,453) 
ASTRA MSM 
2011-2012 
(N=2,248) 
% MSM in 
ASTRA 
represented in 
SOPHID 
  
      
2011 2012 
  n (%) n (%) n (%) (%) (%) 
Area of residence                 
London 14962 (46.5) 15790 (45.8) 1527 (67.9) (10.2) (9.7) 
East of England 1338 (4.2) 1484 (4.3) - - - - 
East Midlands 951 (3.0) 1065 (3.1) - - - - 
West Midlands 1679 (5.2) 1789 (5.2) - - - - 
North East 592 (1.8) 659 (1.9) - - - - 
North West 3464 (10.8) 3691 (10.7) 235 (10.5) (6.8) (6.4) 
Yorkshire and Humber 1173 (3.6) 1309 (3.8) - - - - 
South East 3757 (11.7) 4026 (11.7) 486 (21.6) (12.9) (12.1) 
South West 1502 (4.7) 1641 (4.8) - - - - 
England (Total) 29418 (91.3) 31454 (91.3) 2248 (100) (7.6) (7.1) 
Wales 788 (2.4) 833 (2.4) - - - - 
Northern Ireland 271 (0.8) 339 (1.0) - - - - 
Scotland 1561 (4.8) 1609 (4.7) - - - - 
Other
†
 166 (0.5) 218 (0.6) - - - - 
Age group (years)                 
15-24 903 (2.8) 980 (2.8) 16 (0.7) (1.8) (1.6) 
25-34 5894 (18.3) 6361 (18.5) 300 (13.3) (5.1) (4.7) 
35-44 10896 (33.8) 10898 (31.6) 728 (32.4) (6.7) (6.7) 
45-54 10030 (31.1) 11081 (32.2) 817 (36.3) (8.1) (7.4) 
55-64 3425 (10.6) 3879 (11.3) 273 (12.1) (8.0) (7.0) 
>65 1056 (3.3) 1254 (3.6) 58 (2.6) (5.5) (4.6) 
Ethnicity                  
White 28159 (87.4) 29987 (87.0) 1974 (87.8) (7.0) (6.6) 
Black-Caribbean 683 (2.1) 729 (2.1) 42 (1.9) (6.1) (5.8) 
Black-African 468 (1.5) 527 (1.5) 23 (1.0) (4.9) (4.4) 
Black-other/Black-unspecified 343 (1.1) 372 (1.1) 11 (0.5) (3.2) (3.0) 
Indian/Pakistani/Bangladeshi 410 (1.3) 444 (1.3) 17 (0.8) (4.1) (3.8) 
Other Asian/Oriental  534 (1.7) 629 (1.8) 28 (1.2) (5.2) (4.5) 
Other/mixed 1508 (4.7) 1635 (4.7) 116 (5.2) (7.7) (7.1) 
On ART 26921 (83.6) 29573 (85.8) 1904 (84.7) (7.1) (6.4) 
CD4 count (cells/mm3)* 
       
  
<350 4993 (15.5) 4520 (13.1) 348 (15.5) (7.0) (7.7) 
350-499 8067 (25.0) 7816 (22.7) 539 (24.0) (6.7) (6.9) 
>499 18497 (57.4) 20332 (59.0) 1331 (59.2) (7.2) (6.5) 
Not reported 647 (2.0) 1785 (5.2) 30 (1.3) (4.6) (1.7) 
† Other area of residence: British isles, no fixed abode, not reported, or abroad; * CD4 count recorded from 
study log for ASTRA MSM. 
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3.11 Conclusion 
Overall, comparison to SOPHID data showed that MSM are over-represented in ASTRA while black 
African individuals and women are under-represented. While this may present limitations in terms of 
how informative the study is to the HIV-diagnosed women and black African people receiving HIV care in 
the UK, the focus of this thesis is MSM only. The socio-demographic characteristics of ASTRA 
participants differed between participating clinics, reflecting the variability of local populations in terms 
of ethnicity, gender/sexuality, and socio-economic status.  
 
The comparisons presented in this chapter suggest that the ASTRA study sample represents up to 7% of 
HIV-diagnosed MSM accessing NHS care in the UK during 2011-2012. While ASTRA does have some 
limitations in terms of addressing the aims of the thesis, these are discussed in detail in relation to 
specific analyses in relevant results chapters, and in the final chapter. Due to the  substantive sample 
size, comprehensive data collection and linkage to clinical data, the ASTRA study can offer enhanced 
understanding of sexual behaviours of HIV-diagnosed MSM in the UK, and of the co-factors (socio-
demographic, psychological, health, lifestyle, HIV-related) that these may be associated with. The 
study’s results will thus have important implications for improved care of HIV-diagnosed people and for 
targeting national HIV prevention efforts. 
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4 Condomless sex among HIV-diagnosed MSM: prevalence 
and co-factors 
4.1 Chapter aims 
This chapter examines the prevalence of and factors associated with recent condomless sex and other 
sexual behaviours among HIV-diagnosed MSM participating in the ASTRA study. The aims of these 
analyses are to investigate: (i) the prevalence of measures of recent condomless sex (CLS), other sexual 
behaviours, sexually transmitted infections (STIs), and attitudes to condom use, (ii) the association of 
socio-demographic, HIV-related, and psychological factors with CLS and CLS with HIV-serodifferent 
partners (CLS-D), (iii) the factors associated with reporting CLS-D and CLS with HIV-seroconcordant 
partners only (CLS-C without CLS-D) versus condom-protected sex, and (iv) the prevalence of other 
measures of sexual behaviour among those reporting CLS-D, and CLS-C without CLS-D, compared to 
condom-protected sex. Results from these analyses are then discussed in the context of studies 
reviewed in Chapter 2. Associations of lifestyle factors (recreational drug use and alcohol) with sexual 
behaviour are presented in chapter 6. 
4.2 Introduction 
The concept of CLS as ‘high risk’ has evolved substantially over the past two decades, firstly with the 
introduction of combination antiretroviral therapy (ART) for treatment of HIV (1995/1996), secondly, 
with the first change in advice about high risk sex in the ‘Swiss Statement’ (2008), and subsequently with 
increasing evidence from observational studies and randomised controlled trials on the crucial role of 
HIV viral load (VL) suppression on reducing HIV transmission (2008 onwards). Results from recent trials 
(since 2012) have also shown the substantial protective effect conferred by oral pre-exposure 
prophylaxis (PrEP) in reducing the risk of HIV acquisition among HIV-negative individuals (section 1.3.5). 
As a result, the concept of high risk CLS continues to evolve with additional evidence and use of PrEP. 
There have been few studies of sexual behaviour among HIV-diagnosed MSM in the UK since the ‘Swiss 
Statement’. It is important to understand the factors that contribute to having different types of CLS 
(with HIV-serodifferent, HIV-seroconcordant partners or both) as opposed to having condom-protected 
sex or not having sex among HIV-diagnosed MSM.  
4.3 Methods 
 Study population  4.3.1
MSM who were diagnosed for three or fewer months prior to ASTRA questionnaire completion may 
potentially be reporting sexual behaviours that occurred prior to their HIV positive diagnosis. (Section 
3.10.2.1) To examine whether there were any significant differences between MSM diagnosed for ≤3 
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months (‘recently diagnosed’) and MSM diagnosed for >3 months prior to ASTRA, these two groups 
were compared in univariable analysis on key socio-demographic, lifestyle, psychological, and HIV-
related factors, using chi-squared tests. As the majority of sexual behaviour questions had a three 
month recall period, and to improve validity of sexual behaviour questions, recently diagnosed MSM 
were then excluded from remaining analyses in this chapter; the sample was thus comprised of MSM 
diagnosed with HIV for longer than three months prior to ASTRA questionnaire completion.  
 Condomless sex (CLS) definitions 4.3.2
Detailed definitions of derived variables for sexual behaviours have been given in section 3.8.4. In brief, 
sex refers to reporting any anal sex with a man and/or vaginal or anal sex with a woman in the previous 
three months. Condomless sex (CLS) refers to sex without a condom; CLS with an HIV-serodifferent 
partner (CLS-D) refers to CLS with a partner who did not have HIV or whose HIV-status the participant 
did not know; CLS with an HIV-seroconcordant partner (CLS-C) refers to CLS with a partner who was 
known to also have HIV. Condom-protected sex was defined as reporting having sex in the previous 
three months but not having CLS (including not having CLS-D and/or CLS-C). All questions on CLS had a 
three-month recall period. 
 Sexual behaviour classification  4.3.3
A single variable was derived, classifying all MSM into one of the following four mutually exclusive 
hierarchical categories according to sexual behaviour in the past three months, in the following order:  
1. Condomless sex with HIV-serodifferent partners (CLS-D)  
2. Condomless sex with HIV-seroconcordant partners only  (‘CLS-C without CLS-D’) 
3. Condom-protected sex only  
4. No anal or vaginal sex  
Therefore, a man who reported CLS-D and CLS-C would be classified as having CLS-D (category 1), while 
a man who reported anal or vaginal sex but did not report CLS-D or CLS-C would be classified as having 
condom-protected sex only (category 3).  
 
A small number of participants reported having CLS but did not specify their partner’ HIV-serostatus 
(‘CLS-unspecified’). In order to incorporate all MSM into the single variable of sexual behaviour, this 
group was examined separately. The socio-demographic, lifestyle, and sexual behaviours and attitudes 
of MSM who reported CLS-unspecified were compared to those of MSM who reported ‘CLS-C without 
CLS-D’ (category 2) and those who reported CLS-D (category 1), in two separate univariable analyses. 
The CLS-unspecified group were similar to the CLS-D group in terms of socio-demographic and 
behavioural characteristics, (Appendix IV) and so throughout this thesis, the CLS-unspecified group were 
incorporated into the group reporting any CLS-D (including category 1 CLS-D, above).  
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 CLS-D-specific behaviours  4.3.4
Among MSM who had CLS-D in the previous three months, additional questions were asked; number of 
times had CLS-D (once, 2-10, 11-30, more than 30 times); sexual positioning (seropositioning) and 
ejaculation inside a partner. (Section 3.8.4) 
 Other sexual behaviours, STIs, and attitudes towards condom use 4.3.5
Definitions for sexual behaviour variables described in this section can be found in section 3.8.4. To 
recap, among all MSM the following were reported; stable partner’s HIV-serostatus (if in a relationship), 
number of new sexual partners in the past year, self-reported lifetime diagnosis of hepatitis C (HCV); in 
the past three months: number of total, CLS, CLS-D, CLS-C partners, self-reported diagnosis with another 
STI, group sex, used the internet to find a sexual partner, transactional sex (received money or drugs in 
exchange for having sex). Current symptoms of STIs (at questionnaire completion) were any of: 
abnormal discharge from penis, anal discharge, pain on passing urine, pain in the genital area or anus, 
red sores or rash on the genital area or anus. Transmission risk beliefs are series of statements on HIV 
transmission risk and virus undetectability, which categorised participants into ‘most’, ‘moderately’, and 
‘least’ conservative. 
 
Level of agreement to a series of statements on condom use and HIV transmission was determined 
using a 5-level Likert scale (from ‘strongly agree’ to ‘strongly disagree’), including: ‘low condom self-
efficacy’ (defined as tend to or strongly disagree to the statement “I feel confident I can ensure a 
condom is used with any partner in any situation”);  ‘difficulty negotiating condom use’ (defined as 
strongly or tend to agree to “It is difficult for me to discuss condom use with a new sexual partner”); 
‘lower condom use with casual partners’ (defined as strongly or tend to agree to “I am less likely to use a 
condom with a casual partner”), and ‘worry about HIV transmission’ (defined as strongly or tend to 
agree to “I’m worried I could have infected someone else with HIV in the past few months”) 
 
Participants were asked whether any of their HIV-negative sexual partners “have taken HIV drugs to 
reduce the risk of getting HIV”, with options: PrEP (“antiretroviral drugs taken before sex), PEPSE 
(“antiretroviral drugs taken after sex”), and No/“Don’t know”.  
 Statistical analysis 4.3.6
4.3.6.1 Prevalence of sexual behaviours   
The prevalence and 95%CIs of various sexual behaviours was established among all MSM diagnosed 
with HIV for longer than three months prior to ASTRA completion (described in section 4.3.5).  
4.3.6.2 Factors associated with any condomless sex 
Detailed definitions of all independent variables used in the below analyses are presented in sections 
3.8.2 and 3.8.3. Associations were examined of socio-demographic factors (age, ethnicity, employment, 
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place of birth, religion, education, financial hardship, social support), psychological symptoms 
(depression, anxiety), stable partner status, HIV-related variables (time living with HIV, ART status, non-
adherence to ART, study log-recorded and self-reported VL) and reporting:  
(i.) Any condomless sex (CLS) in the previous three months versus not reporting CLS (includes MSM 
who did not have anal or vaginal sex)  
(ii.) Condomless sex with HIV-serodifferent partners (CLS-D) in the previous three months versus 
not reporting CLS-D (incudes MSM who did not have anal or vaginal sex)  
Unadjusted and adjusted modified Poisson regression models were used with robust error variances. In 
multivariable analyses, the two adjustment strategies described in section 3.9.5 were used. Firstly, each 
factor was adjusted separately for a set of ‘core’ factors; age (<30, 30-39, 40-49, 50-59, ≥60 years), 
ethnicity (white, all other), time since HIV diagnosis (≤2, 2-5, 5-10, 10-15, ≥15 years), ART status (on ART, 
off ART), and stable partner status (HIV-positive, HIV-negative or unknown status, no stable partner). In 
the second adjustment strategy, any factor with p<0.10 at unadjusted analysis was a candidate for 
inclusion in the multivariable model in addition to clinic; variables that were correlated were examined 
critically in terms of their importance and relevance and excluded accordingly (specifics for each model 
are discussed in sections 4.4.5 and 4.4.6) Lifestyle factors (recreational drug use, alcohol consumption) 
and non-disclosure of HIV-serostatus were not included in this analysis as they are presented in 
Chapters 6 and 7 respectively.  
4.3.6.3 Sexual behaviours according to single variable  
The prevalence (95%CI) of sexual behaviours in the past three months was established according to the 
mutually exclusive four category variable (CLS-D, ‘CLS-C without CLS-D’, condom-protected sex, and no 
sex, as described in section 4.3.3). Associations of socio-demographic characteristics, psychological 
symptoms, HIV-related factors (as in 4.3.6.2) and this measure of sexual behaviour were examined. Chi-
squared tests (or Fisher’s exact according to cell size), chi-squared tests for trend, or ANOVA were used 
to compare all four groups as well as the three sexually active groups separately. P-values for linear 
trend were derived by Wald test using unadjusted multinomial logistic regression for numerical 
independent variables (age and time since HIV diagnosis) and categorical independent variables with 
natural ordering (e.g. decreasing levels of social support). The distribution of the number of partners in 
the past year according to the single variable of sexual behaviour in the past three months was assessed 
by chi-squared test for linear trend.  
4.3.6.4 Factors associated with reporting condomless or condom-protected sex  
Multinomial logistic regression (MNL) was used to examine socio-demographic, psychological, and HIV-
related factors associated with having CLS compared to condom-protected sex. Only MSM who reported 
anal or vaginal sex in the past three months were included in this analysis, which compared MSM who 
had CLS-D and those who had ‘CLS-C without CLS-D’ to those who had condom-protected sex only 
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(baseline). Any variables with p<0.10 in unadjusted analysis were included in separate MNL models only 
adjusted for clinic; any remaining variables with p<0.05 in clinic-adjusted MNL were then mutually 
adjusted in a single MNL model, in addition to clinic.  
 
The association of other sexual behaviours, STIs, and attitudes and the three categories of sexual activity 
in the past three months (CLS-D, ‘CLS-C without CLS-D’, and condom-protected sex) was examined using 
chi-squared tests, or Fisher’s exact where appropriate.  
4.4 Results  
 Recently diagnosed MSM 4.4.1
A total of 59 (of 2248, 2.6%) MSM had been diagnosed with HIV for three or fewer months prior to 
ASTRA completion. There were significant differences on various factors between recently diagnosed 
MSM and those diagnosed for longer than three months.(Table 4.1) Compared to MSM diagnosed with 
HIV for longer, recently diagnosed MSM were significantly younger, more likely to be of non-white 
ethnicities, and to have higher educational attainment (all p<0.05). MSM who were recently diagnosed 
also reported higher levels of social support, with only 3.4% reporting low social support as compared to 
10.0% of MSM not recently diagnosed (p-trend=0.009). There was some evidence to suggest that MSM 
who were diagnosed for longer had higher prevalence of depression and anxiety symptoms as 
compared to those recently diagnosed. Prevalence of ART use and VL suppression was lower among the 
recently diagnosed MSM compared to MSM diagnosed for longer (p<0.001 for both). There was weak 
evidence to suggest that prevalence of CLS-D in the past three months was higher among recently 
diagnosed MSM (p=0.06). 
 
All remaining analyses in this chapter (and any other chapters identified in Table 3.2) excluded 59 
recently diagnosed MSM, deriving a sample of 2189 ASTRA MSM participants who had been diagnosed 
with HIV for longer than three months.  
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Table 4.1: Differences in socio-demographic, psychological, and HIV-related factors between 
MSM diagnosed with HIV for >3 months or ≤3 months (N=2248) 
 
Diagnosed with HIV 
>3 months ago 
(N=2,189) 
Recently 
diagnosed with 
HIV (≤3 months 
ago) (N=59) 
 
 
n (%) n (%) p-value 
Age group, years (N=2224)      
<30 96 (4.4) 13 (22.4)  
30-49 1416 (65.3) 37 (63.8)  
≥50 655 (30.2) 8 (13.8) <0.001 (T) 
Mean age [SD], years (N=2224) 45.5 [9.4] 39.9 [10.0] <0.001 (T) 
Ethnicity (N=2211)      
White 1928 (89.5) 46 (80.7)  
All other (black, Asian, Mixed, other) 226 (10.5) 11 (19.3) 0.034 
Born in the UK (N=2248)      
No 687 (31.4) 21 (35.6)  
Yes 1502 (68.6) 38 (64.4) 0.492 
Education (N=2205)      
University degree or above 950 (44.2) 33 (58.9)  
No qualifications or up to A levels 1199 (55.8) 23 (41.1) 0.029 
Employment (N=2211)      
Employed  1318 (61.2) 39 (68.4)  
Unemployed or other (student, carer, retired) 836 (38.8) 18 (31.6) 0.268 
Money for basic needs (financial hardship) (N=2215)     
Always 1114 (51.6) 37 (64.9)  
Mostly/sometimes 871 (40.4) 15 (26.3)  
No 173 (8.0) 5 (8.8) 0.143 (T) 
Depressive symptoms (N=2248)      
No 1590 (72.6) 49 (83.1)  
Yes 599 (27.4) 10 (16.9) 0.076 
Anxiety symptoms (N=2248)      
No 1726 (78.8) 52 (88.1)  
Yes 463 (21.2) 7 (11.9) 0.083 
Social support score (N=2228)      
High 1286 (59.3) 44 (75.9)  
Medium 666 (30.7) 12 (20.7)  
Low 218 (10.0) 2 (3.4) 0.009 (T) 
ART status (N=2237)      
On ART 1888 (86.7) 16 (27.1)  
Not on ART 290 (13.3) 43 (72.9) <0.001 
Study log CD4 count, cells/mm
3
 (N=2218)      
≤350 329 (15.2) 30 (51.7)  
>350 1831 (84.8) 28 (48.3) <0.001 
Self-reported viral load, c/mL (N=1905)      
≤50 1570 (83.1) 1 (6.7)  
>50 180 (9.5) 8 (53.3)  
"Don't know" 140 (7.4) 6 (40.0) <0.001 (F) 
Study log viral load, c/mL (N=2214)      
≤50 1680 (77.8) 2 (3.6)  
>50 479 (22.2) 53 (96.4) <0.001 (F) 
HIV transmission risk beliefs (N=2204)      
Most conservative 1029 (47.9) 23 (41.1)  
Moderately conservative 1020 (47.5) 29 (51.8)  
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Diagnosed with HIV 
>3 months ago 
(N=2,189) 
Recently 
diagnosed with 
HIV (≤3 months 
ago) (N=59) 
 
 
n (%) n (%) p-value 
Least conservative 99 (4.6) 4 (7.1) 0.234 (T) 
Any anal or vaginal sex (N=2248) *      
No 797 (36.4) 16 (27.1)  
Yes 1392 (63.6) 43 (72.9) 0.143 
Any condomless sex (N=2248) *      
No 1353 (61.8) 34 (57.6)  
Yes 836 (38.2) 25 (42.4) 0.514 
Condomless sex with HIV-serodifferent partners (N=2248)*    
No 1832 (83.7) 44 (74.6)  
Yes 357 (16.3) 15 (25.4) 0.063 
Condomless sex with HIV-seroconcordant partners(N=2248)*    
No 1561 (71.3) 48 (81.4)  
Yes 628 (28.7) 11 (18.6) 0.091 
p-values by chi-squared test, chi-squared test-for-trend (T), or Fisher's exact test (F)*Three month recall 
period; All factors defined in section 3.8. 
 
 Prevalence of sexual behaviours  4.4.2
The prevalence of sexual behaviours, other STIs, and attitudes was assessed among 2189 MSM. (Table 
4.2)  A total of 1182 (54.5%) MSM reported having a stable partner, of whom 23.3% had an HIV-positive 
stable partner and 31.7% (29.9-33.7%) had an HIV-serodifferent status stable partner. The prevalence of 
any anal/vaginal sex in the past three months was 63.6%. A total of 836 (38.2%) MSM reported having 
any CLS; 326 (16.3%) had CLS-D and 628 (28.7%) had CLS-C. Self-reported diagnosis with another STI in 
the past three months was 10.9% of 2159 MSM with available data (further discussed in Chapter 8). 
Lifetime diagnosis of hepatitis C virus (HCV) was reported by 15.8% (14.3-17.4%) of 2145 MSM. Over a 
fifth of 2141 MSM reported having group sex in the past three months. Only 0.6% of MSM (13/2162) 
reported having transactional sex. The median number of new sexual partners in the past year was 7 
[IQR 3-10]. Over 26% (n=586) of MSM reported having 10 or more new sexual partners in the past year 
(including 53 MSM who had more than one new partner but did not specify the exact number, see 
section 3.8.4). 
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Table 4.2: Prevalence (95%CI) of sexual behaviours among 2189 HIV-diagnosed MSM  
  n % (95%CI) 
Stable partner's HIV-serostatus (N=2189) 
  
  
HIV-positive 510 23.3 (21.6, 25.1) 
HIV-negative or HIV-unknown status (incl. missing)  694 31.7 (29.8, 33.7) 
No stable partner  985 45.0 (42.8, 47.0) 
Any anal and/or vaginal sex  (N=2189) 1,392 63.6 (61.6, 65.6) 
Any condomless sex (CLS)  (N=2189) 836 38.2 (36.2, 40.2) 
CLS with HIV-serodifferent partners (CLS-D) (N=2189) 357 16.3 (14.8, 17.9) 
CLS with HIV-seroconcordant partners (CLS-C) (N=2189) 628 28.7 (26.8, 30.6) 
Sexually transmitted infections (STI) (N=2160) 236 10.9 (9.7, 12.3) 
Lifetime hepatitis C (N=2145) 338 15.8 (14.3, 17.4) 
Current STI symptoms (N=2186) 273 12.5 (11.2, 13.9) 
Group sex (N=2141) 453 21.2 (19.5, 22.9) 
Used the internet to find sex (N=2144) 796 37.1 (35.1, 39.2) 
Transactional sex (N=2189) ‡ 82 3.7 (3.0,4.6) 
Low condom self-efficacy (N=2142) ‡ 139 6.5 (5.5,7.6) 
Difficulty negotiating condom use (N=2125) ‡ 319 14.9 (13.4,16.5) 
Lower condom use with casual partners (N=2126) ‡ 355 16.7 (15.2,18.4) 
Worry about HIV transmission (N=2186) ‡ 141 6.6 (5.6,7.8) 
≥10 new sexual partners in past year (N=2189) 586 26.8 (25.0,28.7) 
 Three month recall unless otherwise specified; ‡ Factors defined in section 4.3.5   
 Number of sexual partners in the past three months  4.4.3
Among 1391 MSM who reported any anal/vaginal sex in the past three months, information on number 
of sexual partners was available for 1356.(Table 4.3) MSM who reported more than one partner in the 
past three months but did not specify the exact number were excluded from calculations of summary 
statistics. The median number of total partners was 2 [IQR: 1-5], with 73.2% reporting up to four 
partners in the past three months. Over 51% of MSM who had CLS-C reported one CLS-C partner only, 
and 57.5% of MSM who had CLS-D also reported only having one CLS-D partner in the past three 
months; 6.0% reported having 20 or more total partners.  
Table 4.3: Distribution and type of sexual partners in the past three months (N=1356*) 
  
Total anal or vaginal sex partners  CLS-C partners  CLS-D partners  
Median [IQR] 2 [1-5] 1 [1-4] 1 [1-3] 
Range 1-150 1-100 1-100 
Mean [SD] 4.9 [10.0] 3.9 [7.2] 3.3 [7.8] 
% reporting number of partners     
1 44.7 51.5 57.5 
2-4 28.5 27.4 28.8 
5-9 12.9 11.1 7.0 
10-19 8.0 6.7 3.8 
≥20 6.0 3.4 2.9 
*Of 1391 MSM reporting any anal or vaginal sex in past 3 months, information on number of partners 
available for 1356, of whom excluded MSM who reported >1 partner but did not specify exact number; 
n=28  anal or vaginal sex partners, n=13 CLS-C, n=13 CLS-D 
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 CLS-D specific behaviours  4.4.4
Among 357 MSM who had CLS-D in the previous three months, 310 provided information on the 
number of times they had CLS-D; the majority had CLS-D between two and ten times, and 4.3% reported 
having CLS-D more than 30 times in the past three months. (Figure 4.1) Over 70% reported having CLS-D 
with casual partners only in the past three months, while 6.0% reported having CLS-D with a stable 
partner and casual partners. Information on sexual positioning was available for 314 MSM who had CLS-
D, of whom 88 (28.0%) were the insertive partner and reported ejaculating inside their partner, 92 
(29.3%) were insertive but did not ejaculate inside their partner, and 126 (40.1%) were the receptive 
partner only.  
Figure 4.1: Sexual behaviours among MSM reporting CLS-D in the past three months  
 
 
 Associations of socio-demographic characteristics, psychological symptoms, 4.4.5
HIV-related factors, and reporting condomless sex (CLS) 
Table 4.4 shows, among all 2189 MSM, unadjusted and adjusted associations of various factors and 
reporting condomless sex (CLS) in the previous three months (n=836, versus to not reporting CLS, which 
includes condom-protected sex and no anal or vaginal sex). In unadjusted analysis, younger age and 
more recent HIV diagnosis were significantly associated with CLS (ptrend<0.001). The prevalence of CLS 
was lower soon after HIV diagnosis (3 months-2 years), increased to a peak five years post-diagnosis 
(46%), and decreased steadily thereafter to the lowest levels at 15 or more years post-diagnosis (30%). 
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Educational qualifications and being employed were associated with higher prevalence of CLS (p<0.05 
for both). Over 60% of MSM who had a stable HIV-positive partner reported having CLS (p<0.001). Not 
being on ART was associated with 30% higher prevalence of CLS in relative terms compared to being on 
ART. Almost 45% of MSM with detectable study log-recorded VL (>50 c/mL) had CLS (p<0.001). No 
significant association was found of ethnicity, place of birth, religion, financial hardship (money for basic 
needs), social support, depression or anxiety symptoms, and reporting any CLS. 
 
In the first multivariable adjustment strategy (Models 1: Table 4.4), each factor was included in a 
separate model adjusted for core factors. While the trend association of younger age and CLS remained 
robust after adjustment for core factors (p-trend<0.001), the trend association of time since HIV 
diagnosis and CLS was no longer significant (p-trend>0.05). Having a stable partner who was HIV-positive 
remained associated with higher prevalence of CLS. The association of ART status, study log VL, and CLS 
was no longer significant, due to adjustment for time since HIV diagnosis. However, MSM who were on 
ART with self-reported undetectable VL remained more likely to report having CLS, after adjustment for 
core factors. 
 
In the second multivariable strategy (Model 2: Table 4.4), any factor with p<0.10 in unadjusted analysis 
was a candidate for inclusion in the multivariable model, in addition to clinic. These were: age, time 
since HIV diagnosis, education, employment, stable partner status, ART status, ART adherence, ART 
status/self-reported VL, and study log-recorded VL. As ART status was collinear with the latter three ART 
variables, only one ART-related variable was selected for inclusion in the model. The role of ART was 
explored in Models 1, so it was decided to only include ART status/self-reported VL in this model. Hence, 
after adjustment for age, time since HIV diagnosis, education, employment, stable partner status, ART 
status/self-reported VL, and clinic, strong associations remained of younger age and CLS, as well as 
having a HIV-positive stable partner and CLS (p<0.05 for both). There remained an association of being 
on ART with self-reported undetectable VL and reporting CLS (p=0.046). 
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Table 4.4: Association of socio-demographic, psychological, HIV-related factors, and reporting any condomless sex (CLS) in the previous 3 months (N=2189)
 
n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
p-value
Model 2: aPR 
[95%CI]
p-value
Age at recruitment, years (N=2167)
<30 56/96 58.3     2.7 [1.9,3.8] 2.1 [1.5,3.0] 2.2 [1.5,3.1]
30-39 233/487 47.8 2.2 [1.6,3.0] 1.8 [1.3,2.4] 1.8 [1.3,2.5]
40-49 354/929 38.1 1.7 [1.2,2.4] 1.6 [1.2,2.1] 1.5 [1.1,2.1]
50-59 154/503 30.6 1.4 [1.0,1.9] 1.3 [1.0,1.8] 1.3 [0.9,1.8]
≥60 33/152 21.7 1.0 <0.001(T) 1.0 <0.001(T) 1.0 <0.001(T)
Ethnicity (N=2154)
White 738/1928 38.3 1.0 1.0
All other (black, Asian, Mixed, other) 86/226 38.1 1.0 [0.8,1.2] 0.948 1.0 [0.8,1.1] 0.751 -
Time since HIV diagnosis (N=2177)
3 months-2 years 72/184 39.1 1.0 1.0 1.0
2-5 years 157/338 46.4 1.2 [1.0,1.5] 1.2 [0.9,1.4] 1.1 [0.9,1.4]
5-10 years 240/550 43.6 1.1 [0.9,1.4] 1.2 [1.0,1.4] 1.1 [0.9,1.4]
10-15 years 168/461 36.4 0.9 [0.7,1.2] 1.0 [0.8,1.3] 1.0 [0.8,1.2]
>15 years 195/644 30.3 0.8 [0.6,1.0] <0.001 (T) 0.9 [0.7,1.2] 0.061(T) 0.9 [0.7,1.1] 0.063(T)
Place of birth (N=2189)
UK 569/1502 37.9 1.0 1.0
Outside the UK 267/687 38.9 1.0 [0.9,1.2] 0.660 1.0 [0.9,1.1] 0.791 -
Religious (N=2152)
Yes 337/919 36.7 1.0 1.0 -
No 487/1233 39.5 1.1 [1.0,1.2] 0.184 1.0 [0.9,1.1] 0.819
Education (N=2149)  
University degree or above 387/950 40.7 1.0 1.0 1.0
No educational qualifications/up to A levels  437/1199 36.4 0.9 [0.8,1.0] 0.042 0.9 [0.8,1.0] 0.075 1.0 [0.9,1.1] 0.557
Employment (N=2142)
Employed full- or part-time 557/1318 42.3 1.0 1.0 1.0
Unemployed 109/310 35.2 0.8 [0.7,1.0] 0.9 [0.8,1.1] 0.9 [0.8,1.1]
Other (carer retired student) 156/514 30.4 0.7 [0.6,0.8] <0.001 0.9 [0.8,1.0] 0.182 0.9 [0.8,1.1] 0.467
Had condomless sex (CLS) (N=836/2,189)
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n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
p-value
Model 2: aPR 
[95%CI]
p-value
Money for basic needs (N=2158) ‡ 
Always 430/1114 38.6 1.0 1.0
Mostly 223/596 37.4 1.0 [0.9,1.1] 1.0 [0.9,1.1] -
Sometimes 107/275 38.9 1.0 [0.9,1.2] 1.0 [0.9,1.2]
No 65/173 37.6 1.0 [0.8,1.2] 0.834 (T) 1.0 [0.8,1.2]  0.871(T)
Social support (N=2170) ‡ 
Highest 493/1286 38.3 1.0 1.0 -
Medium 262/666 39.3 1.0 [0.9,1.2] 1.1 [1.0,1.2]
Low 76/218 34.9 0.9 [0.7,1.1] 0.446 (T) 1.1 [0.9,1.3] 0.239(T)
Depressive symptoms (N=2189) ‡ 
No 606/1590 38.1 1.0 1.0
Yes 230/599 38.4 1.0 [0.9,1.1] 0.903 1.1 [0.9,1.2] 0.334 -
Anxiety symptoms (N=2189) ‡ 
No 661/1726 38.3 1.0 1.0
Yes 175/463 37.8 1.0 [0.9,1.1] 0.845 1.0 [0.9,1.2] 0.607 -
Stable partner status (N=2189)
HIV-positive stable partner 309/510 60.6 1.0 1.0 1.0
HIV-negative or HIV-unknown status stable partner 202/694 29.1 0.5 [0.4,0.6] 0.5 [0.4,0.6] 0.8 [0.7,1.0]
None 325/985 33.0 0.5 [0.5,0.6] <0.001 0.6 [0.5,0.6] <0.001 1.1 [0.9,1.3] <0.001
ART status (N=2178)
On ART 693/1888 36.7 1.0 1.0 -
Not on ART 140/290 48.3 1.3 [1.2,1.5] <0.001 1.1 [1.0,1.3] 0.147
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n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
p-value
Model 2: aPR 
[95%CI]
p-value
ART adherence (N=2178) ‡ 
On ART adherent 617/1705 36.2 1.0 1.0
On ART non-adherent 76/183 41.5 1.1 [1.0,1.4] 1.1 [1.0,1.4] -
Not on ART 140/290 48.3 1.3 [1.2,1.5] <0.001 1.2 [1.0,1.3] 0.056
ART status/self-reported VL (N=2143) ‡ 
On ART reports undetectable VL 594/1568 37.9 1.0 1.0 1.0
On ART does not report undetectable VL 90/285 31.6 0.8 [0.7,1.0] 0.8 [0.7,1.0] 0.8 [0.7,1.0]
Not on ART 140/290 48.3 1.3 [1.1,1.5] 0.001 1.1 [0.9,1.3] 0.012 1.1 [0.9,1.3] 0.046
Study log-recorded VL  (N=2159)
≤50c/mL 612/1680 36.4 1.0 1.0 -
>50 c/mL 215/479 44.9 1.2 [1.1,1.4] <0.001 1.1 [1.0,1.2] 0.195
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; ‡ Factors defined in chapter 3 VL: viral load; Adjusted PRs (aPR) by modified Poisson 
regression; Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time since HIV diagnosis, stable partner's HIV serostatus, ART status. Denominators 
vary due to missing data in each model. Models for ART adherence, ART status/self-reported VL, and study log VL omit variable on ART due to collinearity. Model 2:  Any factor with 
p<0.10 in unadjusted analysis included in a single model, plus clinic.  
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 Associations of socio-demographic, psychological, HIV-related factors, and 4.4.6
reporting condomless sex with HIV-serodifferent partners (CLS-D) 
Table 4.5 shows, among 2189 MSM, associations of various factors with having CLS-D in the previous 
three months (n=357), versus not reporting CLS-D (which includes having ‘CLS-C without CLS-D’, 
condom-protected sex, and no anal or vaginal sex). In unadjusted analysis, a significant negative trend 
was observed with increasing age; 25% of MSM under 30 years had CLS-D compared to 12% of those 
over 60 years (p-trend=0.004). The prevalence of CLS-D was also lower among those diagnosed for 
longer compared to those recently diagnosed (up to two years ago). Having an HIV-serodifferent stable 
partner was associated with almost two-fold higher prevalence of CLS-D compared to having an HIV-
positive partner (p<0.001). There was a weak indication that the prevalence of CLS-D was 20% higher 
among those not on ART compared to those on ART (p=0.092). There was no significant association 
between CLS-D and ethnicity, place of birth, religion, education, employment, financial hardship, social 
support, depression or anxiety symptoms, ART adherence, and study log-recorded viral load.  
 
In core-adjusted models (Models 1: Table 4.5), only stable partner status remained significantly 
associated with reporting CLS-D; the prevalence of CLS-D was two-fold higher for those with an HIV-
serodifferent stable partner compared to an HIV-positive partner (p<0.001). There was a weak 
indication that the prevalence of CLS-D was higher among younger MSM (p-trend=0.10).  
 
In the second multivariable strategy (Model 2: Table 4.5), the following factors with p<0.10 in 
unadjusted analysis were candidates for inclusion in a single model in addition to clinic: age, time since 
HIV diagnosis, ART status, and ART status/self-reported VL. As the last two variables were collinear, only 
ART status/self-reported VL was retained in the final model. Younger age and having and HIV-
serodifferent stable partner remained significantly associated with reporting CLS-D (p<0.05 for both). 
There remained no association of time since HIV diagnosis, ART status/self-reported VL, with CLS-D.    
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Table 4.5: Association of socio-demographic, psychological, HIV-related factors and reporting any condomless sex with HIV-serodifferent partners (CLS-D) in the 
previous 3 months (N=2189) 
 
n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
Model 2: aPR 
[95%CI]
p-value
Age at recruitment, years  (N=2167)
<30 24/96 25.0 2.1 [1.2,3.6] 1.8 [1.0,3.2] 2.0 [1.1,3.7]
30-39 83/487 17.0 1.5 [0.9,2.3] 1.2 [0.7,2.0] 1.4 [0.8,2.3]
40-49 159/929 17.1 1.4 [0.9,2.3] 1.3 [0.8,2.1] 1.4 [0.9,2.3]
50-59 69/503 13.7 1.1 [0.7,1.8] 1.1 [0.7,1.8] 1.2 [0.7,2.0]
≥60 18/152 11.8 1.0 0.004(T) 1.0 0.099(T) 1.0 0.029(T)
Ethnicity (N=2154)
White 310/1928 16.1 1.0 1.0
All other (black Asian Mixed other) 40/226 17.7 1.1 [0.8,1.5] 0.529 1.1 [0.8,1.4] 0.613 -
Time since HIV diagnosis (N=2177)
3 months-2 years 32/184 17.4 1.0 1.0 1.0
2-5 years 63/338 18.6 1.1 [0.7,1.6] 1.2 [0.8,1.8] 1.1 [0.7,1.6]
5-10 years 100/550 18.2 1.0 [0.7,1.5] 1.2 [0.8,1.8] 1.0 [0.7,1.5]
10-15 years 74/461 16.1 0.9 [0.6,1.3] 1.1 [0.7,1.6] 0.9 [0.6,1.4]
>15 years 86/644 13.4 0.8 [0.5,1.1] 0.018(T) 0.9 [0.6,1.3] 0.180(T) 0.8 [0.5,1.2] 0.105(T)
Place of birth (N=2189)
UK 241/1502 16.0 1.0 1.0
Outside the UK 116/687 16.9 1.0 [0.8,1.2] 0.621 1.0 [0.8,1.2] 0.928 -
Religious (N=2152)
Yes 156/919 17.0 1.0 1.0
No 192/1233 15.6 0.9 [0.8,1.1] 0.382 0.9 [0.7,1.1] 0.239 -
Education (N=2149)
University degree or above 158/950 16.6 1.0 1.0
No educational qualifications/up to A levels  192/1199 16.0 1.0 [0.8,1.2] 0.700 1.0 [0.8,1.2] 0.985 -
Had condomless sex with HIV-serodifferent partner(s) (CLS-D) (N=357/2189)
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n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
Model 2: aPR 
[95%CI]
p-value
Employment (N=2142)
Employed full- or part-time 226/1318 17.1 1.0 1.0
Unemployed 51/310 16.5 1.0 [0.7,1.3] 1.1 [0.8,1.5] -
Other (carer retired student) 71/514 13.8 0.8 [0.6,1.0] 0.228 0.9 [0.7,1.2] 0.538
Money for basic needs (N=2158) ‡ 
Always 176/1114 15.8 1.0 1.0
Mostly 92/596 15.4 1.0 [0.8,1.2] 1.0 [0.8,1.3] -
Sometimes 45/275 16.4 1.0 [0.8,1.4] 1.0 [0.8,1.4]
No 37/173 21.4 1.4 [1.0,1.9] 0.166(T) 1.4 [1.0,1.9] 0.125(T)
Social support (N=2170) ‡ 
Highest 206/1286 16.0 1.0 1.0
Medium 119/666 17.9 1.1 [0.9,1.4] 1.2 [0.9,1.4] -
Low 31/218 14.2 0.9 [0.6,1.3] 0.985(T) 0.9 [0.6,1.4] 0.624(T)
Depressive symptoms (N=2189) ‡ 
No 255/1590 16.0 1.0 1.0
Yes 102/599 17.0 1.1 [0.9,1.3] 0.575 1.1 [0.9,1.3] 0.549 -
Anxiety symptoms (N=2189) ‡ 
No 276/1726 16.0 1.0 1.0
Yes 81/463 17.5 1.1 [0.9,1.4] 0.435 1.1 [0.8,1.4] 0.566 -
Stable partner status (N=2189)
HIV-positive stable partner 56/510 11.0 1.0 1.0 1.0
HIV-negative or HIV-unknown status stable partner 148/694 21.3 1.9 [1.5,2.6] 2.0 [1.5,2.7] 2.0 [1.5,2.6]
None 153/985 15.5 1.4 [1.1,1.9] <0.001 1.4 [1.1,1.9] <0.001 1.4 [1.1,1.9] <0.001
ART status (N=2178)
On ART 298/1888 15.8 1.0 1.0 -
Not on ART 57/290 19.7 1.2 [1.0,1.6] 0.092 1.1 [0.9,1.5] 0.386
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n had CLS/N row %
unadjusted PR 
[95%CI]
p-value
Models 1: aPR 
[95%CI]
Model 2: aPR 
[95%CI]
p-value
ART adherence (N=2178) ‡ 
On ART adherent 274/1705 16.1 1.0 1.0
On ART non-adherent 24/183 13.1 0.8 [0.6,1.2] 0.8 [0.5,1.2] -
Not on ART 57/290 19.7 1.2 [0.9,1.6] 0.147 1.1 [0.8,1.5] 0.394
ART status/self-reported VL (N=2143) ‡ 
On ART reports undetectable VL 259/1568 16.5 1.0 1.0 1.0
On ART does not report undetectable VL 35/285 12.3 0.7 [0.5,1.0] 0.7 [0.5,1.0] 0.7 [0.5,1.0]
Not on ART 57/290 19.7 1.2 [0.9,1.5] 0.059 1.1 [0.8,1.4] 0.131 1.0 [0.8,1.4] 0.189
Study log-recorded viral load (N=2159)
≤50 c/mL 264/1680 15.7 1.0 1.0
>50  c/mL 89/479 18.6 1.2 [1.0,1.5] 0.132 1.1 [0.8,1.4] 0.608 -
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; ‡ Factors defined in chapter 3; VL: viral load; Adjusted PRs (aPR) by modified Poisson 
regression; Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time since HIV diagnosis, stable partner's HIV serostatus, ART status. Denominators vary due to 
missing data in each model. Models for ART adherence, ART status/self-reported VL, and study log VL omit variable ART status due to collinearity. Model 2:  Any factor with p<0.10 in unadjusted 
analysis included in a single model, plus clinic.  
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 Prevalence of sexual activity according to single variable 4.4.7
Using the single variable classifying all 2189 MSM into four mutually exclusive categories of sexual 
behaviour in the past three months, the prevalence was:  
1. CLS-D: N=357, 16.3% (95%CI 14.8-17.9%) 
2. ‘CLS-C without CLS-D’: N=479, 21.9% (20.2-23.7%) 
3. Condom-protected sex only: N=556, 25.4% (23.6-27.3%) 
4. No anal or vaginal sex: N=797, 36.4% (34.4-38.4%)  
A total of 31 MSM reported having CLS but did not report their partners’ HIV-serostatus (CLS-
unspecified). The CLS-unspecified group was compared to 479 MSM who had ‘CLS-C without CLS-D’, and 
326 MSM who had CLS-D. (Appendix IV) Overall, men who had CLS-unspecified tended to be more 
similar to the CLS-D group than the ‘CLS-C without CLS-D’ group on a number of factors including: time 
living with diagnosed HIV, stable partner status, other STIs, hepatitis C, number of sexual partners, and 
attitudes to condom use and HIV transmission. (Appendix IV) On the basis of these results, the CLS-
unspecified group was incorporated into the CLS-D group (1) in the single variable classifying sexual 
behaviour in the past three months. 
4.4.7.1 Associations of socio-demographic, psychological, and HIV-related factors 
with single variable of sexual behaviour  
The four categories of sexual behaviour in the past three months were compared on key factors. (Table 
4.6) Compared to the three sexually active groups (CLS-D, ‘CLS-C without CLS-D’, and condom-protected 
sex), MSM who did not have sex in the previous three months were significantly different on almost all 
factors (p<0.05); they tended to be older, diagnosed with HIV for longer, were less likely to be born in 
the UK, have educational qualifications, and to be employed. Prevalence of low social support, 
symptoms of depression and anxiety were highest among MSM who did not have sex compared to the 
other three groups (p<0.05 for all). MSM who did not have sex were also more likely to not have a stable 
partner compared to the three sexually active groups (p<0.001). This group were also more likely to be 
on ART and virally suppressed. Over 40% of those who did not have sex reported being on ART with self-
reported detectable VL, the highest prevalence of all groups (p<0.001). 
 
There were few significant differences in socio-demographic factors between the three sexually active 
groups, except for age; MSM who had ‘CLS-C without CLS-D’ were slightly younger than MSM who had 
CLS-D or condom-protected sex (Table 4.6). In addition, MSM who had CLS-D were more likely to report 
financial hardship compared to those who had CLS-C and those who had condom-protected sex (p-
trend=0.021). The prevalence of depression and anxiety symptoms followed a similar pattern, being 
higher in the CLS-D group, followed by CLS-C, and lowest for the condom-protected group (p<0.10 for 
both). No significant differences were found between the three sexually active groups on HIV-related 
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factors; the prevalence of ART use, ART adherence and viral load non-suppression was similarly 
distributed.  
 
Multinomial logistic regression (MNL) was used to examine associations between factors and reporting 
CLS-C or CLS-D as compared to condom-protected sex (baseline).(Table 4.7) In unadjusted MNL, younger 
age, having a stable partner, and reporting symptoms of depression were significantly associated with 
having CLS-C relative to condom-protected sex (p<0.05 for all). The odds of having CLS-D relative to 
condom-protected sex were 1.55 times greater for MSM reporting financial hardship compared to those 
who did not p=0.01). Not knowing one’s personal VL was associated with lower prevalence of CLS-C and 
CLS-D relative to condom-protected sex compared to knowing personal VL (p<0.05 for both). In 
multivariable MNL adjusting for clinic plus all factors with p<0.10 in unadjusted MNL (age, financial 
hardship, stable partner, depression symptoms, and self-reported VL), these associations remained 
significant. The prevalence of CLS-D relative to condom-protected sex was 39% lower among those who 
knew their personal VL compared to those who did not (p=0.007).  
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Table 4.6: Socio-demographic, psychological, HIV-related factors according to mutually exclusive categories of sexual behaviour in past 3 months (N=2189) 
 
p-value 
across 
groups 1-4
p-value 
across 
groups 1-3 
n % n % n % n %
Mean age [SD] (N=2167) 44.6 (9.3) 42.9 (8.8) 44.7 (9.6) 48.6 (9.0) <0.001(T) 0.003(T)
Median years since HIV diagnosis [IQR] (N=2177) 9 [4-15] 8 [4-14] 9 [4-15] 12 [7-18] <0.001(T)  0.711(T)
Ethnicity (N=2154)
White 310 (88.6) 428 (90.3) 477 (87.5) 713 (90.8)
All other 40 (11.4) 46 (9.7) 68 (12.5) 72 (9.2) 0.223 0.374
Place of birth (N=2189)
UK 241 (67.5) 328 (68.5) 357 (64.2) 576 (72.3)
Outside the UK 116 (32.5) 151 (31.5) 199 (35.8) 221 (27.7) 0.017 0.315
Religious (N=2152)
No 192 (44.8) 181 (38.0) 232 (42.6) 350 (44.6)
Yes 156 (44.8) 181 (38.0) 232 (42.6) 350 (44.6) 0.107 0.120
Education (N=2149)
University degree or above 158 (45.1) 229 (48.3) 255 (46.6) 308 (39.6)
No educational qualifications/up to A levels only  192 (54.9) 245 (51.7) 292 (53.4) 470 (60.4) 0.010 0.661
Employment (N=2142)
Employed full- or part-time 226 (64.9) 331 (69.8) 370 (68.1) 391 (50.3)
Unemployed 51 (14.7) 58 (12.2) 84 (15.5) 117 (15.1)
Other (carer retired student) 71 (20.4) 85 (17.9) 89 (16.4) 269 (34.6) <0.001 0.334
Money for basic needs (N=2158)
Always 176 (50.3) 254 (53.5) 313 (57.3) 371 (47.1)
Mostly 92 (26.3) 131 (27.6) 143 (26.2) 230 (29.2)
Sometimes 45 (12.9) 62 (13.1) 53 (9.7) 115 (14.6)
Never 37 (10.6) 28 (5.9) 37 (6.8) 71 (9.0) 0.001(T) 0.021(T)
Social support (N=2170) ‡
Highest 111 (31.2) 158 (33.3) 198 (35.7) 217 (27.6)
Medium 202 (56.7) 265 (55.8) 303 (54.7) 458 (58.3)
Lowest 43 (12.1) 52 (10.9) 53 (9.6) 110 (14.0) 0.003(T) 0.239(T)
(1) CLS-D (n=357)*
(2) 'CLS-C without CLS-D' 
(n=479)
(3) Condom-protected sex 
only (n=556) 
(4) No anal/vaginal sex 
(n=797)
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p-value 
across 
groups 1-4
p-value 
across 
groups 1-3 
n % n % n % n %
Depression symptoms (N=2189) ‡
No 255 (71.4) 351 (73.3) 443 (79.7) 541 (67.9)
Yes 102 (28.6) 128 (26.7) 113 (20.3) 256 (32.1) <0.001 0.008
Anxiety symptoms (N=2189) ‡
No 276 (77.3) 385 (80.4) 464 (83.5) 601 (75.4)
Yes 81 (22.7) 94 (19.6) 92 (16.5) 196 (24.6) 0.003 0.068
Stable partner status (N=2189)
None 153 (42.9) 172 (35.9) 241 (43.3) 419 (52.6)
HIV-positive stable partner 56 (15.7) 253 (52.8) 80 (14.4) 121 (15.2)
HIV-negative or HIV-unknown 148 (41.5) 54 (11.3) 235 (42.3) 257 (32.2) <0.001 <0.001
ART status (N=2178)
On ART 264 (74.8) 348 (73.4) 421 (76.4) 647 (82.8)
Not on ART 57 (16.1) 83 (17.4) 82 (14.8) 68 (8.6) <0.001 0.534
ART adherence (N=2178) ‡
On ART adherent 274 (77.2) 343 (71.8) 431 (77.8) 657 (83.1)
On ART non-adherent 24 (6.8) 52 (10.9) 41 (7.4) 66 (8.3)
Not on ART 57 (16.1) 83 (17.4) 82 (14.8) 68 (8.6) <0.001 0.102
ART status/self-reported VL (N=2143) ‡ 
On ART reports undetectable VL 259 (73.8) 335 (70.8) 381 (70.0) 593 (76.5)
On ART does not report undetectable VL 35 (10.0) 55 (11.6) 81 (14.8) 114 (14.7)
Not on ART 57 (16.2) 83 (17.6) 82 (17.1) 68 (8.8) <0.001 0.202
Study log-recorded viral load (N=2159)
≤50 c/mL 264 (74.8) 348 (73.4) 421 (76.4) 647 (82.8)
>50 c/mL 89 (25.2) 126 (26.6) 130 (23.6) 134 (17.2) <0.001 0.543
P-values by chi-squared test or (T): chi-squared test for linear trend (Wald test by multinomial logistic regression); * CLS-D includes 31 MSM who reported CLS but did not specify the HIV 
serostatus of their sexual partners ('CLS-unspecified'; ‡ Factors are defined in chapter 3
(1) CLS-D (n=357)*
(2) 'CLS-C without CLS-D' 
(n=479)
(3) Condom-protected sex 
only (n=556) 
(4) No anal/vaginal sex 
(n=797)
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Table 4.7: Odds ratios (ORs) and confidence intervals (95%CIs) for the association of factors with CLS-C or CLS-D as compared to condom-protected sex in the 
past 3 months (multinomial logistic regression among 1392 HIV-diagnosed MSM who reported sex in past 3 months)  
Condom-
protected 
sex 
(N=556)
N* RRR [95%CI] p-value RRR [95%CI] p-value 
Age at recruitment (per year increase) 1362 ref 0.98 [0.97,0.99] 0.002 1.00 [0.98,1.01] 0.890
White ethnicity (vs all other) 1369 ref 1.33 [0.89,1.97] 0.162 1.10 [0.73,1.67] 0.639
Time since HIV diagnosis (per year increase) 1375 ref 1.00 [1.00,1.01] 0.475 1.00 [0.99,1.01] 0.866
Financial hardship (vs none‡) 1371 ref 1.18 [0.86,1.63] 0.303 1.55 [1.11,2.17] 0.010
Has stable partner (vs does not) 1380 ref 1.39 [1.08,1.79] 0.010 1.04 [0.79,1.36] 0.795
Depression symptoms (vs none) 1392 ref 1.43 [1.07,1.91] 0.015 1.57 [1.15,2.14] 0.004
Anxiety symptoms (vs none) 1392 ref 1.23 [0.90,1.69] 0.199 1.48 [1.06,2.07] 0.021
Not on ART (vs on ART) 1387 ref 1.21 [0.87,1.69] 0.263 1.10 [0.76,1.59] 0.608
Unknown self-reported viral load (vs known) 1171 ref 0.63 [0.37,1.05] 0.076 0.40 [0.21,0.76] 0.005
Self-reported viral load >50c/mL (vs unknown) 194 ref 0.65 [0.33,1.27] 0.207 0.34 [0.15,0.73] 0.006
Age at recruitment (per year increase) ref 0.97 [0.96,0.99] 0.001 0.99 [0.98,1.01] 0.370
White ethnicity (vs all other) - - -
Time since HIV diagnosis (per year increase) - - -
Financial hardship (vs none‡) ref 1.25 [0.85,1.83] 0.265 1.54 [1.03,2.28] 0.035
Has stable partner (vs does not) ref 1.67 [1.25,2.24] 0.001 1.19 [0.88,1.62] 0.263
Depression symptoms (vs none) 1.42 [1.01,2.01] 0.046 1.53 [1.07,2.20] 0.020
Anxiety symptoms (vs none) - - -
Not on ART (vs on ART) - - -
Unknown self-reported viral load (vs known) ref 0.60 [0.35,1.04] 0.069 0.39 [0.20,0.77] 0.007
Self-reported viral load >50c/mL (vs unknown) - - -
*Number with available information in each model; adjusted model includes all variables with p<0.15 in unadjusted models plus clinic; ref: reference category; ‡Financial 
hardship defined as money for basic needs: "sometimes or never" versus "always or most of the time"
CLS-C but not CLS-D (N=479) CLS-D (N=357)
Adjusted 
model
Unadjusted 
models
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4.4.7.2 Prevalence of other sexual behaviours according to single variable of sexual 
activity  
Among 1392 MSM who reported having sex in the previous three months, the prevalence of various 
sexual behaviours, STIs, and attitudes was assessed according to sexual activity in the past three months 
(CLS-D, ‘CLS-C without CLS-D’, or condom-protected sex). (Figure 4.2) There were significant differences 
in prevalence of all other sexual factors in the past three months between the three sexually active 
groups (p<0.05). Overall, prevalence of all other sexual behaviour measures was lower among the 
condom-protected sex group than the two CLS groups. The prevalence of other diagnosed STIs, current 
STI symptoms, higher partner numbers, group sex, and use of the internet to find sex were highest 
among men having CLS-D, followed by CLS-C, and then condom-protected sex. Prevalence of lifetime 
HCV diagnosis was higher in the CLS-C group compared to the CLS-D (22.6% vs 19.4%, p<0.001). Men 
reporting CLS-D were more likely than the other two sexually active groups to report 30 or more new 
sexual partners in the past year and low condom self-efficacy (p<0.001 for both). Worry about HIV 
transmission was highest in the CLS-D group (40.7%), followed by the condom-protected group (5.7%), 
and was lowest for the CLS-C group (2.5%, p<0.001 across 3 groups). The pattern of agreement to 
statements on difficulty in discussing and using condoms was similar, being highest for MSM in the CLS-
D group, followed by the CLS-C, and condom-protected groups. Only 1.3% of MSM who had condom-
protected sex were categorised as ‘least conservative’ with regards to their views on HIV transmission 
risk, as compared to 5.7% and 10.3% of MSM who had CLS-C and CLS-D respectively (p<0.001).  
 New sexual partners in the past year  4.4.8
The number of new sex partners in the past 12 months was tabulated against the single variable of 
sexual behaviour in the past three months for all 2189 MSM. (Figure 4.3) Prevalence of all CLS in the 
previous three months, particularly of CLS-D, increased with increasing number of new sexual partners 
in the past year (p-trend<0.001). Of the 102 MSM who reported 50 or more new partners in the past 
year, 87.2% reported having CLS (54.9% had CLS-D) in the previous three months, compared to 880 
MSM who did not have any new sex partners, of whom 20.2%  reported having CLS (6.0% had CLS-D).  
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Figure 4.2: Prevalence of other sexual behaviours according to three mutually exclusive 
categories of sexual activity in the past three months (N=1392 reporting any anal or vaginal 
sex in past three months) 
 
0% 20% 40% 60% 80%
Other diagnosed STIs (n/N=203/1377)
Current symptoms of STIs (176/1392)
≥10 sexual partners  (185/1329) 
Participated in group sex (428/1367)
Used internet to find sex (702/1368)
Transactional sex (79/1392)
Lifetime hepatitis C diagnosis (230/1364)
≥30 new sexual partners in past year (178/1319) 
HIV-negative partners took PEP or PrEP
(27/1391)
Low condom self-efficacy (96/1371) ‡ 
Difficulty negotiating condom use (220/1372) ‡ 
Lower condom use with casual partners 
(266/1362)‡ 
Worry about HIV transmission (107/1364)‡ 
Least conservative HIV transmission risk beliefs 
(70/1367) ‡ 
(3) Condom-protected sex only (n=556) (2) 'CLS-C without CLS-D' (n=479) (1) CLS-D  (n=357)
Three month recall unless otherwise specified; *p-values by chi-squared test or Fisher's exact (F) 
across groups 1-3; ‡Factors defined in chapter 3, section 4.3.5; CLS-D: condomless sex with HIV-
serodifferent partners; CLS-C: condomless sex with HIV-seroconcordant partners; PEP: post-
exposure prophylaxis; PrEP: pre-exposure prophylaxis; STI: sexually transmitted infection  
p<0.001 for all 
factors * 
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Figure 4.3: Number of new sexual partners in the past 12 months according to prevalence of 
each mutually exclusive category of sexual behaviour in the past 3 months (N=2189)  
 
4.5 Discussion 
 Summary of findings 4.5.1
In this study of 2189 HIV-diagnosed MSM in the UK, over 63% reported having any anal or vaginal sex in 
the previous three months. Condomless sex (CLS) in the previous three months was prevalent (38%): 
29% had CLS-C and 16% had CLS-D. When categorising sexual behaviour in mutually exclusive groups, 
16% of MSM had CLS-D, 22% had CLS-C only (without any CLS-D partners), 25% had condom-protected 
sex, and 36% did not have any anal or vaginal sex in the past three months. Younger age and having an 
HIV-positive stable partner were associated with higher prevalence of any CLS in the past three months, 
after adjustment for socio-demographic and HIV-related factors. Compared to MSM who had any anal 
or vaginal sex, MSM who did not have sex were older, diagnosed with HIV for longer, had low 
educational qualifications, low social support, symptoms of depression and anxiety, but were more 
likely to be on ART with suppressed VL. There were few significant differences between the three 
sexually active groups (CLS-D, ‘CLS-C without CLS-D’, and condom-protected sex); compared to those 
who had condom-protected sex only, those who had CLS-D reported greater financial hardship and 
0%
20%
40%
60%
80%
100%
0 1 2-4 5-9 10-19 20-49 ≥50 
Number of new sexual partners (past 12 months) 
(1) CLS-D (n=357) (2) CLS-C without CLS-D (n=479)
(3) Condom-protected sex only (n=556) (4) No anal/vaginal sex (n=797)
N:            880         82             318                 245               220                211         102 
 
‡ test for linear trend for each category (1-4) 
p<0.001
‡ for all 
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symptoms of depression, were more likely to know their personal VL, and had higher prevalence of 
other STIs, group sex, and high partner numbers. Those who had ‘CLS-C without CLS-D’ tended to be 
younger than those who had condom-protected sex only, and were more likely to have an HIV-positive  
stable partner, symptoms of depression, and lifetime HCV infection. 
 Prevalence of condomless sex (CLS) 4.5.2
There have been few representative studies of sexual behaviour among HIV-diagnosed MSM in the UK 
in the past decade (summarised in Table 2.1 and Table 2.2).  
4.5.2.1 Any CLS 
Similar prevalence estimates of CLS were observed in earlier self-completed questionnaire studies of 
HIV-diagnosed MSM recruited from HIV-outpatient clinics in the UK; over 38% reported any condomless 
CLS in the past three months in ASTRA, compared to 38% in the East London study (2004-2005) and 51% 
in the HIV clinic sample of the London Gyms study (2008).
103,131
 The prevalence in ASTRA is also 
comparable to pooled estimates from a US meta-analysis of 30 cross-sectional studies (1996-2009), in 
which prevalence of any CLS in the past three months ranged from 25% to 68%.
111
 Two recent studies of 
HIV-outpatient MSM have found differing prevalence estimates; 46% in the past three months in the 
USA ATN study of 991 young HIV-diagnosed MSM
177
 and 46% in the past six months among 300 
outpatient HIV-diagnosed MSM in the Netherlands.
201
 
  
Studies of HIV-positive MSM from convenience samples (gay and other community venues, bars, 
saunas) report variable estimates of greater magnitude compared to clinic-based studies.(Table 2.2) The 
prevalence of any CLS among HIV-positive MSM in the past year was: 44% (n=187 HIV-positive MSM) in 
the UK behavioural surveillance system (2004)
97,140
, 82.1% (n=243) in the GMSS (2008)
134,144
, 25% (n=59) 
in the Scotland GMSHS (2011)
142
, and 52.6% (n=1494) in the London GMSHS (2013).
143
 Samples of self-
reported HIV-positive MSM recruited from venue-based studies are not representative of all HIV-
diagnosed MSM in the UK in terms of patterns of sexual behaviour. Studies that systematically recruit 
HIV-positive MSM from hospital clinics are likely to be the most representative, as in the UK the vast 
majority of adults newly diagnosed with HIV (98%) attend for care at specialist National Health Service 
(NHS) clinics, and rates of retention in care are high.
228
 
4.5.2.2 Condomless sex with HIV-serodifferent partners (CLS-D) 
The prevalence of CLS with HIV-serodifferent partners (HIV-negative or HIV-unknown) in the past three 
months was 16% (n/N=357/2189) in ASTRA. Earlier UK studies of HIV-diagnosed MSM recruited from 
clinics have found variable estimates (using the same definition of CLS-D and recall period as in ASTRA), 
but are based on much smaller sample sizes. In addition, these studies have not excluded participants 
with a date of diagnosis occurring within the recall period of sexual behaviour. If such individuals are not 
excluded from the ASTRA sample, the prevalence of CLS-D in the past three months was 15.6% 
(n/N=357/2248), as compared to: 27% (n/N=40/148) in ‘London Gyms’, 5% (25/481) in the clinic sample 
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of the ‘Internet and HIV’ study, 20% (144/715) in the ‘East London’ study, and 15% (69/415) in the 
‘Switching’ study.
103,114,131,151
 The prevalence of CLS-D in the past three months in ASTRA is lower than 
the pooled CLS-D estimate reported in the earlier US meta-analysis (26%)
111
; this difference may be due 
to population characteristics, as studies included in the meta-analysis recruited self-reported HIV-
positive MSM from gay venues in addition to HIV-diagnosed MSM from HIV clinics. In the US Medical 
Monitoring Project (see Table 2.1), the prevalence of CLS-D among 1010 HIV-diagnosed MSM was 20.0% 
(95%CI 17.0-23.0%) in the past year.
157
 Findings from ASTRA are also in line with those from the START 
trial of early versus deferred ART initiation.
156
 Among 1173 HIV-diagnosed ART-naïve MSM in the 
European START sub-sample, 15.1% reported CLS-D (with HIV-negative or unknown status partners) in 
the past two months.
156
 When excluding MSM diagnosed in the past three months (as in this ASTRA 
analysis) the prevalence of CLS-D was 12.1%. 
 
While a number of studies have examined the prevalence of CLS-D among HIV-outpatient MSM in the 
USA
113,152,157,169,180,181
 and Western Europe
124,229
, comparison between estimates is not straightforward. 
Estimates from convenience samples (gay clubs, saunas, and websites) of HIV-positive MSM vary widely, 
but again, tend to be of higher magnitude compared to clinic studies.
73,105,134,142,143,171,230
 This is likely due 
to overestimation of the prevalence of sexual risk behaviour inherent in populations sampled from 
commercial gay venues or the internet, which may select more ‘high risk’ MSM.
231
 Interpreting 
estimates of CLS-D from different studies can thus be challenging, as the sampled population may not be 
representative of the underlying population of HIV-diagnosed MSM. Studies also define CLS-D in 
different ways (with HIV-unknown status or HIV-negative partners, or both), and have different recall 
windows (in the past 3, 6, 12 months or at last sex). Nevertheless, the consistency in estimates of CLS-D 
prevalence between the aforementioned UK clinic-based studies and ASTRA is encouraging in 
supporting our ability to reliably and repeatedly measure such behaviour and capture trends. These 
results suggest that prevalence of CLS-D among HIV-diagnosed MSM in the UK attending for care has 
remained fairly stable during the past decade.  
 
A minority of MSM who reported CLS but did not specify their partner’s serostatus (‘CLS-unspecified’) in 
ASTRA had similar sexual behaviours as MSM who had CLS-D, including high partner numbers and 
prevalence of other STIs. (Appendix IV) When including this group, prevalence of CLS-D rose slightly, to 
16.3% in the previous three months.  
 
Consistent with other studies,
9,73,111
 results from ASTRA suggest that perceived risk reduction strategies, 
such as being the receptive partner and withdrawal before ejaculation, are (to a certain extent) being 
used during CLS-D. It remains unclear whether these were consciously chosen strategies to avoid HIV 
transmission or circumstantial preferences.
111,232
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4.5.2.3 Condomless sex with HIV-seroconcordant partners (CLS-C) 
In this study, CLS with other HIV-positive partners was prevalent, suggesting actual or perceived 
serosorting (selecting sexual partners based on HIV status). When including all MSM reporting CLS-C in 
ASTRA (including those who also reported CLS-D), prevalence was 28.6% in the past three months. This 
is comparable to the earlier meta-analysis of US cross-sectional studies among HIV-diagnosed MSM, 
which reported pooled prevalence estimates of CLS-C at any point in time of 30% (95%CI 25-35%).
111
 It 
was not possible to ascertain whether the HIV-positive status of reported CLS-C partners was assumed 
or known with confidence. However, the prevalence of CLS-C excluding those who also reported CLS-D 
in the previous three months in ASTRA (21.9%) is similar to that observed in  the earlier UK clinic studies, 
which had smaller sample sizes; prevalence of CLS-C in the previous three months among HIV-diagnosed 
MSM was 24.3% (36/148) in the clinic sample of ‘London Gyms’ (in 2008), 14% (98/715) in the ‘East 
London’ study, and 7.1% (34/481) in the clinic sample of ‘Internet and HIV’.
103,128
 Some studies from the 
USA have reported variable estimates of CLS-C compared to ASTRA; 36% (178/496) in the previous three 
months among HIV-diagnosed clinic attendees in the Positive STEPS study
113
 and 39% in the previous 12 
months among HIV-diagnosed STI clinic outpatients in Seattle.
181
  
 Factors associated with CLS  4.5.3
4.5.3.1 Socio-demographic characteristics 
A number of co-factors have been identified as correlates of CLS among HIV-diagnosed MSM, but these 
vary according to the population sampled, the range of factors considered and the study design.(Section 
2.6) In ASTRA, CLS was significantly more common among younger men (under 30 years), a finding 
corroborated in the European START sub-sample, the Swiss HIV Cohort study, and the Australian 
‘Positive Health’ surveys,
9,124,233
 but not in the earlier ‘East London’ and ‘Internet and HIV’ studies.
103,151
 
The association with younger age could be explained by the variation in sexual function by life stage 
observed in the general population as well; stratified probability surveys in the UK, such as the National 
Survey of Sexual Attitudes and Lifestyles (Natsal), show that low sexual activity overall is associated with 
increasing age.
234
 The discrepant findings observed may also be due to diverse recruitment methods. 
Online surveys of MSM (of mixed HIV-serostatus), such as EMIS, tend to be biased towards a lower 
median age of participants, but this is not the case for HIV-diagnosed MSM, who have been 
overrepresented in older age groups.
235
  
 
No consistent association has been found between ethnicity/race and CLS or CLS-D among MSM living 
with HIV in a number of studies from the USA.
157,165,169–172
 In ASTRA the majority of MSM were of white 
ethnicity and no differences were observed in the prevalence of any CLS by ethnicity. 
 
While there was some indication that HIV-diagnosed MSM who had lower educational levels and were 
not employed reported lower prevalence of CLS, the associations were not significant after adjustment 
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for age. The lack of association between these two factors and CLS has been previously reported in 
studies from the UK
103
 and USA.
110,113,175,176
 However, in the London GMSHS (2000-2013), HIV-positive 
MSM educated up to two years after age 16 were 30% more likely to report CLS in the past year 
compared to those educated up to age 16.
143
 However, this group included MSM with undiagnosed HIV 
as well as HIV-diagnosed MSM who had CLS, and so the true effect of education on CLS in HIV-diagnosed 
MSM could not be untangled. In ASTRA, HIV-diagnosed MSM who reported not having anal or vaginal 
sex in the previous three months were significantly more likely to not have any educational 
qualifications or employment, compared to those who had sex (condomless or condom-protected). The 
majority of studies in the past decade have examined educational and employment status within the 
context of reporting any sex (i.e. comparing condomless sex versus condom-protected sex). Our study 
shows that HIV-diagnosed MSM who are disadvantaged in terms of education and employment are 
more likely to report not having any sex, compared to those who report having sex.   
4.5.3.2 HIV-related factors 
Uncertainty remains around the association of time elapsed since an HIV diagnosis and CLS. Longitudinal 
studies among MSM have observed a sharp reduction in the prevalence of CLS after a HIV-positive 
diagnosis, followed by an increase and then plateauing long-term.
93,111,181
 In ASTRA, prevalence of CLS 
and CLS-D was lower soon after diagnosis (up to 2 years), then increased (at 2-5 years), and steadily 
decreased thereafter to the lowest levels (at >15 years post-diagnosis). The association remained 
significant even after adjustment for participant’s age. These findings are in line with START and other 
recent USA studies,
110,179,181,230
 but not with earlier studies of clinic outpatients from the UK or the USA, 
which did not find the prevalence of CLS to vary by the length of time diagnosed.
103,111,113,167,175
 The 
association of time since HIV diagnosis and CLS may be dependent on whether participants who are 
recently HIV-diagnosed are excluded; this ensures that participants reporting CLS prior to HIV diagnosis 
are not accounted for.  
 
In line with the 2009 meta-analysis of 30 cross-sectional US studies and the earlier ‘East London’ 
study,
103,111
 ASTRA shows that MSM who were on ART were less likely to report any CLS. This 
association, however, was not independent of time since HIV diagnosis. The prevalence of CLS-D was 
lower among MSM on ART compared to those not on ART. There was some evidence to suggest that 
MSM with detectable study log-recorded VL (>50c/mL) were slightly more likely to report CLS, but not 
with HIV-serodifferent partners. It is thus possible that this association is driven by MSM with detectable 
VL who have CLS with other HIV-positive partners only.  
 
Perceived virological status may also affect decisions on condom use. In ASTRA, a small proportion of 
MSM reported not knowing their personal VL (6.4% of 2189); this group were less likely to have any CLS 
(including CLS-D) compared to those who reported having suppressed VL (<50c/mL). In addition, MSM 
who did not know their VL were more likely to report having condom-protected sex compared to any 
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CLS, even after adjustment for socio-demographic and other factors. Among MSM on ART, prevalence of 
CLS and CLS-D tended to be higher among those with self-reported undetectable VL compared to those 
on ART without undetectable VL (including those who did not know their VL and those who had 
detectable VL). These findings may indicate that decisions on condom use may be influenced by 
perceived viral load status. Coupled with the high prevalence of detectable viremia among those who 
reported ‘CLS-C without CLS-D’, these results may also suggest HIV-serosorting for transmission risk 
reduction, especially in the absence of effective ART.  
 
There have been no studies examining the association of non-adherence to ART and CLS in the UK to 
date. MSM who reported non-adherence in ASTRA tended to be less likely to report having CLS-D 
compared to those who reported good adherence. Comparison across different sexual behaviours in the 
past three months showed that almost a third of MSM who were non-adherent reported not having 
anal or vaginal sex  (versus condomless or condom protected sex). The earlier US meta-analysis (2009) 
showed that HIV-positive MSM reporting more than 90% adherence were not more likely to have CLS, 
but these findings were based on a small subset of studies with available adherence information.
111
   
4.5.3.3 Psychological wellbeing 
Symptoms of depression or anxiety were not found to be significantly associated with the binary 
classification of CLS in ASTRA, in line with previous research of HIV-diagnosed heterosexual men and 
women.
154,186–188,236
 Disentangling the causality of the association between psychological factors (such as 
depression and anxiety) and CLS is challenging, especially in cross-sectional studies. The association may 
be bidirectional, as negative affects could promote CLS or CLS may in turn promote anxiety and 
depression. Use of the mutually exclusive categories of sexual behaviour, however, highlighted more 
complex underlying associations of depression with different types of sex; MSM with symptoms of 
depression or anxiety were significantly more likely to report not having anal or vaginal sex compared to 
having sex. The prevalence of psychological symptoms was also high among those who had CLS (and was 
higher for those who had CLS-D rather than CLS-C) compared to those who had condom-protected sex. 
Hence, depression may have a curvilinear relationship with sexual behaviour, being associated with both 
low levels of sexual activity and more sexual risk behaviours.
190
 HIV-positive people with symptoms of 
depression may have low libido overall or experience higher sensitivity to potential risks, thus adopting 
more risk-averse behaviours; on the other hand, those with depression may also have maladaptive 
thought processes which reduce motivations for effective self-care and lead to ‘riskier’ behaviours (such 
as recreational drug use or CLS).
190
  
 
Our study did not have completely overlapping periods for the measures of psychological symptoms and 
sexual behaviours (depression and anxiety measured in the past two weeks and sexual behaviours in the 
past three months), which may have underestimated the strength of any association. However, the 
PHQ-9 and GAD-7 have been found to have high accuracy and validity among HIV-positive people.
209,237
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Few studies have examined the relationship between perceived social support and CLS among HIV-
diagnosed MSM, all having small sample sizes. (Section 2.6.3) An association similar to that of 
depression and sexual behaviour was observed for low functional social support and sexual behaviours. 
While low social support was not associated with reporting CLS overall (using the binary classification), 
when using the mutually exclusive categories, a curvilinear association emerged; prevalence of low 
social support was highest among MSM who did not have anal or vaginal sex, followed by those who 
had CLS-D (14% vs 12% respectively).  
4.5.3.4 Partner-related factors  
Having a stable partner was significantly associated with having CLS in ASTRA. Specifically, MSM were 
more likely to report CLS with an HIV-positive stable partner, than with an HIV-negative or HIV-unknown 
status stable partner. This finding, corroborated in other studies,
113,134,136,143,152,166,195,196
 may indicate 
that HIV-diagnosed MSM are more likely to use condoms when there is perceived risk of HIV 
transmission. Preference for seroconcordant stable relationships may also be a lifestyle choice in 
reducing the risk of HIV transmission to HIV-serodifferent partners. For those with an HIV-serodifferent 
stable partner, however, the likelihood of reporting CLS-D was much higher than for those who did not 
have a partner or who had an HIV-positive stable partner. The concordance between stable partner’s 
serostatus and reporting CLS/CLS-D is encouraging as it shows that the measure of CLS-D used in the 
ASTRA questionnaire has a degree of internal validity. 
4.5.3.5 Other sexual behaviours and STIs 
Compared to MSM who had ‘CLS-C without CLS-D’ and those who had condom-protected sex only, MSM 
who had CLS-D were more likely to also report high partner numbers, recent STI diagnoses and 
symptoms, group sex, and to have least conservative beliefs about HIV transmission risk. There was a 
strong association between the number of new sex partners in the past year and any CLS in the past 
three months, particularly for CLS-D. Maintaining consistent condom use is likely to be challenging in the 
context of high partner numbers for HIV-diagnosed MSM. Accurate ascertainment of partners’ HIV 
status may be harder and uncertain with high partner numbers. Specifically, a number of men reporting 
‘CLS-C without CLS-D’ indicated high numbers of CLS-C partners (>50 in the past year), which suggests a 
higher possibility of assumed rather than confirmed HIV-positive status of partners. The association also 
suggests that reporting high turnover of new partners among MSM with HIV could be considered a 
marker of CLS in research or clinical settings.  
 
MSM who reported ‘CLS-C without CLS-D’ in the previous three months were significantly more likely to 
have a stable HIV-positive partner compared to those who had CLS-D or condom-protected sex. Few 
studies have distinguished between CLS with HIV-seroconcordant partners exclusively (no HIV-
serodifferent partners) and CLS with HIV-seroconcordant and HIV-serodifferent partners. In the latter 
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case, if an HIV-positive partner’s status is not known with confidence, the risk of HIV transmission 
remains. While it is encouraging that a sizeable proportion of HIV-diagnosed MSM in ASTRA appear to 
restrict CLS to partners with HIV, this behaviour does not eliminate the risk of transmission of other STIs. 
In fact, MSM who had CLS-C only had the highest prevalence of lifetime HCV, high prevalence of group 
sex, and high partner numbers. Dense sexual networks of serosorting HIV-diagnosed MSM may 
contribute to transmission of other STIs, as evidenced in recent UK studies linking CLS-C with ongoing 
outbreaks of other STIs (discussed in Chapter 8).
147,238
  
 Conclusions and Implications 4.5.4
Overall, evidence from this chapter shows that there were not marked associations between socio-
demographic factors and measures of CLS. This indicates that HIV/STI prevention efforts remain 
important across all socio-demographic groups. However, the consistent associations of CLS measures 
with younger age may suggest the need for particular focus on younger men with HIV. 
 
Measures of condomless sex tended to be more prevalent among those not on ART and those recently 
diagnosed. These findings further support a policy of earlier ART initiation for HIV and STI prevention. 
Although levels of CLS (and, possibly, of CLS-D) were higher among those on ART with self-reported 
undetectable VL, compared to those on ART without self-reported undetectable VL, levels still tended to 
be lower than those among MSM not on ART.  
 
The vast majority of epidemiological studies examining factors associated with sexual behaviours of HIV-
diagnosed MSM use binary classifications of CLS (versus no CLS) and CLS-D (versus no CLS-D). Analyses 
from this chapter showed that in addition to use of this binary classification, use of the mutually 
exclusive categories of sexual behaviour (CLS-D, ‘CLS-C without CLS-D’, condom-protected sex, no sex) is 
particularly helpful in disentangling complex underlying associations of various co-factors with different 
sexual behaviours. This was particularly the case for examining the effect of psychological symptoms, 
self-reported VL, and social support on sexual behaviours, which were lost using the binary 
classification.  
 
In conclusion, among HIV-diagnosed MSM in the UK, condomless sex in the previous three months was 
prevalent, but in line with results from similar UK studies in the past decade. The high prevalence of 
condomless sex with other HIV-positive partners may indicate active serosorting and warrants further 
attention as transmission of other STIs remains high. Being on ART was not associated with higher 
prevalence of CLS, or CLS-D. As ART use expands it will remain crucial to promote sustained high ART 
adherence, regular viral load monitoring, and ongoing awareness of personal viral load level.
182
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5 Characterising higher HIV transmission risk condomless sex 
with HIV-serodifferent partners  
5.1 Chapter aims 
This chapter aims to characterise and assess the prevalence of higher HIV risk condomless sex with HIV-
serodifferent partners (CLS-D) using definitions that incorporate various criteria that could impact on 
HIV infectiousness. A literature review is provided of studies that have examined CLS-D with an 
appreciable risk of HIV transmission among HIV-diagnosed MSM in high-income countries. The 
prevalence of higher HIV transmission risk CLS-D is assessed among all ASTRA MSM who were diagnosed 
with HIV for at least three months, according to differing criteria, including clinic-recorded viral load (VL) 
level, ART non-adherence, time since started ART, and self-reported diagnoses of other sexually 
transmitted infections (STIs). Characteristics of MSM who had higher HIV risk CLS-D are compared to 
those of MSM who had other CLS-D. 
5.2 Introduction 
In the era of effective ART, pre-exposure prophylaxis, and treatment as prevention, further refining 
what constitutes sex with a higher risk of HIV transmission is important to consider in the context of HIV 
prevention. Historically, CLS-D denoted ‘risky’ sex in the context of HIV transmission. HIV infectiousness 
now needs to be conceptualised within a broader context of ART treatment.
239
 The following sections 
discuss findings of studies published after conclusive evidence emerged on the extremely low risk of HIV 
transmission during CLS-D while the HIV-positive partner is virally suppressed on ART. 
7,9
 
 Evidence on CLS-D with higher risk of HIV transmission  5.2.1
Few studies have examined prevalence of CLS-D with higher risk of HIV transmission among HIV-
diagnosed MSM. There is, currently, no consensus definition on this concept in epidemiological 
research. Studies that incorporate clinic-recorded VL level into the concept of higher HIV transmission 
risk CLS-D emerged two years after ASTRA concluded recruitment (2014). These studies (summarised in 
Table 5.1) were carried out among HIV-outpatient populations in the USA, France, Thailand, and Brazil, 
and use a variety of definitions for ‘high risk’ sexual behaviour, incorporating a number of other factors 
in addition to VL, such as: counts of sexual partners, proportion of CLS acts, other STI co-infections, or 
ART status. Two of the eight studies shown in Table 5.1 provide estimates of higher HIV risk CLS-D from 
HIV-diagnosed men and women (denoted by *) while the remaining show estimates from HIV-diagnosed 
MSM only (denoted by ◊).  
 
One of the first constructs of HIV transmission risk sex was examined in a sub-study of the international 
SMART trial (2002-2006) of continuous versus CD4-guided episodic ART; this smaller study included sites 
from the USA and measured CLS-D (with HIV-negative or unknown status partners) in the previous two 
months while having VL>1500c/mL.
112
 A total of 6.2% of 875 trial participants (men and women) were 
124 
 
classified as having “transmission risk to HIV negative persons or those with unknown serostatus”. While 
a higher prevalence of this measure was observed over the 2 year follow-up in the ART interruption arm, 
this was because participants spent a longer time with detectable VL.
112
 Results were not stratified by 
gender/sexual orientation and so no estimates are available for MSM.  
 
Direct comparison between prevalence estimates across studies is not possible due to different 
definitions of higher HIV risk CLS-D. Other factors that differ between studies include study design (such 
as eligibility criteria and sampling frame) and implementation (such as method of data collection), which 
may also play an important role in determining the prevalence higher transmission risk CLS-D. In the UK 
Gay Men’s Sexual Health Surveys (GMSHS), between 2000 and 2013, HIV-diagnosed MSM were 
classified as “at risk of transmitting HIV” if they reported CLS but not exclusive serosorting in the 
previous 12 months; this represented 26.4% of all HIV-diagnosed MSM (or 17.1% of all HIV-positive 
MSM) over the study period.
143
 However, the GMSHS did not collect information on ART status or VL 
level, thus misclassifying all HIV-positive men who had CLS-D as potential transmitters of HIV, despite 
the evidence of extremely low transmission risk on effective ART. Consequently the group of MSM who 
actually had CLS-D with a risk of transmitting HIV in the GMSHS is likely to be much smaller.
240
 Similarly, 
a cross-sectional survey from internet sex-seeking MSM living in Latin America (2012) defined high 
transmission sex as CLS-D while not on ART in the previous three months, but did not collect information 
on VL status.
168
 These two studies are not included in Table 5.8 as they did not use a VL criterion in their 
definition of higher HIV risk CLS-D. 
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Table 5.1: Summary of studies measuring CLS-D with higher risk of HIV transmission (CLS-D-HIV-risk) among HIV-diagnosed clinic populations, accounting for 
viral load (VL) 
Study / Data 
collection period / 
Country 
Recruitment, population, 
study type 
Eligibility 
criteria 
N total 
N HIV-
diagnosed 
MSM (%) 
CLS-D 
recall 
period 
Prevalence of 
CLS or CLS-D (all 
men and 
women* or 
MSM only◊) 
Definition of CLS-D-HIV-risk 
Prevalence of CLS-
D-HIV-risk (all men 
and women* or  
MSM only◊) 
Comments 
SMART112  2002-
2006 
 
USA 
Longitudinal sub-study of RCT 
on continuous versus CD4-
guided episodic ART among 
people living with HIV from 
USA sites. Questionnaire on 
sexual behaviours and testing 
for other STIs at baseline, 
months 4, 12, and annually 
thereafter. Results shown here 
are at baseline for all 
participants. 
CD4>350 
cells/mm3 
and willing to 
start or 
discontinue 
ART according 
to 
randomizatio
n assignment 
N=875 
N 
MSM=416 
(47.1%) 
Past 2 
months  
CLS at baseline (all 
participants): 
15.4% * 
Any of the following when 
VL>1500c/mL: CLS-D, needle-
sharing, or a new diagnosis of 
gonorrhoea, chlamydia, or 
syphilis.  
At baseline (among 
all participants): 
6.2% (n/N=54/875) 
* 
Data not 
available for 
MSM  
Fenway 
Health180   
2004-
2007 
 
USA 
HIV-diagnosed MSM clinic 
attendees participating in RCT 
aimed at increasing condom 
use with serodifferent 
partners. Self-completed 
questionnaire, testing for STIs 
at baseline, and medical record 
extraction for CD4/VL/ART use 
subsequently. 
Consent to 
participate to 
HIV 
prevention 
RCT  
N 
MSM=201 
(100%) 
Past 6 
months 
CLS-D: 69.3% ◊ Insertive or receptive CLS-D 
and either: VL>75c/mL or STI 
diagnosis (gonorrhoea, 
syphilis, chlamydia) in past 
year. 
CLS-D-HIV-risk: 
45.0% (90/201) ◊ 
2 criteria met: 
• CLS-D and VL>75: 
33.8% (68/201)  
• CLS-D and STI: 
4.0% (8/201) 
3 criteria met: 
• CLS-D and VL>75 
and STI: 7.0% 
(14/201) 
High 
prevalence of 
detectable VL 
(50.3% had 
VL>75c/m)  
and low ART 
use (43.3%  
not on ART)  
HOPS241  2007-
2010 
 
USA 
Open prospective cohort of 
HIV-diagnosed people receiving 
care in 6 clinics, with annual 
automated telephone survey 
on socio-demographic, sexual 
factors. Results here for MSM.  
HIV-
diagnosed 
MSM 
completing 
survey 
N=1291 
N 
MSM=902 
(70.4%) 
Past 6 
months 
CLS: 71.9% ◊ 
CLS-D 
insertive:16.7% ◊ 
Insertive CLS-D and 
VL≥400c/mL 
3.4% (24/902) ◊ Respondents 
more likely to 
be white, 
university-
educated 
MSM 
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Study / Data 
collection period / 
Country 
Recruitment, population, 
study type 
Eligibility 
criteria 
N total 
N HIV-
diagnosed 
MSM (%) 
CLS-D 
recall 
period 
Prevalence of 
CLS or CLS-D (all 
men and 
women* or 
MSM only◊) 
Definition of CLS-D-HIV-risk 
Prevalence of CLS-
D-HIV-risk (all men 
and women* or  
MSM only◊) 
Comments 
MMP157,158 2009-
2010 
 
USA 
Nationally representative 
annual cross-sectional sample 
of HIV-diagnosed clinic 
attendees. Face-to-face 
interviews on sexual 
behaviours and ART, VL from 
medical records. Results here 
for MSM only. 
HIV-
diagnosed for 
≥12 months 
N=4094 
N 
MSM=189
7 (46.3%) 
Past 12 
months  
CLS-D: 13.0% ◊  CLS-D and VL ≥400c/mL on  ≥1 
occasion in past 12 months  
6.0% (114/1897)◊ Social 
desirability 
bias from face-
to-face 
interviewing 
may have led 
to 
underreportin
g of CLS-D  
HPTN063174  2010-
2012 
Cohort study of HIV-diagnosed 
people in care in Zambia, 
Thailand, Brazil, with self-
completed questionnaire and 
STI testing at baseline. VL data 
only available in Thailand and 
Brazil. Results here for MSM 
only. 
Had to have 
'HIV 
transmission 
risk' in past 12 
months (any 
CLS, or self-
reported STI) 
and ≥2 clinic 
visits in past 9 
months  
N=749 
N 
MSM=200 
(26.7%) 
Past 3 
months 
CLS-D: 69.5% ◊ CLS-D and 'detectable'  VL or 
an STI 
34% (68/200) ◊ Exact VL cut-
off not 
specified 
('detectable' 
within 6 
months of 
assessment)  
ANRS-
VESPA2155 
2011-
2012 
 
Franc
e 
Cross-sectional survey among 
nationally representative 
sample of people living with 
HIV (random sample of HIV 
clinic outpatients). Results here 
for MSM only.  
HIV-
diagnosed for 
>12 months 
and with 
available VL 
data 
N=2638 
N 
MSM=116
3 (44.1%) 
• Past 12 
months 
for stable 
partner 
• Most 
recent for 
casual 
partner 
Not shown "High risk transmission" (HRT) 
defined as ≥1 of: not on ART, 
or on ART and detectable VL, 
or on ART and suppressed VL 
for <12 mths, or on ART and 
suppressed VL for >12mths 
and ≥1 STI in 12mths. 
Versus "low risk transmission" 
(LRT) : on ART and suppressed 
VL for ≥12mths and no STI in 
past 12 mths 
• CLS-D with stable 
partner was 18% 
among HRT MSM 
(p>0.1 for difference 
with LRT) ◊ 
• CLS-D with most 
recent casual 
partner was 10% 
among HRT MSM 
(p>0.1 for difference 
with LRT)  ◊ 
Sexual 
behaviours 
and STIs 
assessed 
through face-
to-face 
interviewing  
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Study / Data 
collection period / 
Country 
Recruitment, population, 
study type 
Eligibility 
criteria 
N total 
N HIV-
diagnosed 
MSM (%) 
CLS-D 
recall 
period 
Prevalence of 
CLS or CLS-D (all 
men and 
women* or 
MSM only◊) 
Definition of CLS-D-HIV-risk 
Prevalence of CLS-
D-HIV-risk (all men 
and women* or  
MSM only◊) 
Comments 
ATN177 2009-
2012 
 
USA 
Cross-sectional questionnaire 
study of young (12-26 years) 
HIV-diagnosed men receiving 
care in one of 20 HIV clinics. 
Results for MSM only.  
Linked to 
care, 
reported anal 
sex with 
another male 
in past 3 
months, on 
ART for >6 
months. 
N total= 
2225 
N MSM= 
991 
(44.5%) 
Past 3 
months 
CLS-D: 31.3% ◊ CLS-D and latest VL≥200c/mL 18.9% (187/991) ◊ Excluded MSM 
on ART for ≤6 
months 
(n=175). High 
prevalence of 
detectable VL 
even among 
on MSM on 
ART >6 
months 
(55.4%)  
Atlanta 
clinics239 
2013-
2014 
 
USA 
Questionnaire survey of HIV-
diagnosed people attending for 
HIV care. Urine screening for 
recreational drug use and 
prospective text-message 
sexual behaviour diary for 28 
consecutive days. Results 
examining association of 
detectable VL (>100c/mL) and 
condomless anal sex for men 
and women combined. 
  N 
total=1040  
N MSM= 
Unknown 
Subseque
nt 28 
consecutiv
e days of 
observatio
n 
CLS: 54.1% * Defined as: any 'unprotected' 
vaginal or anal sex and most 
recent VL>100c/mL  
16.7% (174/1040) * Data not 
available for 
MSM. 
Majority black, 
low-income 
population in 
high HIV 
prevalence 
setting.  
Prevalence estimates shown in each study are for HIV-diagnosed MSM only ◊ or for men and women combined *; ART: antiretroviral therapy; ATN: Adolescent Medicine Trials Network for 
HIV/AIDS Interventions; CLS: condomless sex; CLS-D: condomless sex with HIV-serodifferent partners; HOPS: HIV Outpatient Study; HRT: high risk transmission; MMP: Medical Monitoring Project; 
SMART: Strategies for Management of Antiretroviral Therapy Trial; VL: viral load; RCT: randomised controlled trial; STI: sexually transmitted infection 
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5.3 Methods 
Analyses presented in this chapter include ASTRA MSM diagnosed with HIV for at least three months 
(N=2189).  
 Defining higher HIV risk CLS-D 5.3.1
In order to better reflect the prevalence of HIV transmission risk when the HIV-diagnosed partner is on 
virally suppressive ART,
24,242
 various definitions for CLS-D with an appreciable risk of HIV transmission 
were examined. In the main definition, participants were required to report CLS-D in the past three 
months, plus one of the following two criteria:  
 Study log (clinic-recorded) latest viral load>50c/mL, OR  
 Not on ART at the time of the questionnaire (self-reported) 
The following additional criteria were then incorporated into the main definition, one by one, and then 
all together (see Figure 5.1 for full details):  
 Started ART <9 months ago (according to self-reported date of ART start), OR 
 Non-adherent to ART (self-reported, missing ≥2 consecutive days of ART on ≥2 occasions in the 
past 3 months), OR 
 Diagnosed STI in the past three months (self-reported, for the HIV-diagnosed participant only). 
 Statistical analysis 5.3.2
The prevalence (95%CIs) of CLS-D with an appreciable risk of HIV transmission was assessed among all 
MSM according to combinations of criteria (section 5.3.1.) The main definition of higher HIV risk CLS-D 
(CLS-D and: VL>50c/mL or not on ART) was then used to compare against MSM who had any other CLS-
D (but not higher HIV risk CLS-D). Differences in socio-demographic characteristics, psychological 
symptoms, HIV-related factors, and other sexual behaviours, STIs, and attitudes were examined 
between the two groups reporting CLS-D, using chi-squared tests or Fisher’s exact. All socio-
demographic, HIV-related factors and sexual behaviours have been defined in sections 3.8 and 4.3. 
5.3.2.1 Sensitivity analyses 
Three sensitivity analyses were undertaken to examine the prevalence of higher HIV risk CLS-D 
according to other criteria. Firstly, a higher VL cut-off of >200c/mL was used in each definition (instead 
of >50c/mL). Secondly, the criterion of self-reported diagnosis of STIs in the past three months was 
restricted to STIs that present with genital ulcer disease (syphilis, lymphogranuloma venereum, new or 
recurrent genital herpes). Thirdly, the linked routine clinical data was used to include serial VL 
measurements in the six months preceding ASTRA questionnaire completion. Details of the consent 
rates for linkage of ASTRA questionnaire and routine clinical data are shown in section 3.10.2.5.The 
prevalence of higher HIV risk CLS-D was examined according to whether the participant had only one 
rebound (single VL>50c/mL) or more than one rebound (≥2 consecutive VL>50c/mL) during the six 
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months preceding ASTRA. No restriction was applied to the interval between consecutive VL 
measurements, as long as they were within the six month period under study.  
5.4 Results 
 Prevalence of higher HIV risk CLS-D 5.4.1
As shown in section 4.4.2, the overall prevalence of any CLS-D in the previous three months among all 
2189 MSM was 16.3% (95%CI 14.8-17.9%, n=357). Using the main definition of higher HIV risk CLS-D 
(reporting CLS-D plus: not being on ART or having study log-recorded VL>50c/mL), 93 MSM were 
considered to have higher HIV risk CLS-D, yielding a prevalence of 4.2% (95%CI 3.5-5.2%) among 2189 
MSM. Figure 5.1 also shows the prevalence of additional definitions of higher HIV risk CLS-D in the 
previous three months, according to various criteria incorporated (ART status, time since started ART, 
adherence to ART, and other diagnosed STIs). For example, 4.6% (n=100) of all HIV-diagnosed MSM 
were classified as having higher HIV risk CLS-D if they reported having CLS-D in the previous three 
months and either: were not on ART, or had latest VL>50c/mL, or started ART <9 months ago.  Similarly, 
7.5% (n=165) of all HIV-diagnosed MSM had higher HIV risk CLS-D if they reported having CLS-D in the 
previous three months and either: were not on ART, or had latest VL>50c/mL, or started ART <9 months 
ago, or reported non-adherence to ART, or another diagnosed STI.  The footnote to the figure shows 
that prevalence estimates were similar when excluding 31 MSM who had CLS-D but did not specify their 
partners’ HIV-serostatus (‘CLS-unspecified’, see section 4.3.3). 
 
Among MSM not on ART, prevalence of higher HIV risk CLS-D (using the main definition) was 19.7% 
(57/290). Among MSM on ART with self-reported undetectable VL, prevalence of higher HIV risk CLS-D 
was 0.8% (13/1568), as these individuals had study log-recorded detectable VL despite reporting it as 
undetectable. Among MSM on ART with self-reported detectable VL, prevalence of higher HIV risk CLS-D 
was 7.7% (22/285). 
 Factors associated with higher HIV risk CLS-D 5.4.2
The main definition of higher HIV risk CLS-D was used in this analysis. Men who had higher HIV risk CLS-
D according to this definition (n=93) were compared to men who had CLS-D but not higher HIV risk CLS-
D (labelled ‘other CLS-D’, n=264).(Figure 5.2) MSM who had higher HIV risk CLS-D tended to be younger 
and diagnosed with HIV for a shorter period of time. There were few other significant differences 
between men in the two groups. Not surprisingly, men who had higher HIV risk CLS-D were more likely 
to report detectable VL (>50c/mL) compared to men who had other CLS-D (p<0.001). Prevalence of 
other sexual behaviours, STIs, and attitudes was similar between the two CLS-D groups, with the 
exception of low condom self-efficacy; this was much higher among the higher HIV risk CLS-D group 
compared to the other CLS-D group (23.0% vs 10.0%, p=0.002). There was weak evidence to suggest that 
transactional sex was more prevalent among MSM who had higher HIV risk CLS-D compared to MSM 
who had other CLS-D, although the sample size was small.  
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Figure 5.1: Prevalence (95%CI) of higher HIV risk CLS-D among 2189 MSM, according to specific definitions (incorporating ART status, viral load, time since 
started ART, ART non-adherence, and self-reported STI diagnosis)  
  
4.2 
4.6 
5.0 
6.9 
5.3 
7.0 
7.4 7.5 
%
2%
4%
6%
8%
10%
CLS-D + (not on ART
or VL>50) (n=93)
CLS-D + (not on ART
or VL>50 or started
ART <9 months ago)
(n=100)
CLS-D + (not on ART
or VL>50 or non-
adherent on ART)
(n=110)
CLS-D + (not on ART
or VL>50 or STI)
(n=152)
CLS-D + (not on ART
or VL>50 or started
ART <9 months ago
or non-adherent on
ART) (n=116)
CLS-D + (not on ART
or VL>50 or started
ART <9 months ago
or STI) (n=154)
CLS-D + (not on ART
or VL>50 or non-
adherent on ART or
STI) (n=163)
CLS-D + (not on ART
or VL>50 or started
ART <9 months ago
or non-adherent on
ART or STI) (n=165)
ART: Antiretroviral therapy; CLS-D: condomless sex with HIV-serodifferent partners; non-adherent to ART: missed ≥2 consecutive days of ART on ≥2 occasions in the past 3 
months; VL: latest clinic-recorded viral load (missing for n=30); STI: sexually transmitted infection (includes self-reported previous diagnosis of syphilis, gonorrhoea, 
chlamydia, LGV, new hepatitis B or C, new or recurrent genital herpes or warts, trichomonas, NSU/NGU). Excluding n=31 MSM who had CLS-unspecified, the prevalence (n, 
%) of each higher HIV risk CLS-D definition is: 1. Not on ART or VL>50: n=85 (3.9%); 2. Not on ART or VL>50 or on ART for <9 months: n=92 (4.2%); 3. Not on ART or VL>200 
or non-adherent on ART: n=100 (4.6%); 4. Not on ART or VL>50 or STI: n=143 (6.5%); 5. Not on ART or VL>50 or on ART for <9 months or non-adherent on ART: n=106 (4.8%); 
6. Not on ART or VL>50 or on ART for <9 months or STI: n=145 (6.6%); 7. Not on ART or VL>50 or non-adherent on ART or STI: n=152 (6.9%); 8. Not on ART or VL>50 or on 
ART for <9 months or non-adherent on ART or STI: n=154 (7.0%) 
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Figure 5.2: Prevalence of socio-demographic, psychological characteristics, and sexual 
behaviours of MSM who had higher HIV risk CLS-D† versus MSM who had ‘other CLS-D’ (CLS-
D but not higher HIV risk CLS-D), N=357 
0% 20% 40% 60%
Non-white ethnicity (n/N=40/350)
Non-UK place of birth (241/357)
No educational qualifications/up to A levels (192/350)
Unemployed/carer,retired,student (125/351)
Depression symptoms (102/357)
Anxiety symptoms (81/357)
Has stable partner (202/355)
Self-reported VL>50c/mL (35/306)
Other diagnosed STIs (76/351)
Current symptoms of STIs (58/357)
≥10 sexual partners (93/341) 
Participated in group sex (156/345)
Used internet to find sex (219/345)
Transactional sex (4/350)
HIV-negative partners took PEP or PrEP (27/1391)
Lifetime hepatitis C diagnosis (68/351)
≥30 new sexual partners in past year (90/281) 
Low condom self-efficacy (46/347)
Difficulty negotiating condom use (88/347)
Lower condom use with casual partners (140/344)
Worry about HIV transmission (64/344)
Least conservative HIV transmission risk beliefs…
Higher HIV risk CLS-D† (N=93) Other CLS-D (N=264)
p=0.002 
p=0.055 (F) 
P-values by chi-squared test or Fisher's exact test (F); †CLS-D plus not on ART or study log-recorded viral 
load>50c/mL; Three month recall unless otherwise specified; All factors shown have been defined in section 3.8. 
PEP: post-exposure prophylaxis; PrEP: pre-exposure prophylaxis 
p<0.001 
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5.4.2.1 Sensitivity analyses 
Prevalence of higher HIV risk CLS-D was assessed according to the same criteria, but with a higher VL 
cut-off of >200c/mL. (Figure 5.3) Over 17% of all MSM (n/N=386/2189) had study log-recorded 
VL>200c/mL, of whom 17.1% (66/386) had CLS-D in the past three months. The prevalence of higher HIV 
risk CLS-D was similar to that with a VL cut-off value of >50c/mL, ranging from 3.5% to 7.1% (Figure 5.3). 
 
The prevalence of higher HIV risk CLS-D was then estimated using a reduced definition of self-reported 
previous diagnosis of STIs in the past three months, only including STIs that present with genital ulcer 
disease (GUD): syphilis, LGV, new or recurrent genital herpes.(Figure 5.4) Among 236 MSM who 
reported a diagnosis of STIs in the previous three months, 92 (38.9%) reported having GUD and were 
included in this criterion; 5.4% of 2189 MSM (n=118) had CLS-D plus were either not on ART or had 
VL>50c/mL or had GUD, as compared to 6.9% of MSM (n=152) who had the same criteria but any STIs 
instead of GUD (Figure 5.4). 
 
In the third sensitivity analysis, the linked routine clinical data was used to examine the prevalence of 
higher HIV risk CLS-D incorporating serial VL measurements. Among 2189 MSM, 1810 had available 
linked VL data within six months preceding ASTRA completion. Of these MSM, 24.9% (n =452) had at 
least one rebound (single VL>50c/mL) during the six months prior to questionnaire completion. The 
prevalence of higher HIV risk CLS-D among 1810 MSM ranged from 4.5% (when defined as CLS-D 
preceded by one rebound) to 5.8% (when additionally considering ART status at questionnaire, ART non-
adherence, and time since started ART). (Figure 5.5) 
 
Over 21% (398/1810) of MSM had more than one rebound (≥2 consecutive VL>50c/mL) during the six 
months prior to questionnaire completion. The prevalence of higher HIV risk CLS-D among 1810 MSM 
ranged from 4.0% (when defined as CLS-D preceded by more than one rebound) to 5.6% (when 
additionally considering ART status at questionnaire, ART non-adherence, time since started ART). 
(Figure 5.5) Among those who had higher HIV risk CLS-D, median VL measurements were relatively high; 
those with one rebound had median VL 3.7 log10c/mL and those with more than one rebound had 
median 3.8 log10 c/mL. 
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Figure 5.3: Sensitivity analysis 1- Prevalence (95%CI) of higher HIV risk CLS-D among 2189 MSM, with viral load >200c/mL and additional criteria incorporated 
(ART status, time since started ART, ART non-adherence, and self-reported STI diagnosis) 
3.5 
4.1 4.3 
6.2 
4.8 
6.6 6.8 
7.1 
%
2%
4%
6%
8%
10%
CLS-D + (not on ART
or VL>200) (n=76)
CLS-D + (not on ART
or VL>200 or started
ART <9 months ago)
(n=89)
CLS-D + (not on ART
or VL>200 or non-
adherent on ART)
(n=94)
CLS-D + (not on ART
or VL>200 or STI)
(n=136)
CLS-D + (not on ART
or VL>200 or started
ART <9 months ago
or non-adherent on
ART) (n=106)
CLS-D + (not on ART
or VL>200 or started
ART <9 months ago
or STI) (n=144)
CLS-D + (not on ART
or VL>200 or non-
adherent on ART or
STI) (n=148)
CLS-D + (not on ART
or VL>200 or started
ART <9 months ago
or non-adherent on
ART or STI) (n=156)
Excluding n=31 MSM who had CLS-unspecified, the prevalence of each higher HIV risk CLS-D definition is: 1. Not on ART or VL>50: n=60 (3.2%); 2. Not on ART or VL>50 or 
on ART for <9 months: n=83 (3.8%); 3. Not on ART or VL>200 or non-adherent on ART: n=86 (3.9%); 4. Not on ART or VL>50 or STI: n=129 (5.9%); 5. Not on ART or VL>50 
or on ART for <9 months or non-adherent on ART: n=137 (4.8%); 6. Not on ART or VL>200 or started ART <9 months ago: n=137 (6.3%); 7. Not on ART or VL>200 or non-
adherent on ART or STI: n=139 (6.3%); 8. Not on ART or VL>200 or started ART <9 months ago or non-adherent on ART or STI: n=146 (6.7%) 
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Figure 5.4: Sensitivity analysis 2 - Prevalence (95%CI) of higher HIV risk CLS-D according to 
criteria incorporating genital ulcer disease (GUD) (N=2189) 
 
Figure 5.5: Sensitivity analysis 3 - Prevalence (95%CI) of higher HIV risk CLS-D according to 
clinic-recorded viral load rebounds 6 months prior to ASTRA questionnaire completion 
(N=1801) 
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GUD includes self-reported syphilis, LGV, new or recurrent genital herpes in the past three months; 
Excluding n=31 MSM who had CLS-unspecified, the prevalence of each higher HIV risk CLS-D definition is: 1. 
Not on ART or VL>50 or GUD: n=110 (5.0%); 2. Not on ART or VL>50 or started ART <9 months ago or GUD: 
n=116 (5.3%); 3. Not on ART or VL>200 or non-adherent on ART or GUD: n=122 (5.6%); 4. Not on ART or 
VL>50 or started ART<9 months ago or non-adherent on ART or GUD: n=127 (5.8%) 
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1 rebound: VL measurement>50c/mL in the six months prior to questionnaire; >1 rebound: two consecutive 
VL>50c/mL during same period; Higher HIV risk CLS-D as % of all 2189 MSM was: CLS-D + 1 rebound: 3.7%; 
CLS-D + (1 rebound or not on ART): 4.3%; CLS-D + (1 rebound or not on ART or non-adherent or started 
ART<9 months ago): 4.8%; CLS-D+ >1 rebound: 3.4%; CLS-D + (>1 rebound or not on ART): 4.0%; CLS-D + 
(>1 rebound or not on ART or non-adherent on ART or started ART<9 months ago): 4.7% 
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5.5 Discussion 
 Summary of findings 5.5.1
Among HIV-diagnosed MSM in ASTRA, prevalence of higher HIV risk CLS-D in the past three months 
ranged from 4.2% when considering CLS-D while not on ART or with viral load>50c/mL, to 7.5% when 
additionally considering time since ART initiation or non-adherence or other STI co-infections. Compared 
to the prevalence of any CLS-D in the past three months (16.3% of 2189 MSM), the prevalence of higher 
HIV risk CLS-D was lower by 53-74% in relative terms. MSM who had higher HIV risk CLS-D were very 
similar to those who had other CLS-D with regard to socio-demographic factors and most other markers 
of sexual behaviour. 
 Results in the context of other studies  5.5.2
Most studies (reviewed in Table 5.1) took a similar general approach to defining higher HIV risk CLS-D, 
incorporating current or recent detectable VL and, in some cases recent diagnosed STI, as additional 
criteria, at least one of which was necessary in addition to CLS-D. However, specific definitions varied, 
meaning prevalence estimates cannot easily be compared across studies. 
 
In addition to differences in definitions, study eligibility criteria may influence estimates of the 
prevalence of CLS-D higher HIV risk, as they may introduce selection bias. For example, the French 
ANRS-VESPA2 and the US Medical Monitoring Project (MMP) had nationally representative random 
samples of HIV-diagnosed people and required participants to be diagnosed for at least 12 months (see 
Table 5.1).
155,158
 This inclusion criterion may have masked an association of time since HIV diagnosis, use 
of ART, and prevalence of higher HIV risk CLS-D. ART use is likely to be lower among those recently 
diagnosed. Seroconversion cohorts have suggested that immediately following HIV diagnosis, MSM may 
reduce ‘high risk behaviours’ (such as CLS-D) and revert to stable levels within a year of testing 
positive.
152,243
 It is possible that the prevalence of higher HIV risk CLS-D could be lower if recently 
diagnosed MSM were included in VESPA2 or MMP. In ASTRA and other studies,
180,241
 MSM who were 
younger and diagnosed more recently tended to be report higher prevalence of higher HIV risk CLS-D 
compared to any other CLS-D. In SMART,
112
 younger age and self-reported MSM status were also 
associated with higher HIV risk CLS-D. To date, there is no other evidence on the association between 
age, time since HIV diagnosis, and higher HIV transmission risk CLS-D from studies of HIV-diagnosed 
MSM. Conversely, studies that exclude participants who did not report CLS may also introduce bias as 
they are not representative of the underlying population, in which no sex or condom-protected sex may 
also be prevalent. For instance, both the USA Fenway Health and the international HPTN063 cohort 
studies included MSM “at the greatest risk for HIV transmission”(Table 5.1), which is likely to explain the 
high prevalence of higher HIV risk CLS-D in these studies compared to ASTRA (45% in the past 6 months, 
34% in the previous three months, versus <8% in past three months, respectively).
174,180
 
 
Finally, the method of survey administration is also crucial in studies of sensitive behaviours.
244
 Sexual 
behaviour questionnaires administered via face-to-face interviewing (used in the ANRS-VESPA2 and 
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MMP studies)
155,158
 or telephone interviewing (used in the HOPS study)
241
 may be subject to social 
desirability bias; participants may underreport socially ‘taboo’ behaviours, such as CLS-D, especially with 
higher risk of HIV transmission. The prevalence of higher HIV risk CLS-D in studies that used interviewing 
for data collection (MMP
157,158
, ANRS-VESPA
155
) was lower compared to studies using self-administered 
surveys (SMART
112
, Fenway Health
180
, HPTN063
174
, ATN
177
, Atlanta clinics
239
, and ASTRA), although 
differences in definition also impact on this comparison.  
 Additional criteria for higher HIV risk CLS-D 5.5.3
More evidence is needed to understand whether factors additional to ART use and VL status should be 
incorporated in a definition of CLS-D with higher HIV transmission risk, particularly in the context of CLS-
D with multiple partners. Such information is also important in refining current guidelines and helping 
HIV-diagnosed individuals and their partners make informed decisions on having CLS-D safely. 
Standardised definitions may be useful for epidemiological monitoring studies as well. The factors 
considered in this study (in addition to ART use and HIV plasma VL level) were length of time since ART 
initiation, self-reported diagnosis of co-infection with other STIs (for the HIV-positive partner only), and 
self-reported ART adherence. 
5.5.3.1 Viral load (VL) cut-off 
The VL cut-off considered when defining higher HIV risk CLS-D in ASTRA was set to 50c/mL. This was 
selected firstly, so as to be in line with BHIVA guidelines and other available evidence on transmission 
risk up until 2011 (when ASTRA began recruitment), and secondly, because this is the clinical treatment 
target for VL suppression used in the UK. The BHIVA guidelines, based on the Swiss Statement, stated 
that HIV transmission via vaginal sex is extremely low for individuals on effective ART, provided the HIV-
positive partner has “sustained plasma VL below 50 HIV RNA c/mL for more than six months and that 
the VL is below 50 c/mL on the most recent test”.
245
 Higher VL cut-offs could additionally be considered 
in future research. Once viral suppression is achieved, intermittent episodes of detectable low-level 
viremia (‘blips’) can occur, typically between 50 and 1000c/mL.
246
 HIV transmission studies have 
adopted higher VL thresholds (200c/mL in PARTNER and Opposites Attract)
25,247
, possibly to account for 
isolated viral blips not associated with virological failure. In ASTRA, raising the viral load cut-off to 
200c/mL in the definition of higher HIV risk CLS-D produced similar estimates as with a cut-off of 50c/mL 
(3.5% vs 4.2%, respectively). The Rakai study
8
 found no instances of HIV transmission among the 51 
heterosexual participants with VL≤1500 c/mL, but there are no transmission studies to date that 
incorporate such high VL thresholds when considering anal CLS-D among MSM.  
5.5.3.2 Time since started ART 
A minimum of nine months since ART started was used as one of the additional criteria in alternative 
definitions of higher HIV risk CLS-D in ASTRA. This threshold was chosen as VL suppression is usually 
achieved after three to six months on ART.
248
 BHIVA guidelines also state that assurance of low 
infectiousness requires a six month period of viral suppression (see section 5.5.3.3).
245
 In fact, the 
prospective Partners PREP study of 1592 HIV-serodifferent heterosexual couples showed that there is 
residual risk of HIV transmission during the first six months on ART (until viral suppression is achieved); 
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the HIV incidence rate during this period was close to that among couples where the HIV-diagnosed 
partner was not on ART (2.08 vs 1.79 per 100 person-years, based on 3 seroconversions).
249
 In ASTRA, 
while self-reported dates of starting ART were used to ensure that participants had begun ART at least 
nine months prior to questionnaire completion, it was not possible to check whether participants were 
on ART continuously during those nine months; it may be that treatment discontinuations occurred 
during that period. This was accounted for to some extent when the ART non-adherence criterion was 
additionally used. Incorporating the length of time on ART when considering CLS-D may be important. 
Among people who are starting or have recently started ART, additional strategies are needed to reduce 
the risk of HIV transmission through CLS-D before viral suppression is achieved.  
5.5.3.3 Time with viral suppression 
It was not possible to incorporate time with viral suppression using the full ASTRA dataset, as only a 
single plasma VL measure was available in the study log for all participants. Sensitivity analyses using the 
routine clinical data incorporated serial VL measurements within six months before ASTRA 
questionnaire completion (among MSM who were HIV-diagnosed for at least three months). Viral ‘blips’ 
were not uncommon during this period. The prevalence of CLS-D three months prior to ASTRA among 
MSM with available clinical data was similar to that among MSM with one or more than one rebound. It 
is encouraging that only a small minority of HIV-diagnosed men who had episodes of detectable viremia 
also reported CLS-D. In addition, in the main definition of higher HIV risk CLS-D, no restriction was 
placed on the timing of the latest VL measure from the study log, although BHIVA guidelines state that 
VL testing should be undertaken regularly (every three to four months).
245
 In ASTRA, for the majority of 
MSM the study log VL value was from a test done in the three month period prior to questionnaire 
completion (N=2175, 1.9% had study log VL measurement on the same day as questionnaire 
completion, 59.5% had a measurement ≤3 months ago, 29.0% 3-6 months, 9.2% more than 6 months 
ago, and 0.3% after). The study log VL aimed to be the most recent test that the participant had been 
informed of. Therefore, the VL value used in the definition of higher HIV risk CLS-D may not necessarily 
be the most relevant value for the duration of the three month recall period for sexual behaviour, but 
did occur during this period for the majority of participants. Incorporating these additional factors (time 
with viral suppression and timing of latest VL measure) would result in an increase in prevalence of CLS-
D and a more conservative definition of higher risk HIV transmission sex. 
5.5.3.4 ART adherence 
Good adherence to ART is critical in ensuring continued VL suppression.
250
 The prevalence of higher HIV 
risk CLS-D incorporating non-adherence varies according to the tools used to measure non-adherence 
(self-report, pill counts, or medication event monitoring systems). In ASTRA, clinically significant non-
adherence was self-reported and defined as missing two or more consecutive days of ART on two or 
more occasions in the previous three months (prevalence 25.9%). Incorporating this measure of ART 
non-adherence into the definition of higher HIV risk CLS-D resulted in a marked increase in prevalence. 
This finding highlights the importance of supporting people on ART in remaining adherent to treatment, 
particularly if they are having CLS-D. Self-report is the most commonly used adherence measure and has 
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high specificity, but may have lower sensitivity.
251
 To capture more accurate prevalence of higher HIV 
risk CLS-D when non-adherence is included in the definition, studies could use composite adherence 
measures (combining two or more methods) with higher validity, or take into account ‘forgiving’ ART 
regimens (that sustain viral suppression despite suboptimal adherence).
252
 Importantly, there is a need 
for evidence on the effect of varying degrees of non-adherence on the likelihood of a viral rebound to a 
level that could significantly impact on HIV transmission risk. This evidence is important for 
epidemiological studies, but also for informing people living with HIV on the relative risk of CLS-D when 
specific doses of ART are missed.  
5.5.3.5 STI co-infections 
The role of STI co-infections on onward HIV transmission during CLS-D is discussed in detail in Chapter 8. 
Briefly, STIs may facilitate HIV shedding in mucosal membranes by hindering immunological response to 
ART.
245
 The relevance of STIs in the context of viral suppression however remains unclear. When the 
criterion of other STI diagnosis was incorporated in the definition of higher HIV risk CLS-D, prevalence 
increased by 30-40% in relative terms, compared to only considering ART and VL status. This is driven by 
the underlying prevalence of STIs in the population. For example, in the HPTN 063 multi-cohort study, 
44% of 200 MSM tested positive for either syphilis, gonorrhoea, and chlamydia at baseline; the resulting 
prevalence of higher HIV risk CLS-D (CLS-D and VL>50c/mL or STI diagnosis) was 34% in the previous 
three months.
174
 This estimate is higher than that observed in ASTRA, where 10.9% of MSM had any 
self-reported STI in the previous three months and the resulting prevalence of higher HIV risk CLS-D was 
6.9% (defined as CLS-D and: VL>50c/mL or not on ART or STI diagnosis).  
 
In sensitivity analyses, only STIs that present with genital ulcer disease (GUD) were included in the 
definition of higher HIV risk CLS-D, and the prevalence was overall lower compared to including all STIs. 
Only self-reported STIs for the HIV-positive partner could be recorded in ASTRA. However, to ensure the 
extremely low risk of HIV transmission through vaginal CLS-D when the HIV-positive partner is on 
effective ART, BHIVA guidelines require that both partners do not have an STI, and further stress 
comprehensive STI screening of both partners.
245
 The PARTNER study showed that acquisition of STIs 
during follow-up was not associated with risk of HIV transmission among HIV-serodifferent MSM 
couples, although power to detect a true effect was limited as there were no within-couple HIV 
transmissions.
9
 To improve reliability of estimates of higher HIV risk CLS-D when the STI criterion is 
added, future studies of HIV-serodifferent couples (such as PARTNER and Opposites Attract) may benefit 
from STI testing of both partners concurrent to the CLS-D recall window (e.g. if the recall is in the 
previous three months, STI testing could be conducted within this period).  
5.5.3.6 Plasma versus genital tract HIV RNA concentrations  
The effect of ART on the genital tract is another factor which could be considered when discussing 
higher HIV transmission risk CLS-D. Overall, blood plasma HIV RNA concentrations are mirrored in the 
genital tract,
253
 but a number of recent studies have shown that a minority of men (<10%) on ART with 
suppressed blood VL have detectable seminal VL, albeit low-level.
254–257
 The extent to which discordance 
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between blood and genital viral suppression on ART impacts sexual transmission of HIV remains unclear, 
especially when compounded by genital inflammation caused by other STI co-infections (discussed in 
Chapter 8). For example, a US study of 101 HIV-diagnosed MSM clinic attendees on ART found a much 
higher prevalence of discordance between VL in blood and semen (25%) compared to other studies, 
which was attributed to the high prevalence of concomitant STIs and genital inflammation (9% and 24% 
respectively).
258
 More research is needed on the role of seminal HIV shedding on transmission risk when 
blood VL is suppressed.  
 Implications  5.5.4
It is encouraging that the prevalence of higher HIV risk CLS-D in ASTRA is relatively low, ranging from 
4.5% to 7.5% depending on criteria incorporated. This finding adds evidence to the hypothesis that 
transmission from HIV-diagnosed MSM is thought to contribute a minority of new HIV infections in the 
UK.  
 
In addition, prevalence of higher HIV risk CLS-D was much lower among MSM on ART (versus those not 
on ART), and extremely low (<1%) among MSM on ART with self-reported undetectable VL. As ART use 
continues to expand, the prevalence of higher HIV transmission risk CLS-D is likely to remain far less 
prevalent among MSM on ART with self-reported undetectable VL, compared to those not on ART. With 
more HIV-diagnosed people initiating ART at diagnosis, the proportion of MSM who have higher HIV risk 
CLS-D with self-reported detectable VL on ART may also reach levels similar to those for MSM with self-
reported undetectable VL (from 7.7% to 0.8%) 
 
There are numerous challenges in defining CLS-D with higher HIV transmission risk, both in the clinical 
setting and for standardised use in epidemiological studies. In order for behavioural studies on HIV 
transmission to be representative of the developments in HIV prevention, there is a need to move away 
from the concept of ‘unsafe’ and ‘risky’ sex defined as CLS-D only. Instead, there is a need to examine 
other measures of CLS-D which have a greater potential for HIV transmission. Accounting for VL and ART 
status during CLS-D is one of the ways forward in adapting research to contemporary evidence.  
 
Epidemiological studies of sexual behaviour among HIV-diagnosed MSM could also benefit from 
including higher HIV transmission risk CLS-D as a fifth category when grouping sexual behaviours into 
mutually exclusive categories (higher HIV transmission risk CLS-D, any other CLS-D, ‘CLS-C without CLS-
D’, condom-protected sex, no anal or vaginal sex). This would allow for more detailed examination of 
the association of various factors with different sexual behaviours. Among HIV-diagnosed MSM, 
research measuring ‘any CLS’ still remains relevant for assessment of (non-HIV) STI transmission, but 
higher HIV risk CLS-D will be most relevant for assessment of HIV transmission risk.    
 
Although ASTRA was conducted after the 2008 “Swiss statement”, when expert opinion on reduced risk 
of HIV transmission with suppressed VL was widely publicised, it was conducted prior to the publication 
of conclusive results from HPT052 and PARTNER. The prevalence of higher HIV risk CLS-D may change as 
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ART is made available to everyone with HIV regardless of CD4 count.
17
 In particular, as ART use expands, 
and prevalence of viral suppression increases among people with diagnosed HIV, this would tend to 
result in lower prevalence of higher HIV risk CLS-D. However, sexual behaviour patterns among MSM 
with HIV may also be changing, which could also impact on prevalence of higher HIV risk CLS-D. Future 
studies examining ongoing trends in sexual behaviour will remain important. Additionally, further 
follow-up from studies such as PARTNER and Opposites Attract will further clarify HIV transmission risk 
in the context of undetectable VL at most recent test but with suboptimal reported adherence, less 
frequent VL testing, or a recent STI. 
5.6 Conclusions 
The definitions of higher HIV transmission condomless sex with HIV-serodifferent partners (CLS-D) 
examined in this chapter show that the prevalence of higher HIV risk CLS-D is overall very low, and much 
lower than the prevalence of CLS-D overall. As the concept of ‘high risk sex’ for HIV transmission 
evolves, only considering CLS-D will no longer be the best measure of HIV transmission risk behaviour, 
especially when the HIV-positive partner is on virally suppressive ART. Incorporating viral load in the 
concept of higher risk CLS-D will thus become important both in future studies of sexual behaviour of 
HIV-diagnosed MSM, and in informing safer sexual practices between HIV-serodifferent partners. 
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6 Recreational drug use and condomless sex 
6.1 Chapter aims 
The main aim of this chapter is to examine the association of recreational drug use with sexual 
behaviours among HIV-diagnosed MSM. A review of literature will be undertaken from studies among 
HIV-diagnosed MSM in high-income countries (Western Europe, North America, Australia) between 
1995 and 2016. The review will examine firstly, the prevalence of recreational drug use, secondly, any 
socio-demographic, psychological, HIV-related, lifestyle factors that have been identified as correlates of 
recreational drug use, and thirdly, associations between recreational drug use and sexual behaviours 
(mainly, condomless sex). While the focus of the review will be on HIV-diagnosed MSM, evidence from 
MSM who do not have HIV will also be reviewed to provide context. The aims of these analyses are to 
investigate, among ASTRA MSM: (i) the prevalence and factors associated with recent recreational drug 
use (including measures of polydrug use and chemsex associated drug use), (ii) the association of 
recreational drug use with measures of CLS, other sexual behaviours, and attitudes (iii) the relative 
association of recreational drug use to condom-protected sex compared to CLS, and to  CLS-C compared 
to CLS-D, (iv) the association of specific drugs with CLS-C, CLS-D, and higher HIV risk CLS-D, (v) the 
association of measures of problematic alcohol use and sexual behaviours, accounting for recreational 
drug use, and (vi) the association of recreational drug use and problematic alcohol use with non-
adherence to ART and viral load (VL) non-suppression.     
6.2 Introduction 
 Recreational drugs studied 6.2.1
This chapter focuses on commonly used recreational drugs (summarised in Table 6.1), which are 
controlled and non-controlled under the UK Misuse of Drugs Act 1971. These include stimulants: 3,4-
Methylenedioxymethamphetamine (MDMA, ecstasy), cocaine, methamphetamine (crystal meth), and 
mephedrone; hallucinogens: Lysergic acid diethylamide (LSD) and ketamine; depressants: opioids, 
gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), cannabis; and other substances: inhalants 
(poppers), drugs used in the treatment of erectile dysfunction (ED) taken without prescription (e.g. 
Viagra), and anabolic steroids. The term ‘club drugs’ refers to substances commonly or typically used in 
connection with attending nightclubs, bars, festivals, concerts, parties, or sex on premises venues to 
enhance sociality, enjoyment of music, or dancing.
259,260
 This can encompass stimulants which trigger 
euphoric feelings and increase heart rate (cocaine, ecstasy, GHB/GBL, or mephedrone) as well as 
dissociatives which produce feelings of detachment from one’s body and surroundings (ketamine and 
LSD).  
 
In recent years, the UK has seen the emergence of new psychoactive substances (NPS), which mimic the 
effects of controlled drugs.
261
 NPS does not refer to newly invented substances, rather to those which 
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are either newly available or misused.
262
 These include substances recently controlled under the UK 
Misuse of Drugs Act, such as GHB/GBL (added in 2009), mephedrone (2010), khat (2014), and the 
dissociative methoxetamine (2013); substances which have been controlled for a number of years but 
available as newly modified chemical derivatives (e.g. the synthetic cannabinoid ‘spice’); substances 
which have as yet not been regulated or are under temporary drug orders.
263
 The UK is the single largest 
market of unregulated NPS.
264
 The market is characterized by the speed with which suppliers circumvent 
drug controls by offering new alternatives to restricted products, advertising them as harmless everyday 
products (e.g. bath salts, room fresheners), and marketing them as ‘legal highs’ implying they are safe to 
use.
264
 As of May 2016, all NPS are illegal to supply under the Psychoactive Substances Act 2016.  
 Polydrug use  6.2.2
Polydrug use refers to use of two or more recreational drugs either simultaneously (combining 
substances at the same time) or consecutively (within the same time period but not at the same 
time)
265
. An example of simultaneous polydrug use is inhalation of a mixture of ketamine and ecstasy. 
Consecutive polydrug use can be sequential, in order to induce differing physiological responses (e.g. 
use of cocaine while already under the influence of GHB) or refer to active use during a specific period 
(e.g. number of drugs used in the past three months). Polydrug use may be indicative of a more severe 
substance abuse problem. In addition, drug-drug interactions (DDIs) between recreational drugs can 
lead to severe adverse reactions; for example, co-administration of nitrites (poppers) and the ED drug 
Viagra can cause fatal hypotension and is thus contraindicated.
266,267
  
 
Alcohol, being legal and freely available, is also commonly used alongside recreational drugs 
(particularly stimulants such as amphetamine and cocaine).
144,260,268,269
 Problematic alcohol consumption 
(that increases the risk of or results in harmful consequences to the user or others) can be 
operationalised using a multitude of measures, usually involving number of units consumed over a 
period of time. Concomitant use of recreational drugs and alcohol can also be dangerous; for instance, 
alcohol has been shown to potentiate the sedative effects of GHB, leading to respiratory depression.
270
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Table 6.1: Commonly used recreational drugs: chemical and physiological characteristics, mode of administration, potential for drug interactions267,270–276 
Continued on next page 
Name
Chemical 
classification
Related 
terms
Mode of 
administration
Behavioural and physiological effects 
Drug-drug interactions (DDIs)/other 
health concerns
3,4-
Methylenedioxyme
thamphetamine 
(MDMA)
Stimulant/ 
hallucinogen
Ecstasy, 
molly
swallowed, 
snorted, injected
• Mild hallucinogenic effects; increased empathy, euphoria, 
stimulation, and sexual arousal
• Effects last 3-6 hours  
• Health risks: depression, anxiety, insomnia, impaired 
cognitive performance; ecstasy toxicity (increased body 
tempterature, dehydration, teeth grinding)
• Potential interaction with ATV/r, DRV/r, 
LPV/r
Alkyl nitrites Smooth 
muscle 
relaxant 
Poppers, 
amyls, TNT
inhaled nasally • Rapid onset vasodilation, l ight-headedness, and euphoria; 
relaxation of sphincter muscles 
• Effects last a few minutes
• Concurrent exposure with sildenafil  
citrate (Viagra) is contraindicated
• Potential interaction with PIs 
Anabolic steroids Synthetic 
androgen
Roids injected, 
swallowed, 
applied to skin
• Improve sports endurance and performance, stimulate 
muscle growth
• Health risks: kidney and liver damage; changes in cholesterol 
leading to increased risk of stroke or heart attack; anger, 
aggression
Cannabis Depressant Marijuana, 
THC, weed
smoked, 
ingested (mixed 
in food)
• Enhanced sensory perception, euphoria, 
drowsiness/relaxation; increased heart rate and appetite
• Effects last ≤10 minutes-4 hours (longer if ingested)
• Health risks: problems with learning, memory, concentration; 
anxiety, panic attacks
• Potential interaction with ATV/r, EFV, ETV
Cocaine Stimulant Coke, crack snorted, 
smoked, injected
• Increased euphoria, alertness, confidence; decrease need for 
food and sleep; hypersensitivity to sight, sound, touch; 
increased body temperature, heart rate, blood pressute
• Effects last ≤30 minutes
• Health risks: anxiety, heart attack, stroke, seizure; nasal 
damage
• High interaction with SQV/r
• Potential interaction with ETV/r, DRV/r, 
LPV/r, EFV, ETV, NVP, RPV, and single-tablet 
regimens
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Continued on next page 
Name
Chemical 
classification
Related 
terms
Mode of 
administration
Behavioural and physiological effects 
Drug-drug interactions (DDIs)/other 
health concerns
Erectile dysfunction 
drugs  (EDDs)
Phosphodieste
rase type 5 
(PDE5) 
inhibitors
Viagra, 
caverject, 
cialis, 
kamagra
swallowed, 
sublingual
• Increase blood flow to penis resulting in erection
• Effects last 15 minutes-2 hours
• Health risks: headache; vision impairment and hearing loss; 
prolonged erection; severe low blood pressure; myocardial 
infarction, stoke
• High interaction with all  PI's
• Co-administration with amyl nitrites can 
lead to fatal cardiovascular events
Gammahydroxybut
rate (GHB), 
gammabutyrolacto
ne (GBL)
Depressant/ 
dissociative 
anaesthetic
Liquid 
ecstasy, G
swallowed (as 
l iquid),  injected
• Euphoria-inducing; increased sex drive, decreased 
inhibitions
• Rapid onset (<20mins) and effects last up to 4 hours
• Health risks: can cause coma-like state if combined with 
alcohol;  narrow safety index: small increase in dosage can 
result in GHB toxicity (bradychardia, coma, respiratory 
depression)
• Associated with sexual assault/rape
• Potential interaction with ATV/r, DRV/r, 
LPV/r, single-tablet regimens
• High potential for dependence (and 
withdrawal syndromes upon abrupt 
discontinuation) 
Ketamine Hallucinogen/
dissociative 
anaesthetic
K, special K swallowed, 
snorted, 
smoked, injected 
intramuscularly
• Distortion of time and space, analgesia, hallucinations, 
euphoria
• Rapid onset (<30mins) and last up to 3 hours
• Health risks: panic attack, depression; memory impairment; 
catatonia and delirium("k-hole"); bladder/kidney ulcers
• Regular use can cause severe ulcerative 
cystitis
• Potential interaction with ATV/r, DRV/r, 
LPV/r, EFV, ETV, NVP, single-tablet regimens
Lysergic acid 
diethylamide (LSD) 
Hallucinogen Acid, 
microdotblo
tter
swallowed 
(tablet or l iquid 
or tab: square of 
blotted paper), 
injected
• Intensification of sensory input, feelings of floating and 
dissociation
• Effects last up to 2 hours
• Health risks: LSD toxicity (paranoia, psychosis, flashbacks)
• Low potential for addiction
• Potential interaction with ATV/r, DRV/r, 
LPV/r,  single-tablet regimens
Mephedrone Stimulant Meph, M-
CAT, bath 
salts, meow 
meow
snorted, 
ingested
• Increased motor activity, stimulated mood, sexual 
disinhibition
• Rapid onset (15-45 minutes) and effects last 2-5 hours
• Health risks: convulsions; mephedrone toxicity (agitation, 
tachycardia, hypertension)
• Potential interaction with ATV/r, DRV/r, 
LPV/r
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Name
Chemical 
classification
Related 
terms
Mode of 
administration
Behavioural and physiological effects 
Drug-drug interactions (DDIs)/other 
health concerns
Methamphetamine Stimulant Crystal 
meth, yaba, 
Tina, ice
swallowed, 
snorted, 
injected, 
smoked, rectal 
suppository, 
rubbed into 
gums
• Increased energy, alertness, decreased appetite; decreased 
inhibition, increased sexual confindence
• Effects last 10-12 hours
• Health risks: severe dental disease; insomnia; psychosis; 
stroke, damage to lungs and kindneys; excessive skin picking 
and scratching 
• Potential interactions with ATV/r, DRV/r, 
LPV/r predicted to be of of weak intensity 
• Methamphetamine can mask signs of 
alcohol intoxication (sedation) leading to 
increased consumption of alcohol  
Opioids Depressant/ 
analgesic
Codeine, 
morphine, 
heroin 
(china white, 
smack), 
opium, 
oxycodone
ingested, 
injected, 
smoked, 
snorted, 
suppository
• Euphoria; warm flushing of skin; relaxation and drowsiness; 
analgesia
• Rapid onset (≤5 minutes) and lasting 3-7 hours
• Health risks: constipation; collapsed veins; respiratory 
depression; endocarditis; pneumonia
•Highly physically dependent and 
addictive 
• Potential interaction between codeine, 
morphine, oxycodone and ATV/r, DRV/r, 
LPV/r
• Potential interaction between heroin and 
ATV/r, DRV/r, LPV/r, EFV, ETV predicted to 
be of weak intensity
PI: protease inhibitor; ATV/r: ritonavir-boosted atazanavir; DRV/r: ritonavir-boosted darunavir; EFV: efavirenz; ETV: etravirine; EVG/c: cobicistat-boosted elvitegravir; FTC: 
emtricitabine; NVP: nevirapine; SQV/r: ritonavir boosted-Saquinair; TDF: tenofovir; single-tablet regimens containing EVG/cobicistat/FTC/TDF 
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 Prevalence of recreational drug use in the UK 6.2.3
6.2.3.1 General UK population 
Information on extent and trends in drug use is available from the Crime Survey for England and Wales 
(CSEW), an annual, nationally representative sample of individuals aged 16-59 years resident in England 
and Wales.
277
 In 2014/2015, one in 12 adults had used recreational drugs in the past year and one in 20 
used a drug in the past month. The most commonly used drugs in the past year were cannabis (6.5%), 
cocaine (2.2%), and ecstasy (1.5%). Polydrug use remains an understudied phenomenon in the general 
population in the UK.  
6.2.3.2 All MSM 
Research conducted over the past twenty years has demonstrated that a higher proportion of MSM in 
the UK and abroad use recreational drugs compared to age-comparable non-MSM populations.
278–282
 
Population-wide surveys, such as the CSEW, do not routinely include questions on sexual orientation 
and so cannot monitor drug use among MSM as a distinct group. Hence, data on drug use among MSM 
is derived from studies of convenience samples (online, gyms, clinics, nightclubs, sex-on-premises 
venues). Patterns and prevalence of drug use among MSM have been comprehensively documented in 
literature from Australia and the USA, showing that recreational drug use is common.
283–288
 In the UK, 
various estimates have been reported; prevalence of any drug use in the past year was 55.6% among all 
MSM in the 2002 London Gyms study
289
 (N=653) and 59.9% among MSM in the 2005 GMSS
290
 (N=3913).  
Prevalence of drug use in the past month was 40% among MSM surveyed in the Midlands
291
 between 
2009 and 2011 (N=1843), compared to 16.3% in Brighton, 13.2% in London, and  4.1% in the rest of the 
UK in the 2010 European MSM Internet Survey (EMIS)
292
 (N=13983). The most commonly used drugs in 
the GMSS (2005, 2007, and 2010) have consistently been shown to be nitrites, cannabis, cocaine, and 
ecstasy (all prevalence ≥20% in the past year).
260,290,292
  
 
Approximately 5% of MSM from the UK partaking in EMIS 2010 reported ever having injected drugs.
293
 
In the most recent wave of the GMSS (2014), 1.8% of over 15000 MSM indicated injection drug use 
(IDU) other than anabolic steroids or prescribed medicines in the last 12 months.
144
 Among them, 1.8% 
had injected GHB/GBL, 2.8% heroin, 6.4% amphetamine, 9.9% ketamine, 59.9% crystal 
methamphetamine, and 60.6% mephedrone. 
6.2.3.3 HIV-diagnosed MSM 
MSM are not a homogeneous group with regards to recreational drug use. Studies from the USA and 
Australia show that drug use is more prevalent among HIV-positive compared to HIV-negative men. 
282,287,294–299
 There is a limited number of studies on drug use conducted among large representative 
samples of HIV-diagnosed MSM in the UK, although cross-sectional community-based surveys of MSM 
of mixed HIV-serostatus (such as the GMSS and GMSHS, see Table 2.2) as well as nationally 
representative surveys (such as Natsal-3) also corroborate the difference in prevalence by HIV-
serostatus, with higher drug use apparent among HIV-positive MSM.
281,300–302
 Most venue and internet-
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based behavioural surveys, however, report on drug use as a secondary finding with limited information 
on the types, combinations, and context of drugs used.
303
 Findings from such samples are also likely to 
have limited generalizability. 
 
Behavioural surveys recruiting HIV-diagnosed MSM from outpatient clinics are more representative of 
all MSM living with HIV, and are summarised in Table 6.2. It can be seen that prevalence of drug use was 
high (above 50%) in all studies. In terms of the four UK studies, prevalence of any drug use was: in the 
past 12 months: 53.6% in the 2002 ‘London Gyms’ study
289
 and 55.8% in the GMSS; in the past three 
months: 46.8% in the 2004 Internet & HIV study
151
 and 71.4% in the 2004 Guys and St.Thomas’ clinic.
304
 
Prevalence estimates of specific drugs used also varies and direct comparisons are not always possible 
due to different recall periods. (Table 6.2) Of note, none of the studies reviewed in Table 6.2 (conducted 
in high-income countries between 1996 and 2016) have examined the prevalence of mephedrone use 
among HIV-diagnosed MSM.  
 
Injection drug use among HIV-diagnosed MSM is also understudied in the UK. (Table 6.2) Of the almost 
2% of MSM who injected drugs in the past 12 months in the 2014 GMSS, 11.3% were HIV-diagnosed 
MSM, and 14.4% were HIV-diagnosed MSM living in London (0.3% of all GMSS participants).
144
 By 
comparison, in the 2002 ‘London Gyms’ study prevalence of IDU in the past year was 1.3% among HIV-
diagnosed clinic attendees.
289
 There is some evidence of a significant increase in the prevalence of IDU 
among HIV-diagnosed MSM in the Sydney Gay Community Periodic Surveys (from 14.2% in the past six 
months in 2011 to 20.2% in 2015), but it is unclear whether this is also the case in the UK.
287
  
 Prevalence of polydrug use among HIV-diagnosed MSM  6.2.4
Simultaneous polydrug use (see section 6.2.2) is generally understudied due to difficulties in data 
collection and accuracy. More commonly, polydrug use is classified as consecutive use of a number of 
substances (usually two or more) over a period of time.
265,289,290
 Polydrug use is prevalent in cross-
sectional surveys of MSM attending clubs in the USA
265,305,306
 but evidence on its extent among MSM in 
the UK is limited. (Table 6.2) Among recreational drug users in the 2005 GMSS, polydrug use was the 
norm; of the 9% of MSM who used ketamine in the past year, 89% also used ecstasy, 80% cocaine, and 
23% also used crystal methamphetamine.
281,290
 In the earlier ‘London Gyms’ study, the most common 
combination of drugs in the past three months among HIV-diagnosed clinic outpatient MSM was ecstasy 
and cocaine, followed by ketamine and ecstasy.
289
  
 
As in the case of recreational drug use, alcohol use is more prevalent among MSM compared to non-
MSM populations, and among HIV-positive people compared to HIV-negative.
301,307
 The prevalence of 
harmful/hazardous alcohol use among HIV-diagnosed MSM is understudied, especially among those 
who also use recreational drugs. 
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Table 6.2: Prevalence of recreational drugs used in studies of HIV-diagnosed MSM in high-income countries (1996-2016)* 
          Prevalence (% of HIV-diagnosed MSM participants)  
Study/ Recruitment period/ Country 
N of 
HIV+ 
MSM 
Recall period A
n
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U
 Polydrug use 
(%) 
MACS
308
  1998-2008 USA 57 Past 6 months 66.7 - - - 14.0 - - - - 45.6 - - ≥2 drugs:21.0 
SUMIT 
309,310
 2000-01 USA 1168 Past 3 months  
- - - - 12.3 - - - - - - - 
≥2 drugs:9.1 
≥3 drugs:2.2  
Project BUMPS
311
  2001-02 USA 166 Past 4 months - - 84.9 60.8 - 24.7 46.4 - 67.5 - - - - 
London Gyms
289,312
  2002-03 UK 
116 
(gyms) 
Past 12 months  72.4 - - - - - - - - - - - - 
≥1 x week  - - 5.2 5.2 - - 7.8 - 1.7 - - - - 
≤2 x month - - 17.2 27.6 - - 19.0 - 7.8 - - - - 
338  
(clinic) 
Past 12 months  53.6 - - - - - - - - - - 1.3 - 
≥1 x week  - - 3.4 2.8 - - 2.8 - 0.5 - - - - 
≤2 x month - - 14.4 14.4 - - 10.1 - 3.1 - - - - 
Internet & HIV
151
  2002-03 UK 547 Past 3 months  46.8 - - - - - - - - - - - - 
Guys & St.Thomas' clinic
304
  2002-04 UK 98 Past 3 months  71.4 - - - - - 42.9 - - - - - - 
Sex and Love Project
297
 2002-07 USA 743 Past 3 months  - - 15.8 11.5 - 7.0 7.4 - 15.4 38.9 - - ≥2 drugs:13.4 
Positive Health
313
  2004-05 Australia 274 Past 6 months: at 
least monthly  
83.9 12.0 1.5 1.8 - 1.1 - 0.7 5.5 17.2 1.8 4.4 - 
Positive Connections
314
  2004-09 USA  669 Past 3 months  - 41.0 30.0 - 26.0 - - - - 32.0 - - - 
GMSS
290,315
 2005 UK 507 Past 12 months  55.8 - 50.0 49.4 - 19.0 41.3 11.0 - 60.8 - - - 
German HIV clinics
316
  2009-10 Germany 445 ≤3 x week  - 11.0 2.0 - 9.4 - - 1.8 0.7 21.4 0 - - 
>3 x week - 8.1 1.3 - 2.0 - - 0 0 5.0 1.1 - - 
GCPS Sydney
287
  2011 Australia 352 Past 6 months  - 41.2 - 32.1 40.6 - - - 27.6 52.3 - 14.2 ≥3 drugs:44.0 
EDD: Erectile Dysfunction proprietary drugs such as Viagra(sildenafil), Cialis(tadalafil), or similar; GCPS: Gay Community Periodic Survey; GMSS: Gay Men's Sex Survey; IDU: injection 
drug use; LSD: lysergic acid diethylamide; MACS: Multicenter AIDS Cohort Study; Meth: methamphetamine; Nitrites: poppers; Opioids: codeine, heroin, methadone, morphine, opium; 
Polydrug use refers to use in respective recall period.SUMIT: Seropositive Urban Men's Intervention Trial. Note no information on mephedrone in studies included.  
* Studies have been described in literature review (section 2.5)  
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6.2.4.1 Recreational drug use and HIV: drug-drug interactions (DDIs) 
In the case of HIV, drug use (and polydrug use) further presents issues of interactions with ART leading 
to toxicity
317
 and potential neurological and cardiovascular consequences.
318
 (I have previously 
published results on the prevalence of possible DDIs among ASTRA MSM who use recreational drugs, 
according to type of ART regimen.
319
) The primary mechanism of ART elimination is mediated through 
the hepatic cytochrome p450 (CYP) complex of proteins. This pathway is also shared by recreational 
drugs, which can either induce CYP activity, leading to decrease of ART concentration to sub-therapeutic 
levels, or inhibit it, resulting in toxic drug accumulation.
320
 Not all drugs have high potential for harm 
arising from DDIs; potential for interaction of ART is lowest with alcohol, cannabis, opioids, and nitrites; 
moderate with methamphetamine, ecstasy, and mephedrone; and highest between protease inhibitors, 
EDDs, ketamine.
321
 Despite a substantial increase in the number of GHB-associated deaths in London 
between 2010 and 2015 (n=61, a third of whom were HIV-positive)
322
, the potential for interaction 
between GHB and ART remains unknown.  
 Factors associated with recreational drug use among HIV-diagnosed MSM 6.2.5
6.2.5.1 Socio-demographic factors 
Few consistent associations between socio-demographic characteristics and drug use have been shown 
across different studies. There is some evidence that certain drugs are more commonly used by 
different socio-demographic sub-groups, and therefore results may vary according to study location, 
recruitment, and sample. The most consistent finding relates to age; a number of studies have found 
that, among HIV-diagnosed MSM, younger age is associated with higher prevalence of any recreational 
drug
292,323,324
 and polydrug use.
305
 However, specific drugs may be more commonly used by MSM of 
different age groups. For HIV-diagnosed MSM in Project BUMPS (N=166), a US cohort study of MSM 
using 'club drugs' recruited from gay venues and websites, younger age (<30 years) was significantly 
associated with using GHB and/or ketamine, while older age (≥30 years) was associated with using 
cocaine and/or methamphetamine.
311
 In addition, men aged 30-39 were more likely to use ecstasy 
compared to those in their 20’s, but not compared to those over 40 years.
311
 In the SUMIT trial (see 
Table 2.2), MSM who were older (>45 years) were more likely to use Viagra.
309
  
 
There is mixed evidence on patterns of drug use by race/ethnicity. For example, in the US Positive 
Connections study
314
 (see Table 6.2), white HIV-diagnosed MSM were more likely to report use of 
nitrites in the past three months compared to black MSM, but the pattern was reversed for all other 
drugs. Other studies, including the SUMIT trial,
325
 have not found any association between ethnicity and 
drug use.
323,326
  
 
Three studies showed that higher educational attainment was associated with any drug use (specifically 
with ecstasy and EDDs) in unadjusted analyses,
290,309,310,314
 while four other studies found no significant 
association after adjustment for confounders.
323–325,327,328
 Another US study of 261 HIV-diagnosed MSM 
(EDGE Project)
329,330
 enrolled in a sexual risk reduction intervention for active methamphetamine users 
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found that ‘heavy’ polydrug users (using methamphetamine, cocaine, heroin, hallucinogens, and 
ketamine in the past two months) were less educated compared to ‘light’ polydrug users (using 
methamphetamine, cannabis, and nitrites). It might be expected that employment (and consequently, 
higher disposable income) is associated with recreational drug use; this was corroborated in the 2014 
GMSS
327
 as well as two earlier North American studies of HIV-diagnosed MSM
314,323
 but not in the SUMIT 
trial.
309
  
6.2.5.2 HIV-related factors  
There is limited information on associations of HIV-related factors and recreational drug use. In the 
SUMIT trial, MSM who were diagnosed with HIV for longer were more likely to report anabolic steroid 
use; being on ART was also associated with use of Viagra or steroids.
310
 However, results from this study 
are hard to interpret as no adjustment was conducted for participant’s age. Project BUMPS did not find 
any association between length of time diagnosed with HIV and recreational drug use, despite 
adjustment for age.
311
   
6.2.5.3 Lifestyle factors 
Associations of alcohol misuse and recreational drugs are to be expected, as both frequently co-occur in 
the same social settings.
324,328,331,332
 Although most HIV-diagnosed MSM report some recent alcohol use 
(79–89%), only a minority (8–16%) report frequent and heavy alcohol use.
288,333,334
 The extent of 
hazardous/harmful alcohol use among HIV-diagnosed MSM in the UK is understudied, particularly 
among those who also use drugs.  
 Recreational drug use and sexual behaviour among HIV-diagnosed MSM 6.2.6
Cross-sectional studies from the USA and Australia document strong associations between drug use, 
CLS, and high number of partners among MSM, across all age groups and regardless of HIV-
serostatus.
96,286,295,311,324,335,336
 In prospective studies of HIV-negative MSM, use of nitrites (poppers), 
methamphetamine, and/or erectile dysfunction drugs (EDDs) has been significantly associated with HIV 
seroconversion, through their association with CLS-D.
308,337–340
 Predictive mathematical models
338
 and 
cohort studies
341,342
 also show that recent use of methamphetamine is an independent predictor of HIV 
seroconversion. The association of drug use and CLS among HIV-diagnosed MSM could be causal or 
correlational.
294
 (Further discussed in section 6.5.4) 
 
While there are numerous studies on the association of recreational drug use and sexual behaviour 
among all MSM in high income countries, there are fewer studies among HIV-diagnosed MSM. In this 
population, a number of cross-sectional US studies have shown that use of crystal methamphetamine, 
GHB, and/or ketamine, are associated with CLS-D,
309,310,343,344
 including insertive CLS-D.
286
(Table 6.3) 
Baseline results from the START trial of over 2500 ART-naïve HIV-diagnosed MSM also showed 
significant associations of any drug use in the past month and reporting CLS-D, after adjustment for 
socio-demographic, lifestyle, and HIV-related factors.
156
 In the 2002 ‘London Gyms’ study,
289
 HIV-
diagnosed MSM recruited from clinics who used methamphetamine and/or EDDs reported significantly 
higher prevalence of CLS-D with casual partners compared to those who did not use any drug in the past 
151 
 
three months (p<0.001, unadjusted); this estimate however, was based on a limited sample size (≤50 
MSM). There has since been little information on patterns of recreational drug use, the extent of 
polydrug use, or on any association of different drugs with types of CLS from large, representative 
samples of HIV-diagnosed MSM in the UK. Patterns of drug use may be changing, and there are no 
studies in the UK to date that examine the association of drug use and CLS-D with higher risk of HIV 
transmission.  
 Emerging trends in recreational drug use  6.2.7
Since 2013, health care services and community organisations in the UK have reported shifting trends in 
popularity and use of specific drugs among MSM,
345,346
 suggesting, firstly, an increase in prevalence of 
‘club drug’ use overall, and secondly, the emergence of ‘chemsex’, meaning sex between men that 
occurs under the influence of methamphetamine, mephedrone, and/or GHB/GBL.
259
 These drugs are 
associated with increased feelings of sexual arousal, enabling sexual longevity, and high partner 
turnover. Evidence relating to the extent of chemsex use is limited to a qualitative report (2013) of 30 
chemsex-using MSM (13 HIV-diagnosed) in South London
259
. The report suggested that chemsex occurs 
in a range of settings but most commonly in private homes and that polydrug use is the norm during 
chemsex. A third of men in this study had injected methamphetamine or mephedrone, and the majority 
of HIV-positive men reported chemsex in the context of predetermined decisions to have CLS with 
partners they believed were also HIV-positive. Therefore, it is unclear the extent to which chemsex use 
may be associated with HIV-transmission risk behaviour. Recent Public Health England investigations 
into outbreaks of other STIs (such as S.flexneri and E.coli) have also found that cases are more likely to 
be HIV-positive MSM who engaged in chemsex.
148,346–350
 While there are reports from STI clinics and 
community organisations about the link between chemsex and CLS, there is no robust quantitative 
evidence to date.
351
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Table 6.3: Prevalence of condomless sex (CLS) among HIV-diagnosed MSM who use recreational drugs in studies from high-income countries (1996-2016) 
Study /Location/Data collection 
period 
Study setting and recruitment* N 
HIV+ 
MSM 
Recall period Prevalence of 
recreational drug use 
(% of HIV+ MSM)  
Prevalence of CLS    
(% of HIV+ MSM using drugs) 
MACS 
308
 USA 1998-
2008 
Ongoing prospective study of HIV 
seroconversion with biannual 
questionnaire. Here showing data 
for MSM who seroconverted only.  
57 At current or 
previous 6-month 
visit 
66.7% 42.1% of MSM who used any drug had any 
receptive CLS (12% had ≥5 receptive CLS 
partners) 
SUMIT trial  
309,310
 
USA 2000-
2001 
Baseline results of multisite RCT on 
HIV-positive MSM. Here focus on 
MSM who used Viagra. 
1168 Past 3 months 12.3% used Viagra Of MSM who used Viagra:  
•34.3% had CLS-C insertive 
•26.1% had CLS-D insertive  
London 
Gyms 
289,312
 
UK 2002-
2003 
Here showing data for HIV-
diagnosed MSM recruited from HIV 
outpatient clinic only.   
388 Past 12 months • Any drug use: 53.6% 
• Methamphetamine 
use: 12.6% 
Of MSM who used methamphetamine: 
• 34.7% had CLS-D 
• 18.4% had CLS-C 
Of MSM who used other drug but not 
methamphetamine:  
• 18.9% had CLS-D 
• 9.4% had CLS-C  
Internet & 
HIV
139,151
 
 
UK 2002-
2003 
Here showing combined data for 
HIV-diagnosed MSM recruited from 
HIV outpatient clinic and online.   
547 Past 3 months 46.8% Of MSM used any drug: 
• 7.0% had CLS-D 
• 12.1% had CLS-C  
Guys & 
St.Thomas' 
clinic 
352
 
 
UK 2002-
2004 
MSM with primary HIV infection 
(positive test within 6 months of 
documented negative) recruited 
from sexual health services and 
enrolled in ART intervention.  
98 Past 3 months (at 
12 week follow-up 
after 
seroconversion) 
71.4% Of MSM used any drug: 
19.4% had CLS-D with a regular partner 
and/or CLS with a casual partner 
Positive 
Health
167,313
  
Australi
a  
2004 Observational cohort of HIV-
diagnosed MSM recruited from gay 
community events, organisations, 
HIV clinics, online, with interviewer-
administered questionnaire.  
274 Less than monthly 
or at least monthly 
83.9% •41.2% of MSM who used any drug less 
than monthly had any CLS 
•25.8% of MSM used at least monthly had 
any CLS 
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Study /Location/Data collection 
period 
Study setting and recruitment* N 
HIV+ 
MSM 
Recall period Prevalence of 
recreational drug use 
(% of HIV+ MSM)  
Prevalence of CLS    
(% of HIV+ MSM using drugs) 
START trial 
156
 
Interna
tional 
2009-
2013 
ART-naïve HIV-diagnosed MSM 
enrolled in international RCT on 
deferred or immediate ART 
initiation. Results from MSM at 
baseline pre-randomisation survey 
across all recruitment regions. 
2559  <1 day or ≥1 day 
per week in past 
month  
• <1 day/week: 11.6% 
• ≥1 day/week: 3.1% 
• Of MSM who used drugs <1 day/week 
26.2% had CLS-D 
• Of MSM who used drugs  ≥1 day/week 
29.1% had CLS-D 
Scotland 
GMSHS
301
 
 
UK 2011 Anonymous self-completed 
questionnaire in gay commercial 
venues in 2 cities with oral fluid HIV 
antibody testing. Here showing 
results for MSM who tested HIV-
positive. 
24 Always or 
sometimes using 
drugs during CLS in 
past 12 months 
- 54.2% 
ART: antiretroviral therapy;  CLS: condomless sex;  CLS-D: CLS with HIV-serodifferent partners; CLS-C: CLS with HIV-seroconcordant partners; GMSHS: Gay Men's Sexual Health 
Survey; MACS: Multicenter AIDS Cohort Study; RCT: randomised controlled trial; START: Strategic Timing of AntiRetroviral Treatment; SUMIT: Seropositive Urban Men's 
Intervention Trial 
*Studies described in literature review (section 2.5)  
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6.3 Methods 
This chapter includes MSM participating in the ASTRA study who were diagnosed with HIV for ≥3 
months (N=2189).  
 Recreational drug use 6.3.1
Participants were asked if they had used recreational drugs in the past three months and if so which 
ones, listing the following 18 drugs as phrased here; acid/LSD/magic mushrooms, anabolic steroids, 
cannabis (marijuana), cocaine (coke), crack, codeine, crystal meth (methamphetamine), ecstasy (E), GHB 
(liquid ecstasy), heroin, ketamine (K), Khat (chat), mephedrone, morphine, opium, poppers (amyl 
nitrites), speed (amphetamine), Viagra, and ‘other (please specify)’.(Appendix I) The term opioid was 
used to combine heroin, morphine, and opium. Free-text responses in the ‘other (please specify)’ 
category included slang names or other proprietary medications; these were examined case-by-case and 
recoded to the above categories if applicable, as in Table 6.4. Other drugs used in the treatment of 
erectile dysfunction (ED) were combined with Viagra and classified as ED drugs (EDDs). Use of one or 
more of the following three drugs: methamphetamine, GHB/GBL, or mephedrone was defined as use of 
a ‘chemsex-associated drug’.
259
 Of note, the ASTRA questionnaire did not explicitly enquire about 
chemsex use (any of the three substances used before or during sex specifically), and so the term 
chemsex-‘associated’ drugs is used instead. Use of one or more of the following four drugs: GHB/GBL, 
mephedrone, ketamine, or ecstasy was defined as use of a ‘club drug’. Polydrug use was assessed by the 
number of different drugs used during the previous three months.  
 
Table 6.4: Coding of responses in 'other (please specify)' recreational drug use category 
(N=40) 
 
Participants were asked also whether they had injected recreational drugs in the past three months, and 
if so, whether they shared needles, syringes, or ‘works’ (cotton, cooker, spoon, etc.) with an HIV-
serodifferent person after injecting themselves.  
Slang or proprietary name Frequency Recoded to drug category 
Caverject, Cialis, Kamagra, or 'herbal Viagra' 12 ED drugs
DMT 1 Acid/LSD/magic mushrooms
GBL 2 GHB
'hello kitty' 1 Cocaine
MDMA or 'benzo fury' 11 Ecstasy
'meow meow', NRG, energy, or MCAT 4 Mephedrone
Methadone 2 Opioids
Methoxetamine, MXE, 'moxxy' 2 Ketamine
Poppers 3 Nitrites (poppers)
Not classifiable 2 -
ED drugs; erectile dysfunction 
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 Other factors and sexual behaviours 6.3.2
All socio-demographic, psychological, other lifestyle, and HIV-related factors examined in this chapter 
have been defined in section 3.8. Sexual behaviours (including definitions of CLS variables) are defined in 
section 4.3.  
 Statistical analysis 6.3.3
The prevalence of any recreational drug use, use of 1, 2, 3, 4, ≥5 types of drugs, and injection drug use 
(IDU) was assessed in the past three months. Patterns of drug use were examined according to number 
of drugs used and injection drug status (whether injected drugs or not).  
6.3.3.1 Factors associated with recreational drug use 
Associations were examined of socio-demographic, psychological, lifestyle, and HIV-related factors with:  
(i.) any recreational drug use in the past three months among all MSM;  
(ii.) polydrug use (for the purposes of this analysis defined as use of ≥4 drugs versus 1-3 drugs) 
among MSM who used drugs in the past three months;   
(iii.) use of chemsex-associated drugs (use of one or more of: GHB/GBL, mephedrone, or crystal 
methamphetamine versus use of any other drugs) among MSM who used drugs in the past 
three months. 
Unadjusted and adjusted modified Poisson regression models were used with robust error variances. In 
multivariable analyses, two adjustment strategies were used (see section 3.9.5). Firstly, each factor was 
adjusted separately for core factors, and secondly, any factor with p<0.10 at unadjusted analysis was a 
candidate for inclusion in the multivariable model in addition to clinic; correlated variables were 
assessed and excluded accordingly (specifics for each model are discussed in sections 6.4.2, 6.4.3.) 
6.3.3.2 Association of recreational drug use with sexual behaviours 
Associations were then examined, among all MSM, of recreational drug use, polydrug use (0, 1, 2, 3, 4, 
≥5 drugs), and chemsex-associated drug use with the following sexual behaviours: 
(i.) In the past three months: any anal or vaginal sex, condomless sex (CLS), CLS with HIV-
seroconcordant partners (CLS-C), CLS with HIV-serodifferent partners (CLS-D), higher HIV risk 
CLS-D (CLS-D plus not on ART or latest study log-recorded VL>50c/mL, see section 5.3.1), self-
reported other STI diagnosis, participation in group sex, use of the internet to find sex; 
(ii.) In the past year: having 10 or more new sex partners;  
(iii.) No recall period: low condom self-efficacy, difficulty negotiating condom, lower condom use 
with casual partners, and worry about HIV transmission (all defined in section 4.3). 
As in section 6.3.3.1, unadjusted and adjusted modified Poisson regression was used with robust error 
variances. Models were adjusted for core factors. As some recreational drugs are reported to be used 
solely in a sexual context,
348,349
 the analysis of associations of polydrug use and measures of condomless 
sex (any CLS, CLS-C, CLS-D, and higher HIV risk CLS-D) was repeated in the subgroup of MSM who 
reported any anal and/or vaginal sex in the past three months. In this analysis, models were adjusted for 
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core variables only; the model with higher HIV risk CLS-D as the dependent variable did not include 
adjustment for ART status.  
 
Unadjusted multinomial logistic regression (MNL) was used to examine associations of recreational, 
polydrug, and chemsex-associated drug use with reporting different sexual behaviours according to the 
single four-category variable of sexual behaviour (see section 4.3.3). All MSM were classified into one of 
the following mutually exclusive groups based on sex in the past three months:  
1. Condomless sex with HIV-serodifferent partners (CLS-D)  
2. Condomless sex with HIV-seroconcordant partners only  (‘CLS-C without CLS-D’) 
3. Condom-protected sex only  
4. No anal or vaginal sex  
In examining associations with drug use variables, firstly, MSM who did not report any anal or vaginal 
sex (group 4) were the reference group, compared to each of the other three categories. Secondly, MSM 
who reported no anal or vaginal sex in the past three months were excluded, and MSM who had CLS-D 
(group 1), and those who had ‘CLS-C without CLS-D’ (group 2) were compared to those who had 
condom-protected sex only (group 3, used as the reference category). 
 
In order to assess any differential effect of specific drugs on different types of CLS, associations were 
examined between use of particular drugs with any CLS-D, CLS-C, or higher HIV risk CLS-D among the 
subgroup of MSM who reported any anal and/or vaginal sex in the past three months. Modified Poisson 
models were used with adjustment for core factors. For each drug, the reference category was no 
recreational drug use, and the remaining two categories were use of; the specific drug, and of any other 
recreational drug.   
 
In the last main analysis, the aim was to examine, among MSM who used recreational drugs, which 
drugs were more strongly associated with having CLS-C only (a proxy for HIV-serosorting) compared to 
having CLS-D. This analysis included only MSM who had CLS and used any recreational drug in the 
previous three months. MSM were thus classified into two mutually exclusive categories (either ‘CLS-C 
without CLS-D’ or CLS-D, the reference group). Unadjusted modified Poisson regression was used due to 
the smaller sample size. 
6.3.3.3 Association of alcohol misuse, recreational drug use, and sexual behaviours 
As alcohol is commonly used with recreational drugs, the aim of this analysis was to examine any 
independent associations between alcohol misuse and sexual behaviours (shown in section 6.3.3.2, (i)), 
accounting for recreational drug use. Two measures of problematic alcohol use were used: ‘higher 
alcohol consumption’ (defined as a score ≥6 on the first two questions of the WHO-AUDIT-C 
questionnaire
213
), and ‘evidence of alcohol dependency’ (defined as a score ≥2 on the CAGE 
questionnaire
353
, see section 3.8.2 for both). For each measure of alcohol misuse, separate models were 
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conducted, firstly only adjusting for the alcohol measure and secondly, additionally adjusting for core 
factors plus recreational drug use in the past three months.  
6.3.3.4 Association of recreational drug use, alcohol misuse, and ART outcomes  
It was hypothesized that recreational drug use and alcohol misuse might impact adherence to ART, 
which in turn could lead to viral load (VL) non-suppression on ART. As this was the hypothesised 
direction of association, it was deemed appropriate to not include factors relating to treatment 
outcomes (such as non-adherence) when examining factors associated with drug use (as described in 
section 6.3.3.1), but rather to separately assess the association of drug use (as the independent variable) 
with ART adherence and VL non-suppression (as the dependent variables). This analysis examines, 
among MSM who were on ART only, associations of recreational drug use, polydrug use (1, 2-4, ≥5 
drugs) in the past three months, higher alcohol consumption, evidence of alcohol dependency with: 
(i.) Non-adherence to ART (missed ≥2 consecutive days of ART on ≥2 occasions in the past 3 
months) 
(ii.) VL non-suppression (study log-recorded VL>50c/mL among MSM who started ART ≥6 months 
ago) 
Unadjusted and adjusted modified Poisson regression was used. Models were adjusted for core factors 
(as in section 6.3.3.1), excluding ART status.  
6.3.3.5 Sensitivity analyses 
In the first sensitivity analysis, the aim was to examine associations of recreational drug use and sexual 
behaviours accounting for factors not already included in the set of core variables that were  associated 
with CLS in earlier analyses (section 4.4.5), as these could be considered as potential confounding 
factors. These factors (defined in section 3.8) were: employment status (employed full or part-time, 
unemployed or other), education (no qualifications or up to A levels, university degree or higher), and 
identifying as religious (yes, no). Associations between polydrug use, chemsex-associated drug use and 
measures of sexual behaviour (described in section 6.3.3.2) were examined in two modified Poisson 
regression models adjusted for core factors, clinic and: 
1. employment plus religion 
2. education plus religion  
Employment and education were not mutually adjusted for in a single model as they are collinear. The 
second sensitivity analysis aimed at allowing for valid comparisons of the magnitude of associations of a 
single independent variable (polydrug use) across a number of dependent binary variables of varying 
prevalence (CLS, CLS-D, CLS-C, higher HIV risk CLS-D). (Discussed in section 3.9.4.3) This was done by 
presenting associations of polydrug use and sexual behaviours as odds ratios rather than prevalence 
ratios using logistic regression with adjustment for core variables only.  
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6.4 Results 
 Prevalence of recreational drug use  6.4.1
Among 2189 MSM who were diagnosed with HIV for ≥3 months, the prevalence of any recreational drug 
use was 50.8% (95%CI 48.7-52.8%, n=1111) in the previous three months. 
The most commonly used drugs (prevalence ≥10%) were nitrites (27.0%, 95%CI 25.2-28.9%), cannabis 
(21.3%, 19.7-23.1%), erectile dysfunction drugs, EDDs, (20.5%, 18.9-22.3%), cocaine (20.1%, 18.4-
21.8%), ketamine (12.6%, 11.3-14.1%), ecstasy (11.4%, 10.2-12.8%), and GHB/GBL (9.9%, 8.7-11.2%). 
(Figure 6.1) A total of 330 MSM (15.1%, 13.6-16.6%) had used any chemsex-associated drug 
(methamphetamine, mephedrone, and/or GHB/GBL) in the previous three months. When excluding 831 
MSM who used nitrites and EDDs (which are not illegal in the UK), the prevalence of any recreational 
drug use in the past three months was 38.0% (36.0-40.0%).  
 
Figure 6.1: Prevalence of recreational drug use in the past three months (N=2189 HIV-
diagnosed MSM) 
 
6.4.1.1 Polydrug use  
Among 1111 MSM who had used drugs in the previous three months, 363 (32.7%, 95%CI 30.0-35.5%) 
used one drug, 229 (20.6%, 18.3-23.1%) used two, 173 (15.6%, 13.6-17.8%) used three, 111 (10.0%, 8.4-
11.9%) used four, and 235 (21.2%, 18.8-23.7%) used five or more. Figure 6.2 shows the proportion of 
responses for each drug used as a percentage of the total number of responses, according to number of 
159 
 
drugs taken in the previous three months. Among MSM who used only one drug in the past three 
months, 38.1% used nitrites (poppers), 36.7% cannabis, and 12.2% cocaine only. Of the recreational 
drugs reported among MSM who used two drugs, 26.3% of responses were for nitrites, 21.7% were for 
cannabis, 17.5% for EDDs, and 15.9% for cocaine. As the number of drugs taken increased, so did the 
proportion of responses for EDDs, chemsex-associated drugs, ketamine, and ecstasy. For example, 
among MSM using only one drug, 0.2% used GHB/GBL, whereas GHB/GBL accounted for 9.8% of 
responses among MSM using five or more drugs. Similarly, the corresponding percentages for ketamine 
were 2.5% and 11.0%, for ecstasy 2.5% and 9.7%, and for methamphetamine 1.1% and 7.5%. 
 
Figure 6.2: Type of drug according to number of drugs used in the past three months among 
1111 HIV-diagnosed MSM using one or more drugs. 
 
6.4.1.2 Injection drug use  
Injection drug use was reported by 66 MSM (3.0%, 95%CI 2.4-3.8%) in the past three months, of whom 4 
(6.1%) reported sharing needles, syringes, or ‘works’ with an HIV-serodifferent person. Among 1111 
MSM who used any drug in the past three months, use of specific drugs was compared between 
injection (n=66) and non-injection drug users (n=1045). (Table 6.5) MSM who reported IDU were more 
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Number of drugs used in the previous 3 months  
Nitrites (poppers)
Cannabis
EDDs
Cocaine
Ketamine
Ecstasy
GHB/GBL
Methamphetamine
Mephedrone
Amphetamine
Other drugs
N of MSM   
(N=1111)           363             229               173              111               235  
N of responses 
(N=3241)           360             452               514              438              1477 
 
Other drugs includes opium, morphine, heroin, khat, crack cocaine, codeine, LSD, and anabolic 
steroids; EDDs: erectile dysfunction drugs  
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likely to be polydrug users than MSM who reported non-injection drug use only (93.8% versus 65.7% 
used ≥4 drugs, p<0.001). Over 90% of injection drug users reported use of chemsex-associated drugs, 
compared to 12.8% of non-injection drug users. For example, methamphetamine was used by 84.6% of 
MSM who also injected any drugs compared to 11.1% of MSM who did not inject any drugs (p<0.001). 
Use of each specific drug was significantly higher among injection compared to non-injection drug users, 
with the exception of amphetamines and nitrites (p>0.05). 
Table 6.5: Use of specific recreational drugs among injection and non-injection drug users in 
the previous three months (N=1111) 
 
 Factors associated with recreational drug use 6.4.2
6.4.2.1 Any recreational drug use 
Table 6.6 shows the associations of socio-demographic, psychological, lifestyle, and HIV-related factors 
with any recreational drug use in the past three months. Although prevalence of drug use was high 
across most demographic groups, in unadjusted analysis recreational drug use was strongly associated 
with younger age, more recent HIV diagnosis, not identifying with a religion, being employed, evidence 
of harmful alcohol drinking, having an HIV-positive stable partner, and not being on ART. Drug use was 
not significantly associated with ethnicity, place of birth, education, financial hardship, social support, 
depression, or anxiety.  
 
In the first multivariable analyses (models 1, Table 6.6), each factor was adjusted for core variables in a 
separate model. The following factors remained associated with recreational drug use (p<0.05) with 
little or no attenuation in magnitude of associations: younger age (a significant inverse trend was 
observed with lower drug use prevalence at older ages, such that MSM under 30 years had more than 
twice the prevalence of drug use compared to those 60 or older), not being religious, higher alcohol 
Yes (n=66) No (n=1045)
Use in the past three months row N col % col % p-value
Nitrites (Poppers) 592 46.2 53.7 0.235
EDDs 449 76.9 38.1 <0.001
Cocaine 439 55.4 38.5 0.007
Chemsex-associated drugs 330 90.8 25.9 <0.001
Ketamine 276 46.2 23.5 <0.001
GHB/GBL 216 64.6 16.6 <0.001
Methamphetamine 171 84.6 11.1 <0.001
Mephedrone 155 32.3 12.8 <0.001
Amphetamine 73 7.7 6.5 0.707
Anabolic steroids 59 15.4 4.7 <0.001
Crack cocaine 17 6.2 1.2 0.001 (F)
Opioids 53 24.6 3.5 <0.001
Polydrug use 346 75.4 28.4 <0.001
p-values by chi-squared test or Fisher's exact (F)
*Note: not showing injection of specific drug. P-values for each drug shown for 
comparison of injection versus non-injection drug users; Chemsex-associated drugs: 
mephedrone, GHB/GBL, and/or methamphetamine; EDDs: erectile dysfunction drugs; 
Opioids: opium, morphine, heroin, codeine. Polydrug use: ≥4 recreational drugs in 
the previous 3 months. 
Injection drug use *
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consumption, alcohol dependency, and having an HIV-positive stable partner; MSM who had an HIV-
serodifferent stable partner and those who did not have a stable partner had approximately 20% and 
10% lower prevalence of recreational drug use respectively compared to MSM with an HIV-positive 
stable partner. Associations with shorter time since HIV diagnosis, employment, and not being on ART 
were not significant in the core-adjusted models, primarily due to adjustment for age.  
 
In the second multivariable model, any factor with p<0.10 at unadjusted analysis was a candidate for 
inclusion in the multivariable model, in addition to clinic. (model 2, Table 6.6) These were: age, time 
since HIV diagnosis, religion, employment, higher alcohol consumption, stable partner status, ART 
status, and ART status/self-reported VL. As the last two variables included categories of the other, ART 
status was excluded from the model. After mutual adjustment, while some associations were slightly 
attenuated, the same factors as in model 1 remained significantly associated with recreational drug use. 
6.4.2.2 Polydrug use 
Associations were examined of socio-demographic, psychological, lifestyle, HIV-related factors and 
polydrug use (use of 4 or more drugs compared to 1-3 drugs) among 1111 MSM who used drugs in the 
previous three months. (Table 6.7) In unadjusted analysis, polydrug use was more prevalent among 
MSM who were younger, recently diagnosed, did not identify as religious, had a university degree, were 
employed, had an HIV-positive stable partner, and were not on ART. 
 
After adjustment for core factors (models 1, Table 6.7), the following factors remained significantly 
associated with polydrug use with some attenuation (p<0.05): younger age (with prevalence particularly 
elevated in the <30 year age group), university degree, employment, and having an HIV-positive stable 
partner. Time since HIV diagnosis, ART status, and ART status/self-reported VL were no longer 
significantly associated with polydrug use in multivariable analysis. There remained a weak association 
between not being religious and polydrug use (p=0.07). 
 
In model 2, the following factors were candidates for inclusion in the multivariable model in addition to 
clinic (model 2, Table 6.7): age, time since HIV diagnosis, religion, education, employment, stable 
partner status, ART status, and ART status/self-reported VL. Education and employment were highly 
correlated and so only one could be retained in the model; it was deemed more relevant in this case to 
examine the effect of early socio-economic factors, such as education, on polydrug use. ART status was 
excluded from the model as it was included in the ART status/self-reported VL variable. Hence, after 
adjustment for age, time since HIV-diagnosis, religion, education, stable partner status, ART status/self-
reported VL, and clinic, the same variables were found to be significantly associated with polydrug use 
as in model 1 (p<0.05). The prevalence of polydrug use was two-fold higher among MSM under 30 years 
compared to those 60 or older, 22% higher in relative terms among those with a university degree 
compared to those with lower qualifications, and approximately 50% higher in relative terms among 
MSM with a HIV-positive stable partner compared to those with an HIV-serodifferent partner. There was 
some evidence of an association of not being religious and polydrug use (p=0.07). 
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Table 6.6: Association of socio-demographic, psychological, lifestyle, and HIV-related factors with recreational drug use in the previous three months 
(n/N=1111/2189 HIV-diagnosed MSM)    
  
n used 
drugs/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Age at recruitment, years (N=2167)
<30 61/96 63.5 2.2 [1.6,2.9] 2.1 [1.6,2.9] 2.1 [1.5,2.8]
30-39 300/487 61.6 2.1 [1.6,2.8] 2.1 [1.6,2.8] 2.0 [1.5,2.7]
40-49 484/929 52.1 1.8 [1.4,2.3] 1.8 [1.4,2.3] 1.7 [1.3,2.3]
50-59 210/503 41.7 1.4 [1.1,1.9] 1.4 [1.1,1.9] 1.4 [1.0,1.8]
≥60 44/152 28.9 1.0 <0.001(T) 1.0 <0.001(T) 1.0 <0.001(T)
Ethnicity (N=2154)
White 984/1928 51.0 1.0 1.0 -
All other (black, Asian, Mixed, other) 109/226 48.2 0.9 [0.8,1.1] 0.435 0.9 [0.8,1.0] 0.189
Years since HIV diagnosis  (N=2177)
≤2 111/184 60.3 1.0 1.0 1.0
2-5 183/338 54.1 0.9 [0.8,1.0] 0.9 [0.8,1.1] 0.9 [0.8,1.0]
5-10 275/550 50.0 0.8 [0.7,1.0] 0.9 [0.7,1.0] 0.8 [0.7,1.0]
10-15 230/461 49.9 0.8 [0.7,1.0] 0.9 [0.8,1.1] 0.9 [0.8,1.0]
>15 304/644 47.2 0.8 [0.7,0.9] 0.001(T) 0.9 [0.8,1.1] 0.827(T) 0.9 [0.8,1.1] 0.951(T)
Place of birth (N=2189)
UK 762/1502 50.7 1.0 1.0
Outside the UK 349/687 50.8 1.0 [0.9,1.1] 0.976 1.0 [0.9,1.1] 0.378 -
Religious (N=2152)
Yes 414/919 45.0 1.0 1.0 1.0
No 679/1233 55.1 1.2 [1.1,1.3] <0.001 1.2 [1.1,1.3] <0.001 1.1 [1.0,1.2] 0.004
Education (N=2149)
University degree or above 480/950 50.5 1.0 1.0
No qualifications or up to A levels 615/1199 51.3 1.0 [0.9,1.1] 0.724 1.0 [0.9,1.1] 0.588 -
Recreational drug use (n/N=1111/2189) 
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n used 
drugs/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Employment (N=2142)
Employed 700/1318 44.3 1.0 1.0 1.0
Unemployed or other(carer, student, retired) 389/824 39.9 0.9 [0.8,1.0] 0.011 1.0 [0.9,1.1] 0.822 1.0 [0.9,1.1] 0.582
Money for basic needs (N=2158)
Always 560/1114 50.3 1.0 1.0
Mostly 302/596 50.7 1.0 [0.9,1.1] 1.0 [0.9,1.1]
Sometimes 137/275 49.8 1.0 [0.9,1.1] 1.0 [0.8,1.1] -
Never 100/173 57.8 1.1 [1.0,1.3] 0.198(T) 1.1 [1.0,1.3] 0.415(T)
Social support (N=2170) ‡
High 640/1286 49.8 1.0 1.0
Medium 349/666 52.4 1.1 [1.0,1.2] 1.0 [0.9,1.1] -
Low 118/218 54.1 1.1 [1.0,1.2] 0.138(T) 1.1 [1.0,1.3] 0.126(T)
Depression symptoms (N=2189) ‡
No 793/1590 49.9 1.0 1.0 -
Yes 318/599 53.1 1.1 [1.0,1.2] 0.174 1.1 [1.0,1.2] 0.227
Anxiety symptoms (N=2189) ‡
No 491/1110 44.2 1.0 1.0 -
Yes 109/263 41.4 1.0 [0.9,1.1] 0.678 0.9 [0.8,1.1] 0.832
Higher alcohol consumption(N=2189) ‡
No 898/1823 49.3 1.0 1.0 1.0
Yes 213/366 58.2 1.2 [1.1,1.3] 0.001 1.2 [1.1,1.3] 0.002 1.2 [1.1,1.3] 0.003
Evidence of alcohol dependency (N=2188) ‡
No 869/1768 49.2 1.0 1.0 -
Yes 241/420 57.4 1.2 [1.0,1.2] 0.001 1.1 [1.0,1.2] 0.009
Recreational drug use (n/N=1111/2189) 
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‡ For variable definitions see section 3.8 
 
n used 
drugs/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Stable partner's HIV-serostatus (N=2189)
HIV-positive 294/510 57.6 1.0 1.0 1.0
HIV-negative or unknown status 314/694 45.2 0.8 [0.7,0.9] 0.8 [0.7,0.9] 0.8 [0.7,0.9]
No stable partner 503/985 51.1 0.9 [0.8,1.0] <0.001 0.9 [0.8,1.0] 0.001 0.9 [0.8,1.0] 0.002
ART status (N=2178)
On ART 941/1888 49.8 1.0 1.0 -
Not on ART 167/290 57.6 1.2 [1.0,1.3] 0.009 1.0 [0.9,1.2] 0.682
ART status/self-reported VL (N=2143)
On ART, reports undetectable VL 770/1568 49.1 1.0 1.0 1.0
On ART, does not report undetectable VL† 155/285 54.4 1.1 [1.0,1.2] 1.0 [0.9,1.2] 1.1 [0.9,1.2]
Not on ART 167/290 57.6 1.2 [1.0,1.3] 0.010 1.0 [0.9,1.2] 0.788 1.0 [0.9,1.1] 0.564
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by modified Poisson 
regression; Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time since HIV diagnosis, stable partner's 
HIV serostatus, ART status. Denominators vary due to missing data in each model. Model 2:  Any factor with p<0.10 in unadjusted analysis 
included in a single model, plus clinic. In both cases, model for 'ART status/self-reported VL' omits variable on ART due to collinearity. †Self-
reported viral load (VL)>50c/mL or "don't know"; Alcohol consumption by WHO-AUDIT-C, alcohol dependency by CAGE questionnaire
Recreational drug use (n/N=1111/2189) 
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Table 6.7: Association of socio-demographic, psychological, lifestyle, and HIV-related factors with polydrug use (≥4 drugs versus 1-3 drugs) in the previous three 
months (N=1111 HIV-diagnosed MSM used drugs) 
 
polydrug 
use/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Age at recruitment, years (N=1099)
<30 34/61 55.7 2.0 [1.2,3.5] 1.8 [1.1,3.2] 2.0 [1.1,3.7]
30-39 104/300 34.7 1.3 [0.8,2.1] 1.2 [0.7,2.1] 1.2 [0.7,2.2]
40-49 143/484 29.5 1.1 [0.7,1.8] 1.1 [0.7,1.8] 1.2 [0.7,2.0]
50-59 50/210 23.8 0.9 [0.5,1.5] 0.9 [0.5,1.5] 0.9 [0.5,1.7]
≥60 12/44 27.3 1.0 <0.001(T) 1.0 0.002(T) 1.0 0.002(T)
Ethnicity (N=1093)
White 303/984 30.8 1.0 1.0 -
All other (black, Asian, Mixed, other) 37/109 33.9 1.1 [0.8,1.5] 0.492 1.1 [0.8,1.4] 0.583
Years since HIV diagnosis  (N=1103)
≤2 43/111 38.7 1.0 1.0 1.0
2-5 67/183 36.6 0.9 [0.7,1.3] 1.0 [0.7,1.3] 0.9 [0.7,1.2]
5-10 87/275 31.6 0.8 [0.6,1.1] 0.9 [0.7,1.2] 0.9 [0.6,1.2]
10-15 59/230 25.7 0.7 [0.5,0.9] 0.8 [0.6,1.1] 0.7 [0.5,1.0]
>15 87/304 28.6 0.7 [0.6,1.0] 0.007(T) 0.9 [0.7,1.3]  0.421(T) 0.9 [0.6,1.2] 0.309(T)
Place of birth (N=1111)
UK 234/762 30.7 1.0 1.0
Outside the UK 112/687 32.1 1.0 [0.9,1.3] 0.643 1.0 [0.8,1.2] 0.973 -
Religious (N=1093)
Yes 116/414 28.0 1.0 1.0 1.0
No 226/679 33.3 1.2 [1.0,1.4] 0.072 1.2 [1.0,1.5] 0.066 1.2 [1.0,1.4] 0.075
Education (N=1095)
University degree or above 171/480 35.6 1.0 1.0 1.0
No qualifications or up to A levels 171/615 27.8 0.8 [0.7,0.9] 0.006 0.8 [0.6,0.9] 0.004 0.8 [0.7,1.0] 0.004
Polydrug use (n/N=346/1111)
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polydrug 
use/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Employment (N=1089)
Employed 240/700 34.3 1.0 1.0 -
Unemployed or other(carer, student, retired) 102/389 26.2 0.8 [0.6,0.9] 0.007 0.8 [0.7,1.0] 0.038
Money for basic needs (N=1099)
Always 189/560 33.8 1.0 1.0
Mostly 82/302 27.2 0.8 [0.6,1.0] 0.8 [0.6,1.0]
Sometimes 44/137 32.1 1.0 [0.7,1.2] 0.9 [0.7,1.2] -
Never 28/100 28.0 0.8 [0.6,1.2] 0.208(T) 0.8 [0.6,1.1] 0.129(T)
Social support (N=1107) ‡
High 203/640 31.7 1.0 1.0
Medium 110/349 31.5 1.0 [0.8,1.2] 1.0 [0.8,1.2] -
Low 31/118 26.3 0.8 [0.6,1.1] 0.350(T) 0.8 [0.6,1.2] 0.367(T)
Depression symptoms (N=1111) ‡
No 245/793 30.9 1.0 1.0 -
Yes 101/318 31.8 1.0 [0.8,1.2] 0.778 1.0 [0.8,1.2] 0.971
Anxiety symptoms (N=1111) ‡
No 273/880 31.0 1.0 1.0 -
Yes 73/231 31.6 1.0 [0.8,1.3] 0.865 1.0 [0.8,1.2] 0.868
Higher alcohol consumption (N=1111) ‡
No 276/898 30.7 1.0 1.0 -
Yes 70/213 32.9 1.1 [0.9,1.3] 0.543 1.1 [0.9,1.3] 0.494
Evidence of alcohol dependency (N=1110) ‡
No 278/869 32.0 1.0 1.0 -
Yes 68/241 28.2 0.9 [0.7,1.1] 0.271 0.9 [0.7,1.1] 0.325
Polydrug use (n/N=346/1111)
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‡ For variable definitions see section 3.8 
polydrug 
use/N row %
unadjusted 
PR [95%CI] p-value
Models 1: 
aPR [95%CI] p-value
Model 2: 
aPR [95%CI] p-value
Stable partner's HIV-serostatus (N=1111)
HIV-positive 114/294 38.8 1.0 1.0 1.0
HIV-negative or unknown status 79/314 25.2 0.6 [0.5,0.8] 0.7 [0.5,0.9] 0.7 [0.5,0.9]
No stable partner 153/503 30.4 0.8 [0.6,1.0] 0.001 0.8 [0.6,0.9] 0.003 0.8 [0.7,1.0] 0.005
ART status (N=1108)
On ART 278/941 29.5 1.0 1.0 -
Not on ART 66/167 39.5 1.3 [1.1,1.7] 0.007 1.1 [0.9,1.4] 0.478
ART status/self-reported VL (N=1092)
On ART, reports undetectable viral load 227/770 29.5 1.0 1.0 1.0
On ART, does not report undetectable viral load† 45/155 29.0 1.0 [0.8,1.3] 0.9 [0.7,1.2] 1.0 [0.7,1.3]
Not on ART 66/167 39.5 1.3 [1.1,1.7] 0.024 1.1 [0.8,1.4] 0.625 1.1 [0.8,1.4] 0.818
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by modified Poisson 
regression: Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time since HIV diagnosis, stable partner's 
HIV serostatus, ART status. Denominators vary due to missing data in each model. Model 2:  Any factor with p<0.10 in unadjusted analysis 
included in a single model, plus clinic. In both cases, model for 'ART status/self-reported VL' omits variable on ART due to collinearity. †Self-
reported viral load (VL)>50c/mL or "don't know"; Alcohol consumption by WHO-AUDIT-C, alcohol dependency by CAGE questionnaire.
Polydrug use (n/N=346/1111)
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6.4.2.3 Chemsex-associated drug use 
Among 1111 MSM who used drugs in the previous three months, associations were examined of socio-
demographic, psychological, lifestyle, HIV-related factors with chemsex-associated drug use (GHB/GBL, 
mephedrone, and/or crystal methamphetamine versus any other drug).(Table 6.8) In unadjusted 
analysis, chemsex-associated drug use was more prevalent among MSM who were younger (<30 years), 
diagnosed with HIV more recently (≤2 years), born outside the UK, university educated, employed, 
always had money for basic needs, had lower alcohol consumption, had an HIV-positive stable partner, 
and were not on ART. Ethnicity, being religious, social support, alcohol dependency, depression, anxiety 
were not associated with chemsex-associated use. 
 
After adjustment for core factors (models 1, Table 6.8), the following factors remained independently 
associated with chemsex-related drug use (p<0.05): younger age (with a trend of decreasing prevalence 
of chemsex with older age), non-UK place of birth, university degree, employment, no financial 
hardship, and having an HIV-positive stable partner (to a lesser extent, those with no stable partner had 
higher prevalence of chemsex-associated drug use than those with an HIV-negative/unknown status 
stable partner). There was a weak suggestion that more recent time since HIV diagnosis was associated 
with chemsex-associated drug use (p=0.07). Associations with lower alcohol consumption and not being 
on ART did not remain after adjustment for core factors. 
 
In model 2, the following factors were candidates for inclusion in the multivariable model (p<0.10 at 
unadjusted analysis): age, time since HIV diagnosis, place of birth, education, employment, money for 
basic needs, higher alcohol consumption, stable partner, ART status, and ART status/self-reported VL. 
(Table 6.8) ART status was excluded from the model as it was included in the ART status/self-reported 
VL variable. Education, employment, and money for basic needs were highly correlated; it was decided 
to only retain education so as to examine the effect of early socio-economic factors. Hence after 
adjustment for age, time since HIV diagnosis, place of birth, education, higher alcohol consumption, 
stable partner, ART status/self-reported VL, and clinic, chemsex-associated drug use remained 
associated (p<0.05) with younger age, more recent HIV diagnosis, and having an HIV-positive stable 
partner, or no stable partner.  
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Table 6.8: Association of socio-demographic, psychological, lifestyle, and HIV-related factors with chemsex-associated drug use (GHB/GBL, mephedrone, 
and/or methamphetamine versus any other drug) in the previous three months (N=1111 HIV-diagnosed MSM used drugs)  
 
n used 
chemsex 
drugs/row N
row %
unadjusted 
PR [95%CI]
p-value
Models 1: 
aPR [95%CI]
p-value
Model 2: 
aPR [95%CI]
p-value
Age at recruitment, years (N=1084)
<30 33/59 55.9 3.3 [2.3,4.6] 4.3 [2.8, 6.7] 4.3 [2.8, 6.6]
30-39 116/296 39.2 2.3 [1.7, 3.1] 3.2 [2.3, 4.6] 3.0 [2.1, 4.3]
40-49 131/477 27.5 1.6 [1.1,2.1] 2.0 [1.5, 2.8] 2.0 [1.4, 2.8]
≥50 43/252 17.1 1.0 <0.001(T) 1.0 <0.001(T) 1.0 <0.001(T)
Ethnicity (N=1093)
White 294/984 29.9 1.0 1.0 -
All other (black, Asian, Mixed, other) 31/109 28.4 1.0 [0.7,1.3] 0.757 0.8 [0.5,1.1] 0.107
Years since HIV diagnosis  (N=1103)
≤2 45/111 40.5 1.0 1.0 1.0
2-5 65/183 35.5 0.8 [0.6,1.2] 0.8 [0.6,1.2] 0.7 [0.5,1.0]
5-10 98/275 35.6 0.8 [0.7, 1.2] 0.9 [0.7,1.2] 0.8 [0.6,1.1]
10-15 58/230 25.2 0.6 [0.4,0.8] 0.8 [0.5,1.1] 0.7 [0.5,1.0]
≥15 61/304 20.1 0.5[0.4,0.7] <0.001(T) 0.7 [0.5,1.0]  0.073(T) 0.6 [0.4,0.9] 0.026(T)
Place of birth (N=1111)
UK 206/762 27.0 1.0 1.0 1.0
Outside the UK 124/349 35.5 1.3 [1.1,1.6] 0.003 1.2 [1.0,1.5] 0.042 1.0 [0.8,1.3] 0.781
Religious (N=1093)
Yes 122/414 29.5 1.0 1.0 -
No 204/679 30.0 1.0 [0.8,1.2] 0.840 1.1 [0.9,1.4] 0.330
Education (N=1095)
University degree or above 166/480 34.6 1.0 1.0 1.0
No qualifications or up to A levels 161/615 26.2 0.8 [0.6,0.9] 0.003 0.8 [0.6,0.9] 0.006 0.9 [0.7,1.1] 0.301
Employment (N=1093)
Employed 238/700 34.0 1.0 1.0 -
Unemployed or other(carer, student, retired) 89/396 22.5 0.7 [0.5,0.8] <0.001 0.8 [0.6,1.0] 0.030
Chemsex-associated drug use (n/N=330/1111)
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n used 
chemsex 
drugs/row N
row %
unadjusted 
PR [95%CI]
p-value
Model 1: 
aPR [95%CI]
p-value
Model 2: 
aPR 
[95%CI]
p-value
Money for basic needs (N=1099)
Always 183/560 32.7 1.0 1.0 -
Mostly 84/302 27.8 0.9 [0.7,1.1] 0.8 [0.6,1.0]
Sometimes/never 60/237 25.3 0.8 [0.6,1.0] 0.054(T) 0.8 [0.6,1.0] 0.048(T)
Social support (N=1107) ‡
High 193/640 30.2 1.0 1.0 -
Medium/low 135/467 28.9 1.0 [0.8,1.2] 0.227(T) 1.0 [0.8,1.2] 0.739(T)
Depression symptoms (N=1111) ‡
No 240/793 30.3 1.0 1.0 -
Yes 90/318 28.3 0.9 [0.8,1.1] 0.520 0.9 [0.8,1.2] 0.626
Anxiety symptoms (N=1111) ‡
No 269/880 30.6 1.0 1.0 -
Yes 61/231 26.4 0.9 [0.7,1.1] 0.227 0.8 [0.6,1.1] 0.170
Higher alcohol consumption (N=1111) ‡
No 279/898 31.1 1.0 1.0 1.0
Yes 51/213 23.9 0.8 [0.6,1.0] 0.048 0.9 [0.7,1.2] 0.426 1.0 [0.8,1.3] 0.914
Evidence of alcohol dependency (N=1110) ‡
No 268/869 30.8 1.0 1.0
Yes 62/241 25.7 0.8 [0.7,1.1] 0.133 0.9 [0.7,1.2] 0.573 -
Stable partner's HIV-serostatus (N=1111)
HIV-positive 107/294 36.4 1.0 1.0 1.0
HIV-negative or unknown status 65/314 20.7 0.6 [0.4,0.7] 0.5 [0.4,0.7] 0.5 [0.4,0.7]
No stable partner 158/503 31.4 0.9 [0.7,1.1] <0.001 0.8 [0.6,1.0] <0.001 0.8 [0.6,1.0] <0.001
Chemsex-associated drug use (n/N=330/1111)
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‡ For variable definitions see section 3.8 
 
n used 
chemsex 
drugs/row N
row %
unadjusted 
PR [95%CI]
p-value
Model 1: 
aPR [95%CI]
p-value
Model 2: 
aPR 
[95%CI]
p-value
ART status (N=1108)
On ART 259/941 27.5 1.0 1.0 -
Not on ART 69/167 41.3 1.5 [1.2,1.8] <0.001 1.2 [0.9,1.5] 0.207
ART status/self-reported VL (N=1092)
On ART, reports undetectable viral load 216/770 28.1 1.0 1.0 1.0
On ART, does not report undetectable viral load† 41/155 26.5 0.9 [0.7,1.3] 0.9 [0.6,1.2] 1.0 [0.7,1.4]
Not on ART 69/167 41.3 1.5 [1.2,1.8] <0.001 1.1 [0.9,1.5] 0.366 1.1 [0.9,1.5] 0.614
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by modified Poisson regression 
models: Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time since HIV diagnosis, stable partner's HIV 
serostatus, and ART status. Denominators vary due to missing data in each model. Model 2:  Any factor with p<0.10 in unadjusted analysis 
included in a single model, in addition to clinic. In both cases, model for 'ART status/self-reported VL' omits variable on ART due to collinearity. 
†Self-reported viral load (VL)>50c/mL or "don't know". Alcohol consumption by WHO-AUDIT-C, dependency by CAGE.
Chemsex-associated drug use (n/N=330/1111)
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 Recreational drug use and sexual behaviour 6.4.3
This section describes associations of recreational drug use, polydrug use, chemsex-associated drug use 
(as well as measures of alcohol misuse) with various measures of sexual behaviour, firstly, among all 
2189 MSM, and secondly, among 1392 MSM who reported having any anal or vaginal sex in the past 
three months.  
6.4.3.1 Drug use and sexual behaviour among all HIV-diagnosed MSM 
In unadjusted analyses, compared to MSM who did not use drugs in the previous three months 
(n=1078), MSM who used drugs (n=1111) were more likely to report any anal and/or vaginal sex, any 
CLS (including CLS-C, CLS-D, and higher HIV risk CLS-D), group sex, using the internet to find sex in the 
previous three months, and having 10 or more new sexual partners in the past year (p<0.001 for all, 
Table 6.9) Recreational drug use was also significantly more prevalent among MSM who had low 
condom self-efficacy and those who reported lower condom use with casual partners (p<0.05 for both, 
Table 6.10. No significant association was observed between recreational drug use and difficulty 
negotiating condom use or worry about HIV transmission (p>0.05 for both, Table 6.10, Figure 6.4).  
 
With increasing number of recreational drugs used there were striking increases in the prevalence of 
CLS and all other sexual behaviour outcomes in unadjusted models (p<0.05 for all, Table 6.9) Polydrug 
use was also significantly more prevalent among MSM with low condom self-efficacy and lower condom 
use with casual partners in unadjusted analyses. (p<0.05 for both). After adjustment for core factors, 
polydrug use remained significantly associated with all sexual behaviours. (p<0.001 trend, Figure 6.3)  
For most measures, there was a trend of increasing prevalence with increasing number of drugs; this 
trend was particularly marked for group sex and having 10 or more new partners. The range of adjusted 
prevalence ratios (PR) for MSM using from 1 to ≥5 drugs, compared to MSM using no drugs, respectively 
was: 1.3 to 1.7 for any anal or vaginal sex; 1.3 to 2.7 for any CLS; 1.3 to 3.2 for CLS-C; 1.4 to 2.9 for CLS-
D; 1.3 to 2.9 for other STIs; 1.9 to 6.2 for group sex; 1.2 to 2.8 for using the internet to find sex; and 1.5 
to 3.9  for ≥10 new sexual partners in the past year.(Figure 6.3) Categories were combined for higher 
HIV risk CLS-D due to the lower prevalence of this measure, so that the range of PRs for MSM using from 
1 to ≥4 drugs was 2.2 to 2.6. Polydrug use also remained significantly associated with low condom self-
efficacy and lower condom use with casual partners after adjustment for core factors (p<0.001 trend for 
both, Figure 6.4). There was no statistically significant association of polydrug use with difficulty 
negotiating condom use or with worry about HIV transmission (p>0.05 trend for both, Figure 6.4).   
 
In unadjusted analyses, compared to MSM who did not use chemsex-associated drugs (n=1859), MSM 
who used chemsex-associated drugs (n=330) were more likely to report higher prevalence of all sexual 
behaviours (p<0.05 for all), low condom self-efficacy, and low condom use with casual partners (p<0.01 
for both, Table 6.10). There was no significant association of chemsex use and difficulty negotiating 
condom use or worry about HIV transmission. 
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Table 6.9: Unadjusted associations of any recreational drug use, polydrug use, and chemsex-associated drug use with sexual behaviours in the past three 
months (N=2189 MSM) 
 
Total N† row 
%
PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI] % PR [95%CI]
Recreational drug use
No 1078 48.6 1.0 24.0 1.0 16.5 1.0 10.5 1.0 2.1 1.0 6.9 1.0 9.5 1 24.5 1.0 5.7 1.0
Yes 1111 78.1 1.6 [1.5,1.7] 51.9 2.2 [1.9,2.4] 40.5 2.5 [2.1,2.9] 22.0 2.1 [1.7,2.6] 6.3 3.0 [1.9,4.7] 14.8 2.1 [1.7,2.8] 32.5 3.4 [2.8,4.2] 49.3 2.0 [1.8,2.3] 7.5 2.6 [2.2,3.0]
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Polydrug use 
None 1078 48.6 1.0 24.0 1.0 16.5 1.0 10.5 1.0 2.1 1.0 6.9 1.0 9.5 1.0 24.5 1.0 14.9 1.0
1 363 64.2 1.3 [1.2,1.5] 32.8 1.4 [1.1,1.6] 21.8 1.3 [1.0,1.7] 14.9 1.4 [1.0,1.9] 4.4 2.1 [1.1,3.9] 9.0 1.3 [0.9,2.0] 17.6 1.9 [1.4,2.5] 29.7 1.2 [1.0,1.5] 22.9 1.5 [1.2,1.9]
2 229 79.9 1.6 [1.5,1.8] 48.0 2.0 [1.7,2.4] 33.6 2.0 [1.6,2.6] 23.1 2.2 [1.6,3.0] 7.9 3.7 [2.0,6.7] 13.2 1.9 [1.3,2.9] 26.3 2.8 [2.1,3.7] 48.7 2.0 [1.7,2.4] 32.8 2.2 [1.7,2.8]
3 173 79.2 1.6 [1.5,1.8] 53.2 2.2 [1.9,2.6] 41.6 2.5 [2.0,3.1] 23.1 2.2 [1.6,3.0] 6.4 3.0 [1.5,6.0] 16.3 2.4 [1.6,3.6] 28.3 3.0 [2.2,4.0] 47.4 1.9 [1.6,2.3] 38.7 2.6 [2.0,3.3]
4 111 89.2 1.8 [1.7,2.0] 66.7 2.8 [2.3,3.3] 52.3 3.2 [2.5,4.0] 29.7 2.8 [2.0,4.0] 7.2 3.4 [1.9, 5.9] 16.4 2.4 [1.5,3.8] 45.9 4.8 [3.7,6.4] 71.8 2.9 [2.5,3.4] 49.5 3.3 [2.6,4.2]
≥5 235 91.9 1.9 [1.8,2.0] 77.4 3.2 [2.8,3.7] 69.8 4.2 [3.6,5.0] 27.2 2.6 [2.0,3.4] 23.2 3.4 [2.4,4.7] 58.1 6.1 [4.9,7.6] 70.9 2.9 [2.5,3.3] 61.7 4.1 [3.5,4.9]
p-value(T) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Chemsex-associated use 
No 1859 58.8 1.0 31.8 1.0 22.2 1.0 14.8 1.0 3.7 1.0 8.5 1.0 15.4 1.0 30.9 1.0 20.9 1.0
Yes 330 90.6 1.5 [1.5,1.6] 74.2 2.3 [2.1,2.6] 65.2 2.9 [2.6,3.3] 24.8 1.7 [1.4,2.1] 7.3 2.0 [1.2,3.1] 24.5 2.9 [2.3,3.7] 53.6 3.5 [3.0,4.0] 72.4 2.3 [2.1,2.6] 60.0 2.9 [2.5,3.3]
p-value <0.001 <0.001 <0.001 <0.001 0.003 <0.001 <0.001 <0.001 <0.001
≥10 new sexual  
partners in past 
year (N=586)
Had group sex 
(N=796) 
Used internet to 
find sexual 
partners (N=796)
P-values by chi-squared test and, for polydrug use, by test for trend (T); † Denominators vary due to missing values. Three month recall unless otherwise specified; HIV-serodifferent: HIV-
negative or unknown status partner; CLS-D includes n=31 MSM who reported having CLS but not their partners' HIV-serostatus; Higher HIV risk CLS-D: CLS-D plus either not on ART or latest 
study log-recorded viral load>50c/mL; *Showing prevalence of higher HIV risk CLS-D for MSM who used ≥4 drugs (rather than ≥5) due lower prevalence of this measure; Chemsex-associated 
drug use: GHB/GBL, mephedrone, and/or crystal methamphetamine; STI: sexually transmitted infection
Condomless sex 
(CLS) (N=836)
Condomless sex 
with HIV-
seroconcordant 
partner (CLS-C) 
(N=628)
Condomless sex 
with HIV-
serodifferent 
partner (CLS-D) 
(N=357)
Higher HIV risk 
CLS-D (N=93) 
Diagnosed with 
another STI 
(N=235)
*
Any anal and/or 
vaginal sex 
(N=1392)
174 
 
Table 6.10: Unadjusted associations of any recreational drug use, polydrug use, and chemsex-associated drug use with level of agreement to statements on low 
condom self-efficacy, difficulty negotiating condom use, lower condom use with casual partners, and worry about HIV transmission* (N=2189 MSM) 
 
*All statements defined in section 4.3.5 
Total N† row % PR [95%CI] row % PR [95%CI] row % PR [95%CI] row % PR [95%CI]
Recreational drug use (%)
No 1055 4.6 1.0 14.2 1.0 12.6 1.0 5.7 1.0
Yes 1092 8.2 1.8 [1.3,2.5] 15.5 1.1 [0.9,1.3] 20.6 1.6 [1.3,2.0] 7.5 1.3 [1.0,1.8]
p-value
Polydrug use 
None 1055 4.6 1.0 14.2 1.0 12.6 1.0 5.7 1.0
1 357 6.4 1.4 [0.9,2.2] 15.5 1.1 [0.8,1.5] 15.7 1.2 [0.9,1.7] 6.8 1.2 [0.7,1.9]
2 224 6.3 1.3 [0.8,2.4] 15.9 1.1 [0.8,1.6] 16.8 1.3 [1.0,1.9] 6.3 1.1 [0.6,1.9]
3 172 6.4 1.4 [0.7,2.6] 12.1 0.9 [0.6,1.3] 19.3 1.5 [1.1,2.2] 9.4 1.6 [1.0,2.8]
4 110 10.9 2.3 [1.3,4.3] 17.1 1.2 [0.8,1.9] 24.5 1.9 [1.4,2.8] 10.9 1.9 [1.1,3.4]
≥5 229 13.1 2.8 [1.8,4.3] 16.9 1.2 [0.9,1.6] 30.7 2.4 [1.9,3.1] 6.9 1.2 [0.7,2.1]
p-value (T) <0.001 0.369 <0.001 0.071
Chemsex-associated drug use 
No 1824 5.6 1.0 14.5 1.0 14.5 1.0 6.4 1.0
Yes 323 11.5 2.0 [1.4,2.9] 17.3 1.2 [0.9,1.6] 29.2 2.0 [1.6,2.5] 7.7 1.2 [0.8,1.8]
p-value <0.001 0.180 <0.001 0.385
Difficulty negotiating 
condom use (N=319)
Lower condom use 
with casual partners 
(N=355)
Worry about HIV 
transmission (N=141)
No recall period  for statements;  P-values by Wald test and, for polydrug use, by test for trend (T); † 
Denominators vary due to missing values; PR: unadjusted prevalence ratio; Chemsex-associated drug use: 
GHB/GBL, mephedrone, and/or crystal methamphetamine in the previous three months.
<0.001 0.401 <0.001 0.094
Low condom self-
efficacy (N=139)
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Figure 6.3: Adjusted prevalence ratios [95%CI] for the association of polydrug use in the past 
three months with sexual behaviours (N=2189 MSM) † 
 
Any anal or vaginal sex
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
Condomless sex (CLS)
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
CLS-C
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
CLS-D
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
Higher HIV risk CLS-D*
No drugs
1 drug
2 drugs
3 drugs
>=4 drugs
Other STI diagnosis
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
Had group sex
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
Used internet to find sex
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
>=10 new sexual partners in past year
No drugs
1 drug
2 drugs
3 drugs
4 drugs
>=5 drugs
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
p-value(trend)
  1 3 5 7
Prevalence Ratios [95%CIs] 
by modified Poisson 
regression models adjusted 
for core factors. Three month 
recall unless otherwise 
specified. CLS-C: CLS with 
HIV-seroconcordant 
partners; CLS-D: CLS with 
HIV-serodifferent partners; 
Higher HIV risk CLS-D*: CLS-D 
plus not on ART or latest 
study log VL>50c/mL, 
*collapsed drug use 
categories due to lower 
prevalence of this measure. 
This model does not include 
adjustment for ART status; 
STI: sexually transmitted 
infection.†For 
denominators see Table 6.9 
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Figure 6.4: Adjusted prevalence ratios [95%CI] for the association of polydrug use and level 
of agreement to statements on low condom self-efficacy, difficulty negotiating condom use, 
lower condom use with casual partners, and worry about HIV transmission (N=2189 MSM)† 
 
†All statements defined in section 4.3.5. For denominators see Table 6.10; Prevalence Ratios [95%CIs] by 
modified Poisson regression models adjusted for core factors.   
 
Low condom self-efficacy
No drugs
1 drug
2 drugs
3 drugs
4 drugs
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6.4.3.2 Drug use, alcohol misuse, and sexual behaviour among all HIV-diagnosed 
MSM 
Associations of alcohol misuse, measured by two tools (higher alcohol consumption by WHO-AUDIT-C 
and evidence of alcohol dependency by CAGE questionnaire), and sexual behaviours were assessed by 
unadjusted (Table 6.11) and adjusted modified Poisson regression models (Figure 6.5, Figure 6.6). In 
unadjusted analysis, no significant association was observed between higher alcohol consumption (using 
the WHO-AUDIT-C) with any sexual behaviours, with the exception of CLS-D and higher HIV risk CLS-D, 
the prevalence of both being significantly higher among MSM with higher compared to lower alcohol 
consumption (p<0.05 for both, Table 6.11). These associations were attenuated but remained significant 
after adjustment for core factors and additional adjustment for recreational drug use in the past three 
months. (Figure 6.5) 
 
Alcohol dependency (by CAGE) was not associated with any sexual behaviour in unadjusted or adjusted 
analyses. (p>0.05 for all, Table 6.11, Figure 6.6) 
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Table 6.11: Associations of higher alcohol consumption (by WHO-AUDIT-C), evidence of alcohol dependency (by CAGE questionnaire) with sexual behaviours 
(N=2189, unadjusted) 
 
Total 
N◊
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
row 
%
PR[95%CI]
Higher alcohol consumption† 
No 1823 63.0 1.0 37.5 1.0 28.9 1.0 15.2 1.0 3.7 1.0 11.0 1.0 20.7 1.0 37.4 1.0 26.5 1.0
Yes 366 66.4 1.1 [1.0,1.1] 41.5 1.1 [1.0,1.3] 27.9 1.0 [0.8,1.2] 21.6 1.4 [1.1,1.8] 7.1 1.9 [1.2,3.0] 10.2 0.9 [0.7,1.3] 23.3 1.1 [0.9,1.4] 35.6 0.9 [0.8,1.1] 27.9 1.0 [0.9,1.3]
p-value 0.208 0.141 0.705 0.002 0.003 0.658 0.263 0.503 0.601
Evidence of alcohol dependency‡
No 1768 63.7 1.0 38.1 1.0 28.8 1.0 15.8 1.0 4.0 1.0 10.8 1.0 21.4 1.0 37.1 1.0 26.3 1.0
Yes 420 63.1 1.0 [0.9,1.1] 38.6 1.0 [0.9,1.2] 28.1 1.0 [0.8,1.2] 18.3 1.2 [0.9,1.5] 5.0 1.2 [0.8,2.0] 11.0 1.0 [0.8,1.4] 20.0 0.9 [0.8,1.2] 37.5 1.0 [0.9,1.2] 28.6 1.1 [0.9,1.3]
p-value 0.821 0.848 0.761 0.199 0.366 0.891 0.538 0.879 0.340
Had group sex  
(N=453)
Used internet to 
find sexual 
partners (N=796)
≥10 new  partners 
in past year 
(N=586)
p-values by chi-squared test; Three month recall unless otherwise specified. ◊ Denominators vary due to missing values; † WHO-AUDIT-C score ≥6 on first two questions only; ‡ CAGE 
questionnaire score ≥2; CLS-C: CLS with HIV-seroconcordant partner; CLS-D: CLS with HIV-serodifferent partner; Higher HIV risk CLS-D: CLS-D plus either not on ART or latest study log-recorded 
VL>50c/mL; PR: unadjusted prevalence ratio; STI: sexually transmitted infection
Any anal and/or 
vaginal sex 
(N=1392)
Condomless sex 
(CLS)  (N=836)
CLS-C (N=628) CLS-D (N=357)
Higher HIV risk 
CLS-D  (N=93)
Diagnosed with 
another STI 
(N=235)
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Figure 6.5: Associations of higher alcohol consumption (by WHO-AUDIT-C) and sexual 
behaviours, adjusted for recreational drug use (N=2189) 
 
Prevalence ratios [95%CI] by modified Poisson regression; p-value by Wald test; Three month recall for 
sexual behaviours unless otherwise specified. Reference group is low/medium alcohol consumption 
versus higher alcohol consumption (score <6 versus ≥6 on WHO-AUDIT-C first two questions); Core: 
adjusted for core factors (age, ethnicity, time since HIV diagnosis, stable partner status, ART status); 
Core+drugs: adjusted for core factors and recreational drug use. Model for Higher HIV risk CLS-D does 
not include adjustment for ART status. 
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Figure 6.6: Associations of evidence of alcohol dependency (by CAGE questionnaire) and 
sexual behaviours, adjusted for recreational drug use (N=2189) 
 
Prevalence ratios [95%CI] by modified Poisson regression; p-value by Wald test; reference group is no 
evidence of alcohol dependency (score <2 on CAGE questionnaire) versus evidence of alcohol dependency 
(score ≥2 on CAGE); Core: adjusted for core factors (age, ethnicity, time since HIV diagnosis, stable 
partner status, ART status); Core+drugs: adjusted for core factors and recreational drug use; Three 
month recall for sexual behaviours unless otherwise specified. Model for higher HIV risk CLS-D does not 
include adjustment for ART status. 
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6.4.3.3 Drug use and sexual behaviour among HIV-diagnosed MSM who had sex in 
the past three months 
Only MSM who reported any anal or vaginal sex in the past three months were included in analyses 
described in this section (N=1392). The aim of the first analysis was to examine the effect of polydrug 
use on CLS among those who reported having sex. After adjustment for core factors, the associations of 
polydrug use with CLS, CLS-C, CLS-D remained significant (p<0.001 trend, Figure 6.7), but not for higher 
HIV risk CLS-D. For higher HIV risk CLS-D, the last two polydrug use categories were collapsed into one 
category (≥4 drugs) due to lower prevalence of this measure.  
 
Associations were then examined between specific drugs and CLS-C, CLS-D, and higher HIV risk CLS-D 
among MSM who reported any sex in the past three months. (Figure 6.8) After adjustment for core 
factors, significant associations were observed for specific drugs and CLS-C (p<0.05 for all); compared to 
MSM who did not use drugs, those who used methamphetamine had the highest prevalence of CLS-C 
(PR=2.0, 1.8-2.3), followed by those who used EDDs (1.8, 1.6-2.1), or chemsex-associated (1.6, 1.4-1.9) 
(Figure 6.8). Compared to MSM not using drugs, MSM who used EDDs had the highest prevalence of 
CLS-D in the past three months (PR=1.7, 95%CI 1.4-2.1), followed by similar prevalence of CLS-D for 
MSM who used methamphetamine (1.5, 1.1-2.1), nitrites (1.5, 1.2-1.9), ‘club drugs’ (1.5, 1.2-1.9), or 
chemsex-associated drugs (1.3, 1.1-1.6). The prevalence of higher HIV risk CLS-D was, relative to MSM 
who did not use drugs, highest for MSM who used nitrites (2.0, 1.3-3.2) or methamphetamine (2.0, 1.0-
3.9), followed by those who used chemsex-associated drugs (1.8, 1.2-2.8), or cocaine (1.9, 1.2-3.1). 
 
The last analysis in this section aimed at examining which specific drugs were associated with reporting 
‘CLS-C without CLS-D’ compared to CLS-D.(Figure 6.9) Only MSM who reported having CLS and using 
recreational drugs in the past three months were included (N=557). In unadjusted modified Poisson 
regression, use of chemsex-associated drugs was significantly associated with higher prevalence of ‘CLS-
C without CLS-D’ compared to CLS-D (PR=1.3, 95%CI 1.1-1.5); when examining methamphetamine 
separately (versus any other drug) only the association with CLS-C remained robust (1.2, 1.1-1.4). The 
prevalence of ‘CLS-C without CLS-D’ (versus CLS-D) was lower among MSM who used nitrites (poppers) 
compared to those who used any other drug (0.8, 0.7-0.9). There were no significant differences in 
reporting ‘CLS-C without CLS-D’ versus CLS-D among MSM who used EDDs, cocaine, or cannabis (p>0.05 
for all). 
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Figure 6.7: Adjusted prevalence ratios [95%CI] for the association of polydrug use and types 
of condomless sex in the previous three months (N=1392 MSM reported any anal or vaginal 
sex only) 
 
Prevalence Ratios [95%CIs] by modified Poisson regression models adjusted for core factors. Three month 
recall unless otherwise specified. CLS-C: CLS with HIV-seroconcordant partners; CLS-D: CLS with HIV-
serodifferent partners; *Higher HIV risk CLS-D: CLS-D plus not on ART or latest study log VL>50c/mL; Collapsed 
drug use categories due to lower prevalence of this measure. This model does not include adjustment for ART 
status.  
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Figure 6.8: Adjusted prevalence ratios [95%CI] for the association of use of specific drugs and 
reporting CLS-C, CLS-D, or higher HIV risk CLS-D in the past three months (N=1392 MSM 
reported any anal or vaginal sex) 
 
Prevalence Ratios [95%CIs] by modified Poisson regression adjusted for core factors. CLS-C: condomless sex(CLS) with 
HIV-seroconcordant partner; CLS-D: CLS with HIV-serodifferent partner; Higher HIV risk CLS-D: CLS-D plus not on ART 
or latest study log VL>50c/mL (This model does not include adjustment for ART status); EDD: erectile dysfunction 
drugs; Chemsex-associated drugs: methamphetamine, mephedrone, GHB/GBL; ‘Club drugs’: ketamine, ecstasy, 
GHB/GBL, mephedrone 
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Figure 6.9: Unadjusted associations between use of specific drugs and reporting condomless 
sex with HIV-seroconcordant partners only (CLS-C) versus with HIV-serodifferent partners 
(CLS-D) among 557 MSM who reported any CLS and using drugs in the past three months. 
 
 
 
Prevalence Ratios [95%CIs] by modified Poisson regression. EDDs: erectile dysfunction drugs; Chemsex-associated 
drugs: methamphetamine, mephedrone, GHB/GBL; ‘Club drugs’: ketamine, ecstasy, GHB/GBL, mephedrone 
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6.4.3.4 Drug use and the four-category variable of sexual behaviour 
In this analysis, all 2189 MSM were classified into one of the following mutually exclusive groups of 
sexual behaviour in the past three months (as described in section 4.4.7):  
1. CLS-D (n=357)  
2. ‘CLS-C without CLS-D’ (n=479)  
3. Condom-protected sex only (n=556) 
4. No anal or vaginal sex (n=797) 
Unadjusted multinomial logistic regression was used to examine the effect of recreational drug use on 
the three categories of sexual behaviour (1-3) compared to no sex (category 4) (Table 6.12 panel A) and 
on the two CLS categories (1 and 2) compared to condom-protected sex (category 3) (Table 6.12 panel 
B). Relative to MSM who did not have any anal or vaginal sex, prevalence of CLS-D and ‘CLS-C without 
CLS-D’ was five-fold higher for drug users compared to MSM who did not use drugs, while prevalence of 
condom-protected sex was higher by more than twofold.(Table 6.12 panel A) Strong trends were also 
observed between polydrug use and higher prevalence in each of the two CLS categories: as the number 
of drugs used increased, so did the prevalence of having ‘CLS-C without CLS-D’ and CLS-D relative to not 
having any sex in the past three months (p<0.001 trend for both). The association with polydrug use was 
strongest for ‘CLS-C without CLS- D’, followed by CLS-D, and was less strong for condom-protected sex. A 
similar pattern was observed for chemsex-associated drug use (p<0.001 for all, Table 6.12). 
 
After excluding MSM who did not have sex in the past three months (Table 6.12 panel B), the magnitude 
of associations attenuated but remained strong; the prevalence of ‘CLS-C without CLS-D’ relative to 
condom-protected sex was twice as high among MSM who used recreational drugs compared to those 
who did not, and over four times higher among MSM who used chemsex-associated drugs compared to 
MSM who did not. Similar findings were observed for CLS-D relative to condom-protected sex. Polydrug 
use was also strongly associated with increasing prevalence of both CLS-C and CLS-D, relative to 
condom-protected sex (p<0.001 trend for both).  
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Table 6.12: Unadjusted associations (by multinomial logistic regression) of recreational drug use, polydrug use, chemsex-associated drug use with sexual 
behaviours in past three months among: (A.) all MSM (N=2189) and (B.) among MSM who reported any anal or vaginal sex (N=1392).  
 
 
(A.)
No anal or 
vaginal 
sex 
(n=797)
(B.)
Condom-
protected 
sex 
(n=556)
OR [95%CI] p-value OR [95%CI] p-value OR [95%CI] p-value OR [95%CI] p-value OR [95%CI] p-value
Recreational drug use Recreational drug use
No 1.0 1.0 1.0 No 1.0 1.0
Yes 2.5 [2.0,3.2] <0.001 5.2 [4.1,6.7] <0.001 5.0 [3.8,6.5] <0.001 Yes 2.1 [1.6,2.7] <0.001 2.0 [1.5,2.6] <0.001
Polydrug use Polydrug use 
1 1.0 1.0 1.0 1 1.0 1.0
2 1.8 [1.2,2.8] 2.5 [1.5,4.0] 2.8 [1.7,4.6] 2 1.4 [0.9,2.2] 1.5 [0.9,2.5]
3 1.4 [0.9,2.4] 2.9 [1.7,4.9] 2.7 [1.5,4.6] 3 2.0 [1.2,3.3] 1.9 [1.1,3.2]
4 2.4 [1.1,4.9] 6.8 [3.4,13.9] 6.6 [3.2,13.8] 4 2.9 [1.6,5.2] 2.8 [1.5,5.1]
≥5 2.2 [1.2,4.1] 0.002(T) 13.1 [7.4,23.4] <0.001(T) 8.6 [4.6,15.8] <0.001(T) ≥5 5.9 [3.6,9.6] <0.001(T) 3.9 [2.3,6.5] <0.001(T)
Chemsex-associated drug use 
No 1.0 1.0 1.0 No 1.0 1.0
Yes 2.7 [1.7,4.2] <0.001 12.7 [8.5,19.1] <0.001 7.4 [4.8,11.4] <0.002 Yes 4.8 [3.4,6.7] <0.001 2.8 [1.9,4.0] <0.001
ref: reference (baseline) category; p-values by Wald test and, for polydrug use, test for trend (T); OR: odds ratio; Mutually exclusive categories of sexual behaviour; CLS-D: 
condomless sex with HIV-serodifferent partners; CLS-C: condomless sex with HIV-seroconcordant partners only (no CLS-D partners); chemsex-associated drugs:  GHB/GBL, 
mephedrone, and/or crystal methamphetamine.
Condom-protected 
sex (n=556)
CLS-C without CLS-D 
(n=479)
CLS-D (n=357)
CLS-C without CLS-D 
(n=479)
CLS-D (n=357)
ref ref
ref ref
Chemsex-associated drug use 
ref ref
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 Recreational drug use, alcohol misuse, and ART outcomes 6.4.4
Among 1888 MSM who were on ART, associations were examined between recreational drug use, 
polydrug use (1, 2-4, ≥5 drugs) in the past three months, higher alcohol consumption (≥6 on the 
modified WHO-AUDIT-C), evidence of alcohol dependency (≥2 on CAGE questionnaire) and: 
(i.) Non-adherence to ART (prevalence 9.7%, 95%CI 8.4-11.1%, n/N=183/1888) 
(ii.) Viral load (VL) non-suppression among MSM who started ART ≥6 months ago (9.8%, 8.5-11.3%, 
n/N=172/1744) 
Significant associations were observed between recreational drug use, higher alcohol consumption, 
alcohol dependency, and non-adherence to ART after adjustment for age, ethnicity, time since HIV 
diagnosis, and stable partner status.(p<0.05 for all, Table 6.13) There was also evidence of a positive 
trend between polydrug use and non-adherence to ART (p<0.001). Recreational drug use and polydrug 
use were not significantly associated with VL non-suppression on ART in unadjusted or adjusted 
analyses. This was also the case for higher alcohol consumption and evidence of alcohol dependency. 
The magnitude of associations between each measure of alcohol misuse (WHO-AUDIT-C versus CAGE) 
and non-adherence to ART was similar.  
 
Table 6.13: Associations of recreational drug use, polydrug use, higher alcohol consumption, 
evidence of alcohol dependency and non-adherence to ART and VL non-suppression (N=1888 
MSM on ART) 
row 
N
row 
%
PR [95%CI] aPR[95%CI]
row 
N
row 
%
PR [95%CI] aPR[95%CI]
Recreational drug use
No 947 6.8 1.0 1.0 880 9.0 1.0 1.0
Yes 941 12.6 1.9 [1.4,2.5] 1.7 [1.2,2.2] 864 10.8 1.2 [0.9,1.6] 1.1 [0.8,1.4]
p-value <0.001 0.001 0.212 0.690
Polydrug use
No drugs 947 6.8 1.0 1.0 880 9.0 1.0 1.0
1 drug 320 10.0 1.5 [1.0,2.2] 1.3 [0.8,1.9] 291 9.6 1.1 [0.7,1.6] 1.0 [0.7,1.5]
2-4 drugs 435 13.3 2.0 [1.4,2.8] 1.8 [1.3,2.6] 407 9.6 1.1 [0.7,1.5] 0.9 [0.6,1.3]
≥5  drugs 186 15.6 2.3 [1.5,3.5] 2.0 [1.3,3.1] 166 15.7 1.7 [1.2,2.6] 1.6 [1.0,2.4]
p-value(T) <0.001 <0.001 0.055 0.266
Higher alcohol consumption (WHO AUDIT-C)‡
No 1581 8.6 1.0 1.0 1468 9.4 1.0 1.0
Yes 307 15.3 1.8 [1.3,2.4] 1.8 [1.3,2.5] 276 12.3 1.3 [0.9,1.9] 1.3 [0.9,1.9]
p-value <0.001 <0.001 0.133 0.109
Evidence of alcohol dependency (CAGE)◊
No 1540 8.7 1.0 1.0 1411 9.2 1.0 1.0
Yes 348 14.1 1.6 [1.2,2.2] 1.6 [1.1,2.1] 332 12.3 1.3 [1.0,1.9] 1.3 [0.9,1.8]
p-value 0.002 0.004 0.082 0.174
Viral load non-suppression*  
(n/N=172/1744)
Non-adherence to ART
 (n/N=183/1888)†
†Missed ≥2 consecutive days of ART on ≥2 occasions in the past three months; *Study log-recorded 
VL>50c/mL among MSM on ART for≥6 months; ‡ modified WHO-AUDIT score ≥6 (first two questions only); ◊ 
CAGE questionnaire score ≥2; p-values by Wald test and, for polydrug use, by test for trend; PR: prevalence 
ratios; aPRs: adjusted for age, ethnicity, time since HIV diagnosis, stable partner status. 
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 Sensitivity analyses 6.4.5
In sensitivity analysis 1, the association between polydrug use and measures of sexual behaviour was 
examined in models adjusted for core factors, clinic, employment, and religion. (Figure 6.10) The range 
of adjusted PRs for MSM using 1 to ≥5 drugs compared to MSM who did not use any drugs was very 
similar to those observed in the main analysis adjusted for core factors only (Figure 6.3). In sensitivity 
analysis 2, the association between polydrug use and sexual behaviours was examined in models 
adjusted for core factors, clinic, education, and religion. (Figure 6.11) The range of adjusted PRs for 
MSM using 1 to ≥5 drugs was identical to those observed in sensitivity analysis 1.  
 
In sensitivity analysis 3 the aim was to examine the magnitude of associations of polydrug use and 
sexual behaviours using logistic regression to derive odds ratios (ORs), rather than prevalence ratios. 
(Figure 6.12) From this figure, it is more meaningful to compare the magnitude of associations between 
the different sexual behaviour measures. Increasing polydrug use was more strongly associated with 
CLS-C, group sex, use of the internet to find sex, and >=10 new sexual partners, compared to CLS-D, 
higher HIV risk CLS-D and other STI diagnosis. After adjustment for core factors the range of ORs for 
MSM using 1 to ≥5 drugs compared to MSM who did not use drugs was: 2.0 to 10.3 for any anal or 
vaginal sex; 1.6 to 9.4 for any CLS; 1.4 to 11.4 for CLS-C; 1.5 to 3.8 for CLS-D; (from 1 to ≥4 drugs) 2.5 to 
3.1 for higher HIV risk CLS-D; 1.3 to 3.5 for other STIs; 2.1 to 13.7 for group sex; 1.3 to 7.9 for use of the 
internet to find sex; and 1.7 to 9.1 for ≥10 new sex partners in the past year.  
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Figure 6.10: Sensitivity analysis 1: Associations of polydrug use in the past three months and 
sexual behaviours, adjusted for core factors, employment, religion, and clinic (N=2189 
MSM). 
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Figure 6.11: Sensitivity analysis 2: Associations of polydrug use in the past three months and 
sexual behaviours, adjusted for core factors, education, religion, and clinic (N=2189 MSM). 
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Figure 6.12: Sensitivity analysis 3: Odds ratios [95%CIs] for associations of polydrug use in 
the past three months with sexual behaviours (N=2189 MSM) † 
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6.5 Discussion 
 Summary of findings 6.5.1
In this large, multicentre cross-sectional study of 2189 HIV-diagnosed MSM, half of the men surveyed 
had used recreational drugs and almost a quarter had used at least three types of drugs in the past 
three months. Over 15% of MSM had used chemsex-associated drugs and less than 3% injected drugs. 
Drug use and polydrug use were significantly associated with younger age, higher educational 
attainment, current employment, higher alcohol consumption, and having an HIV-positive stable 
partner. In particular, among MSM who used drugs, use of chemsex-associated drugs was more 
prevalent among MSM who were younger, employed, had university degree, and an HIV-positive stable 
partner. There were strong and consistent associations between increasing numbers of drugs used and 
increasing prevalence of all types of CLS (including with HIV-serodifferent or HIV-seroconcordant 
partners) as well as with higher HIV transmission risk CLS-D, group sex, high partner numbers, low 
condom self-efficacy, and lower condom use with casual partners. Among MSM who reported any anal 
or vaginal sex in the past three months, increasing polydrug use remained significantly associated with 
higher prevalence of any CLS, CLS-C, and CLS-D; the association with higher HIV risk CLS-D was 
attenuated. Compared to MSM having condom-protected sex, polydrug use was most prevalent among 
MSM who had ‘CLS-C without CLS-D’, as well as those who had CLS-D. Chemsex-associated drugs were 
more prevalent among MSM who had CLS-C, while nitrites were more prevalent among those who had 
CLS-D. Higher alcohol consumption was associated with higher prevalence of CLS-D and of higher HIV 
risk CLS-D, independently of recreational drug use. While drug and polydrug use, higher alcohol 
consumption, and evidence of alcohol dependency were significantly associated with non-adherence to 
ART, there was no significant association with VL non-suppression. 
 Prevalence and patterns of recreational drug use among HIV-diagnosed MSM  6.5.2
Almost 51% of MSM in ASTRA had used any recreational drug in the past three months, similar to 
estimates from earlier UK HIV clinic studies (Internet & HIV
151
 and Guys and St.Thomas’ clinic
352
), which 
measured prevalence during the same recall window. Direct comparison to other studies (Table 6.2) is 
not straightforward due to different recall periods, but there is evidence of a substantial prevalence of 
drug use from all studies of HIV-diagnosed MSM, ranging from 55.8% to 66.5% in the past year
290,341
  and 
as high as 83.9% in the past six months.
313
  
 
The pattern of most commonly used drugs in ASTRA mirrors that observed in earlier studies of HIV-
diagnosed MSM from the USA, Western Europe, and Australia,
287,290,297,301,308,313,315,316
 with nitrites, 
cannabis, EDDs, and cocaine being most prevalent, and opioids being least prevalent. However, ASTRA is 
the only UK study to date to report on mephedrone, used by 7.1% of all MSM (14% of all drug-using 
MSM). Evidence regarding this particular drug began to accumulate in 2015/2016 (more than three 
years after ASTRA concluded recruitment), when qualitative studies and community organisations 
reported use of mephedrone among MSM in sexual settings (chemsex).
278,321,354
 In the 2014 GMSS, 
prevalence of mephedrone use among all MSM (mixed HIV-serostatus) in the past month was 5.3%.
144
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By comparison, among 1484 HIV-negative or undiagnosed MSM recruited to the AURAH study from 
GUM clinics in the UK (2013-14), prevalence of mephedrone use was 19.1% in the past three months.
355
 
Previous comparable data on specific drugs used among HIV-diagnosed MSM in the UK derive 
predominantly from the 2002-2003 ‘London Gyms’ study, which surveyed HIV-negative and HIV-positive 
MSM at gyms and outpatient clinics (see Table 2.1); prevalence of recreational drug use in the previous 
year in the HIV-diagnosed outpatient sample (N=388) was 54%.
289
 It is possible to informally compare 
use of specific drugs in the previous three months among ASTRA MSM from London clinics only 
(N=1482) to drug use in the past month (‘once-twice per month’) among MSM in the ‘London Gyms’ HIV 
outpatient sample. Prevalence of the following drugs was higher in ASTRA compared to ‘London Gyms’: 
methamphetamine (10% versus 4%), cocaine (23% versus 18%), and IDU (in the past 12 months: 4% 
versus 1%); prevalence was similar for ketamine (12% versus 13%) and amphetamine (3% versus 2%); 
and prevalence of ecstasy use was lower in ASTRA (11% versus 17%).
289
 The ‘London Gyms’ study did not 
collect information on GHB/GBL and mephedrone. This may suggest changing patterns of drug use 
among HIV-diagnosed MSM, with possible increases in methamphetamine and IDU, which would be 
consistent with anecdotal reports of patterns in drug use, and an increase in use of chemsex drugs. 
Overall, comparisons are not straightforward due to different recall periods for drug use, potential 
confounding factors in the comparison, and lack of data from other comparable studies in the UK. 
 
Over a third of MSM in ASTRA reported using two or more drugs (almost a quarter used three or more) 
in the past three months. Estimates on prevalence of polydrug use also range widely due to different 
definitions and locations of recruitment. Four studies from the USA and Australia have reported on 
prevalence of polydrug use among HIV-positive MSM (Table 6.2); only one recruited MSM attending for 
HIV care in clinics (SUMIT trial),
309,310
 while the rest recruited HIV-positive MSM from gay 
venues,
287,297,308
 which tend to over-represent MSM who report ‘sensitive’ behaviours (such as polydrug 
use and CLS).
356
 For instance, polydrug use (defined here as using three or more drugs) was reported by 
2.2% of SUMIT participants in the past three months and by 44.0% of Sydney Gay Community Periodic 
Survey (GCPS) participants in the past six months.
287
 There are even fewer studies of polydrug use 
among representative samples of HIV diagnosed MSM in the UK. Polydrug use was common among men 
who used recreational drugs in the ‘London Gyms’ study;  over 90% of the 49 HIV-diagnosed MSM who 
used methamphetamine during the previous year had  used at least one other drug during this time, and 
over 80% of the 162 cocaine users had used other drugs.
289
 In ASTRA, although there is no information 
on the timing of use of different drugs, the high prevalence of polydrug use in the previous three 
months (over a fifth of MSM were using five or more drugs) is concerning, especially in light of potential 
drug-drug interactions (DDIs) between recreational drugs (e.g. EDDs and nitrites
357
), with alcohol (e.g. 
GHB and alcohol
317
), and the potential for polydrug use to interfere with the effectiveness of 
antiretroviral drugs.
318
  
 
Injection drug use (IDU) was overall low in ASTRA (3%), but higher than that observed among HIV-
diagnosed clinic attendees in the ‘London Gyms’.
289
 Prevalence of IDU was much higher in the past six 
194 
 
months in the Australian Positive Health
313
 and GCPS surveys compared to ASTRA (4.4% and 14.2% 
respectively).
296
 Although the ASTRA questionnaire did not enquire about injection of specific drugs, 
significant associations were observed between any IDU and use of chemsex-associated drugs 
(especially methamphetamine), EDDs, and polydrug use.  
 Factors associated with recreational drug use 6.5.3
In ASTRA, recreational drug use was more prevalent among MSM who were younger (particularly those 
under 30 years), a finding also observed in two previous studies in Australia
313,324
 and the USA.
311
 This 
was also the case for EDDs (27.1% of MSM under 30 years used EDDs compared to 14.5% of those 60 or 
older), which were also more prevalent among older MSM (over 45 years) in the SUMIT trial.
310
 In 
ASTRA, polydrug use was highest in the under 30’s group. The prevalence of any drug use mirrors that 
observed in the general UK population, whereby young adults have three times the prevalence of last 
year drug use compared to older adults (≤25 versus >25 years).
277,358
  
 
Alcohol misuse was also strongly associated with recreational drug use. This finding was expected, as 
drug and alcohol use frequently co-occur. High prevalence of ‘excessive’ alcohol use is commonly 
reported among MSM, but estimates vary considerably due to different modes of reporting. In ASTRA, 
17% of MSM were classified as having higher alcohol consumption (score of ≥6 on the first two 
questions on the WHO-AUDIT-C) and 19% as having alcohol dependency (≥2 on the CAGE 
questionnaire). The reported prevalence of alcohol drinking among HIV-diagnosed individuals varies 
widely, from 40% to 82% for any and 3% to 35% for severe/harmful alcohol consumption.
331,359–362
 
Definitions of alcohol misuse are usually based on units of alcohol consumed, which also vary by county 
(e.g. one unit is equivalent to 14g of pure alcohol in the US compared to 8g in the UK). Despite the 
difference in prevalence, there was a significant association between both measures of alcohol misuse 
and recreational drug use, which has also been observed in previous studies.
313,360,363–365
  
 
In addition, MSM who had a stable HIV-positive partner were more likely to report any drug use and 
polydrug use in ASTRA. This finding has not been previously reported, as earlier studies reported on 
partner status (casual or long-term) rather than incorporate stable partners’ HIV-serostatus. For 
instance, in the Australian Positive Health cohort
313
 (2004-05) HIV-diagnosed MSM were more likely to 
have used drugs in the past six months if they were not in a monogamous relationship, compared to 
being in an open relationship or having casual partners only.  
 
Markers of socio-economic status (SES), such as higher educational attainment and current employment 
were not associated with any drug use. However, among MSM who used drugs, higher SES was 
independently associated with polydrug use and chemsex drug use. Two US studies of HIV-diagnosed 
MSM found that use of EDDs and nitrites was higher among those with higher education,
309,310,314
 but no 
associations have been reported yet with polydrug use. Studies of all MSM (regardless of HIV-
serostatus), such as the GMSS, have also reported that university degree and full-time employment are 
associated with any drug use.
327
 The opposite effect was observed in the UK AURAH study, as HIV-
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negative or undiagnosed MSM with lower SES (lower educational attainment and higher financial 
instability) were more likely to report polydrug and chemsex-associated drug use in the past three 
months.
355
 It is unclear whether the association of higher SES and polydrug use would be observed in 
smaller or suburban gay populations compared to the large populations with a vibrant ‘gay scene’ 
concentrated in London, Brighton, and Manchester, which recruited men to ASTRA. Polydrug use may 
require higher disposable income due to the high cost of multiple drugs, which could explain the 
association with higher SES.    
 
Symptoms of depression and anxiety were not associated with drug use.
313,366
 In the Australian Positive 
Health survey there was also no association of drug use with measures of “mental or emotional 
wellbeing”.
313
 On the other hand, in the AURAH study of HIV-negative or undiagnosed MSM, polydrug 
and chemsex-associated drug use were significantly more prevalent among MSM with symptoms of 
depression and anxiety compared to those without.
355
 Overall, drug use is more prevalent among MSM 
than age-comparable non-MSM populations, which has been hypothesized to be in part due to complex 
reasons associated with emotional wellbeing. These include coping with interpersonal prejudice or 
discrimination (minority stress) or HIV-related stress and stigma
190
, internalised homophobia or negative 
feelings of self-worth with deeper sources
259
, as well as the positive effect of drugs on displacing 
anxieties on self-esteem and body image by boosting confidence
367
. In our study, drug use was not 
incompatible with good mental health, which may indicate that drug use is perceived as a positive way 
to engage with the gay and HIV-positive community. However, any such hypothesis could not be 
extrapolated from our data and qualitative studies are best suited to generate theories on motivations 
behind drug use.  
 Recreational drug use and sexual behaviour  6.5.4
In this study, recreational drug use and particularly polydrug use were associated with being sexually 
active and more strongly associated with all measures of CLS, independently of socio-demographic and 
HIV-related factors. Drug use was also strongly associated with other STIs, group sex, greater numbers 
of sexual partners, and low condom self-efficacy. Although a minority of HIV-diagnosed MSM reported 
CLS-D (16.3%) and even fewer fulfilled criteria for CLS-D that could confer a higher risk of HIV 
transmission (4.3%), increasing polydrug use was independently associated with an increasing trend in 
prevalence of both CLS-D measures. Among MSM who had any anal or vaginal sex in the past three 
months, use of methamphetamine, EDDs, and nitrites was strongly associated with CLS-D (including 
higher HIV risk CLS-D) and CLS-C, and MSM who used these drugs had higher prevalence of CLS-D than 
MSM using other common drugs (such as cannabis and cocaine). Previous cross-sectional studies have 
found associations between use of methamphetamine and CLS-D among HIV-diagnosed MSM in the 
USA
283,305,329,330,340,366,368,369
 and the UK,
289,300,351
 but none have incorporated VL level in their measures.  
 
Trends of increasing prevalence of sexual behaviour measures with increasing polydrug use were 
strongest for CLS-C, group sex, and higher number of new partners. Among MSM who used drugs and 
had any CLS in the past three months, chemsex-associated drug use (and particularly 
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methamphetamine) was more prevalent among MSM who had CLS-C compared to those who had CLS-
D; the opposite pattern was observed for nitrites. Use of odds ratios allowed for comparison of the 
magnitude of associations between polydrug use and multiple sexual behaviours, showing that the odds 
of having CLS-C and group sex were 11-fold and 13-fold greater respectively among MSM who used five 
or more drugs compared to those who did not; these odds ratios were considerably greater than those 
associated with CLS-D measures. Similarly associations of chemsex drug use were stronger for CLS-C 
than CLS-D. Coupled with evidence that, among drug users, chemsex-associated drug use was linked to 
having an HIV-positive stable partner and not being on ART, it could be hypothesized that some HIV-
positive MSM may engage in group chemsex sessions and CLS with other HIV-positive partners. This may 
be circumstantial, a sexual preference, or a decision to reduce HIV transmission risk to HIV-negative 
partners (serosorting). The strong link between chemsex and CLS-C is in line with the qualitative 
chemsex study in London (2013), in which two thirds of men who had chemsex were HIV-diagnosed and 
had made pre-determined decisions to have CLS-C.
259
 While there is no risk of HIV transmission during 
CLS-C, such seroadaptive practices facilitate transmission of other STIs, as evidenced by recent 
outbreaks of other STI epidemics among HIV-diagnosed MSM who report chemsex with other HIV-
positive partners (discussed in chapter 8).
370
  
 
The difficulties in attributing a causal relationship to the associations between recreational drug use and 
higher risk sexual behaviours in cross-sectional studies have been well documented. Evidence from 
prospective studies suggests a causative link between methamphetamine use and HIV seroconversion. 
Certain case-control
367
 and cohort studies
341,371,372
 have accounted for increasing number of CLS partners 
in the association of methamphetamine use and HIV seroconversion. For example, in the MACS study
341
, 
a joint dose-response relationship of methamphetamine use and increasing number of CLS receptive 
partners was observed (relative hazard of HIV seroconversion ranged from 2.7 for recent 
methamphetamine users with one partner to 13.6 for ≥5 partners), which is not surprising. However, 
the 2.7-fold increased risk of HIV seroconversion associated with methamphetamine use with only one 
CLS receptive partner is noteworthy, as it shows that methamphetamine use increases the risk of HIV 
acquisition over and above the risk of increasing numbers of CLS partners. A retrospective analysis of 
recreational drug use among HIV-negative MSM enrolled in an HIV screening programme in the USA 
(2008-14) showed that men who started using methamphetamine between visits (and had never used it 
previously) were significantly more likely to report higher prevalence of receptive CLS with HIV-positive 
partners and overall increased number of sex partners.
371
 The temporal relationship shown in this study 
provides strong evidence that initiation of methamphetamine use may increase sexual risk behaviour 
among HIV-negative MSM. Causal links between drug use and CLS may in part be explained by sexual 
disinhibition, higher libido, altered mental state, and reduced ability to experience pain conferred by 
drug use (and chemsex-associated drugs in particular); these effects could in turn lead to low condom 
self-efficacy, and increased risk of physically traumatic sex. Drug use could also lead to increased 
duration of sexual contact or increased number of partners, factors which may themselves result in 
greater likelihood of, or amount of, CLS. On the other hand, the association may not be causal, as 
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recreational drug use could be a marker of ‘risky’ or sensation-seeking/impulsive personal 
characteristics, which have been associated with both drug use and CLS.
305
 Drug use could be a mediator 
in the pathway between impulsivity and CLS.  
 
There is a need for longitudinal, episode-level studies comparing times in which drugs have or have not 
been used during episodes of CLS in the same individual; these could provide more evidence on 
temporality and causality. Irrespective of causal attributions, this ASTRA analysis demonstrates that 
polydrug use and CLS are strongly linked among HIV-diagnosed MSM in the UK, and that polydrug users 
are likely to be a group at possible risk for transmission of HIV and other STIs.  
 Associations of alcohol misuse, recreational drug use, and sexual risk 6.5.5
behaviours 
The association between alcohol misuse and sexual risk behaviours has not been well studied among 
HIV-diagnosed MSM in the UK. A recent systematic review of 27 US studies among HIV-diagnosed men 
and women found significant associations between three measures of alcohol use (any alcohol 
consumption, problematic drinking, and alcohol consumption in sexual settings) and higher prevalence 
of any CLS.
373
 The majority of these studies, however, did not differentiate gender/sexual orientation or 
perform adjusted analyses (e.g. for recreational drug use), thus not accounting for possible mediating 
factors. As with recreational drug use, any association between alcohol misuse and higher risk sex is 
complex and not necessarily causative. Alcohol intoxication can have disinhibitory effects which could 
reduce condom self-efficacy, but other factors (such as drug use, sensation seeking/impulsivity
374
) might 
predispose individuals to both alcohol misuse and CLS.
116
  
 
In ASTRA, higher alcohol consumption (measured by the WHO-AUDIT-C) was independently associated 
with CLS-D and higher HIV risk CLS-D, even after adjustment for core factors and recreational drug use. 
The association with higher HIV risk CLS-D may in part be driven by not being on ART or having 
detectable VL. There was no significant association of alcohol consumption with other measures of 
sexual behaviours (including CLS-C). Evidence of alcohol dependency (measured by the CAGE 
questionnaire) was not associated with any sexual behaviour in unadjusted or adjusted analyses. The 
discrepancy between the two alcohol measures in associations with CLS may be due to the screening 
tools themselves. While the CAGE is valid for detection of alcohol dependence in inpatients, the AUDIT is 
able to screen for less severe forms of drinking.
217
 Poorer mental or physical health status may be 
associated with both lower prevalence of alcohol use and of any sex; hence, inclusion of those with 
lower alcohol consumption (on the AUDIT) in the comparison could have inflated the effect sizes 
between alcohol consumption and CLS-D.  
 Recreational drug use and ART outcomes 6.5.6
In this study, both recreational drug use and alcohol misuse were associated with non-adherence to 
ART, independently of core socio-demographic and HIV-related factors. This finding is consistent with 
previous research demonstrating the significant role of alcohol misuse in lower adherence to ART,
116,375
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and adds to the limited published literature
376
 linking drug use and non-adherence. No association was 
observed between drug use, alcohol misuse, and VL non-suppression in ASTRA (although there was 
some suggestion of a weak association between polydrug use, alcohol misuse, and lower prevalence of 
suppressed VL in unadjusted analyses, and confidence intervals were relatively wide). Hence, it is 
important to note that 87% of HIV-diagnosed MSM on ART who used recreational drugs and 83% of 
those on ART who used five or more drugs had suppressed VL, demonstrating that drug use is not 
incompatible with good ART adherence.  
 Limitations 6.5.7
The findings from this study must be interpreted in light of limitations. Under-reporting of drug use and 
specific sexual behaviours is possible and could have led to underestimation of prevalence, or bias in 
assessing associations. For example, in the ‘London Gyms’ study, among HIV-positive MSM, the 
prevalence of drug use was lower among those recruited from HIV outpatient clinics compared to those 
recruited from social venues (gyms, clubs, saunas).
289
This may mean that the true prevalence of drug 
use among HIV-diagnosed MSM in the UK is higher than that reported in ASTRA, which is also a clinic 
sample.   
 
It was not possible to examine chemsex per se, as the questionnaire enquired about use of chemsex-
associated drugs (GHB/GBL, mephedrone, methamphetamine) in the past three months rather than 
specifically use before or during sex. Similarly, the questionnaire examined IDU overall rather than 
injection of specific drugs. The temporality of associations between drugs and sexual behaviours cannot 
be ascertained due to the cross-sectional study design. At the time of ASTRA recruitment (2011-2012), 
new psychoactive substances (NPS), such as methoxetamine and  mephedrone, were not yet controlled 
under the UK Misuse of Drugs Act 2016, and some NPS were later reclassified into more serious offenses 
(e.g. ketamine was moved to class B in 2014). As a result, trends in drug use may have changed since 
ASTRA was completed, with possible increases in IDU, chemsex, or newer drugs. Analyses on the 
association of polydrug use and higher HIV risk CLS-D were underpowered, but categories were 
collapsed to account for this.  
 
Despite its limitations, ASTRA is the largest questionnaire study of HIV-diagnosed MSM in the UK to 
date, and was the first to provide estimates on the prevalence of recreational drug and polydrug use in 
the UK since the 2002 ‘London Gyms’ study. A further strength of the study is the comprehensive 
information collected on self-reported polydrug use (as well as mephedrone and GHB use specifically) 
and recent sexual behaviour. 
 Conclusion & Implications 6.5.8
In conclusion, among HIV-diagnosed MSM in the UK, recreational drug use and polydrug use are 
prevalent, and strongly associated with CLS and multiple new sexual partners. These findings have 
implications for clinical care, HIV/STI prevention, and epidemiological research. There is ongoing need to 
prioritise harm reduction services that meet the needs of HIV-diagnosed MSM who use recreational 
199 
 
drugs. Cross-agency collaboration between HIV treatment and substance misuse services may be 
beneficial in providing tailored, judgment-free harm reduction advice and support to HIV-diagnosed 
MSM who use recreational drugs, particularly given the reported rise in injection drug use linked to 
chemsex. All HIV-diagnosed MSM, and particularly younger men, may benefit from support and 
awareness of the side-effects of drug use, particularly when combined with multiple other drugs, 
alcohol, or with ART regimens. Peer-led interventions may also be productive in outreach among HIV-
diagnosed men who are polydrug users and have multiple sexual partners. National STI and HIV 
prevention strategies should address recreational drug use and alcohol-related issues. Toolkits for 
effective interventions in various settings are needed. 
 
More research is needed in understanding the drivers of polydrug and chemsex use and the variations in 
drug use among MSM in local areas, accounting for change over time. Future epidemiological research 
could benefit from polydrug use profiles (or polysubstance use when accounting for alcohol) that 
incorporate measures of frequency and severity, rather than focusing on binary measures of drug use. 
There remains a need for longitudinal, within-subject studies of drug use, comparing episodes of CLS 
during which drugs were or were not used. Such designs allow for better understanding of the 
temporality and direction of associations, and may therefore provide further evidence on causality.  
 
The extent and implications of chemsex have yet to be studied, as it is a relatively new phenomenon. 
The facilitators of chemsex are likely to be both technological and structural. The migration towards NPS 
could be due to the internet and geosocial networking applications (which display information on the 
geographic location of a user relative to others) facilitating the development of online drug 
marketplaces
377
 and thus more accessible sex. The impact of smartphone apps in sourcing NPS and 
facilitating chemsex, however, remains unknown. 
 
Finally, it is important to avoid sensationalising drug use and sexual behaviour in research and the 
media, as this could lead to stigmatisation and marginalisation of HIV-diagnosed MSM.
378
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7 Non-disclosure of HIV-serostatus and condomless sex 
7.1 Chapter aims 
This chapter aims to investigate, among HIV-diagnosed MSM from ASTRA, non-disclosure of HIV 
serostatus to a stable partner and non-disclosure in a sexual context. A review of literature is conducted 
with a focus on studies from high income countries since the introduction of ART, examining various 
constructs of non-disclosure, the prevalence of non-disclosure in social settings and to sexual partners, 
factors associated with non-disclosure to stable or new sex partners, and associations between non-
disclosure (to stable or new partners) and sexual behaviours. The aims of the analyses are to examine, 
among ASTRA MSM: (i) the prevalence of non-disclosure according to confidant, (ii) associations of 
socio-demographic, psychological, HIV-related factors with non-disclosure to a stable partner, (iii) 
prevalence of lower HIV-serostatus disclosure to new sexual partners, (iv) socio-demographic, 
psychological, HIV-related factors associated with lower sexual disclosure, and (v) associations of non-
disclosure to a stable partner and lower sexual disclosure with specific sexual behaviours, including 
condomless sex (CLS). The prevalence of social disclosure overall is included in order to provide context 
to the results regarding stable and sexual partners.  
7.2 Introduction 
Disclosure of HIV-serostatus refers to the situation in which an HIV-diagnosed individual tells someone 
else that they have been diagnosed with HIV. Conversely, non-disclosure refers to not to telling 
someone else of one’s HIV-positive diagnosis. Disclosure itself can be a difficult decision, balancing risks 
and benefits. In addition, choosing who to disclose to (family, friends, employers and co-workers, stable 
long-term partners or spouses, casual sexual partners) has different motivations and implications, and 
depends on the nature of the relationship with each confidant. Disclosure to family and friends may 
provide closeness in relationships, which in turn could help in overcoming a diagnosis which may be 
more complex than other chronic conditions.
379
 Disclosure to a stable partner or casual sexual partners 
carries different implications given potential consequences for HIV transmission.  
 
Studies have focused on disclosure as a means of obtaining social and psychological support for the HIV-
positive individual and also as a public health prevention tool in reducing HIV transmission to sexual 
partners. However, a causal link between disclosure and condom use (or conversely non-disclosure and 
CLS) is difficult to establish from observational studies. In fact, various intervention studies have been 
efficacious in increasing disclosure to sexual partners, but whether this had any effect on reducing the 
prevalence of CLS remains uncertain.
380
 Disclosing to a sex partner is not necessarily sufficient in 
promoting HIV risk reduction behaviours, and additional communication about specific sexual 
behaviours (such as using condoms, positioning during CLS with HIV-serodifferent partners (CLS-D), and 
ejaculation inside a serodifferent partner among others) may be relevant as well. Since the publication 
of conclusive evidence on the extremely low risk of HIV transmission when the HIV-positive partner is on 
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virally suppressive ART,
9
 the role of non-disclosure to sexual partners (including casual and stable 
partners) remains unclear. There is scarce recent information on attitudes to disclosure of HIV-status to 
new sexual partners among UK MSM, and whether this may be influenced by knowledge of viral load 
(VL) status. In addition, the relationship between HIV serostatus non-disclosure and sexual risk 
behaviour remains inconsistent across studies. 
 Non-disclosure in the social context 7.2.1
This section reviews literature on non-disclosure to family, friends, and other social settings (such as the 
workplace) with a focus on prevalence estimates among HIV-diagnosed MSM in high income countries 
(North America, Western Europe including the UK, Australia) since the introduction of widespread ART 
(1996-2016).  
7.2.1.1 Barriers to HIV-serostatus disclosure 
Expectations of negative reactions and consequences constitute significant disincentives to disclosure of 
HIV-serostatus. These barriers include the lack of a social network, fears of stigma, ostracism, and abuse, 
subsequent disclosure of stigmatised behaviours (sexual orientation, injecting drug use), conflicts with a 
partner, potential loss of social support, and breach of confidentiality.
236,381–385
 The need to not burden 
family with one’s health issues has also been a deterrent of disclosure.
382,386
 Additionally, the HIV-
positive person may take time to come to terms with their diagnosis, or may feel their health is a private 
matter.
386,387
  
 
In the UK, the Equality Act 2010 makes it unlawful to discriminate against people living with HIV in the 
workplace.
388
 Employers must make adjustments to assist HIV-diagnosed people in their work (such as 
allowing time away from work to attend clinic appointments) and protect personal sensitive 
information. However, in order to benefit from the Act, people living with HIV must disclose their status 
to their employer. Fears of being discriminated against at work or of losing employment constitute 
substantial barriers to disclosure in the workplace. Taken together, the host of psychosocial and legal 
barriers contribute to choosing not to disclose one’s HIV serostatus.  
7.2.1.2 Prevalence of non-disclosure  
Various constructs of non-disclosure have been used across study settings. These include the number or 
proportion of people disclosed to
389
, levels of disclosure
199,390,391
 (never, sometimes, always disclose), 
mean scores on attitudinal questions derived from Likert scales (for example, “I have disclosed to (insert 
number) of friends/family”)
392
, and more commonly, as a binary concept of either disclosed to at least 
one other person, or not disclosed to anyone.
393,394
 Research shows that the prevalence of non-
disclosure of HIV-serostatus in a social context (family, friends, and work colleagues) varies by socio-
demographic and HIV-related factors of individuals surveyed. Overall, evidence from Western Europe 
and the USA suggests that MSM tend to report lower prevalence of non-disclosure in the social context 
compared to heterosexual individuals, regardless of confidant.
133,395,396
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While there have been numerous studies examining non-disclosure in the social context (family, 
friends), many do not differentiate participants’ sexual orientations and so prevalence estimates of non-
disclosure cannot be disaggregated for MSM.
236,385,393,396–398
 As summarised in Table 7.1, few studies 
from high-income countries have measured non-disclosure in the social context among HIV-outpatient 
clinic attendees; data are particularly scarce from MSM in the UK. Overall, a minority of HIV-diagnosed 
MSM report non-disclosure to anyone in these studies, with prevalence higher among ethnic 
minorities.
386,391,399,400
 In two earlier UK studies with similar study populations and recruitment methods 
as ASTRA (see Table 2.1), prevalence of non-disclosure to anyone in the social context among MSM was 
2.4% in the ‘East London’ study
394
 (2004-2005) and 4.9% in the ‘Switching Study’
114,133
 (2005-2006).  
 
Non-disclosure in the workplace is a not well-studied and the effect it could have on a person’s 
psychological wellbeing remains unclear. In the ‘East London’ study, the vast majority of MSM in 
employment did not disclose in the workplace, with non-disclosure being much higher towards 
employers than colleagues.
394
(Table 7.1) In addition, white MSM were more likely to disclose to 
colleagues compared to ethnic minority MSM in this study. 
7.2.1.3 Correlates of non-disclosure 
There is some evidence that belonging to a racial/ethnic minority is associated with higher prevalence of 
non-disclosure in the social context among MSM in UK and US studies.
379,394,395,398,401
 The HIV-diagnosed 
person’s age may also play a role in deciding whether or not to disclose; in the ‘East London’ study, non-
disclosure was associated with older age for MSM.
394
 No association was found in the US study of 362 
young (<24 years) racial minority MSM not in care.
386
 Disclosure to friends and family could be a gradual 
process that evolves over time. Evidence of this gradual effect with time since receiving an HIV diagnosis 
was shown in the ‘East London’ study, and also in a US longitudinal clinic study of 135 white MSM, in 
which disclosure to parents increased over a period of 15 years (from less than 30% to over 65%).
402
 
Factors not shown to be consistently associated with non-disclosure in the social context include socio-
demographic (education, financial status) and HIV-related measures (ART status, adherence to ART, lab-
confirmed VL, and perceived VL).
154,382,398
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Table 7.1: Studies from high income settings on prevalence of non-disclosure in the social context among HIV-diagnosed MSM (2004-2012) ‡ 
Study Country Data 
collection 
period 
Study setting and recruitment  Population  Definition of non-disclosure measure  Prevalence of non-disclosure 
measure * 
 
East 
London
394
 
 
UK 2004-
2005 
Cross-sectional questionnaire 
survey of HIV outpatients 
receiving care in one of 6 NHS 
clinics in northeast London.  
1407 men 
and women 
740 MSM 
"Have you told anyone that 
you have HIV?" If yes, ‘‘Whom have you 
told?’’ 
Non-disclosure to anyone  4.9%  
Not disclosed to parents 61.8%  
Not disclosed to friends 21.2%  
Non-disclosure to 
employer (n=415 
employed) 
71.6%  
Non-disclosure to 
colleagues (n=415) 
58.6%  
Switching 
study
114,133
 
 
 
UK 2005-
2006 
Cross-sectional questionnaire 
survey of HIV outpatients 
receiving care in one of 5 NHS 
clinics in London and South east 
England.  
778 men and 
women 
496 MSM  
Participants indicated whether they had 
friends or family members and whether 
disclosed to each of those. Proportion of 
friends and family not disclosed to was 
calculated (total number of people not 
disclosed to/ total number identified 
within each relationship) 
Non-disclosure to anyone  2.4%  
Atlanta 
Clinics
399
 
 
USA 2006-
2008 
Black minority MSM who were 
on ART recruited from HIV 
agencies and organizations in 
inner-city areas. Must have 
indicated sex with men at last 
sex encounter. 
156 MSM Participants indicated whether they had 
family members and whether disclosed 
to these family 
members (proportion of family 
members not disclosed to) 
Non-disclosure to any 
family members 
33.0%  
'Young 
MSM of 
color 
initiative'
386
 
USA 2006-
2009 
Young ethnic minority HIV-
positive MSM (13-24 years) not 
currently in care (newly 
diagnosed or out of HIV care for 
362 MSM Report the persons whom participants 
disclosed to from a list of options 
(mother, other relatives, friends etc.) 
Non-disclosure to anyone 
at baseline 
3.0%  
Non-disclosure to any 
family member 
23.5%  
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Study Country Data 
collection 
period 
Study setting and recruitment  Population  Definition of non-disclosure measure  Prevalence of non-disclosure 
measure * 
 
 ≥6 months) recruited from 
outreach initiative focused on 
linkage to care. Face-to-face 
interview at one of 8 study sites 
at baseline and 6 months later. 
Non-disclosure to friends 39.8%  
Project 
CONNECT 
403
 
USA 2007-
2012 
Retrospective analysis of routine 
data and self-administered 
questionnaire collected from a 
cohort of HIV-positive people 
attending to establish care at 
HIV clinic (data from first visit) 
490 men and 
women 
294 MSM 
Disclosure status at initial entry into HIV 
care: (i) non-disclosure (to no one), (ii) 
selective disclosure (to only one group 
of confidants that was mutually 
exclusive), and (iii) broad disclosure (to 
>1 group). 
Non-disclosure at initial 
entry into HIV care  
12.9%  
ANRS- 
VESPA2
400
 
France  2011-
2012 
National representative 
probability sample of HIV-clinic 
attendees from 73 hospitals. 
Cross-sectional survey via face-
to-face interview using a CASI.  
3016 men 
and women 
1180 MSM 
Whether disclosed to anyone and if yes, 
to whom (close family, other relatives, 
friends, colleagues). Three hierarchical 
clusters created (high, medium, low).  
Low disclosure level  31.4%  
*Prevalence estimates shown are for HIV-diagnosed MSM in each study only; ART: antiretroviral therapy; CASI: computer assisted self-interviewing; NHS: National 
Health Service; ‡ Studies detailed in systematic review, section 2.5 
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 Non-disclosure to a stable partner 7.2.2
Non-disclosure of HIV status to stable partners differs from non-disclosure to other close family or 
friends, as such a partnership usually involves a sexual relationship and thus the potential for HIV 
transmission. Serostatus disclosure allows the HIV-negative partner to make informed decisions about 
personal acceptability of risk and any further actions to be taken (such as HIV testing, use of PrEP, or 
other risk reduction behaviours, if deemed appropriate).
404
  
7.2.2.1 Barriers to HIV-serostatus disclosure to stable partner 
In this context, decisions about non-disclosure are complicated by factors such as; assumptions or 
inferences about a partner’s HIV status, considerations of the responsibility to disclose to sexual 
partners, use of HIV risk-reduction strategies (such as seropositioning) instead of disclosure, particularly 
when the HIV-positive person is on effective ART. Fear of rejection, abuse, and stigmatisation are 
important disincentives of disclosure to a sexual partner. In addition, considerations about disclosure to 
casual partners are likely to differ from those for stable or longer-term partners; for example disclosure 
within a close trusting relationship may be more strongly linked to improved social support. 
 
Another important issue is the potential for legal prosecution in the case of non-disclosure before sex 
with an HIV-serodifferent partner (regardless of whether or not condoms were used). Since 2001, 
approximately 30 prosecutions for “reckless sexual transmission of HIV” have been brought in the UK.
405
 
In England and Wales, the offence applies if the HIV-diagnosed person understands how HIV is 
transmitted, did not disclose their HIV diagnosis before having CLS, and can be proven to be the source 
of HIV transmission.
406
 These prosecutions undermine the efforts to prevent HIV transmission, raise 
complex ethical questions, and increase HIV-associated stigma. With conclusive evidence on the 
extremely low risk of HIV transmission when the HIV-positive partner is on virally suppressive ART
9
, 
disclosure of HIV serostatus to a stable (or otherwise sexual) partner may not be the most relevant HIV 
prevention effort.  
7.2.2.2 Prevalence of non-disclosure to stable partner 
Evidence on the prevalence of non-disclosure to a long-term/stable partner among MSM from the UK is 
limited. Table 7.2 shows the distribution of prevalence estimates of non-disclosure to stable partners in 
studies of HIV-diagnosed MSM from high-income countries since the introduction of effective ART in 
1995. In the ‘East London’ study, almost 14% of MSM in a stable relationship reported not disclosing to 
their partner
394
, while in the French ANRS-VESPA1 probability sample, only 4.5% had not disclosed.
229
 
Overall, a number of diverse studies have shown that individuals are more likely to disclose to stable 
partners compared to casual sex partners.
229,386,396,407–410
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Table 7.2: Summary of studies from high income countries on non-disclosure of HIV-serostatus to stable partners among HIV-diagnosed MSM (2000-2012) ‡ 
Study /Country/ Data collection 
period 
Study setting and recruitment Population 
Definition of non-disclosure 
measure 
Prevalence of 
non-disclosure 
Prevalence of 
CLS-D among 
non-disclosed 
Healthy Living 
Project 
408
 
 
USA 2000-
2002 
Baseline assessment of HIV-diagnosed 
people recruited from clinics and community 
agencies participating in an RCT of a 
cognitive behaviour intervention 
742 MSM with a 
main partner 
Non-disclosure to main 
partner 
12.3% 3.3% 
Guys & 
St.Thomas' HIV 
clinic
304
 
 
UK  2002-
2004 
MSM with PHI recruited from sexual health 
services and enrolled in an ART intervention 
study a median of 7 days post-diagnosis. 
Electronic questionnaire at baseline and at 
12 week follow-up.  
52 MSM with a 
regular partner 
Non-disclosure to regular  
partner  
11.5% 66.7% 
ANRS-VESPA1
229
 
 
France  2003 National cross-sectional survey among a 
random stratified sample of HIV-diagnosed 
people attending HIV clinics. Restricted to 
MSM with a stable partner for ≥12 months. 
285 MSM with a 
regular HIV-
serodifferent 
partner 
Non-disclosure to regular 
partner  
4.5% 35.3% 
East London
394
 
 
UK 2004-
2005 
Cross-sectional questionnaire survey of HIV 
outpatients receiving care in one of 6 NHS 
clinics in northeast London. 
388 MSM with a 
stable partner 
Non-disclosure to current 
partner 
13.9% Not shown 
Latino MSM
195
  USA 2005 Cross-sectional questionnaire study on 
disclosure by Latino HIV-positive MSM to 
social networks, recruited from clinics and 
research sites. Restricted to MSM who had 
sex in past 12 months.  
219 MSM Non-disclosure to main 
partner ('had an ongoing 
intimate sexual and 
emotional relationship') 
19.0% Not shown 
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Study /Country/ Data collection 
period 
Study setting and recruitment Population 
Definition of non-disclosure 
measure 
Prevalence of 
non-disclosure 
Prevalence of 
CLS-D among 
non-disclosed 
Adolescent 
Medicine Trials 
Network (ATN)
411
   
USA  2011 Cross-sectional questionnaire survey of 
young (16-24) HIV-diagnosed MSM receiving 
care in clinics in 14 US cities. Restricted to 
those who had sex with a male partner in 
past 3 months. 
991 MSM Non-disclosure to current sex 
partner (not a boyfriend) or 
to current boyfriend 
('someone you knew for a 
while with whom you have 
an ongoing relationship') 
53.2% Not shown 
SAFE Talk
404
 
 
USA 2012 Baseline assessment of 'Safe Talk' RCT 
evaluating efficacy of motivational 
interviewing-based safer sex intervention of 
people in HIV care. This analysis restricted to 
sexually active with only one partner in past 
3 months. 
69 MSM Non-disclosure to current 
sexual partner  
18.8% 30.8% 
ART: antiretroviral therapy; CLS-D: condomless sex with an HIV-serodifferent partner (HIV-negative or of HIV-unknown status); NHS: National Health Service; Not shown: study 
did not provide relevant information; PHI: Primary HIV infection; RCT: randomised controlled trial; ‡Studies described in detail in systematic review, section 2.5. 
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7.2.2.3 Correlates of non-disclosure to stable partner 
A partner’s HIV serostatus has consistently been shown to be a significant correlate of non-disclosure to 
stable and casual sexual partners for MSM; highest proportions of non-disclosure have been observed 
towards partners of unknown HIV-serostatus, followed by lower proportions of non-disclosure towards 
known HIV-negative partners, and lowest non-disclosure (i.e. highest prevalence of disclosure) towards 
known HIV-positive partners.
167,236,407,408,412
 This finding may reflect the dynamics of mutual disclosure of 
HIV status in sexual relationships. More recent HIV diagnosis has also been associated with higher 
proportions of non-disclosure to a stable partner among MSM, suggesting that disclosure of HIV-status 
may take time, even to a stable partner.
408,413
 It remains unclear whether relationship-related factors, 
such as length of time in the relationship and cohabitation with the stable partner are associated with 
non-disclosure to this partner. In addition, it is uncertain whether being on ART or having an 
undetectable VL are linked to  non-disclosure to stable partners, given that these factors would be 
associated with reduced HIV transmission risk.   
 Non-disclosure to casual sexual partners 7.2.3
The barriers to disclosure to casual sex partners are similar to those discussed in section 7.2.2.1 on non-
disclosure to stable partners, namely, the fear of rejection, abuse, stigma, and breach of privacy. When 
the risk of HIV transmission is extremely low, such as when a condom is used, or when VL is 
undetectable on ART, some HIV-diagnosed people may also feel there is no need to disclose their HIV-
serostatus. On the other hand, disclosing to sex partners could facilitate discussions about sex.
414
 
 
Prevalence of non-disclosure to casual sexual partners has been extensively studied in the USA, but less 
so in the UK. An earlier systematic review on levels and patterns of HIV disclosure (1997-2008) found 12 
US studies among MSM; the prevalence of non-disclosure to any sexual partners ranged from 20% to 
46%, while the prevalence of non-disclosure to ‘casual’ sex partners was higher, ranging from 58% to 
62%.
379
 Table 7.3 shows the distribution of prevalence estimates for non-disclosure to casual sex 
partners among HIV-diagnosed MSM from studies in high-income countries (including studies that were 
published after the aforementioned systematic review and outside the USA). Prevalence of non-
disclosure to casual sex partners varies widely (from 9-66%), according to study setting (HIV clinics or 
community venues), ART coverage (whether on or off ART), ethnicity (racial minority or not), as well as 
the method of survey administration (interview or self-completed). In addition, various constructs have 
been used to describe casual partners in studies of non-disclosure, such as “most recent partner”
415,416
, 
“casual sex partner”
195,199
, “any sex partner”
408
, or new sex partners
389
. Non-disclosure itself can be 
operationalised in a number of ways; as a proportion of the number of sex partners the participant 
disclosed to over a period of time
389,390
, a binary construct (disclosed or not at last sex
195,415,416
), or as a 
categorical variable of degree to which disclosed to casual partners (none, some, all).
199,241,390,392
 
 
Another method of studying patterns of disclosure to sexual partners is to ascertain attitudes towards 
non-disclosure to casual partners. This has been less commonly studied. For example, the UK “What Do 
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You Need?” needs-assessment survey of HIV-diagnosed people recruited online, at clinics, or through 
charities (n=1200 MSM, 2007-2008); 32% of HIV-diagnosed MSM felt ‘”worried about disclosing to a 
sexual partner” and 38% were “worried about transmitting HIV to sexual partners”.
417
  
7.2.3.1 Correlates of non-disclosure to casual sex partners 
There is some evidence to suggest that non-disclosure of HIV serostatus to casual sex partners is highest 
among MSM who are recently diagnosed.
408,417,418
 However, This finding was not observed in the SUMIT 
study of 858 HIV-diagnosed MSM (see Table 7.3); time since HIV diagnosis was not associated with non-
disclosure to casual sex partners in the past three months.
199
  
 
Evidence on the association between age of the HIV-diagnosed participant and non-disclosure is also 
somewhat mixed. In the UK “What Do You Need” survey, MSM who worried about disclosing to sexual 
partners were significantly younger than MSM who did not have this concern.
417
 In the Dublin HIV clinic 
study of 97 HIV-diagnosed MSM (Table 7.3), men who were older had higher odds of non-disclosure to 
any sexual partner compared to those who were younger.
390
 No association was found between age and 
non-disclosure to casual partners in the past three months in two US studies (‘Positive Connections’
418
 
and SUMIT baseline survey
199
). Other socio-demographic variables (ethnicity, income, education, 
employment) were also not found to be associated with non-disclosure in the two aforementioned 
studies.  
 
HIV-related factors have not been consistently found to be associated with non-disclosure to casual 
partners; there are mixed findings on the role of ART status, self-reported VL, CD4 count, and 
undetectable VL on prevalence of non-disclosure to sex partners.
408,416–418
  In ‘Positive Connections’ (see 
Table 7.3), non-disclosure to casual partners was associated with not knowing personal CD4 count and 
self-reported undetectable VL, after adjustment for ethnicity, number of partners, and time since HIV 
diagnosis.
418
 A mathematical model estimating the efficacy of disclosure in reducing HIV transmission 
risk using baseline data from a US RCT of 144 HIV-diagnosed MSM (measuring non-disclosure at last sex) 
showed no association of self-reported VL and non-disclosure in unadjusted analyses.
416
 Among over 
1800 HIV-diagnosed MSM from the ‘Healthy Living Project’ (see Table 7.3), having undetectable VL was 
also not associated with higher non-disclosure to any sex partners in unadjusted analyses.
408
 Overall, 
information on factors associated with non-disclosure to sexual partners among representative samples 
of HIV-diagnosed MSM in the UK is lacking. 
 Evidence on associations of non-disclosure and condomless sex 7.2.4
Few studies have examined the association of HIV-serostatus disclosure and condom use among HIV-
diagnosed MSM. It has been hypothesized that disclosure to sexual partners could be linked to higher 
prevalence of ‘safer sex’ (condom-protected sex or CLS with other HIV-positive men only, CLS-C), 
however this implies a causal relationship which has not been empirically supported.
408
 A review of 
eight US studies (1991-2003) examining non-disclosure and ‘sexual safety’ among MSM found mixed 
results (and none accounted for confounding variables); half of the studies reported no significant 
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association of non-disclosure to sexual partners with measures of ‘unsafe sex’ (any CLS) and the 
remaining found that disclosure to HIV-negative casual partners was associated with ‘safer sex’ 
(consistent condom use).
381
 All of the studies included in the review were conducted before the 
introduction of widespread ART (prior to 1996), and therefore may be less relevant in the current HIV 
epidemic.  
 
Since that review, certain studies have suggested that non-disclosure is associated with higher 
prevalence of CLS,
199,389,409,418
 other studies have not found a significant association
195,201,236,381,404,415
, and 
others yet have shown that, compared to MSM who disclose to all partners, those who do not disclose 
are more likely to report having condom-protected sex only.
419
 For example, two US studies of HIV-
diagnosed MSM (Positive Connections
418
 and Healthy Living Project
408
, see Table 7.3) found that about 
one in five MSM did not disclose their HIV-serostatus to any casual partners in the past three months. 
This group had significantly higher odds of reporting CLS-D compared to those who had disclosed to all 
partners, even after adjustment for other socio-demographic, lifestyle, and sexual behaviour-related 
factors.
408,409
 On the other hand, among young MSM in the US ATN trials, those who disclosed their HIV-
serostatus to sex partners were significantly more likely to report any CLS compared to those who did 
not disclose to any sex partners, after adjustment for socio-demographic and lifestyle factors.
177,411
 In 
addition, disclosure in this study was not associated with CLS-D, which may indicate that many young 
MSM were having CLS-C, with mutual disclosure of HIV-status. Studies that examine levels of disclosure 
to sexual partners (disclosed to none, some, most or all partners) have shown that those who disclose to 
some partners tend to report higher levels of CLS compared to those who disclose to none or most/all 
partners.
199,241,392,418,419
 
 
Only two studies from the UK (‘East London’
394
 and Guys’ clinic
304
, see Table 7.3) have shown prevalence 
estimates of non-disclosure to sexual partners, but none examined associations between non-disclosure 
and CLS. The prevalence of, and factors associated, with non-disclosure of HIV serostatus, as well as any 
link between non-disclosure and CLS among HIV-diagnosed MSM in the UK remains unclear.  
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Table 7.3: Summary of studies from high income countries on prevalence of non-disclosure to casual sex partners among HIV-diagnosed MSM‡ 
Study /Country/ Data 
collection period 
Study setting and recruitment 
N HIV-
diagno
sed 
MSM 
Definition of non-disclosure 
measure 
Prevalence of 
non-disclosure 
(% of HIV-
diagnosed 
MSM) 
Prevalence of CLS or 
CLS-D among non-
disclosed (% of HIV-
diagnosed MSM) 
SUMIT
164,199
  
 
USA 2000-
2001 
Baseline assessment from SUMIT RCT restricted to HIV-
diagnosed MSM who had sex with a casual or non-
primary male partner in past 3 months  
N=858 Non-disclosure to casual sex 
partners with whom had sex 
in past 3 months  
33.0% 23% had insertive CLS-D 
32% receptive CLS-D 
Healthy 
Living 
Project 
408
 
 
USA 2000-
2002 
Refer to Table 7.2  N=1828 Non-disclosure to any casual 
sex partner 
21.5% 16.9% had CLS-D 
Dutch 
Hospitals
201
  
Nethe
rlands 
2002-
2003 
Self-administered questionnaire survey of HIV-
diagnosed MSM attending for HIV care aged 20-65 
years.  
N=296 Have never/rarely informed 
casual sex partners about 
HIV+-positive status 
59.8% Not shown 
Latino 
MSM
195
 
USA 2005 Refer to Table 7.2 N=219 Non-disclosure to most 
recent casual partner  
66.0% 31.3% had CLS-D 
Positive 
Connection
s
418
  
USA 2005-
2006 
Baseline survey of self-reported HIV-positive MSM 
recruited from 'AIDS service organisations' in 6 cities. 
Reported ≥1 occasion of CLS with a man in past year. 
N=675 Non-disclosure to any 
'secondary' partners in past 3 
months 
19.6% Not shown 
HIV 
Outpatients 
Study 
(HOPS)
241
 
USA 2007-
2010 
Ongoing open prospective cohort of HIV-diagnosed men 
and women receiving care in 8 HIV clinics in 6 cities. 
Results here from cross-sectional annual automated 
telephone survey among MSM who reported any sex in 
past 6 months.  
N=704 Non-disclosure to any sexual 
partners  
9.2% Not shown 
LISA
389
 
 
BC, 
Cana
da 
2007-
2010 
Interviewer-administered survey of people on ART 
recruited through HIV clinics and organisations. 
N=243 Don't always disclose to new 
sex partners in the past 6 
months (up to 75% of the 
time versus always disclose, 
76-100% of the time) 
48.6% 16.4% report not using 
condoms 100% of the 
time  
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Study /Country/ Data 
collection period 
Study setting and recruitment 
N HIV-
diagno
sed 
MSM 
Definition of non-disclosure 
measure 
Prevalence of 
non-disclosure 
(% of HIV-
diagnosed 
MSM) 
Prevalence of CLS or 
CLS-D among non-
disclosed (% of HIV-
diagnosed MSM) 
DiSH
410
  
 
USA 2008-
2009 
Baseline data from behavioural intervention study to 
reduce sexual risk behaviours among black HIV-positive 
and HIV-negative MSM in NYC, recruited at street and 
venue locations, local organisations, gay press, online. 
Eligible if reported ≥2 partners and CLS with a man in 
past 3 months. Survey by ACASI + HIV testing (if status 
not known). Here showing results for MSM HIV-
diagnosed for ≥6 months.  
N=205 Non-disclosure during last 
sexual encounter with a male 
partner  
30.2% Not shown 
Positive 
Choices
419
 
 
USA  2009-
2011 
RCT testing brief risk reduction intervention to newly 
diagnosed people (≤3 months) at STI clinic. Restricted to 
MSM reporting CLS in 3 months prior to diagnosis and 
completed both screening (time 1) and baseline 
assessments (time 2: 3 months after time 1) by CASI.  
N=92 Disclosure to no partners in 3 
months post HIV-diagnosis 
(at time 2) 
32.6% 4.4% had any CLS 
SafeTalk
407
 USA 2012 Refer to Table 7.2 : Data shown here for all MSM who 
reported any sex in past 6 months  
N=138 Did not fully disclose to all 
sexual partners (disclosure to 
<100% of partners) 
31.2% Not shown 
Dublin HIV 
clinic
390
  
Irelan
d 
2013 Cross-sectional questionnaire study of HIV-outpatients 
attending largest HIV clinic in Dublin. Restricted to MSM 
with at least one casual sex partner in past 6 months. 
N=97 Never disclosed to casual 
partners in past 6 months  
34.0% Not shown 
Atlanta 
clinics
420
  
USA 2013-
2014 
Cross-sectional survey of HIV-diagnosed men from 
community services and STI clinics who had anal or 
vaginal sex in past month. Included urine test for 
recreational drug use, unannounced phone-based ART 
pill counts, and daily text-diary assessment for sexual 
behaviour during previous day, for 28 consecutive days. 
N=538 Had CLS-D without disclosing 
to any partners during 28 day 
prospective  
Not shown 16.4% had CLS-D 
ACASI: audio computer assisted self-interviewing; ART: antiretroviral therapy; CASI: computer assisted self-interviewing; CLS: condomless sex; CLS-D: condomless sex with HIV-
serodifferent partners; LISA study: Longitudinal Investigations into Supportive and Ancillary health services; Not shown: study does not provide relevant information; RCT: 
randomised controlled trial; STI: sexually transmitted infection; SUMIT: Seropositive Urban Men's Intervention Trial; ‡Studies described in section 2.5, unless otherwise specified. 
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7.3 Methods 
Analyses presented in this chapter include MSM diagnosed with HIV for ≥3 months prior to ASTRA 
completion (N=2189).  
 Disclosure in the social context 7.3.1
Participants were asked “Apart from health care staff, have you told anyone that you have HIV?” If they 
answered “Yes”, they specified whether they had told family members, friends and, if applicable, work 
colleagues, or a stable partner (section 7.3.2). If participants had not disclosed to anyone in these 
categories they were classified as not having disclosed to anyone in a social context.   
 
Among those who indicated having disclosed to at least one person, participants specified whether they 
told “none”, “some”, or “most or all” family members or friends. A combined variable (‘disclosure to 
friends and family’) was defined with three categories: (i) “none”, if participants had not disclosed to any 
friends or family (“none” in both, or no answer in one and “none” in the other), (ii) “some”, if 
participants indicated disclosed to “some” in at least one of the two variables, or “most or all” in one 
and either no answer, “none”, or “some” in the other, and (iii) “most or all” if participants disclosed to 
“most or all” of their friends and “most or all” of their family members. 
 
Among participants reporting current full- or part-time employment, non-disclosure in the workplace 
was defined as having disclosed to “none” of their work colleagues.  
 Disclosure to a stable partner/spouse 7.3.2
Non-disclosure to a stable partner was defined as a “No” to the question “I have told a 
partner/wife/husband that I have HIV” and was assessed only among those who indicated being in an 
ongoing relationship with a partner (defined as “wife/husband or civil partner or girlfriend/boyfriend”). 
 
Those with missing values for the overall disclosure variable were excluded. Similarly, those with missing 
values for any of the disclosure sub-variables (family/friends, stable partner, and workplace) were 
excluded from that specific variable. The variables disclosure to; family/friends, a stable partner, and the 
workplace, have a higher proportion of missing values compared to the overall disclosure variable, as a 
number of participants who indicated disclosure to at least one person did not provide information on 
type of confidant. A missing answer in type of confidant disclosed to was thus not assumed to indicate 
non-disclosure. This approach was taken as it was hypothesized that exclusion of missing values would 
lead to less bias than classification as ‘non-disclosure’. 
  
 Lower sexual disclosure 7.3.3
Participants stated their level of agreement to the statement “I‘d expect to tell a new partner that I’m 
HIV-positive before we have sex” on a 5-level Likert scale (strongly agree, tend to agree, undecided/no 
opinion/not relevant to me, tend to disagree, and strongly disagree). A dichotomous ‘sexual disclosure’ 
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variable was created, merging ‘strongly agree’ and ‘tend to agree’ into one category (higher sexual 
disclosure) and ‘undecided’, ‘tend to disagree’ and ‘strongly disagree’ into the second category (lower 
sexual disclosure).  
 Socio-demographic, lifestyle, mental health, HIV-related factors and sexual 7.3.4
behaviours 
All factors included in these analyses have been defined in sections 3.8 and 4.3. To increase power in 
examining associations, some categorical variables were further collapsed (e.g. age, time since HIV 
diagnosis, time in relationship, money for basic needs, social support), as shown in sections 7.4.2 and 
7.4.3.  
 Statistical analysis  7.3.5
Analyses were restricted to MSM who were diagnosed with HIV for three months or longer (N=2189). 
Prevalence of disclosure was assessed overall (no one, at least one person), by confidant (family, friends, 
co-workers, stable partner), and extent (none, some, most or all). The prevalence of lower sexual 
disclosure (as defined in section 7.3.3) was assessed among MSM who reported any anal or vaginal sex 
in the past three months only (N=1392), as it was hypothesized that the validity of the question on likely 
disclosure to new partners was increased by including sexually active MSM only.  
7.3.5.1 Factors associated with non-disclosure  
In this section the aim was to examine: 
1. The association of socio-demographic, psychological, HIV-related, and relationship factors with 
non-disclosure to a stable partner (versus disclosure to the stable partner) only among HIV-
diagnosed MSM who reported currently being in an ongoing relationship with a partner.  
2. The association of socio-demographic, psychological, HIV-related, factors with lower sexual 
disclosure (versus higher sexual disclosure, as defined in section 7.3.3) among HIV-diagnosed 
MSM who reported any anal or vaginal sex in the previous three months only.  
For both objectives, modified Poisson regression models with cluster-robust error variances were used 
to produce unadjusted and adjusted prevalence ratios (PRs) with 95% confidence intervals. Two 
adjustment strategies (core and stepwise) were used, as described in section 3.9.5.  
 
The association of lifestyle factors and lower sexual disclosure was examined separately. These included: 
recreational drug and polydrug use in the past three months (defined in section 6.3.1), evidence of 
alcohol dependency, and higher alcohol consumption (by CAGE questionnaire and by WHO-AUDIT-C 
respectively, both defined in section 3.8.2). Unadjusted and adjusted (for core factors only) modified 
Poisson regression was used.  
7.3.5.2 Association of non-disclosure and sexual behaviours 
Among MSM in an ongoing relationship with an HIV-serodifferent (HIV-negative or unknown status) 
stable partner, descriptive statistics were used to examine the association of non-disclosure and CLS-D 
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with the stable partner in the past three months. Due to limited sample size it was not possible to 
perform multivariable analyses. 
 
Among MSM who had any anal or vaginal sex in the previous three months, associations were then 
examined of lower sexual disclosure with sexual behaviours (CLS, CLS-C, CLS-D, higher HIV risk CLS-D, 
group sex, use of the internet to find sex, STIs in the past three months; and new sexual partners in the 
past year.) Modified Poisson regression was used to produce unadjusted and adjusted prevalence ratios; 
for each sexual behaviour, separate models were run with adjustment for the sexual disclosure variable 
in addition to core factors. In models with higher HIV risk CLS-D as the dependent variable, ART status 
was excluded from the core set of factors, as this was defined as CLS-D plus not being on ART or 
VL>50c/mL (so this model was adjusted for age, ethnicity, time since HIV diagnosis, stable partner 
status, and sexual disclosure only.) 
 
Among MSM who reported any anal or vaginal sex in the past three months, multinomial logistic 
regression (MNL) was used to examine associations of lower sexual disclosure with reporting different 
types of sex according to the single three-category variable of sexual behaviour (see section 4.3.6.3). 
MSM were classified into one of the following mutually exclusive categories based on sex in the past 
three months:  
1. Condomless sex with HIV-serodifferent partners (CLS-D)  
2. Condomless sex with HIV-seroconcordant partners only (‘CLS-C without CLS-D’) 
3. Condom-protected sex only  
MSM who had CLS-D (group 1), and those who had ‘CLS-C without CLS-D’ (group 2) were compared to 
those who had condom-protected sex only (group 3, the reference category). Multivariable MNL 
included adjustment for core factors (in addition to the sexual disclosure variable).  
 Sensitivity analyses 7.3.6
All sensitivity analyses were conducted on the sample of MSM who reported any anal or vaginal sex in 
the past three months. 
 
In the first sensitivity analysis, in assessing the adjusted association of lower sexual disclosure with 
sexual behaviours, the ART variable (on/off ART) was replaced by the ART/self-reported VL variable. This 
was done as it was hypothesized that MSM who self-reported undetectable VL on ART would be less 
likely to disclose HIV-serostatus to new sexual partners. It would not be possible to adjust both for ART 
status (as a core factor) and ART status/self-reported VL due to collinearity. In models with higher HIV 
risk CLS-D as the dependent variable, the ART variable was replaced with the self-reported VL variable 
(self-reported undetectable VL/self-reported detectable VL/does not know personal VL). 
 
In the second sensitivity analysis, sexual disclosure was reclassified into a categorical variable, according 
to levels of agreement to the statement “I would expect to tell a new partner that I’m HIV-positive 
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before we have sex”: (i.) Higher sexual disclosure (strongly or tend to agree), (ii.) Undecided 
(undecided/no opinion/not relevant to me), and (iii.) lower sexual disclosure (strongly or tend to 
disagree). This was done to disentangle any differences in the prevalence of sexual behaviours between 
categories (ii) and (iii), which were grouped into one category in main analyses. Associations were then 
examined of the three categories of sexual disclosure and sexual behaviours, using modified Poisson 
regression adjusted for core factors (as in section 7.3.5.1).  
 
The third sensitivity analysis aimed at allowing for comparisons of the magnitude of associations of a 
single independent variable (lower sexual disclosure) across a number of dependent binary variables of 
varying prevalence (discussed in section 3.9.4.3). This was done by presenting associations of lower 
sexual disclosure and sexual behaviours (CLS, CLS-D, CLS-C, higher HIV risk CLS-D, STIs, group sex, and 
≥10 new sex partners in past 12 months) as odds ratios rather than prevalence ratios, using logistic 
regression with adjustment for core factors only. 
7.4 Results 
 Prevalence of non-disclosure  7.4.1
A total of 2181 (97.0% of 2189) MSM diagnosed with HIV for at least three months provided information 
on HIV serostatus disclosure. Of these, 4.7% (n=103) had not disclosed their status to anyone. (Table 
7.4) Prevalence of non-disclosure to family members was higher than to friends. A total of 1318 MSM 
were currently employed, of whom 1117 provided information on workplace disclosure; 53.9% of these 
reported not disclosing to any work colleagues. When including recently diagnosed MSM (n=59) the 
prevalence of non-disclosure among 2189 MSM was slightly higher: overall non-disclosure was 5.0% 
(95%CI 4.2-6.0%, n=112), to friends/family combined 12.9% (11.5-14.4%, n=261), to work colleagues 
54.2% (51.3-57.1%, n=1146). 
 
Among 1080 MSM who were in an ongoing relationship with a partner, 4.5% (n=49) had not disclosed 
their HIV-serostatus to a stable partner. When including recently diagnosed MSM, prevalence of non-
disclosure to a stable partner among 1109 MSM in an ongoing relationship was 4.8% (3.7-6.2%, n=53).
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Table 7.4: Prevalence of non-disclosure measures among HIV-diagnosed MSM participating 
in ASTRA (N=2181 with available disclosure information) 
 
7.4.1.1 Prevalence of lower sexual disclosure  
Among 1392 MSM who had been diagnosed for at least three months and reported any anal or vaginal 
sex in the previous three months, 1373 (98.7%) provided information on sexual disclosure, as defined by 
level of agreement to the statement “I’d expect to tell a new partner that I’m HIV-positive before we 
have sex”. (Figure 7.1) Over 34% of MSM strongly agreed with the statement and almost 11% strongly 
disagreed. The first two categories (strongly and tend to agree) and last three (undecided, tend to and 
strongly disagree) were combined into two groups of higher and lower sexual disclosure respectively; 
43.7% of MSM were thus classified as having lower sexual disclosure. 
 
Among 600 MSM with lower sexual disclosure, over 93% (n=563) had disclosed their HIV serostatus to 
anyone in their social circle (family, friends, a stable partner, work colleagues) and 6.0% (n=36) had not 
(p=0.001). 
 
  n % [95%CI] 
Overall disclosure status 
(N=2181) 
      
Disclosed to at least one person 2078 95.3 [94.3,96.1] 
Not disclosed to anyone 103 4.7 [3.9,5.7] 
Disclosure to family (N=1839)     
None 720 39.2 [36.9,41.4] 
Some 608 33.1 [30.9,35.2] 
Most or all 511 27.8 [25.8,29.9] 
Disclosure to friends (N=1946)       
None 267 13.7 [12.3,15.3] 
Some 1081 55.5 [53.3,57.7] 
Most or all 598 30.7 [28.7,32.8] 
Disclosure to friends/family 
combined (N=1979)* 
    
None 245 12.4 [11.0,13.9] 
Some 1366 69.0 [66.9,71.0] 
Most or all 368 18.6 [16.9,20.4] 
Disclosure to work colleagues 
(N=1117 currently employed) 
      
None 602 53.9 [51.0,56.8] 
Some 443 39.7 [36.8,42.6] 
Most or all 72 6.4 [5.1,8.0] 
Disclosure to stable partner 
(N=1080 in ongoing relationship) 
    
No 49 4.5 [3.4,6.0] 
Yes 1031 95.5 [94.0,96.6] 
*Combination categories created from disclosure to friends and 
disclosure to family variables as follows; none: none in both, or 
no answer in one and none in the other; some: some in at least 
one of the two variables, or most/all in one and either no 
answer, none, or some in the other; most/all: both variables 
most/all. Missing for n=202 
 
218 
 
Figure 7.1: Level of agreement to statement “I’d expect to tell a new partner that I’m HIV-
positive before we have sex” and derivation of binary grouping of sexual disclosure (N=1392 
MSM had any anal or vaginal sex in past three months) 
 
 Factors associated with non-disclosure 7.4.2
7.4.2.1 Socio-demographic, psychological, relationship-, HIV-related factors and 
associations to non-disclosure to stable partner 
Among 1080 MSM diagnosed with HIV for ≥3 months and in an ongoing relationship, prevalence of non-
disclosure to a stable partner was higher among MSM: of non-white ethnicity, who were not religious, 
did not always have money for basic needs, had medium/low social support, had an HIV-negative or 
unknown status stable partner, and were not on ART (unadjusted analysis, all p<0.10).(Table 7.5) A 
significant negative trend was also observed between more recent HIV diagnosis and higher prevalence 
of non-disclosure to a stable partner.  
 
After adjustment for core factors, three factors remained significantly associated with non-disclosure to 
a stable partner (p<0.05, models 1: Table 7.5): non-white ethnicity, not always having money for basic 
needs, and medium/low social support. There was weak evidence of a negative trend between more 
recent HIV diagnosis and non-disclosure to a stable partner (p=0.06). Age, place of birth, education, 
employment, symptoms of depression or anxiety, years in the current relationship, cohabitation status 
with the stable partner were not significantly associated with non-disclosure.  
 
34.3 
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Strongly
disagree (n=145)
"I'd expect to tell a new partner that I'm HIV-positive before we have 
sex" 
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56.3% (53.7-58.9%, n=773) 
Lower sexual disclosure:  
43.7% (41.1-46.3%, n=600) 
Excluding no answer for n=19. Bars and lines show prevalence and 95%CIs  
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In model 2, the following factors were candidates for inclusion in the multivariable model (p<0.10 at 
unadjusted analysis): ethnicity, time since HIV diagnosis, religion, money for basic needs, social support, 
stable partner’s HIV serostatus, ART status, and ART status/self-reported VL. ART status was excluded 
from the model as it was included in the ART status/self-reported VL variable. Hence, after adjustment 
for ethnicity, time since HIV-diagnosis, religion, money for basic needs, social support, stable partner 
status, ART status/self-reported VL, and clinic, there were no significant associations between any factor 
and non-disclosure to a stable partner (model 2: Table 7.5). It is worth noting that power was lower for 
this analysis due to the larger number of covariates included. The following factors had weak evidence 
of associations to non-disclosure to a stable partner: being religious (p=0.08), not having money for 
basic needs (p=0.07), and medium/low social support (p=0.06). 
 
There was no observed association of non-disclosure in the social circle (to friends, family, co-workers, 
and a stable partner) and psychological symptoms (as dependent variables); results of this work can be 
found in the published paper
421
 shown in Appendix VII. 
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Table 7.5: Associations of socio-demographic, psychological, HIV-, and partner-related factors with non-disclosure to a stable partner (N=1080 MSM in an 
ongoing relationship) 
 
 
Unadjusted 
PR [95%CI] p-value
Models 1
aPR [95%CI] p-value
Model 2 
aPR [95%CI] p-value
Age at recruitment, years (N=1073)
<50 1.0 1.0
≥50 1.0 [0.6,1.8] 0.948(T) 1.2 [0.6,2.2] 0.636(T) -
Ethnicity (N=1071)
White 1.0 1.0 1.0
All other (black, Asian, Mixed, other) 2.3 [1.2,4.5] 0.016 2.2 [1.1,4.2] 0.023 1.6 [0.7,3.3] 0.245
Years since HIV diagnosis  (N=1074)
<5 2.1 [1.2, 4.0] 2.0 [0.9,4.3] 2.0 [0.9,4.3]
5-10 1.1 [0.6,2.3] 1.0 [0.4,2.3] 1.0 [0.4,2.3]
>10 1.0 0.024(T) 1.0 0.062(T) 1.0 0.097(T)
Place of birth (N=1080)
UK 1.0 1.0
Outside the UK 0.7 [0.4,1.2] 0.231 1.0 [0.6,1.8] 0.886 -
Religious (N=1071)
Yes 1.0 1.0 1.0
No 0.5 [0.3,0.9] 0.027 0.6 [0.3,1.1] 0.103 0.6 [0.3,1.1] 0.078
Education (N=1065)
University degree or above 1.0 1.0 -
No qualifications or up to A levels 0.9 [0.5,1.6] 0.739 1.0 [0.6,1.8] 0.913
Employment (N=1065)
Employed 1.0 1.0
Unemployed or other (sick, carer, retired, student) 1.1 [0.6,2.1] 0.664 1.2 [0.7,2.3] 0.490 -
Money for basic needs (N=1068)
Always 1.0 1.0 1.0
Mostly/sometimes/never 2.4 [1.3,4.2] 0.004 2.3 [1.2, 4.1] 0.007 1.8 [1.0,3.4] 0.070
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Unadjusted PR 
[95%CI] p-value
Models 1
aPR [95%CI] p-value
Model 2 
aPR [95%CI] p-value
Social support (N=1072) ‡
High 1.0 1.0 1.0
Medium/low 2.1 [1.2,3.7] 0.007 2.1 [1.2,3.7] 0.016 1.8 [1.0,3.4] 0.058
Depression symptoms (N=1080) ‡
No 1.0 1.0 -
Yes 1.2 [0.6,2.4] 0.514 1.3 [0.7,2.5] 0.443
Anxiety symptoms (N=1080) ‡
No 1.0 1.0 -
Yes 1.2 [0.6,2.5] 0.578 1.3 [0.6,2.5] 0.531
Stable partner's HIV-serostatus (N=1080)
HIV-positive 1.0 1.0 1.0
HIV-negative or unknown status 1.7 [0.9,3.0] 0.097 1.5 [0.8,2.8] 0.179 1.4 [0.8,2.6] 0.254
Years in current relationship (N=1048)
≤2 1.0 1.0
2-5 1.4 [0.6,3.4] 1.4 [0.5,3.6] -
>5 1.0 [0.5,2.2] 0.822(T) 1.4 [0.6,3.3] 0.437(T)
Cohabitation with stable partner (N=1080)
No 1.0 1.0
Yes 1.2 [0.6,2.2] 0.663 1.3 [0.7,2.5] 0.488 -
ART status (N=1076)
On ART 1.0 1.0 -
Not on ART 2.0 [1.0,3.8] 0.038 1.6 [0.8,3.4] 0.211
ART status/self-reported VL (N=939)
On ART, reports undetectable VL 1.0 1.0 1.0
On ART, does not report undetectable viral load † 1.4 [0.6,3.3] 1.4 [0.6,3.3] 1.3 [0.5,3.2]
Not on ART 2.2 [1.1,4.2] 0.070 1.8 [0.8,3.9] 0.356 1.7 [0.8,3.8] 0.429
Global p-values by Wald test or test for trend(T); †Self-reported viral load (VL)>50c/mL or "don't know"; PR: prevalence ratio; CI: confidence interval; 
adjusted PRs (aPR) by modified Poisson regression models; Models 1:  Each factor adjusted in separate model for 'core' variables: age, ethnicity, time 
since HIV diagnosis, stable partner's HIV serostatus, and ART status. Denominators vary due to missing data in each model; Model 2: Any factor with 
p<0.10 in unadjusted analysis included in a single model, plus clinic. In both cases, model for 'ART status/self-reported VL' omits variable on ART due to 
collinearity. ‡ For variable definitions refer to section 3.8
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7.4.2.2 Socio-demographic, psychological, HIV-related factors associated with lower 
sexual disclosure 
Associations of various factors with lower sexual disclosure were assessed among 1373 MSM who 
reported anal or vaginal sex in the past three months and had available disclosure information. (Table 
7.6)  In unadjusted analysis, lower sexual disclosure was more prevalent among MSM who were older 
(≥50 years), not born in the UK, had higher educational attainment, always had money for basic needs, 
had medium/low social support, had an HIV-serodifferent stable partner or no stable partner, and 
reported undetectable VL on ART.(all p<0.10, Table 7.6) 
 
After core adjustment (models 1: Table 7.6) the following factors remained associated with lower sexual 
disclosure (p<0.05), with minor attenuation of estimates: non-white ethnicity, non-UK place of birth, 
university degree or higher, always having money for basic needs, having an HIV-serodifferent or no 
stable partner, and reporting undetectable VL on ART.  
 
In model 2, any factor with p<0.10 at unadjusted analysis was a candidate for inclusion in the 
multivariable model, in addition to clinic. These were: age, ethnicity, place of birth, education, money 
for basic needs, social support, stable partner status, and knowledge of personal VL. Ethnicity and place 
of birth were strongly correlated so the latter was excluded from the model; this was done as place of 
birth may not distinguish between ethnic groups, thus aggregating the underlying diversity in race, 
culture, and religion, which may be of particular relevance to non-disclosure. Hence, after adjustment 
for age, ethnicity, education, money for basic needs, social support, stable partner status, ART 
status/self-reported VL, and clinic, there was no longer a significant trend association with younger age 
(p>0.05). There was some suggestion of weak associations of non-white ethnicity (p=0.08), medium/low 
social support (p=0.06), and lower sexual disclosure. (model 2: Table 7.6) Lower sexual disclosure 
remained significantly more prevalent among MSM with a university degree or higher, who always had 
money for basic needs, had an HIV-serodifferent partner or no stable partner, and those who reported 
undetectable VL on ART (all p<0.05).  
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Table 7.6: Associations of socio-demographic, psychological, HIV-related factors with lower sexual disclosure (N=1373 MSM had anal or vaginal sex in past 
three months) 
 
 
n low sexual 
disclosure/ N row %
unadjusted PR 
[95%CI] p-value
Models 1: aPR 
[95%CI] p-value
Model 2: aPR 
[95%CI] p-value
Age at recruitment, years (N=1358)
<30 37/87 42.5 1.0 1.0 1.0
30-39 154/371 41.5 1.0 [0.7,1.3] 1.0 [0.7,1.3] 0.8 [0.6,1.1]
40-49 236/562 42.0 1.0 [0.8,1.3] 1.0 [0.7,1.3] 0.9 [0.7,1.2]
≥50 165/338 48.8 1.1 [0.9,1.5] 0.090(T) 1.1 [0.8,1.5] 0.158(T) 1.0 [0.8,1.3] 0.168(T)
Ethnicity (N=1350)
White 515/1205 42.7 1.0 1.0 1.0
All other (black, Asian, Mixed, other) 75/145 51.7 1.2 [1.0,1.4] 0.028 1.2 [1.0,1.4] 0.054 1.2 [1.0,1.4] 0.085
Years since HIV diagnosis  (N=1369)
≤2 54/132 40.9 1.0 1.0
2-5 107/251 42.6 1.0 [0.8,1.3] 1.0 [0.8,1.3] -
5-10 161/375 42.9 1.0 [0.8,1.3] 1.0 [0.8,1.3]
10-15 124/271 45.8 1.1 [0.9,1.4] 1.1 [0.8,1.4]
>15 153/340 45.0 1.1 [0.9,1.4] 0.306(T) 1.0 [0.8,1.3] 0.944(T)
Place of birth (N=1373)
UK 373/920 40.5 1.0 1.0 -
Outside the UK 227/453 50.1 1.2 [1.1,1.3] 0.001 1.2 [1.1,1.4] <0.001
Religious (N=1349)
Yes 244/555 44.0 1.0 1.0 -
No 343/794 43.2 1.0 [0.9,1.1] 0.780 0.8 [0.7,0.9] 0.776
Education (N=1353)
University degree or above 323/629 51.4 1.0 1.0 1.0
No qualifications or up to A levels 268/724 37.0 0.7 [0.6,0.8] <0.001 0.7 [0.6,0.8] <0.001 0.8 [0.7,0.9] <0.001
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n low sexual 
disclosure/ N row %
unadjusted PR 
[95%CI] p-value
Models 1: aPR 
[95%CI] p-value
Model 2: aPR 
[95%CI] p-value
Employment (N=1346)
Employed 406/917 44.3 1.0 1.0
Unemployed or other (sick, carer, student, retired)183/436 42.0 0.9 [0.8,1.1] 0.428 0.9 [0.8,1.0] 0.158 -
Money for basic needs (N=1352)
Always 356/733 48.6 1.0 1.0 1.0
Mostly 142/361 39.3 0.8 [0.7,0.9] 0.8 [0.7,0.9] 0.8 [0.7,1.0]
Sometimes/never 93/258 36.0 0.7 [0.6,0.9] <0.001(T) 0.7 [0.6,0.9] <0.001(T) 0.8 [0.6,0.9] 0.002(T)
Social support (N=1367) ‡
High 354/844 41.9 1.0 1.0 1.0
Medium/low 243/523 46.5 1.1 [1.0,1.3] 0.099 1.1 [0.9,1.2] 0.344 1.1 [1.0,1.3] 0.061
Depression symptoms (N=1373) ‡
No 461/1035 44.5 1.0 1.0 -
Yes 139/338 41.1 0.9 [0.8,1.1] 0.279 0.9 [0.8,1.0] 0.105
Anxiety symptoms (N=1373) ‡
No 491/1110 44.2 1.0 1.0 -
Yes 109/263 41.4 0.9 [0.8,1.1] 0.420 0.9 [0.8,1.1] 0.235
Stable partner's HIV-serostatus (N=1373)
HIV-positive 130/386 33.7 1.0 1.0 1.0
HIV-negative or unknown status 205/430 47.7 1.4 [1.2,1.7] 1.4 [1.2,1.7] 1.4 [1.2,1.6]
No stable partner 265/557 47.6 1.4 [1.2,1.7] <0.001 1.4 [1.2,1.6] <0.001 1.3 [1.1,1.6] <0.001
ART status (N=1369)
On ART 512/1152 44.4 1.0 1.0 -
Not on ART 87/217 40.1 0.9 [0.8,1.1] 0.249 0.9 [0.7,1.1] 0.312
ART status/self-reported VL (N=1352)
On ART, reports undetectable VL 450/966 46.6 1.0 1.0 1.0
On ART, does not report undetectable VL † 56/169 33.1 0.7 [0.6,0.9] 0.7 [0.6,0.9] 0.8 [0.6,1.0]
Not on ART 87/217 40.1 0.9 [0.7,1.0] 0.005 0.8 [0.7,1.0] 0.006 0.8 [0.7,1.0] 0.026
Global p-values by Wald test or test for trend(T); PR: prevalence ratio; CI: confidence interval; †Self-reported viral load (VL)>50c/mL or "don't know"; Adjusted PRs (aPR) by modified Poisson 
regression models: Models 1:  Each factor adjusted in separate model for core factors. Denominators vary due to missing data in each model. Model 2:  Any factor with p<0.10 in unadjusted 
analysis included in a single model, in addition to clinic.In both cases, model for 'ART status/self-reported VL' omits variable on ART due to collinearity.  ‡ For variable definitions refer to 
section 3.8
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7.4.2.3 Lifestyle factors associated with lower sexual non-disclosure  
There was weak evidence of an association of alcohol dependency (by CAGE) and lower sexual 
disclosure (Table 7.7). No significant differences were observed between other lifestyle factors (drug 
and polydrug use in the past three months, higher alcohol consumption) and prevalence of lower sexual 
disclosure.  
Table 7.7: Association of lifestyle factors with lower sexual disclosure (N=1373 MSM 
reporting anal or vaginal sex in the past three months) 
 
 Associations of non-disclosure and sexual behaviours  7.4.3
7.4.3.1 Non-disclosure to a stable partner and CLS-D  
Among 1080 MSM in an ongoing relationship, 192 (17.8%) had any CLS-D in the past three months, of 
whom 172 (89.6%) provided information on CLS-D specifically with the stable partner; 71 (41.3%) had 
CLS-D with their stable partner only, 17 (9.9%) had CLS-D with their stable partner and other casual 
partners, and 84 (48.9%) only had CLS-D with casual partners but not their stable partner. Due to limited 
sample size it was not possible to perform significance tests. 
7.4.3.2 Association of lower sexual disclosure and sexual behaviours  
Among 1373 MSM who reported any anal or vaginal sex in the past three months and provided 
information on sexual disclosure, the prevalence of lower sexual disclosure was examined according to 
sexual behaviours in the past three months (or in the past year).(Table 7.8) Any CLS and CLS-C were 
more prevalent among those with higher sexual disclosure, while CLS-D, group sex, use of the internet 
to find sex in the past three months, and ≥10 new sexual partners in the past year were more prevalent 
among those with lower sexual disclosure (p<0.05 for all, Table 7.8). There was no significant association 
of lower sexual disclosure with higher HIV risk CLS-D or other STIs in the past three months. 
 
The pattern of associations remained after adjustment for core factors.(Figure 7.2) The prevalence of 
any CLS was 20% lower among MSM with lower sexual disclosure compared to those with higher sexual 
  
n lower 
sexual 
disclosure/N row % 
unadjusted 
PR [95%CI] p-value 
aPR 
[95%CI] p-value  
Recreational drug use (N=1373)           
No 231/516 44.8 1.0 
 
1.0   
Yes 369/857 43.1 1.0 [0.9,1.1] 0.535 1.0 [0.9,1.1] 0.931 
Polydrug use (N=857) 
     
  
1-3 drugs 241/545 44.2 1.0 
 
1.0   
≥4  drugs 128/312 41.0 0.9 [0.8,1.1] 0.368 1.0 [0.8,1.2] 0.785 
Higher alcohol consumption (WHO AUDIT-C‡) (N=1373)       
No 486/1137 42.7 1.0 
 
1.0   
Yes 114/236 48.3 1.1 [1.0,1.3] 0.106 1.1 [1.0,1.3] 0.131 
Evidence of alcohol dependency (CAGE◊) (N=1372) 
   
  
No 473/1111 42.6 1.0 
 
1.0   
Yes 127/261 48.7 1.1 [1.0,1.3] 0.066 1.1 [1.0,1.3] 0.096 
p-values by Wald test; ‡ Modified WHO-AUDIT-C score ≥6; ◊ CAGE score ≥2; PR; prevalence ratios by modified 
Poisson regression; aPR; adjusted PRs for core factors (age, ethnicity, time since HIV diagnosis, stable partner 
status, ART status) 
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disclosure (PR=0.8, 95%CI 0.8-0.9), but this differed by type of CLS. Compared to MSM with higher 
sexual disclosure, MSM with lower sexual disclosure had 30% lower prevalence of CLS-C (PR=0.7, 0.6-
0.8), and 30% higher prevalence of CLS-D (PR=1.3, 1.1-1.6) in the past three months. The prevalence of 
group sex in the past three months and high new partner numbers in the past year was also significantly 
higher among MSM with lower sexual disclosure (p<0.05 for both). There was a weak association of 
lower sexual disclosure and using the internet to find sex (p=0.07). As with univariable analysis, no 
significant association was observed of lower sexual disclosure with other STIs and higher HIV risk CLS-D 
(the latter model does not include adjustment for ART status).  
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Table 7.8: Prevalence of lower sexual disclosure according to sexual behaviours‡ (N=1373 MSM had anal or vaginal sex in the past three months) 
 
‡ Sexual behaviours defined in section 3.8.4
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Sexual disclosure
Higher 511/773 (66.1) 416/773 (53.8) 169/773 (21.9) 50/773 (6.5) 114/766 (14.9) 212/766 (27.7) 371/765 (48.5) 252/773 (32.6)
Lower 313/600 (52.2) 204/600 (34.0) 180/600 (30.0) 40/600 (6.7) 87/594 (14.6) 213/593 (35.9) 326/595 (54.8) 273/600 (45.5)
p-value 
STI Group sex 
Higher HIV 
risk CLS-D
Three month recall of sexual behaviours unless otherwise specified. P-values by chi-squared test; CLS: condomless sex; CLS-C: condomless sex 
with HIV-seroconcordant partners; CLS-D: condomless sex with HIV-serodifferent partners; Higher HIV risk CLS-D: CLS-D plus not on ART or 
VL>50c/mL; STI: sexually transmitted infection. CLS-D includes n=31 MSM who reported CLS but did not specify partner's HIV-serostatus 
0.883
Used the 
internet to find 
sex
≥10 new 
partners in the 
past year
<0.001 0.001<0.001 0.903 <0.001 0.021 <0.001
Any 
condomless sex 
(CLS)
CLS-DCLS-C
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Figure 7.2: Unadjusted and adjusted associations of lower sexual disclosure and sexual 
behaviours‡ (N=1373 MSM had any anal or vaginal sex in the past three months)  
 
Prevalence Ratios [95%CI] by modified Poisson regression. Reference group is higher sexual disclosure. 
Three month recall unless otherwise specified. CLS-C: CLS with HIV-seroconcordant partner; CLS-D: CLS 
with HIV-serodifferent partner; Higher HIV risk CLS-D: CLS-D plus either not on ART or latest VL>50c/mL; 
STI: sexually transmitted infection; Multivariable models include (in addition to sexual disclosure 
variable) adjustment for core factors: age, ethnicity, time since HIV diagnosis, stable partner status, ART 
status. Model for higher HIV risk CLS-D excludes ART status. ‡All sexual behaviours defined in section 
3.8.4 
Any condomless sex (CLS)
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
CLS-C
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
CLS-D
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
Higher HIV risk CLS-D
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
STI
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
Had group sex
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
Used internet to find sex
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
>=10 new sexual partners in past year
Higher sexual disclosure
Lower sexual disclosure(unadjusted)
Lower sexual disclosure (adjusted)
name
Parameter
<0.001
<0.001
<0.001
<0.001
0.001
0.006
0.883
0.459
0.903
0.732
0.001
0.003
0.021
0.072
<0.001
<0.001
p-value
  10.5 2
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7.4.3.3 Association of lower sexual disclosure and the three-category variable of 
sexual behaviour  
In this analysis, all 1373 MSM who reported any anal or vaginal sex and provided information on sexual 
disclosure were classified into one of the following mutually exclusive groups of sexual behaviour in the 
past three months (as described in section 4.3.6.3).  
1. CLS-D (n=349)  
2. ‘CLS-C without CLS-D’ (n=476)  
3. Condom-protected sex only (n=548) 
The prevalence of lower sexual disclosure was 51.6% among MSM in the CLS-D group (n=180), 27.9% in 
the ‘CLS-C without CLS-D’ group (n=133), and 52.0% in the condom-protected group (n=285). 
Unadjusted and adjusted (for core factors) multinomial logistic regression was used to examine the 
effect of lower sexual disclosure on reporting CLS, using the above three mutually exclusive groups. 
Relative to MSM who had condom-protected sex, MSM with lower sexual disclosure were significantly 
less likely to have ‘CLS-C without CLS-D’ (p<0.001, Table 7.9). Meaning, that disclosure of HIV-serostatus 
was highest with other HIV-positive partners. There was no significant association between lower sexual 
disclosure and reporting CLS-D relative to condom-protected sex. This difference in results compared to 
the previous analysis for CLS-D, is that in that previous analysis, the ‘no CLS-D’ group included men who 
had ‘CLS-C without CLS-D’, resulting in a group with higher levels of disclosure compared to those having 
CLS-D. Here it can be seen that levels of disclosure were similar in the ‘condom-protected sex’ and ‘CLS-
D’ groups. 
 
Table 7.9: Associations of lower sexual disclosure and sexual behaviours in past three 
months (N=1373 MSM who reported any anal or vaginal sex). 
 
 Sensitivity analyses 7.4.4
In the first sensitivity analysis, associations of lower sexual disclosure and sexual behaviours in the past 
three months were examined using modified Poisson regression adjusted for age, ethnicity, time since 
HIV diagnosis, partner status, and ART status/self-reported VL (rather than ART status). This was done as 
there was a significant association of self-reported undetectable VL on ART and lower sexual disclosure 
(Table 7.6). The magnitude of associations was similar to those observed in the core-adjusted model; 
Sexual disclosure
unadjusted 
OR [95%CI]
adjusted 
OR [95%CI]
unadjusted 
OR [95%CI]
adjusted 
OR [95%CI]
Higher 1.0 1.0 1.0 1.0
Lower 0.4 [0.3,0.5] 0.4 [0.3,0.5] 1.0 [0.8,1.3] 1.0 [0.8,1.3]
p-value <0.001 <0.001 0.900 0.991
'CLS-C without CLS-D' 
(n=476)
CLS-D (n=349)
Odds Ratios [95%CIs] by multinomial logistic regression; Mutually exclusive 
categories of sexual behaviour in the past three months. Ref.: reference(baseline) 
group. Adjustment for 'core' factors: age, ethnicity, time since HIV diagnosis, stable 
partner status, ART status.
Condom-
protected 
sex (n=548)
ref
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lower sexual disclosure was significantly associated with lower prevalence of any CLS and CLS-C, and 
with higher prevalence of CLS-D, group sex, and higher new partner numbers.(Figure 7.3) There was no 
significant association of lower sexual disclosure with STIs, use of the internet to find sex, or higher HIV 
risk CLS-D (this model included adjustment for self-reported VL but not ART status, see 7.3.6).  
 
Figure 7.3: Sensitivity analysis 1: Association of lower sexual disclosure and sexual 
behaviours‡, additionally adjusted for ART status/self-reported viral load (VL) (N=1373 MSM 
had anal or vaginal sex in past three months) 
 
Three month recall unless otherwise specified. Prevalence Ratios [95%CI] by modified Poisson regression 
adjusted for age, ethnicity, time since HIV diagnosis, stable partner status, ART status/self-reported VL; 
Model for higher HIV risk CLS-D excludes ART status (adjusted for all other factors and self-reported VL 
only); CLS-C: CLS with HIV-seroconcordant partner; CLS-D: CLS with HIV-serodifferent partner; STI: 
sexually transmitted infection; ‡All sexual behaviours defined in section 3.8.4 
 
In the second sensitivity analysis, the sexual disclosure variable was re-categorised to include the middle 
group (‘undecided/no opinion/not relevant to me’ in the statement “I'd expect to tell a new partner that 
I'm HIV-positive"). Associations were examined between the three categories of sexual disclosure 
(higher, undecided, lower sexual disclosure) and sexual behaviours, among 1373 MSM who had anal or 
vaginal sex in the past three months.(Figure 7.4) The pattern of associations was similar to analyses 
Any condomless sex (CLS)
Higher sexual disclosure
Lower sexual disclosure
CLS-C
Higher sexual disclosure
Lower sexual disclosure
CLS-D
Higher sexual disclosure
Lower sexual disclosure
Higher HIV risk CLS-D
Higher sexual disclosure
Lower sexual disclosure
STI
Higher sexual disclosure
Lower sexual disclosure
Had group sex
Higher sexual disclosure
Lower sexual disclosure
Used internet to find sex
Higher sexual disclosure
Lower sexual disclosure
>=10 new sexual partners in past year
Higher sexual disclosure
Lower sexual disclosure
<0.001
<0.001
0.009
0.185
0.622
0.006
0.121
<0.001
p-value
  
1 2 30.5
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using the binary sexual disclosure categorisation (see Figure 7.2). In terms of CLS variables, the 
‘undecided’ group were similar to the lower disclosure group. MSM who were undecided or had lower 
sexual disclosure were less likely to report any CLS and CLS-C, and more likely to report CLS-D compared 
to MSM with higher sexual disclosure (p<0.05 for all). MSM with lower sexual disclosure were 
significantly more likely to have group sex (PR=1.4, 95%CI 1.2-1.6), use the internet to find sex (1.2, 1.1-
1.3), and have higher partner numbers (1.5, 1.3-1.8) compared to those with higher sexual disclosure; 
however, those who were undecided on sexual disclosure did not have significantly higher prevalence of 
these three behaviours compared to MSM with higher sexual disclosure (group sex: PR=1.1, 0.9-1.4; 
internet to find sex:1.0, 0.8-1.2; ≥10 new partners: 1.1, 0.9-1.4). There was no significant association of 
sexual disclosure and higher HIV risk CLS-D or other STIs (p>0.05 for both).  
 
In the final sensitivity analysis, the aim was to examine the magnitude of associations between lower 
sexual disclosure and sexual behaviours using logistic regression to derive odds ratios (ORs), rather than 
prevalence ratios.(Figure 7.5) Using this plot, it is possible compare the magnitude of associations 
between the different sexual behaviour measures. Lower sexual disclosure was most strongly associated 
with lower prevalence of CLS-C; it was also more strongly associated with higher prevalence of ≥10 new 
sex partners, than it was with CLS-D and group sex.   
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Figure 7.4: Sensitivity analysis 2: Adjusted associations of sexual disclosure (three categories) 
and sexual behaviours‡ (N=1373 MSM had any anal or vaginal sex in past three months) 
Three month recall unless otherwise specified. Prevalence ratios [95%CIs] by modified Poisson regression 
adjusted for core factors. Model for higher HIV risk CLS-D excludes ART status. Showing level of 
agreement to statement “I’d expect to tell a new partner that I’m HIV-positive before we have sex”: 
higher sexual disclosure (‘strongly or tend to agree’), undecided (‘no opinion/not relevant to me’), and 
lower sexual disclosure (‘tend to or strongly disagree’); CLS-C: CLS with HIV-seroconcordant partner; CLS-
D: CLS with HIV-serodifferent partner; Higher HIV risk CLS-D: CLS-D plus not on ART or latest study-log 
VL>50c/mL; STI: sexually transmitted infection; ‡ All sexual behaviours defined in section 3.8.4 
 
 
Any condomless sex (CLS)
Higher sexual disclosure
Undecided
Lower sexual disclosure
CLS-C
Higher sexual disclosure
Undecided
Lower sexual disclosure
CLS-D
Higher sexual disclosure
Undecided
Lower sexual disclosure
Higher HIV risk CLS-D
Higher sexual disclosure
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Lower sexual disclosure
Diagnosed STI
Higher sexual disclosure
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Used internet to find sex
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n/N
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54.1
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Figure 7.5: Sensitivity analysis 3: Odds ratios [95%CIs] for the association of lower sexual 
disclosure and sexual behaviours‡ (N=1373 MSM had anal or vaginal sex) 
 
Three month recall unless otherwise specified. Odds ratios [95%CI] by logistic regression adjusted for 
core factors; Model for higher HIV risk CLS-D excludes ART status. CLS-C: CLS with HIV-seroconcordant 
partner; CLS-D: CLS with HIV-serodifferent partner; STI: sexually transmitted infection; ‡ All sexual 
behaviours defined in section 3.8.4 
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CLS-D
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Used internet to find sex
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0.005
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7.5 Discussion 
 Summary of findings 7.5.1
Among 2240 HIV-diagnosed MSM participating in the ASTRA study, a small minority of participants 
(approximately 5%) had not disclosed their HIV-serostatus to anyone. Of MSM in an ongoing 
relationship, a similar proportion had not disclosed to their stable partner. Among MSM who reported 
sex in the past three months, a much higher proportion (almost 44%) were classified as having lower 
sexual disclosure to new sex partners, which included 11% who stated strong disagreement with the 
statement on HIV-serostatus disclosure to a new sexual partner. There was some indication that more 
recent diagnosis, non-white ethnicity, higher financial hardship, and lower social support were 
associated with higher prevalence of non-disclosure to a stable partner. On the other hand, higher 
socio-economic status (university education, no financial hardship) was associated with lower sexual 
disclosure. Non-UK place of birth and having an HIV-serodifferent or no stable partner were also 
associated with lower sexual disclosure. In addition, MSM who were on ART with self-reported 
suppressed VL had lower sexual disclosure than those who were on ART without self-reported 
suppressed VL and those not on ART. Recreational drug use and alcohol misuse were not associated 
with lower sexual disclosure. Higher sexual disclosure was also more prevalent among MSM who had 
CLS compared to those who did not, but this differed by the HIV-serostatus of the sexual partner(s). 
Compared to MSM with higher sexual disclosure, those with lower sexual disclosure had lower 
prevalence of CLS-C (compared to no CLS-C), and higher prevalence of CLS-D (compared to no CLS-D), 
group sex, and high partner numbers. Consideration of the mutually exclusive sexual behaviour variable 
demonstrated that levels of sexual disclosure were similar among MSM who had condom-protected sex 
and those who had CLS-D, but sexual disclosure was greater among those who had ‘CLS-C without CLS-
D’.  
 Prevalence of non-disclosure of HIV-serostatus among MSM 7.5.2
Prevalence of non-disclosure in ASTRA was comparable to estimates from the earlier ‘East London’
394
 
(2004-2005) and Switching
114,133
 (2005-2006) studies of UK HIV-diagnosed clinic attendees, as well as the 
more recent ‘Young MSM of Color Initiative’
386
 (2006-2009) from the USA (all ≤5%, see Table 7.1). These 
studies used similar constructs of non-disclosure as in ASTRA. Non-disclosure was higher towards family 
than towards friends in ASTRA; this finding was corroborated in the ‘East London’ study
394
, but not in 
the ‘Young MSM of Color Initiative’, for whom the prevalence of non-disclosure to friends was higher 
than to family.
386
  
 
The majority of employed participants had not disclosed to any co-workers (54%). Discrimination against 
people living with HIV in the workplace is unlawful in the UK.
422
 However, the high prevalence of non-
disclosure to work colleagues in this sample may be influenced by prevailing fear of harassment and 
breach of privacy. It may also reflect personal choice regarding disclosure confidants. There is a need for 
employers to enact clear policies, which demonstrate commitment to confidentiality and non-
discrimination of HIV-diagnosed employees.  
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The prevalence of non-disclosure to a stable partner in ASTRA MSM (4.8%) was overall lower than that 
found in earlier studies (see Table 7.2), with the exception of the French ANRS-VESPA1; this nationally 
representative cross-sectional survey found that 4.5% of MSM had not disclosed to their regular HIV-
serodifferent partner.
229
 In the ‘East London’ study
394
, 14% of MSM had not disclosed to their stable 
partner, but there have not been other comparable UK studies since on this subject. In addition, 
prevalence estimates may differ because of diverse definitions used for the concept of a stable 
partner
423
; this could refer to a partner with whom the participant has regular sex
229
, a main partner 
among other casual partners
408
, a monogamous long-term partner
195,394
, or a current partner with whom 
the participant had sex during a specific recall period.
177,404
 The way these concepts are explained to 
survey participants also affects responses.
423
 In certain studies, colloquial terms are used (e.g. 
“boyfriend”, “lover”)
233,386,411
 while in others, as in ASTRA, an explanation is provided to differentiate 
between partner types.
195,424
 Some studies do not provide any description apart from a single term (e.g. 
“main partner” or “in a relationship”).
103,304,408
 In ASTRA, it was not possible to ascertain whether 
disclosure was specifically to a stable partner (phrased as “I have told a partner/wife/husband”), 
therefore prevalence of non-disclosure to the current stable may have been underestimated. However, 
restricting answers to MSM who were in an ongoing relationship aimed to increase the sensitivity of this 
non-disclosure measure.  
 Factors associated with non-disclosure to a stable partner 7.5.3
There was no evidence of a significant association between participants’ age and non-disclosure to a 
stable partner. In the ‘East London’ study, older age (>60 years) was significantly associated with higher 
prevalence of non-disclosure to parents but not to a stable partner.
394
 It is possible that older MSM 
experience or perceive a greater level of stigma surrounding HIV disclosure than younger people, but 
this may be less relevant in the context of an ongoing relationship with a partner. On the other hand, 
older people may feel more able to manage HIV without the need to tell others.  
 
Non-disclosure to a stable partner was highest among MSM of black, Asian, Mixed, or other (non-white) 
ethnicity compared to white MSM. This finding may reflect cultural and structural drivers of non-
disclosure among ethnic minority MSM who may experience perceived and actual stigma.
394
 Attention 
should be directed to groups with highest non-disclosure so as to better understand circumstances that 
encourage or discourage it.  
 
Shorter time since HIV diagnosis tended to be associated with greater non-disclosure to a stable partner, 
even among MSM in this analysis (who were diagnosed with HIV for at least three months). A 
comparable finding was observed in the ‘Healthy Living Project’ of 1828 HIV-diagnosed MSM in the USA 
(Table 7.2), in which the odds of non-disclosure to all partners (including main and casual) were higher 
among MSM who were diagnosed for under 5 years.
408
 In the ‘Young MSM of Color Initiative’
386
 there 
was no evidence of a significant difference in prevalence of disclosure to stable partners among those 
who were newly diagnosed and those re-engaged in HIV care at baseline; there was weak evidence that 
disclosure to steady partners increased by 20% at six months follow-up (p=0.06). Disclosure of HIV 
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status may thus be a gradual process, whereby a newly-diagnosed individual may take time to adjust to 
their diagnosis and prepare to tell others; this may apply even for close relationships. These findings 
highlight the need for health facilities to provide a supportive context as soon as possible after 
diagnosis, and to assist individuals in building communication skills, coping strategies, and in mobilizing 
support for those who need it.  
 
In terms of socio-economic factors, although education and employment status were not associated 
with non-disclosure to a stable partner, financial hardship was associated with non-disclosure. MSM 
who  reported not having money for basic needs or who had money only “most” or “some” of the time 
had significantly higher prevalence of non-disclosure to a stable partner compared to those who always 
had money  (p=0.002 for “no/most/sometimes” versus “yes, all of the time”). This was independent of 
the effect of non-white ethnicity. 
 
While HIV status disclosure has been seen as an important step towards enhancing mental health 
through increased social support,
425
 evidence remains mixed; the majority of results stem from 
heterosexual HIV-diagnosed populations reporting on overall non-disclosure (to friends and 
family).
394,395,398,426
 Evidence on the association between social support, measures of mental health 
status, and disclosure to a stable partner is scarce. In ASTRA, there was evidence that medium or low 
functional social support was associated with higher prevalence of non-disclosure to a stable partner. 
There was no significant association of depression or anxiety symptoms with non-disclosure to a stable 
partner. In the ‘East London’ study, MSM who had suicidal thoughts had higher odds of non-disclosure 
to their current partner; the effect was significant only for white compared to ethnic minority MSM.
394
 
Any association between depression, anxiety and non-disclosure may be mediated by low social 
support
236
 and be bidirectional; pre-existing symptoms of poorer mental health and low social support 
may discourage HIV-serostatus disclosure to a stable partner, or it may be that non-disclosure creates 
feelings of isolation, decreased peer social support, and more mental health symptoms.  
 
In ASTRA, non-disclosure to a stable partner was independently associated with the current partner’s 
unknown HIV serostatus, consistent with earlier studies of HIV clinic attendees from the UK
412
 and the 
USA.
408
 Participants who did not know their stable partner’s HIV-serostatus were more likely to have not 
disclosed their own serostatus, which may reflect the dynamics of mutual disclosure. HIV-diagnosed 
MSM may be more likely to disclose to a stable partner who is also HIV-positive as the fear of rejection 
may be lower.
381
 Research on the association between relationship-related factors (such as length of 
time in the relationship, cohabitation) and non-disclosure to a stable partner among MSM is scarce; no 
association was found in ASTRA or in the ‘East London’ study.
394
 
 
Although ASTRA MSM not on ART tended to have higher levels of non-disclosure to a stable partner, this 
association was largely explained by shorter time since HIV diagnosis; results were not significant in 
multivariable models. There was some evidence that men who reported undetectable  VL were more 
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likely to disclose to a stable partner (compared to those who did not report undetectable VL and those 
not on ART) after adjustment for ethnicity, time since HIV diagnosis, and partner’s HIV serostatus. A 
detectable or unknown VL level may be an indicator of lack of engagement in medical care, or could 
possibly suggest denial or avoidance of HIV-status, which may be closely linked to non-disclosure to a 
partner.                                                                         
 Non-disclosure to a stable partner and sexual behaviours 7.5.4
There were no significant associations of non-disclosure to a stable partner with any sexual behaviour in 
the past three months or in the past year, although there was low power to examine these associations. 
Although there was some evidence to suggest that MSM who had not disclosed to their stable partner 
were more likely to have CLS-C compared to those who disclosed, this association was not significant 
after adjustment for partner’s HIV serostatus. Similarly, MSM who had not disclosed were less likely to 
have high partner turnover (10 or more new sexual partners) in the past year compared to those who 
disclosed, however this association did not reach significance.  
 
Disclosure does not necessarily lead to safer sexual behaviour but could inform choice in type of sex 
within and outside of a stable relationship. Couples’ HIV testing and counselling, whereby two people 
planning to be in a sexual relationship receive HIV testing together, has been shown to facilitate mutual 
disclosure of serostatus and is associated with a reduction in sex with outside partners and lower 
prevalence of CLS.
427
  
 Prevalence of lower sexual disclosure 7.5.5
This study used level of agreement to the statement “I’d expect to tell a new partner that I’m HIV-
positive before we have sex” as a proxy for lower sexual disclosure. Overall, almost 44% were classified 
as having lower sexual disclosure. The prevalence of non-disclosure to casual sex partners ranges widely 
according to the population sampled and the question posed to participants. For example, in the Dutch 
hospitals study (see Table 7.3), almost 60% of HIV-diagnosed MSM attending for care reported that they 
‘never’ or ‘rarely’ disclosed to casual sex partners in the past six months
201
, compared to 34% of MSM 
recruited from the largest HIV clinic in Dublin (‘never’ disclosed to casual partners in past six months).
390
 
The lowest prevalence estimate was reported in HOPS, whereby 9.2% of MSM who had any sex in the 
past six months had not disclosed to ‘any sexual partners’.
241
 The wide range of prevalence estimates 
observed is likely due to varying definitions of non-disclosure behaviour and attitudes (number or 
proportion of partners disclosed to over period of time versus intent to disclose to future partners) as 
well as classifications of casual partners (any sex partner including stable, new sex partners, or casual 
but recurring sex partner).   
 Factors associated with lower sexual disclosure  7.5.6
There was no evidence of an association of age and lower sexual disclosure. Results from previous 
studies are mixed. In the Dublin HIV clinic study (n=84 MSM) older age was associated with higher odds 
of not disclosing to casual partners compared to sometimes or always disclosing (adjusted for gay 
community attachment, HIV-related optimism, and number of partners).
390
 On the other hand, there 
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was no evidence of a significant association between age and non-disclosure to casual partners in the 
SUMIT baseline survey
199
 or in Positive Connections
418
 studies from the US. Results similar to those 
observed in ASTRA were evident in the baseline assessment of a US RCT aiming to assist MSM in 
disclosing to casual sex partners (2009-2014).
392
 This study of 340 HIV-diagnosed MSM recruited via 
community venues and websites assessed agreement to the statement ‘‘I plan to tell my future sexual 
partners with whom I have anal sex without a condom about my HIV status’’ on a four-point Likert scale. 
The majority of MSM agreed to the statement and no evidence of an association with age was 
observed.
392
  
 
Socio-demographic factors emerged as independent correlates of lower sexual disclosure in this study, 
but the pattern of associations tended to be opposite to that seen for disclosure to a stable partner. 
MSM who were more educated (university degree versus none or up to A levels) and those who always 
had money for basic needs (versus not always) were more likely to have lower sexual disclosure. This is 
in contrast to results from SUMIT and Positive Connections, in which no association was observed 
between education, income, and non-disclosure to casual sex partners in the past three months.
199,418
 
 
Levels of sexual disclosure were highest among MSM with an HIV-positive stable partner, lower among 
those with an HIV-negative or HIV-unknown serostatus stable partner, and were lowest for MSM who 
did not have a stable partner. This association remained significant after adjustment for socio-
demographic and HIV-related factors. This may be explained by the fact that MSM with HIV-positive 
stable partners are more likely to disclose to their stable partner, and therefore consider a higher 
likelihood of disclosure to a new sexual partner. Possibly, this may also be influenced by a positive 
experience of mutual disclosure. Although it was not possible to examine attitudes towards non-
disclosure to new sex partner by casual partners’ HIV-serostatus, these findings are in line with the 
baseline survey of the US ‘SafeTalk’ trial (n=138 MSM),
407
 which showed that disclosure was highest to 
other HIV-positive partners, lower towards HIV-negative partners, and was lowest towards HIV-
unknown status casual partners.  
 
Additionally, there was an association of self-reported undetectable VL and lower prevalence of 
disclosure to new sex partners, which was not attenuated by adjustment for core socio-demographic 
factors. This finding may suggest that HIV-diagnosed MSM with perceived undetectable VL were more 
likely to consider HIV-serostatus disclosure as not necessary due to their low HIV infectiousness. This 
also provides further evidence that knowledge of VL status may influence sexual attitudes and 
behaviour, an effect which may become more apparent with increasing awareness of the impact of ART 
on infectiousness. To date, no other observational studies have reported on this association. The only 
other information comes from a US mathematical probability model (based on 164 MSM, see section 
7.2.2.3) evaluating effectiveness of disclosure in reducing the risk of HIV transmission, which found no 
association between self-reported VL and non-disclosure to casual sex partners.
416
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 Lower sexual disclosure and sexual behaviours 7.5.7
MSM with higher sexual disclosure were significantly more likely to have CLS overall and CLS-C. 
However, those with lower sexual disclosure were more likely to have CLS-D, group sex, and high partner 
numbers compared to those with higher sexual disclosure. These findings reflect the dynamics of mutual 
disclosure between HIV-positive partners and also indicate that higher disclosure is linked to possible 
HIV-serosorting. In fact, use of the mutually exclusive categories of sexual behaviour further provided 
evidence that levels of disclosure to sexual partners were significantly associated with having ‘CLS-C 
without CLS-D’, which could indicate HIV-serosorting. In addition, the association of lower sexual 
disclosure and higher prevalence of CLS-D may reflect the perception that once HIV-positive serostatus 
is disclosed, HIV-negative partners may not wish to have CLS with an HIV-positive man. Hence, HIV-
diagnosed men may be inclined to not disclose to an HIV-serodifferent partner. Further, no association 
was observed of lower sexual disclosure with higher HIV risk CLS-D. This may also highlight that, to some 
extent, HIV-diagnosed MSM factor in their personal VL level in the decision to not disclose and have CLS-
D, as the risk of HIV transmission when the HIV-positive partner is on effective ART is extremely low. 
 
In earlier US studies of HIV-outpatients (see Table 7.3) prevalence of CLS-D among MSM who did not 
disclose to casual sex partners (any or new partners) was found to range between 16% and 
31%.
199,389,408,420,428
 Evidence on the association between non-disclosure to casual sex partners and CLS 
remains mixed. There was no indication of a significant difference in prevalence of CLS-D among those 
who did and did not disclose to casual sex partners in four diverse US studies.
177,195,404,410
 On the other 
hand, non-disclosure to casual partners was independently associated with higher odds of having CLS-D 
in two US studies after adjustment for socio-demographic and lifestyle factors. 
409,418
  
 
Lower sexual disclosure was also strongly associated with having high partner numbers in the past year. 
Similar findings were observed in the US ‘Positive Choices’
419
 and Canadian LISA studies
389
(Table 7.3). In 
ASTRA, strong associations were also observed of lower sexual disclosure with group sex, which has not 
been previously studied. There was some suggestion that lower sexual disclosure was associated with 
using the internet to find sex. Further studies are needed to examine the role of the internet in 
facilitating or discouraging disclosure of HIV-serostatus, particularly since the widespread availability of 
geosocial and sexual networking (GSN) mobile apps in the late 2010’s.
429,430
  
 Limitations 7.5.8
The direction of associations between socio-demographic, psychological, HIV-related factors and non-
disclosure could not be ascertained. It is possible that pre-existing factors (e.g. depression or being on 
ART) encourage non-disclosure and vice versa.  
 
Prevalence of non-disclosure may be influenced by non-response; if non-disclosure was more prevalent 
among those who refused study participation, then our study would underestimate non-disclosure. 
There was a significant proportion of missing data for the disclosure category sub-questions, but not for 
the overall non-disclosure question on which primary analyses were based. In addition, it was not 
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possible (from the question wording) to ascertain whether disclosure to a stable partner was to the 
current stable partner, a previous/concurrent partner, or a casual partner, which could underestimate 
prevalence of non-disclosure to the current partner. To increase the validity of the partner non-
disclosure measure, analysis was restricted to MSM who reported being in an ongoing relationship only. 
Small sample sizes precluded a more robust examination of associations between non-disclosure to a 
stable partner and sexual behaviours.  
 
Non-disclosure to new sexual partners was not explicitly ascertained in ASTRA. The statement “I’d 
expect to tell a new partner that I’m HIV-positive before we have sex” was considered a proxy measure 
instead. It is encouraging that the prevalence estimates of lower sexual disclosure were comparable to 
other studies on non-disclosure to new sex partners. Future studies could benefit from employing 
partner-level analysis of non-disclosure (e.g. number of CLS-D casual partners the participant disclosed 
to among all partners over a period of time). Finally, it should be emphasised that, while epidemiological 
studies such as ASTRA provide insight into patterns of non-disclosure among a clinic-based population, 
they are not able to capture the complex circumstances, motivations, and challenges that may surround 
the issue of disclosure for an HIV-positive individual. 
7.6 Conclusions and Implications 
The prevalence of non-disclosure of HIV-serostatus to the social circle, to a stable partner, and new sex 
partners was overall low among MSM participating in the ASTRA study. A higher proportion of men 
indicated that they would not always disclose to new sexual partners. These findings provide important 
insights into non-disclosure among people living with HIV in the UK.  
 
A number of North American studies have examined non-disclosure to stable or casual partners and 
sexual behaviours among HIV-diagnosed MSM, but evidence from the UK is lacking. Interpretation of 
findings on associations between non-disclosure and CLS is not straightforward due to methodological 
differences across studies (diverse populations, non-disclosure measures, and definitions of stable or 
casual partners). These varying findings, coupled with evidence that HIV disclosure may differ by 
socioeconomic, HIV-related, and contextual factors, point to the need for additional research in 
examining patterns of HIV disclosure (type of confidant) and any effects on sexual risk behaviours.
411
  
 
In addition, the role of HIV-serostatus disclosure to sexual partners in the era of effective ART may be 
changing. Emphasis on HIV-serostatus disclosure to sexual partners places the majority of responsibility 
of reducing HIV transmission risk on HIV-diagnosed individuals who may already experience perceived 
or enacted stigma.
408
 No association was observed between non-disclosure to a stable partner and any 
CLS among MSM in an ongoing relationship in ASTRA, but power to examine associations was low.  
 
Lower sexual disclosure was associated with reporting CLS-D, group sex, and high partner numbers; 
however, over 90% of MSM with lower sexual disclosure who also had CLS-D, were on ART with 
suppressed VL. With evidence that self-reported undetectable VL is associated with lower sexual 
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disclosure in our study, it will be important for future studies to continue to assess the impact of self-
reported VL on sexual behaviour and attitudes, as ART use expands. The strong association of higher 
sexual disclosure and CLS-C may further suggest that HIV transmission risk reduction is taking place, in 
the form of disclosure to HIV-positive partners and HIV-serosorting. Use of the mutually exclusive 
categorisation of sexual behaviour (condom-protected sex, ‘CLS-C without CLS-D’, CLS-D) provided 
further evidence that higher disclosure is linked to possible HIV-serosorting. Future studies could benefit 
from using this mutually exclusive categorisation of sexual behaviour, in order to disentangle 
associations of levels of non-disclosure with different types of sex.  
 
Therefore, HIV-diagnosed MSM may not disclose to sex partners but still practice some form of HIV risk 
reduction, be it having CLS-D while on suppressive ART, or having HIV-seroconcordant partners only. 
Discussion and agreement on condom use or non-use and acceptable levels of risk for both partners 
may be more relevant in the context of reducing HIV transmission risk.
381,414
 Prevention efforts could 
benefit from assisting HIV-diagnosed people in effectively communicating and negotiating acceptable 
sexual behaviours with sex partners, and in providing a supportive context for those who choose not to 
disclose their status to their social circle, a stable or casual partner. 
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8 Hepatitis C co-infection, other sexually transmitted 
infections, and condomless sex 
8.1 Chapter aims 
The aim of this chapter is to examine the association of socio-demographic, HIV-related, lifestyle factors, 
and sexual behaviours with prevalent and incident sexually transmitted infections (STIs) among HIV-
diagnosed MSM. A background of the aetiology, natural history, treatment, management of relevant 
bacterial and viral STIs will be provided, along with the impact of each class of STIs on HIV transmission 
risk and vice versa. A review of the prevalence of any STI, based on self-report, will be undertaken, 
focussing on studies of HIV-diagnosed MSM clinic attendees in high-income countries between 1995 and 
2016. The review will examine firstly, the prevalence and patterns of any self-reported STI, the 
prevalence of chronic hepatitis C (HCV), and the incidence of HCV; secondly, any socio-demographic, 
psychological, HIV-related, lifestyle factors, and sexual behaviours that have been identified as 
correlates of prevalent STIs, HCV, and of incident HCV. The aims of the analyses are to investigate, 
among ASTRA MSM: (i) the prevalence of any and of specific self-reported STIs, and the cross-sectional 
association of socio-demographic, psychological, lifestyle, and HIV-related factors with any STI co-
infection, (ii) the cumulative prevalence of HCV using linked routine clinical data, and the cross-sectional 
association of the above factors with chronic HCV, (iii) the incidence of new HCV over follow-up, using 
linked routine clinical data, and the prospective association of factors associated with incident HCV.  
8.2 Introduction 
STIs remain a major public health concern. In 2012, the World Health Organisation estimated that, 
globally, there were almost 184 million new cases of the four most common curable STIs among males 
(chlamydia, gonorrhoea, syphilis, and trichomonas, see section 8.2.1).
431
 STIs can cause morbidity in 
affected individuals and their sexual partners and present a substantial burden on healthcare services. 
Increasing resistance and decreased susceptibility to antimicrobials is of particular concern (section 
0).
432
  
 
For HIV-positive individuals, concurrent infection with another STI can cause long-term morbidity and 
may require treatment modifications. STIs are both a marker of condomless sex (CLS) as well as a 
possible causal factor in HIV transmission and acquisition. HIV-diagnosed MSM in the UK are 
disproportionally affected by STIs (discussed in section 8.2.8).
433
 The high incidence of STIs observed in 
this population may in part be due to increases in STI testing over the past decade. It could also be due 
to a genuine increase in incidence, driven by high number of sexual partners, or increased serosorting 
practices (with lower condom use) among HIV-diagnosed MSM (such as CLS with other HIV-
seroconcordant partners, CLS-C). While CLS-C does not pose a risk of HIV transmission when HIV-
serostatus is confirmed, it does pose the risk of transmission of other STIs. There is evidence  that co-
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infection with specific STIs and HIV may increase the risk of onward HIV transmission
22,434–441
, but it is 
unclear whether this is still the case when the HIV-positive partner is on effective ART. Understanding 
the drivers of the increase in STI/HIV co-infections among HIV-diagnosed MSM thus warrants further 
study. 
 Sexually transmitted infections (STIs) included 8.2.1
This chapter focuses on STIs of public health importance among HIV-diagnosed MSM in the UK. They are 
separated by aetiologic pathogen: STIs caused by infection with bacteria or parasites are summarised in 
Appendix VI (Table VI.1) and include syphilis, gonorrhoea (NG), chlamydia (CT), lymphogranuloma 
venereum (LGV), non-specific urethritis/non-gonococcal urethritis (NSU/NGU), and trichomonas (TV).
442–
452
 STIs caused by infection with a virus are summarised in Appendix Table VI.2 and include genital 
herpes caused by herpes simplex viruses type 1 and 2 (HSV-1, HSV-2) and genital warts caused by 
human papilloma virus (HPV).
450,451,453,454
 Hepatitis C virus (HCV) infection is discussed separately 
(section 8.2.6) as a major chronic pathogen among HIV-diagnosed individuals. As the focus of this thesis 
is on MSM, the clinical presentation of these STIs is discussed among males only (symptoms and natural 
history vary in females).  
 
CT, NG, NSU/NGU, and TV can be thought of as short-lived curable STIs; they tend to be asymptomatic 
among males, have high transmission probability and high reinfection rates. While syphilis is a chronic 
STI that can cause morbidity throughout its natural history if untreated, it is transmissible only during 
the first one to three years of infection (early stage); it then enters a prolonged latent stage that is not 
infectious but can be associated with considerable morbidity.
442
 LGV, caused by a CT serovar, has a 
variety of acute and chronic manifestations analogous to syphilis, but the majority of patients recover 
without sequelae. Viral STIs are longer-lasting, tend to be symptomatic, and have low transmission 
probability. Once they resolve, viral STIs enter a latent state characterised by recurrence of symptoms 
and episodes of asymptomatic shedding over a long infectious period (particularly for HSV). HPV 
infection is normally transient but, in a fraction of cases, can become chronic; some HPV serotypes can 
progress, among males, to cancer of the penis, anus and oropharynx.
451
  
 
The term ‘co-infected’ in this chapter refers to concurrent infection with HIV and another STI, while 
‘mono-infected’ refers to those who are diagnosed with only one STI (for example, HCV-monoinfected 
refers to those diagnosed with HCV but not another STI or HIV, HIV-monoinfected refers to those 
diagnosed with HIV only and so on, see section 8.2.7.6).  
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 Bacterial STIs and HIV co-infection  8.2.2
Bacterial STIs (bSTIs) have been recognised as important cofactors in the transmission of HIV since the 
beginning of the HIV epidemic.
455
 As discussed in section 1.4.4, cohort studies and RCTs have shown that 
HIV positive people (both diagnosed and undiagnosed) co-infected with other STIs are more likely to 
transmit HIV compared to those who are HIV positive but not STI co-infected.
456
 Below is a summary of 
the effect of bSTIs on HIV progression, transmission, and on antimicrobial resistance.  
8.2.2.1 Impact of bacterial STI co-infections on HIV   
Genital tract bSTIs (including CT, GC, syphilis, TV) increase the detection and concentration of HIV RNA 
shedding in the genital tract.
456,457
 This is particularly the case when infection is associated with 
recruitment of inflammatory and immune cells to the genital tract. At cellular level, bSTIs can upregulate 
HIV leading to elevated plasma HIV VL; lesions (as in LGV or syphilis) can also lead to increased HIV RNA 
genital shedding, but it is unclear if this is still the case when plasma VL is suppressed on ART.
439,458
  
8.2.2.2 Antimicrobial resistance 
Antimicrobial resistance (AMR) occurs when bacteria develop alterations in their genetic code, which 
render the antibiotic used to cure infection with that microorganism ineffective.
432
 AMR has 
complicated STI treatment as most available or convenient (e.g. single dose) drugs are no longer 
effective. The emergence and spread of antimicrobial resistant gonococcal strains is a particular threat 
to global public health
432,444
; many strains are now resistant to former first and second-line therapies 
and increasingly more strains are no longer susceptible to third-generation therapies.
451,459
 In the UK, a 
microbial culture of NG is required to detect reduced antimicrobial sensitivity and a test of cure (TOC) is 
recommended for all cases of NG to monitor treatment failure.
444
 Guidelines continue to change rapidly 
in response to emerging AMR.
448
 
 Genital herpes and HIV co-infection 8.2.3
Genital herpes is an ulcerative STI, caused by infection with herpes simplex virus (HSV) types 1 and 2 
(see Appendix VI, Table VI.2). Although antiviral treatment can reduce the duration and severity of 
herpetic symptoms and control recurrences, HSV infection is lifelong.
460
 A substantial body of evidence 
has documented the epidemiological synergy between HSV and HIV.
461,462
 The predominant target cell 
for HSV is the CD4 lymphocyte
451
 and as such, HSV is associated with both increased risk of HIV 
transmission and acquisition; in turn,  HIV infection can increase the severity of clinical HSV disease 
(among HIV-positive people).
463
  
8.2.3.1 Impact of genital herpes on HIV  
As discussed in section 1.4.4, among HIV/HSV-2 co-infected individuals, meta-analyses show that HSV-2 
shedding increases the concentration of genital HIV RNA, even after accounting for CD4 count and time 
since HIV diagnosis.
437,456
 There is also some indication from the pre-ART era that HSV-2 reactivation 
may be associated with higher levels of genital HIV RNA, but recent robust results are lacking.
464
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A number of prospective studies and placebo-controlled RCTs (2004-2010) 
52,463,465–470
  have shown that 
HSV-2 antiviral treatment with excellent adherence significantly reduced HIV RNA and genital HSV-2 
ulcers; however, no reduction was observed in the incidence of HIV transmission to HIV-negative sexual 
partners. The lack of efficacy of HSV-2 therapy in reducing HIV transmission risk in suggests that a 
greater reduction in plasma HIV VL would be required to reduce risk of HIV transmission.  
8.2.3.2 Impact of HIV on natural history of HSV 
There is marked difference in the natural history of HSV between HIV-positive and HIV-negative people. 
Among ART-naïve HIV/HSV co-infected people, the degree of immunosuppression resulting from HIV is 
the most important risk factor for HSV recurrence; primary and recurrent genital HSV commonly present 
with persistent anogenital lesions and serious complications (particularly during advanced HIV infection 
with low CD4 counts).
450
 While ART reduces the frequency of HSV recurrence, it is less efficacious on 
reducing asymptomatic HSV shedding.
463
 In addition, the efficacy of antiviral therapy for HSV is lower in 
HIV-positive compared to HIV-negative people.  
 Genital warts and HIV co-infection 8.2.4
Genital warts are benign skin lesions caused by the human papillomavirus (HPV), of which over 100 
genotypes have been identified (see Appendix VI, Table VI.2).
453
 Over 90% of anogenital warts are 
caused by HPV types 6 or 11 and usually resolve spontaneously within a year. Although warts are 
treatable, recurrence is common and accounts for over 40% of all genital wart diagnoses in the UK.
471
 
Among MSM in the UK, infection with high risk HPV types (16, 18, 31, 45) is the causative agent of 
invasive anal cancer and of a subset of oral cancers.
460
 The impact of HPV/HIV co-infection on the 
progression of HIV among those on ART has not been well studied.  
8.2.4.1 Impact of HIV on genital wart progression 
HIV-immunosuppression may hinder spontaneous clearance of genital warts and reactivate latent HPV; 
this may in turn lead to faster progression of HPV-associated cancerous lesions.
454
 A meta-analysis of 
nine studies among MSM reported that the incidence of HPV-associated anal cancer was higher among 
HIV-diagnosed men compared to HIV-negative (46 versus 5 per 100,000/year); among HIV-diagnosed 
men, there was a marked increase observed in the annual incidence of HPV-related anal cancers, from 
22 per 100,000 in the pre-ART era (prior to 1996) to 78 per 100,000 after the introduction of ART (1996 
onwards).
472
 These estimates were not adjusted for age and may be in part explained by improved 
survival conferred by ART and ageing of the HIV-positive population.
454
 The incidence of HPV-related 
oral malignancies is also increasing among HIV-diagnosed men, with a reported increase of oral warts 
among those on ART.
436,473,474
 It is also hypothesized that ART-related immune restoration may not be 
enough to clear long-standing HPV or that improved survival allows for longer time to develop anal 
cancer.
475
 It remains unclear to what extent CD4 count contributes to HPV disease progression. 
 Impact of STIs on acquisition of HIV in HIV-negative individuals  8.2.5
Two biological mechanisms have been identified as contributing to increased susceptibility to HIV 
acquisition among HIV-negative people who have other (non-HIV) STIs. Firstly, lesions (caused by bSTIs 
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or HSV-2) and genital warts disrupt genital mucosa allowing a portal of entry for HIV. Secondly, as STIs 
are reactivated, inflammatory cells (predominantly HIV target cells, CD4) are recruited in the anogenital 
tract and targeted by HIV, even after lesions or warts have resolved.
463,476–478
 Ulcers in both partners can 
also facilitate blood-to-blood contact and thereby HIV transmission.
439,457
  
8.2.5.1 STI control as an HIV prevention strategy 
Since 1996, nine RCTs have been conducted worldwide to evaluate whether treatment of STIs can 
reduce STI prevalence among HIV-serodifferent partners and hence reduce HIV transmission. All were 
conducted among heterosexual populations in Africa; five focused on control of bSTIs
479–484
 and the 
remaining four on HSV-2.
469,470,485
 Only one of these studies showed a significant reduction in HIV 
incidence as a result of population-level bSTI treatment.
479
 This is in part explained by the low 
prevalence of bSTIs in the populations recruited, additional HIV prevention services introduced in the 
comparison arm of these trials, low power to evaluate HIV incidence, and different HIV epidemic phases 
in different populations.
486
 Hence there is insufficient evidence to evaluate effects of STI treatment on 
reducing incidence of HIV and an absence of this sort of research among MSM.
487
  
 Hepatitis B virus (HBV) 8.2.6
HBV is a DNA virus whose primary target cell is the hepatocyte (liver cell).
488
 Transmission is by 
parenteral exposure to infected blood and body fluids, through sexual contact, injecting drug use, blood 
to-blood contact, and perinatal transmission.
489
 HBV can progress to chronic infection associated with 
increased risk of chronic liver disease and hepatocellular carcinoma (HCC).
488
 HBV can be effectively 
prevented by immunisation; since 1992, the UK offers vaccination of individuals at high risk of exposure 
to the virus (incl. HIV-diagnosed people). There are important distinctions in the epidemiology of HIV co-
infection with hepatitis B or C; the prevalence of hepatitis C tends to be highest among PWID, followed 
by MSM, and is lowest in the general population (section 8.2.8). In contrast, prevalence of HBV is overall 
lower, and similar across exposure groups (MSM, HIV-diagnosed MSM, PWID, and the general 
population).
490
 For these reasons, HCV is of greater focus in this chapter.  
 Hepatitis C virus (HCV) 8.2.7
HCV is an RNA virus, which, like HBV, primarily targets and replicates within hepatocytes.
451
 Genetic 
variability is high and reflected by different genotypes and subtypes in diverse geographical transmission 
risk populations; seven main genotypes are recognised (1-7), which are further divided into subtypes 
(each assigned a letter).  
8.2.7.1 HCV transmission 
HCV is primarily transmitted via direct blood-to-blood contact. Needle sharing during injection drug use 
(IDU) is estimated to account for over 50% of HCV infections in high-income countries. For this reason, 
accounting for prevalence of IDU in studies of HCV is important in interpreting HCV prevalence 
estimates. While there is evidence that HCV is present in seminal fluid in acute and chronic infection, it 
is less efficient in sexual transmission (compared to other viral STIs).
491
 Sexual transmission of HCV is 
uncommon among heterosexuals. However, among HIV-diagnosed MSM, sexual transmission has been 
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high and ongoing in Europe, the USA, and Australia since 2000. Surveillance of HCV outbreaks has 
revealed large international networks of HCV transmission among HIV-diagnosed MSM, associated with 
increases in sexual risk behaviours (such as CLS).
492,493
 This chapter focuses on sexual transmission of 
HCV.  
8.2.7.2 Life cycle and serology  
HCV can cause acute and chronic hepatitis. Acute infection, classed as infection in the first six months 
since exposure, is asymptomatic in over 60% of patients. (Figure 8.1)  Plasma HCV RNA can be detected 
within 2-14 days of exposure, rising rapidly, and then plateauing. Within two months post-exposure, 
levels of HCV RNA begin to decline and two patterns are seen: (i) HCV RNA continues to decline leading 
to spontaneous HCV clearance within six months of initial infection, or (ii) HCV RNA stops declining, may 
rise to some extent and then stabilise, indicating chronic infection. (Figure 8.1) HCV-specific antibodies 
(anti-HCV) gradually appear within two months of initial exposure, and persist among those with both 
acute and chronic HCV.
494
 HCV seroconversion can be delayed significantly in HIV positive people.
495
 
8.2.7.3 Diagnosis 
It is estimated that clearance of HCV occurs in a quarter of HCV-infected individuals, while chronic 
infection remains in the rest (although spontaneous clearance is lower in the HIV positive population).
496
 
Coupled with the fact that all individuals exposed to HCV develop anti-HCV, screening for anti-HCV 
(using enzyme linked immunoassays, EIAs) is thus the first-line diagnostic test for HCV infection. Third-
generation EIAs for anti-HCV have specificity over 99%.
497
 In cases of clinically suspected acute HCV 
while anti-HCV is negative, HCV-RNA testing is used to confirm infection. In the case of a positive anti-
HCV, HCV RNA tests are conducted to establish whether HCV infection is active or cleared.
496
 Among 
HIV-diagnosed individuals, anti-HCV seroconversion may be delayed and HCV RNA may be needed for 
diagnosis.
495,498
  
8.2.7.4 Disease progression  
Chronic HCV infection leads to liver fibrosis, the result of liver’s wound-healing response to repeated 
injury.
499
 Cirrhosis is a late stage of fibrosis development that results in widespread distortion of liver 
architecture. A meta-analysis of over 100 prognostic studies showed that advanced liver fibrosis 
progresses to cirrhosis after a median of 30 years in approximately 35% of those with chronic HCV; this 
progression is more rapid in those with HIV co-infection and in the presence of hazardous alcohol use.
500
 
Ultimately, cirrhosis leads to liver failure.
499
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Figure 8.1: Serological course of acute HCV with (A) clearance and (B) progression to chronic 
infection501  
 
8.2.7.5 HCV treatment 
The goal of therapy is to cure HCV infection so as to prevent complications including fibrosis, cirrhosis, 
and HCC.
496
 This is measured by sustained virological response (SVR), defined as undetectable HCV RNA 
(≤15IU/mL) 12 weeks after end of therapy. A discussion of treatment options is beyond the scope of this 
thesis; briefly, up until 2011, standard treatment for HCV consisted of a combination of pegylated-
interferon plus ribavirin (pIFN/Rib), which resulted in SVR in HCV mono-infected patients of 40-45% of 
those with genotype 1 HCV and 70-80% of those with genotypes 2 or 3 HCV.
502,503
 HIV/HCV co-infected 
patients had lower SVR rates to pIFN/Rib based therapies. Treatment has rapidly evolved with the 
advent of directly acting agents (DAAs), which became available after 2011 (in the UK, DAAs became 
more widely available through the NHS after 2015). This represented a major advance in HCV treatment. 
A number of randomised trials have shown that DAAs can achieve SVR in >95% of individuals with any 
HCV genotype. This response to DAA is similar in both HCV mono-infected and HIV co-infected 
patients.
504–506
 Latest European treatment guidelines recommend a range of options including new 
DAAs.
496,498,507
 
8.2.7.6 Impact of HCV co-infection on HIV  
There is conflicting evidence of the effect of HCV co-infection on progression of HIV to AIDS. A number 
of cohort studies conducted in the pre-ART era (prior to 1996) found no effect of HCV on CD4 count and 
HIV VL, or on progression of HIV to a new AIDS event or death (adjusting for HIV-related factors and 
Image removed for copyright reasons 
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IDU).
508,509
 A meta-analysis of 27 studies in the ART era (1996-2008) showed that the risk of overall 
mortality was significantly higher among HCV/HIV co-infected patients on ART compared to HIV-
monoinfected individuals (Risk Ratio=1.35, 95%CI 1.11-1.63).
510
 More recent results have corroborated 
these findings adjusting for ART status.
511,512
  
 
Evidence on the effect of HCV co-infection on immunological and virological response to ART is also 
mixed. A meta-analysis of eight cohort studies (1996-2001) showed that compared to HIV-monoinfected 
individuals, HCV/HIV co-infected individuals had reduced CD4 counts after 48 weeks on ART.
513
 In 
addition, no significant difference was observed in the virological response to ART between HCV/HIV co-
infected and HIV mono-infected individuals.
513,514
 Mixed findings may be due the different confounding 
factors accounted for in various study settings, such as ART adherence, length of time on ART, HCV 
treatment, prevalence of IDU and co-morbidities in the cohort.  
8.2.7.7 Impact of HIV on HCV  
Longitudinal studies show that risk of progression to chronic HCV and liver disease is elevated among 
HCV/HIV co-infected individuals compared to those who have HCV, but not HIV (HCV-monoinfected).
515
 
Conversely, high CD4 counts and being on ART have been associated with lower risk of liver disease 
(including HCC) among co-infected compared to HCV-monoinfected individuals.
516,517
 Hepatotoxicity 
(liver damage induced by drugs) can occur in response to ART. Among HCV/HIV co-infected individuals 
on ART there is an increased risk of developing hepatotoxicity compared to HIV mono-infected 
individuals.
68,518
 This may require consideration of choice of ART regimens and monitoring for liver 
damage caused by ART, particularly in the period after ART initiation or switch.
519,520
 HIV infection may 
also facilitate HCV transmission by increasing HCV RNA levels and through its negative effects on the 
lower gastrointestinal immune system.
68
 
 STI epidemiology in the UK 8.2.8
Recent trends and epidemiology of STIs in England are compiled using data from mandatory reporting of 
free open-access STI tests and diagnoses made in sexual health clinics and community-based settings. 
These are then submitted to the PHE-managed Genitourinary Medicine Clinic Activity Dataset 
(GUMCADv2), which also incorporates reliable data on sexual orientation from sexual health clinics 
(>90% completion since 2011).
521
  
 
In the case of HCV, data is based on opportunistic testing in England. As HCV can be asymptomatic 
during seroconversion and for a prolonged period after infection (section 8.2.7.2), estimating the 
number of individuals with antibodies to HCV is complex. Evidence is synthesised from various data 
sources including statutory laboratory notifications, unlinked anonymous testing of IDU accessing 
specialist services (including drug treatment services and prisons), sentinel surveillance of blood-borne 
virus testing in blood donors, GUM, ante-, and neonatal clinics, as well as community screening surveys 
in people of South Asian origin.
522,523
 Risk factor information (HCV transmission route) is recorded only in 
laboratory reports, which account for a small minority of prevalent HCV infections.
524,525
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In 2015, over 434,000 new STI diagnoses were made in England; the most prevalent STIs were CT (46%), 
new genital warts (16%), NSU/NGU (10%), and NG (10%).
471
 
8.2.8.1 All MSM  
Over the past decade, diagnoses of NG, syphilis, and genital herpes in England have increased 
considerably among males, compared to females. This is explained mostly by the increase in diagnoses 
among MSM. (Figure 8.2) In 2015, approximately 224,000 STI diagnoses were made among males 
attending sexual health clinics, of which over 53,000 were in MSM. This group accounted for the 
following proportions of diagnoses made among all males; 84% of syphilis diagnoses, 70% of NG, 21% of 
CT, 12% of genital herpes, and 9% of genital warts diagnoses.
471
 NG was the most commonly diagnosed 
STIs among MSM in 2015. While the majority of MSM presented with genital NG infection, a quarter 
presented with rectal and a sixth with only pharyngeal NG infection; this may suggest that a 
considerable number of NG transmissions occurred through CLS. The continuing and rapid rise in syphilis 
is also of concern and suggests high prevalence of CLS.
526
 In 2015, half of acute and probable acute cases 
of HBV (approx. 500) in the UK had associated exposure information recorded, of which 16% were 
attributed to sex between men. This proportion was similar to that reported in 2014.
489
  
 
Figure 8.2: Number of new STI diagnoses made among all MSM in sexual health clinics in 
England (GUMCADv2 data, 2011-2015). Adapted from527 
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8.2.8.2 HIV-diagnosed MSM  
Since 2009, STI diagnoses have been steadily increasing among HIV-diagnosed MSM in the UK. 
Compared to HIV-negative or HIV-unknown status MSM, HIV-diagnosed MSM have four times the 
population prevalence of acute bSTIs.
471
 In 2015, HIV-diagnosed MSM accounted for approximately 40% 
of syphilis diagnoses among all MSM, 24% of CT, 20% of NG, and 17% of anogenital herpes (first 
episode).
528
 Outbreaks of previously rare STIs, such as LGV, have also been observed since 2003 among 
HIV-diagnosed MSM.
149,445,529
 Between 2004 and 2015, 78% of UK LGV cases were among HIV-diagnosed 
MSM, of whom 4% were diagnosed with HIV within three months of LGV diagnosis.
446,471
 Ongoing 
outbreaks of sexually transmissible (non-travel related) enteric infections have also been observed 
among HIV-diagnosed MSM; these include outbreaks of Shigella flexneri
147,238,530
, toxin-producing 
Escherichia coli
531
, and hepatitis A.
532,533
 It has been suggested that CLS between HIV-positive men is 
strongly linked to these outbreaks and is contributing to ongoing STI transmission in this population.
433
  
 
Evidence from systematic reviews shows that the incidence of HCV is significantly higher among HIV-
positive compared to HIV-negative men.
66,534–536
 In recent years, outbreaks of acute HCV have been 
recognised among HIV-positive MSM worldwide.
537–542
   Enhanced surveillance of newly acquired HCV 
infection in MSM in England suggests ongoing but levelling off of rates of sexual transmission of HCV 
among HIV-positive MSM.
520,543
 Between 2008 and 2012 a significant decrease in HCV incidence has 
been observed in HIV-positive MSM, from 0.73 to 0.24 per 100 PY.
544
  
8.2.8.3 Prevalence of self-reported STIs among HIV-diagnosed MSM  
Table 8.1 reviews evidence from cross-sectional and cohort studies conducted among HIV-diagnosed 
MSM in high-income countries since 1996, which include information on self-reported STI status. 
Prevalence of any self-reported STI in the past 12 months was found to range from 13.0% in the French 
ANRS VESPA2
545
 to 41.0% in the UK behavioural surveillance study.
141
 Information on the prevalence of 
specific self-reported STIs is scarce. Only one study reported on multiple STI co-infections, with 22.6% of 
HIV-diagnosed MSM reporting two or more STIs (in addition to HIV) in the past 12 months.
545
 
Information presented in Table 8.1 relates to studies based on STI screening (of asymptomatic 
individuals), which enables undiagnosed STIs to be accounted for as well.  
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Table 8.1: Prevalence of STIs in studies of HIV-diagnosed MSM in high-income countries between 1996 and 2016, according to method of STI ascertainment 
(self-reported or laboratory-confirmed)  
            Prevalence of specific Sexually Transmitted Infection (%) 
  Study Observation 
period 
Country  N HIV+ 
MSM 
Recall period (self-reported 
only)/ Timing of STI screen or 
diagnostic test* (lab-confirmed 
only) 
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e
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e
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 S
TI
s UK behavioural surveillance
141  2003-2004 UK 248 Past 12 months  41.0 - - - - - - - - 
Sex and Love project298  2006 USA 122 Past 12 months  - - - 6.5 8.2 9.8 7.5 - - 
SHCS546  2009-2010 Switzerland 112 Past 12 months  19.0 16.1 4.5 14.3 - - - - - 
ANRS VESPA2545  2011-2012 France  1037 Past 12 months  13.0 - - - - - - - 22.6 
Scotland GMSHS142  2011 UK 59 Past 12 months  25.4 - - - - - - - - 
Presse Gays et Lesbiennes204  2011 France  1258 Past 12 months  30.8 - - - - - - - - 
Essen HIV clinic547  2012-2014 Germany  233 Past 2 years  17.2 2.3 4.3 9.8 - 8.2 3.0 0.5 - 
La
b
o
ra
to
ry
-c
o
n
fi
rm
e
d
 S
TI
s 
Amsterdam STI clinic548  2002-2003 Netherlands  222 Screening at single clinic visit - - 15.8 4.2 † - - - - - 
SHCS549  2004-2006 Switzerland 2650 Routine annual syphilis serology: 
% positive tested during 
observation period 
- - - 23.2 - - - - - 
UCLA Medical Center550  2004-2006 USA  212 Screening at first HIV clinic visit 28.0 5.7 8.0 - - - - - - 
Positive Health551  2005-2006 Australia  295 Screening at enrolment - 8.0 3.2 18.6 - - - - - 
Kings College HIV clinic552  2006 UK 77 Diagnostic testing of 
symptomatic patients  
49.0 8.0 12.0 13.0 † 15.6 5.2 0.0 1.3 - 
University Hospitals553  2007-2008 Netherlands  616 Screening at enrolment  16.0 8.6 5.2 5.0 † - - - - - 
SHCS546  2009-2010 Switzerland 112 Screening at enrolment - 10.7 2.7 34.8 - - 51.8 0.9 - 
Maple Leaf Medical Clinic554  2010-2012 Canada 294 Screening at single STI clinic visit - 1.0 0.3 11.0 † - 67.6 55.9 - - 
Ohio sexual health clinic555  2012-2013 USA  41 Screening at single STI clinic visit - - - - - - - - - 
CT: chlamydia; NG: gonorrhoea, NSU/NGU: non-specific urethritis/non-gonococcal urethritis; HCV: hepatitis C; LGV: lymphogranuloma venereum; SHCS: Swiss HIV Cohort Study; † 
Syphilis estimates in these studies are for early (infectious) syphilis only, remaining studies show combined early and latent syphilis estimates. *Screening refers to STI testing of 
asymptomatic (but potentially at risk) individuals while diagnostic testing aims at establishing the presence/absence of STIs in symptomatic individuals (or asymptomatic individuals with 
a positive screen).  
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 Cumulative prevalence of hepatitis C among HIV-diagnosed MSM  8.2.9
Table 8.2 summarises estimates of HCV prevalence among HIV-diagnosed MSM observed from studies 
in clinical settings in high-income countries.
537,556–558
 These are presented as cumulative prevalence, 
meaning the proportion of individuals with positive anti-HCV results or HCV RNA detected out of all 
individuals under follow-up who had ever tested, or out of all individuals under follow-up in a given year 
and tested by the end of that year. In the four longitudinal studies shown, the cumulative prevalence of 
HCV ranged from 3.0% to 7.2%; two studies
537,557
 did not exclude HCV infection through IDU, while 
another study
558
 only included those who did not report IDU as a HIV risk factor or following HIV 
diagnosis. The three cross-sectional studies shown in Table 8.2 reported HCV prevalence among non-IDU 
HIV-diagnosed MSM, ranging from 3.6% to 8.7%.
554,559,560
 Recently, a systematic review of HCV 
prevalence in 13 studies from North America, Western Europe, and Japan (2000-2015) reported a 
pooled estimate of 7.1% (5.1-9.0%) among over 9500 HIV-diagnosed MSM with no prior or current 
IDU.
536
  
 Incidence of hepatitis C among HIV-diagnosed MSM  8.2.10
Four meta-analyses have reported pooled HCV incidence rates among HIV-diagnosed MSM in Europe, 
Asia, Australia, and North America, from 1984 to 2016.
66,534–536
 All presented estimates from studies that 
do not distinguish between MSM with and without history of IDU. Pooled HCV incidence (per 100 PY) in 
these meta-analyses was similar: 0.53 (95%CI 0.49-0.58)
66
, 0.61 (0.52-0.70)
534
, 0.64 (95%CI 0.46-0.81)
536
, 
and 0.78 (0.60-0.96).
535
 As CLS has emerged as an important route of HCV transmission among HIV-
positive MSM since the early 2000’s, more recent studies have considered IDU status in population 
eligibility criteria. Table 8.3 summarises the incidence rates of HCV per 100 PY observed in cohort 
studies of HIV-diagnosed MSM in high-income countries, according to whether self-reported IDU (ever, 
current) was excluded from the calculation. In the five cohort studies of HIV-diagnosed MSM with no 
history of IDU, HCV incidence ranged from 0.11 to 1.38 per 100 PY.
561,562
 Some of these studies might 
overestimate incidence in HIV-diagnosed MSM overall, as they require participants to be tested during 
follow-up in order to include them in the denominator; in an observational cohort it may be those at 
greatest risk who are tested more frequently. 
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Table 8.2: Prevalence of hepatitis C virus (HCV) in cohort and cross-sectional studies of HIV-diagnosed MSM from high income countries (1996-2016) 
Study Observation 
period 
Country Study type N HIV+ 
MSM 
Observation period/HCV 
prevalence measure  
Overall HCV prevalence 
(95%CI)‡ 
HCV prevalence among non-
IDU (95%CI) ‡ 
Amsterdam 
Cohort 
Study
537
   
1984-2003 Netherlands  Cohort 504 Retrospective anti-HCV screening 
among MSM with ≥2 cohort visits 
during FU 
3.0% (-) - 
SHCS
556
 2000-2004 Switzerland Cohort 2550 Cumulative anti-HCV prevalence 
among those with ≥1 serological 
HCV test result during FU  
4.0% (-) 34.0% (-) 
UK CHIC
557
 2000-2007 UK Cohort 12059 Cumulative anti-HCV prevalence 
over FU 
7.2% (-) - 
OCS
558
 2000-2010 Canada Cohort 1227 Cumulative anti-HCV prevalence 
over FU (incl. those with anti-HCV 
positive at first test)  
- 7.7% (-) 
NHBS
559
 2004 and 
2008 
USA  Cross-
sectional 
serial 
survey 
207 Anti-HCV point prevalence at each 
survey round 
2004: 15.2% (7.7-22.7%)  
2008: 8.3% (1.9-15.5%) 
 2004: 8.7% (1.9-15.5%)  
2008: 4.5% (0.1-8.9%) 
GMSS
560
 2008 UK Cross-
sectional 
serial 
survey 
168 Anti-HCV point prevalence at 
recruitment  
7.7% (4.2-12.9%) - 
Maple Leaf 
Medical 
Clinic
554
 
2010-2012 Canada Cross-
sectional  
survey 
294 Anti-HCV point prevalence at 
recruitment  
10.4% (7.1-14.5%) 3.6% 
‡ 95%CIs where available; anti-HCV: HCV antibody; FU: follow-up; GMSS: Gay Men's Sexual Health Survey; IDU: injection drug use; NHBS: National HIV Behavioural Surveillance 
System; OCS: Ontario Cohort Study;  SHCS: Swiss HIV Cohort Study; UK CHIC: UK Collaborative HIV Cohort Study 
255 
 
Table 8.3: Incidence rate (IR) of hepatitis C virus (HCV) in cohort studies of HIV-diagnosed MSM in high-income countries (1983-2016) 
Study 
Obser
vation 
period 
Country 
N 
HIV+ 
MSM 
Inclusion criteria 
% IDU  in 
sample 
N HCV 
serocon
versions 
Overall IR/100 PY 
(95%CI)‡ 
IR/100 PY among 
non-IDU (95%CI) 
Amsterdam 
Cohort 
Study
537
   
1983-
2003 
Netherlands  514 Anti-HCV positive serology before 2003 was re-
tested to determine if participant was HCV-
positive at entry or, if not, to establish HCV 
seroconversion date. Followed by confirmatory 
HCV RNA 
- 8 0.18 (0.08-0.36) - 
MACS
67
  1984-
2003 
USA 2041 Anti-HCV positive test at≥2 FU visits  - 99 0.42 (-) - 
SHCS
561
   1998-
2001 
Switzerland 3333 Anti-HCV negative at entry and had ≥1 HCV test 
during FU. Excluding MSM with history of IDU 
and those with HCV re-infection over FU. 
2.1% 101 - 1998: 0.11 (0.03-0.35) 
2011: 3.56 (2.19-5.53) 
CASCADE
563
  1998-
2007 
Europe and 
Canada 
3014 Anti-HCV negative with ≥2 FU tests only after 
routine HCV data collection began in each of 11 
cohorts 
- 92  2005: 1.68 (1.03-2.74) 
 2007: 2.34 (0.82-6.69)  
- 
CASCADE
564
 1990-
2014 
Europe, 
Australia, 
Canada 
4326 As above in each of 16 cohorts of MSM only  - 279  1990: 0.30 (0.04-1.80) 
 2014: 2.10 (1.00-4.20) 
- 
SHCS
556
  2000-
2004 
Switzerland 1571 Anti-HCV negative at entry and had ≥1 HCV test 
during FU. Excluding MSM with history of IDU. 
1.8% 14 - Had CLS: 0.70 (0.30-1.40) 
 No CLS: 0.20 (0.07-0.43) 
OCS
558
 2000-
2010 
Canada 1534 Anti-HCV negative at entry and ≥1 HCV test 
during FU. Excludes MSM with IDU as HIV risk 
factor or IDU following HIV diagnosis. 
- 41 - 0.51 (0.39-0.67) 
London & 
Brighton 
GUM/HIV 
clinics
540
  
2002-
2006 
UK 42985 
patient
-years  
Case-series reports: newly acquired HCV 
defined as HCV RNA detected or anti-HCV 
positive test with ≥1 HCV negative test in past 
3 years  
- 398 0.9 (-) - 
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Study 
Obser
vation 
period 
Country 
N 
HIV+ 
MSM 
Inclusion criteria 
% IDU  in 
sample 
N HCV 
serocon
versions 
Overall IR/100 PY 
(95%CI)‡ 
IR/100 PY among 
non-IDU (95%CI) 
Chase 
Brexton 
Health 
Care
565
  
2004-
2014 
USA  899 ≥1 clinic visit between 2011 and 2013, engaged 
in care for >1 year, and initial anti-HCV 
negative followed by ≥1 subsequent anti-HCV 
test. Excluding those with history of IDU 
- 31 -  2004-2007: 1.31-1.58 
 2008-2011: 0.27-0.62 
 2013-2014: 1.00-1.33 
Melbourne 
Sexual Health 
Centre
562
 
2008-
2016 
Australia 822 Anti-HCV negative at first test with ≥1 anti-HCV 
FU test and no history of IDU  
- 37 - 1.19 (0.99-1.38)  
‡ 95%CIs where available; Anti-HCV: HCV antibody; CASCADE: Concerted Action on SeroConversion to AIDS and Death in Europe; CLS: condomless sex; FU: follow-up; GUM: genito-
urinary medicine; IDU: injection drug use; IR: incidence rate; MACS: Multicenter AIDS Cohort Study; OCS: Ontario Cohort Study; PY: person-years at risk; SHCS: Swiss HIV Cohort 
Study 
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 Factors associated with STI-HIV co-infections  8.2.11
This section summarises literature incorporating individual-level factors (socio-demographic and HIV-
related, sexual behaviours), which may be associated with higher prevalence of any STI co-infection 
(including prevalent and incident HCV) among HIV-diagnosed MSM in high-income countries since the 
introduction of ART (1996 onwards). Of the 39 studies included in this review (and another five meta-
analyses discussed), five studies
547,548,556,561,566,567
 adjusted for condomless sex (CLS) or other sexual 
behaviours (number of sexual partners over a period of time) when examining factors associated with 
prevalent or incident STIs. These five studies aimed to assess factors that are associated with STIs over 
and above the effect of CLS, which may be indicative of increased risk or vulnerability to STIs even after 
accounting for levels of sexual behaviour. Level of CLS is likely to be the dominating factor in STI risk; 
studies that do not adjust for CLS thus explore factors associated with prevalent or incident STI, which 
may be the same ones as those that are associated with higher prevalence of CLS. 
8.2.11.1 Socio-demographic characteristics 
Evidence on the association between a participant’s age and prevalence of bacterial STI co-infections 
(bSTIs) is mixed. Of the five studies identified, none adjusted for levels of CLS or other sexual 
behaviours; two did not find any association between age and co-infection with any (lab-confirmed) 
prevalent STI,
553,554
 one found that older age was associated with higher risk of positive syphilis 
serology
549
, and two studies showed that younger HIV-diagnosed MSM had higher risk of incident STIs 
(NG, CT, syphilis) over follow-up.
550,562
 It is possible that the association of younger and incident STIs in 
these studies is explained by higher prevalence of CLS or higher partner numbers, which have not been 
accounted for. 
 
The significance of age as a risk factor for HCV among HIV-diagnosed MSM is also heterogeneous across 
studies. HCV prevalence among HIV-diagnosed MSM did not differ significantly by participants’ age in 
two UK cross-sectional questionnaire surveys, SHARP (N=308 HIV-positive MSM)
568
 and the 2008 GMSS 
(N=168).
560
 Two other studies, which adjusted estimates for socio-demographic, lifestyle factors, and 
other STIs (but not level of CLS) showed mixed results; in a Canadian cross-sectional survey of almost 
300 HIV-diagnosed MSM attending sexual health services, older age was significantly associated with 
HCV co-infection,
554
 while in the French ANRS VESPA2 national probability sample survey (N=1037), HCV 
co-infection was associated with younger age.
545
  
 
Similar mixed findings have been observed between age and incident HCV. Two sub-studies of the Swiss 
HIV Cohort Study (SHCS) of HIV-diagnosed MSM with no history of IDU, adjusted for condom use (and 
other factors) in the association of age and incident HCV; in both sub-studies, while younger MSM were 
at elevated risk of HCV seroconversion, the association was not significant after adjustment for 
CLS.
556,561
 In the MACS cohort (N=2377 HIV-diagnosed MSM), every 10-year increase in age conferred a 
44% higher risk of HCV seroconversion; this estimate was adjusted for socio-demographic factors but 
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not CLS or number of sex partners.
67
 In this case, the authors hypothesise that older age may be 
indicative of a lower HCV infection threshold, but direct evidence is lacking.  
 
Among HIV-diagnosed MSM, ethnicity and educational attainment have consistently not been found to 
have any association with prevalence of any (self-reported or lab-confirmed) bSTI
554,558,560
, prevalent, or 
incident HCV.
545,554,558,560,561,565,568
 As in the case of participant’s age, current employment was not 
significantly associated with prevalent bSTIs in SHARP or the 2008 GMMS.
560,568
 The US Chase Brexton 
retrospective cohort study (see Table 8.3) used electronic medical records from over 900 HIV-diagnosed 
MSM attending for HIV care and engaged in care for more than a year (2004-2014).
565
 After adjustment 
for a number of socio-demographic, lifestyle factors, and other STIs, current employment was 
significantly associated with higher risk of incident HCV only when MSM with no history of IDU were 
excluded from analyses. No association was observed between employment status and HCV incidence 
when including MSM with prior IDU. This latter finding was also observed in the ANRS VESPA2 study.
545
  
8.2.11.2 HIV-related factors  
The role of ART status on prevalent STIs remains unclear. A worldwide systematic review of 37 studies 
(2000-2009) reported on clinically or lab-diagnosed genital ulcers and bSTIs among HIV-diagnosed men 
and women; this review showed that the overall STI point prevalence in 14 studies that reported 
participants receiving ART did not differ significantly from that in studies that did not on report ART use 
(16.2% vs 16.5% respectively).
569
 Within studies reporting on ART use, no significant association was 
observed between ART use and prevalent STI co-infections, either. One of the studies included in this 
meta-analysis, a cross-sectional questionnaire study of over 200 HIV-diagnosed MSM attending for free 
STI testing in Amsterdam (see Table 8.1) found that not being on ART in the past six months was 
associated with almost three-fold prevalence of rectal NG compared to being on ART (adjusted for 
CLS).
548
 This association could be explained by time since HIV diagnosis, as STIs may have been acquired 
at a time of higher risk, when HIV was transmitted. In the case of incident HCV, four studies
67,561,568
 
showed no significant effect of ART at baseline/time updated. In the Ontario HIV Cohort Study
558
 and 
the ANRS VESPA2
545
, ART use was associated with HCV seroconversion.  
 
CD4 count is an important marker of immune system function in HIV-diagnosed people, and as such, 
would be expected to have some association with higher prevalence or incidence of STIs. A repeat cross-
sectional survey of over 200 HIV outpatient MSM attendees in California (2004-2006, see Table 8.1) 
showed that for every 100cell/mm
3
 increase in CD4 count, the risk of incident NG and CT increased by 
15% (adjusted for repeat measures only).
550
 The SHCS did not observe a significant association between 
CD4 count and positive syphilis serology among over 2600 HIV-diagnosed MSM (2004-2006).
549
 In the 
MACS cohort
67
, HCV incidence was inversely proportional to CD4 cell count among HIV-diagnosed MSM 
with CD4≤500cells/mm
3
; in contrast, no association was observed between CD4 count and HCV 
incidence when CD4 was >500cells/mm
3
. In the Melbourne Sexual Health Centre study of over 800 HIV-
diagnosed MSM under care (see Table 8.3), nadir CD4 prior to HCV testing was associated with 
increased risk of HCV seroconversion after adjustment for age and HIV VL; most recent CD4 count, 
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however, was not associated with HCV incidence.
562
 In other studies, no significant effect was reported 
between CD4 count and HCV prevalence or incidence.
545,558,561,568
 In fact, of 101 incident HCV infections 
in the SHCS (see Table 8.3), 93% occurred among MSM on ART and over 96% among those with CD4 
counts>200cells/mm
3
.
561
  
 
In two studies that have assessed prevalent bSTIs by self-report rather than laboratory/clinician-
confirmation, detectable HIV VL (>50c/mL) was associated with higher prevalence of bSTIs in the past 
three months, following adjustment for socio-demographic, HIV-related, and lifestyle covariates.
239,547
 
No other studies were identified as showing any association between HIV plasma VL and bSTIs or HCV 
(refer to Table 8.1 and Table 8.2).
545,549,550,558,561,565,568
  
 
The role of length of time living with diagnosed HIV has scarcely been examined as a correlate of STI co-
infection among HIV-diagnosed MSM. In one sub-analysis of the SHCS, the risk of newly detected 
syphilis was significantly higher among MSM diagnosed with HIV longer (>3 vs ≤3 years), even after 
adjustment for age.
549
 Two other studies that assessed time since HIV diagnosis did not observe any 
significant association with incident HCV
558
 or re-infection with HCV after SVR (see 8.2.7.5).
570
 
8.2.11.3 Prior syphilis and HCV seroincidence  
In a recent meta-analysis of 28 studies from Europe, North America, Australia, and Taiwan, syphilis 
emerged as a risk factor for HCV incidence in eight studies; lifetime prevalence of syphilis as well as 
acute syphilis (in the past 6,12,18 months or during the study period) were both associated with 
increased risk of HCV among all MSM (mixed HIV serostatus).
535
 Among HIV-diagnosed MSM in the US 
Chase Brexton cohort who did not report IDU (current, ever), a history of anogenital ulcerative STIs 
(syphilis and warts) was also associated with increased risk of HCV incidence, independent of other 
sexual behaviours.
565
  
8.2.11.4 Non-injection recreational drug use and condomless sex (CLS) 
Sexual transmission of HCV may be mediated by non-injection recreational drug use (NIDU), as drug-
induced sexual disinhibition can lead to traumatic and prolonged sex practices that facilitate blood-
borne virus transmission (see section 6.5.4). NIDU and more recently, chemsex-associated drug use, has 
been identified as a key factor in the transmission of enteric bSTIs and HCV among HIV-diagnosed MSM 
in the UK (see section 8.2.8.2).
148,370,539,568,571,572
 However, very few studies have considered NIDU use as 
a risk factor for HCV transmission. Chemsex drug use in particular is characterised by high prevalence of 
IDU.
573,574
  
 
An important distinction between studies examining the association of NIDU and incident or prevalent 
STIs, is whether analyses include adjustment for sexual behaviours (such as CLS and number of 
partners), as CLS is the main risk factor for STIs. When studies adjust for CLS in the association of NIDU 
and STIs, they aim to explore the additional risk that NIDU confers to STI acquisition, over and above the 
existing risk conferred by CLS. Two studies of HIV-diagnosed MSM who did not have history of or current 
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IDU (SHCS
561
 and Chase Brexton
565
) explored the association of NIDU and incident HCV; in the SHCS, 
current NIDU was not significantly associated with incident HCV after adjustment for CLS and number of 
sex partners; the authors hypothesised that the lack of association may have been due to 
underreporting of NIDU in this cohort. However, it may also be that the association was mediated by 
CLS in the first place, and so it would be expected that NIDU no longer remains significant after 
adjustment for CLS. In the US Chase Brexton cohort, non-injection polydrug use (≥2 non-injection drugs) 
was associated with five-fold higher risk of HCV seroconversion (p=0.02), but no adjustment was made 
for CLS.
565
 Therefore, the association of NIDU and incident HCV in Chase Brexton probably parallels the 
underlying association of CLS and incident HCV in the cohort.  
8.2.11.5 Other sexual behaviours  
A number of studies have examined other sexual behaviours as potential risk factors for HCV 
seroconversion among HIV-diagnosed MSM, but the majority have only provided unadjusted 
estimates
568
 or included MSM with current or lifetime IDU in analyses
557,560
 (meaning that HCV 
transmission via needle sharing cannot be ruled out). Four studies
556,561,566,573
 reported adjusted 
estimates among non-IDU HIV-diagnosed MSM, showing that various sexual behaviours were associated 
with an increased risk of HCV seroconversion. These include “unsafe sex”
556
, receptive CLS with 
ejaculation
67,566
, receptive fisting (without gloves or sharing gloves), inconsistent condom use
561
, sex 
while “high” on methamphetamine
566
, and use of inhaled drugs.
573
  Similarly, prevalent HCV among HIV-
diagnosed MSM has been associated with receptive CLS
538,560,575
 and fisting.
538,539,573,576,577
 High numbers 
of sexual partners have been associated with prevalent and incident bSTIs and HCV.
282,545,557,567
 In the 
MACS study (section 8.2.11.4), the risk of HCV seroconversion was examined according to CLS status and 
number of male sex partners in the past six months. Compared to HIV-diagnosed MSM with no or one 
sex partner, those with multiple sex partners but only one receptive CLS partner were not at higher risk 
of incident HCV (p=0.33); those who had receptive CLS with multiple partners, however, had three-fold 
higher risk of incident HCV (p=0.001).
67
 These estimates were adjusted for socio-demographic factors 
but not recreational drug use.  
8.3 Methods 
Analyses presented in sections 8.4.1-8.4.3 include 2189 ASTRA MSM diagnosed with HIV for ≥3 months, 
while analyses in sections 8.4.4-8.4.8 include a subgroup of the above, with 1811 MSM who also 
consented to linkage of ASTRA to routine clinical data.   
 Sexually transmitted infections  8.3.1
Participants were asked whether they had been diagnosed with an STI (not including HIV) in the past 
three months, and if so, which ones of the following: syphilis, gonorrhoea, chlamydia, LGV, new 
hepatitis B, new hepatitis C, genital herpes (new or recurrent), genital warts (new or recurrent), 
trichomonas, NSU (non-specific urethritis), NGU (non-gonococcal urethritis), and ‘other (please specify)’. 
Free-text responses in the ‘other (please specify)’ category were examined case-by-case and recoded to 
the above categories if applicable, or left as ‘other’ if not classifiable (e.g. reporting STI symptoms such 
as testicular pain).  
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 Other factors and sexual behaviours 8.3.2
Participants were asked whether they currently had any of the following symptoms: abnormal discharge 
from penis, anal discharge, pain on passing urine, pain in the genital area or anus, red sores or rash on 
the genital area or anus. STI screening was assessed by the question “in the past two years, have you 
had a sexual health screen (tests for sexually transmitted infections, not including HIV)?” 
All other socio-demographic, psychological, lifestyle, HIV-related factors, and sexual behaviours 
examined in this chapter have been defined in sections 3.8 and 4.3. Measures of recreational drug use 
and alcohol consumption/dependency are defined in section 6.3. 
 Statistical analysis – prevalence of any STI 8.3.3
The prevalence of any STI and of each specific STI was assessed in the past three months. Prevalence of 
specific STIs was examined according to number of STIs reported in the past three months.  
8.3.3.1 Factors associated with any STI among all MSM 
Associations were examined of socio-demographic, psychological, HIV-related, and lifestyle factors, with 
any self-reported STI in the past three months among all MSM with available STI data. Unadjusted and 
adjusted modified Poisson regression models were used with robust error variances. In multivariable 
analyses, two adjustment strategies were used, as described in section 3.9.5. Firstly, each factor was 
adjusted separately for core factors, and secondly, any factor with p<0.10 at unadjusted analysis was a 
candidate for inclusion in the multivariable model in addition to clinic. Collinear variables were excluded 
accordingly (see sections 8.4.2, 8.4.7) In both multivariable strategies, models for the association of 
study log-recorded viral load (VL) and any self-reported STI excluded the variable ART status as they 
were correlated.  
 
Associations were then examined of sexual behaviours in the past three months (any anal or vaginal sex, 
any CLS, any CLS-D, any CLS-C, group sex, use of the internet to find sex, total number of sex partners),  
number of new sex partners in the past year, with any self-reported STI in the past three months. 
Modified Poisson regression was used for unadjusted and adjusted models. Slightly different 
multivariable adjustment strategies were used in these analyses. Firstly, each factor was adjusted 
separately for core factors (as above), and secondly, each factor was adjusted separately for core factors 
plus recreational drug use in the past three months (yes/no).  
8.3.3.2 Factors associated with any STI among MSM reporting any anal or vaginal 
sex  
MSM who did not report any anal or vaginal sex in the previous three months were excluded, and all 
remaining MSM were classified into one of the following mutually exclusive categories based on sex in 
the past three months (see section 4.3.3).  
1. Condomless sex with HIV-serodifferent partners (CLS-D)  
2. Condomless sex with HIV-seroconcordant partners only  (‘CLS-C without CLS-D’) 
3. Condom-protected sex only  
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Associations of this three-category variable and reporting any STI in the past three months were 
examined in unadjusted and adjusted modified Poisson regression, with condom-protected sex (group 
3) as the reference category. In this analysis, models were first adjusted for core factors only (as in 
8.3.3.1), then for core factors plus recreational drug use in the past three months (yes, no), and lastly, 
for core factors, recreational drug use, and total number of sex partners in the past three months (1, 2-
4, 5-9, 10-19, ≥20). 
 Cumulative prevalence of hepatitis C (HCV) 8.3.4
8.3.4.1 Sample derivation  
Analyses in this section include HIV-diagnosed MSM (diagnosed for ≥3 months) who consented to 
linkage of ASTRA and routine clinical data, and for whom clinic data were available at any point prior to 
questionnaire completion. (Figure 8.6) Details of consent to routine clinic linkage are discussed in 
section 3.6. Of the eight clinical centres recruiting ASTRA participants, four provided linked routine 
hepatitis clinical data; three in London (Homerton, Mortimer Market, Royal Free hospital) and one in 
Brighton.  
 
Cumulative prevalence of HCV was defined as any positive anti-HCV or HCV-RNA test result at any point 
prior to questionnaire completion (chronic/prevalent HCV). The prevalence of chronic HCV is also 
shown: (i). including MSM who also reported lifetime prevalence of HCV on the questionnaire (defined 
as a positive answer to the question “have you ever been told by a doctor that you have hepatitis C?”), 
and (ii). excluding MSM who reported any IDU in the past three months on the questionnaire.  
8.3.4.2 Statistical analysis  
To examine associations of socio-demographic, psychological, lifestyle, and HIV-related factors with 
chronic/prevalent HCV, unadjusted and adjusted modified Poisson regression was used with robust 
error variances. In multivariable models, the two adjustment strategies were used (core adjustment and 
stepwise, as in section 3.9.5).  
 
Adjusted associations of sexual behaviours and any other self-reported diagnosed STIs with cumulative 
HCV prevalence were examined using slightly different adjustment strategies. First, each sexual 
behaviour and STI variable was adjusted in separate models for core factors only. Second, each sexual 
behaviour and STI variable was then adjusted for core factors plus IDU in the past three months. This 
was done firstly, in order to account for possible IDU as a route of HCV transmission, and secondly as it 
would not be possible to include all sexual behaviours in a single model due to multicollinearity.  
 Incident hepatitis C (HCV) over follow-up  8.3.5
8.3.5.1 Cohort derivation  
Individuals were included in the analysis of HCV incidence if they were tested for either anti-HCV or 
HCV-RNA at any point from ASTRA questionnaire completion onwards (start of follow-up, FU). All HCV 
tests up until the end of one year after the start of follow up (FU) were used to define an individual’s 
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HCV status at the start of FU. For participants with changing results in the first year of FU, only the first 
results were used to define their HCV status.  
MSM with the following criteria were included in the analysis (details in Figure 8.6):  
(i.) Negative anti-HCV test and negative or missing HCV-RNA test at the beginning of FU, and 
(ii.) ≥1 further test for either anti-HCV or HCV-RNA  
MSM with any of the following criteria were excluded from the analysis:   
(i.) Self-reported lifetime HCV diagnosis at questionnaire (positive answer to “have you ever been 
told by a doctor that you have hepatitis C?”), or 
(ii.) Positive anti-HCV test or positive HCV-RNA test prior to the date of questionnaire completion, 
or 
(iii.) Positive anti-HCV test or positive HCV-RNA test on the same date as questionnaire completion, 
or  
(iv.) Did not have any HCV test results available after the questionnaire.  
New (incident) infection was defined as any positive anti-HCV or HCV-RNA test after the start of FU. 
Individuals were followed up from the date of ASTRA questionnaire completion until they had a positive 
anti-HCV or positive HCV-RNA test result or until they were last seen (last FU). The latest date for which 
clinical hepatitis records were available was 22 July 2014.  
8.3.5.2 Statistical analysis 
Incidence rate of HCV (95%CIs) was calculated by dividing the total number of incident HCV infections by 
the total number of person years (PY) of FU. Associations were examined of socio-demographic, HIV-
related, lifestyle factors, sexual behaviours and other STIs with new HCV diagnosis. The small number of 
incident events in this analysis allowed for estimation of unadjusted incidence rate ratios (IRRs) per 100 
PY, with p-values derived by exact significance tests.  Clinic-recorded VL and CD4 counts were the test 
results nearest to the HCV diagnosis date. 
8.4 Results 
 Prevalence of self-reported STIs 8.4.1
Among 2189 MSM diagnosed with HIV for ≥3 months prior to ASTRA questionnaire completion, 
information on self-reported STIs was available for 2160 (98.7%). The prevalence of any self-reported 
STI in the past three months among all 2189 MSM was 10.9% (95%CI 9.7-12.3%, n=236). Figure 8.3 
shows that the most prevalent self-reported STIs (>2% prevalence) were CT (3.0%, 2.4-3.8%), NG (2.5%, 
1.9-3.3%), and syphilis (2.3%, 1.7-3.0%). New HCV or HBV, LGV, and any other STIs (not specified), were 
each reported by under 1% of MSM. There were no participants who reported TV in the past three 
months.   
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Figure 8.3: Prevalence (95%CI) of self-reported STIs in the past three months (N=2189) 
 
Among 236 HIV-diagnosed MSM with a self-reported STI, 172 (72.9%, 95%CI 66.8-78.2%) had one STI, 55 
(23.3%, 18.3-29.2%) had two, and 9 (3.8%, 2.0-7.1%) had three or more STIs. Overall, 58.4% of 310 
responses were for bSTIs (CT, NG, LGV, syphilis), 28.4% were for viral STIs (new HCV, HBV, genital warts 
and herpes), and the remaining were for NSU/NGU and other (unspecified) STIs.   
 
Current symptoms of STIs (at questionnaire completion) were reported by 273 MSM (12.5% of 2189). 
The most prevalent current symptoms (>5%) among 2189 MSM were pain (6.5%) and red sores/rash 
(5.7%) in the anogenital area. Among 273 MSM who reported any symptoms, 64.8% reported one 
symptom, 27.1% reported two, and 8.1% reported three or more symptoms. A total of 211 MSM (9.8% 
of 2160) did not report a diagnosed STI but did report symptoms of STIs. (Figure 8.4) This proportion 
represents those with potentially undiagnosed symptomatic STIs in the sample.  
 
Over 78% of 2189 MSM reported having a sexual health screen (for any STI other than HIV) in the past 
two years. 
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Figure 8.4: Prevalence of specific current STI symptoms according to self-reported diagnosed 
STIs in the past three months or current self-reported STI symptoms without STI diagnosis 
(N=447)  
 
 
 Factors associated with prevalence of any self-reported STI in the past three 8.4.2
months  
8.4.2.1 Socio-demographic, psychological, HIV-related, and lifestyle factors  
Table 8.4 shows the associations of socio-demographic, psychological, HIV-related, and lifestyle factors 
with any self-reported STI co-infection in the past three months (N=2160 MSM with available STI data). 
In unadjusted analysis, prevalence of STIs was strongly associated with younger age, non-white 
ethnicity, more recent HIV diagnosis, non-UK place of birth, being employed, financial hardship, having 
an HIV-positive stable partner, not being on ART, having detectable VL, recreational drug, and polydrug, 
injection, and chemsex-associated drug use. STI co-infection was not significantly associated with 
country of birth, education, religion, social support, depression, anxiety, harmful alcohol drinking or 
dependency, or CD4 count. 
 
After adjustment for core factors (models 1, Table 8.4), the following factors remained associated with 
self-reported STI co-infection (p<0.05) with little or no attenuation in magnitude of associations: 
younger age (a significant inverse trend was observed with lower STI prevalence at older ages), not 
being on ART, and having detectable VL; MSM with study log-recorded VL>50c/mL had 30% higher 
prevalence of any STI in the past three months compared to those with VL≤50c/mL. A significant positive 
trend was also observed between higher number of recreational drugs used and prevalence of STI co-
infections. Strong associations were observed of IDU, chemsex-associated drug use, and STI co-
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infections. The associations with shorter time since HIV diagnosis and employment were not significant 
in the core-adjusted models, primarily due to adjustment for age.  
 
In model 2, any factor with p<0.10 at unadjusted analysis was a candidate for inclusion in the 
multivariable model, in addition to clinic. (Table 8.4) These were: age, ethnicity, time since HIV 
diagnosis, place of birth, employment, financial hardship, stable partner status, ART status, and ART 
status/self-reported VL, recreational drug use, number of drugs used, chemsex-associated, and injection 
drug use. As these last four (drug use) variables incorporated the same factors, only recreational drug 
use was retained. ART status was also excluded from the model as it was incorporated in the ART 
status/self-reported VL variable. Hence, after adjustment for age, ethnicity, time since HIV diagnosis, 
place of birth, employment, financial hardship, detectable study log-recorded VL, recreational drug use, 
and clinic, the following factors remained significantly associated with self-reported STI co-infection: 
younger age, higher financial hardship, detectable VL, and recreational drug use. There was also a weak 
association of non-UK place of birth and prevalence of self-reported STIs (p=0.05). 
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Table 8.4: Association of socio-demographic, psychological, HIV-related, lifestyle factors with any self-reported STI in the past three months (n/N=236/2160) 
  n reporting 
STI/N 
row 
% 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Age at recruitment, years (N=2138) 
    
  
 
    
<30 20/95 21.1 2.6 [1.6,4.2] 
 
2.2 [1.3,3.8] 
 
1.4 [0.8,2.5]   
30-39 84/482 17.4 2.2 [1.6,3.0] 
 
2.0 [1.4,2.9] 
 
1.3 [0.9,1.9]   
40-49 78/915 8.5 1.1 [0.8,1.5] 
 
1.0 [0.7,1.4] 
 
0.7 [0.5,1.0]   
≥50 52/646 8.0 1.0 <0.001(T) 1.0 <0.001(T) 1.0 0.021(T) 
Ethnicity (N=2127)                 
White  197/1908 10.3 1.0 
 
1.0 
 
1.0   
All other (black, Asian, Mixed, other) 34/219 15.5 1.5 [1.1,2.1] 0.017 1.4 [1.0,1.9] 0.082 1.0 [0.7,1.5] 0.818 
Years since HIV diagnosis  (N=2149) 
    
  
 
    
≤2  27/182 14.8 1.0 
 
1.0 
 
1.0   
2-5 39/335 11.6 0.8 [0.5,1.2] 
 
0.9 [0.5,1.4] 
 
1.0 [0.6,1.6]   
5-10 65/542 12.0 0.8 [0.5,1.2] 
 
1.1 [0.7,1.7] 
 
1.3 [0.8,2.0]   
10-15  47/455 10.3 0.7 [0.4,1.1] 
 
1.1 [0.7,1.8] 
 
1.3 [0.8,2.0]   
>15 57/635 9.0 0.6 [0.4,0.9] 0.017(T) 1.1 [0.7,1.7] 0.656(T) 1.1 [0.7,1.8] 0.870(T) 
Place of birth (N=2160)                 
UK 140/1487 9.4 1.0 
 
1.0 
 
1.0   
Outside the UK 96/673 14.3 1.5 [1.2,1.9] <0.001 1.3 [1.0,1.6] 0.059 1.3 [1.0,1.7] 0.050 
Religious (N=2126) 
    
  
 
    
Yes 104/904 11.5 1.0 
 
1.0 
 
-   
No 128/1222 10.5 0.9 [0.7,1.2] 0.452 0.9 [0.7,1.2] 0.454     
Education (N=2123)                 
University degree or above 109/943 11.6 1.0 
 
1.0 
 
-   
No qualifications or up to A levels 123/1180 10.4 0.9 [0.7,1.2] 0.405 0.9 [0.7,1.2] 0.584     
Employment (N=2116) 
    
  
 
    
Employed 154/1305 11.8 1.0 
 
1.0  
 
1.0   
Unemployed or other(carer, student, retired) 76/811 9.4 0.8 [0.6,1.0] 0.083 0.9 [0.7,1.2] 0.418 0.8 [0.6,1.1] 0.097 
Money for basic needs (N=2132)                 
Always 112/1103 10.2 1.0 
 
1.0 
 
1.0   
Mostly 58/590 9.8 1.0 [0.7,1.3] 
 
0.9 [0.7,1.2] 
 
1.0 [0.7,1.3]   
Sometimes 40/269 14.9 1.5 [1.0,2.0] 
 
1.3 [0.9,1.9] 
 
1.7 [1.2,2.4]   
Never 22/170 12.9 1.3 [0.8,2.0] 0.060 (T) 1.2 [0.8,1.9]  0.194(T) 1.5 [0.9,2.5] 0.031(T) 
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  n reporting 
STI/N 
row 
% 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Social support (N=2152) ‡ 
    
  
 
    
High  123/1276 9.6 1.0 
 
1.0 
 
    
Medium 89/661 13.5 1.4 [1.1,1.8] 
 
1.3 [1.0,1.7] 
 
-   
Low 22/215 10.2 1.1 [0.7,1.6] 0.118(T) 0.9 [0.5,1.4] 0.613(T)     
Depression symptoms (N=2160) ‡                 
No 161/1568 10.3 1.0 
 
1.0 
 
-   
Yes 75/592 12.7 1.2 [1.0,1.6] 0.109 1.2 [0.9,1.5] 0.281     
Anxiety symptoms (N=2160) ‡ 
    
  
 
    
No 179/1702 10.5 1.0 
 
1.0 
 
-   
Yes 57/458 12.4 1.2 [0.9,1.6] 0.238 1.1 [0.8,1.5] 0.458     
Stable partner's HIV-serostatus (N=2160)                 
HIV-positive 61/505 12.1 1.0 
 
1.0 
 
1.0   
HIV-negative or unknown status  56/680 8.2 0.7 [0.5,1.0] 
 
0.7 [0.5,1.0] 
 
0.8 [0.5,1.1]   
No stable partner 119/975 12.2 1.0 [0.8,1.3] 0.028 1.0 [0.7,1.3] 0.061 1.0 [0.8,1.4] 0.194 
ART status (N=2152) 
    
  
 
    
On ART 186/1867 10.0 1.0 
 
1.0 
 
-   
Not on ART 49/285 17.2 1.7 [1.3,2.3] <0.001 1.5 [1.1,2.0] 0.029     
ART status/self-reported VL (N=2119)* ‡                 
On ART, reports undetectable VL 158/1556 10.2 1.0 
 
1.0 
 
    
On ART, does not report undetectable VL 26/278 9.4 0.9 [0.6,1.4] 
 
0.8 [0.5,1.2] 
 
-   
Not on ART 49/285 17.2 1.7 [1.3,2.3] 0.001 1.4 [1.0,2.0] 0.043     
Study log-recorded VL (N=2159)*                 
≤50c/mL 157/1658 9.5 1.0 
 
1.0 
 
1.0   
>50c/mL 71/472 15.0 1.6 [1.2,2.0] 0.001 1.3 [1.0,1.8] 0.027 1.4 [1.1,1.9] 0.019 
Study log-recorded CD4 count (N=2159) 
    
  
 
    
>350cells/mm
3
 199/1808 11.0 1.0 
 
1.0 
 
-   
≤350cells/mm
3
 29/323 9.0 0.8 [0.5,1.2] 0.282 0.8 [0.5,1.1] 0.210     
Higher alcohol consumption(N=2159) ‡                 
No 189/1742 10.9 1.0 
 
1.0 
 
-   
Yes 46/417 11.0 1.0 [0.8,1.4] 0.915 1.0 [0.7,1.3] 0.839     
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  n reporting 
STI/N 
row 
% 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Evidence of alcohol dependency (N=2160) ‡ 
No 199/1798 11.1 1.0 
 
1.0 
 
-   
Yes 37/362 10.2 0.9 [0.7,1.3] 0.639 1.0 [0.7,1.3] 0.801     
Recreational drug use (N=2160) 
    
  
 
    
No 74/1063 7.0 1.0 
 
1.0 
 
1.0   
Yes 162/1097 14.8 2.1 [1.6,2.8] <0.001 1.9 [1.5,2.5] <0.001 2.0 [1.5,2.6] <0.001 
Number of recreational drugs used (N=2160)               
None 74/1063 7.0 1.0 
 
1.0 
 
    
1 32/355 9.0 1.3 [0.9,1.9] 
 
1.3 [0.8,1.9] 
 
-   
2-4 76/509 14.9 2.1 [1.6,2.9] 
 
2.0 [1.4,2.7] 
 
    
≥5 54/233 23.2 3.3 [2.4,4.6] <0.001(T) 2.8 [2.0,4.0] <0.001(T)     
Injection drug use (IDU) (N=2160) 
    
  
 
    
No  215/2095 10.3 1.0 
 
1.0 
 
    
Yes 21/65 32.3 3.1 [2.2,4.6] <0.001 2.6 [1.8,3.9] <0.001 -   
Type of recreational drug used (N=2160) ‡                 
None 74/1063 7.0 1.0 
 
1.0 
 
    
Chemsex-associated drugs 80/326 24.5 3.5 [2.6,4.7] 
 
2.9 [2.1,4.1] 
 
-   
All other (not chemsex-associated) 82/771 10.6 1.5 [1.1,2.1] <0.001 1.5 [1.1,2.0] <0.001     
Global p-values by Wald test or test for trend (T); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by modified Poisson regression; Models 1: Each factor adjusted in 
separate model for core variables: age, ethnicity, time since HIV diagnosis, stable partner's HIV serostatus, and ART status. Denominators vary due to missing data in each model. 
Model 2: Any factor with p<0.10 in unadjusted analysis included in a single model, plus clinic. (Only recreational drug use retained in model 2 due to collinearity with number of 
drugs, IDU, type of drugs used). *In both cases, models for study log-recorded VL and for 'ART status/self-reported VL' omit variable on ART due to collinearity. Alcohol consumption 
by WHO-AUDIT-C, alcohol dependency by CAGE questionnaire. Chemsex-associated drugs: mephedrone, crystal methamphetamine, GHB/GBL. 
‡ Variables defined in sections 3.8 and 6.3 
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8.4.2.2 Sexual behaviours associated with any self-reported STI  
Table 8.5 shows the association of various sexual behaviours and any self-reported STI in the past three 
months (N=2160 MSM with available STI data). Of 782 MSM who reported not having any anal or 
vaginal sex in the past three months, 4.1% (n=32) also reported having one or more STIs in the same 
period. Among these 32 men, there were 38 STIs specified; the most prevalent STIs (>10% of 38 
responses) were genital warts (23.7%), genital herpes (18.4%), syphilis (18.4%), CT (13.2%), and new 
HCV (10.5%).  
 
All sexual behaviours shown in Table 8.5 were associated with self-reported STI co-infection in 
unadjusted analysis. There was a striking association of higher partner numbers (measured by total 
number of partners in the past three months, or number of new partners in the past year), with greater 
prevalence of STIs. 
 
In core-adjusted models (models 1A, Table 8.5), all sexual behaviours remained significantly associated 
with prevalent STIs, with some attenuation (p<0.001 for all). In models adjusted for core factors and 
recreational drug use in the past three months (models 1B, Table 8.5), estimates for all sexual 
behaviours were attenuated slightly, but remained strong; the prevalence of any STI was 2.5-fold higher 
among MSM who had any CLS compared to those who did not. Compared to MSM with only one sex 
partner in the past three months, MSM with 20 or more partners had over four-fold prevalence of STIs 
(aPR=4.5, 95%CI 2.9-7.1, p-trend<0.001); compared to MSM with only one new sex partner in the past 
year, MSM with 30 or more new sex partners had over two-fold prevalence of STIs (aPR=2.4, 1.8-3.2, p-
trend<0.001). 
271 
 
Table 8.5: Association of sexual behaviours and any self-reported STI in the previous three months (n/N=236/2160) 
  
n reporting 
STI/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1A: Core 
only aPR [95%CI] p-value 
Models 1B: Core 
+ drugs  aPR 
[95%CI] p-value  
Any anal and/or vaginal sex  (N=2160) 
   
    
 
  
No 32/782 4.1 1.0 
 
1.0   1.0   
Yes 204/1378 14.8 3.6 [2.5,5.2] <0.001 3.4 [2.3,4.9] <0.001 2.9 [2.0,4.3] <0.001 
Condomless sex (CLS)  (N=2160)               
No 83/1335 6.2 1.0 
 
1.0   1.0   
Yes 153/825 18.5 3.0 [2.3,3.8] <0.001 2.8 [2.1,3.6] <0.001 2.5 [1.9,3.3] <0.001 
CLS with HIV-seroconcordant partners (CLS-C) (N=2160) 
 
    
 
  
No 113/1541 7.3 1.0 
 
1.0   1.0   
Yes 123/619 19.9 2.7 [2.1,3.4] <0.001 2.6 [2.0,3.4] <0.001 2.3 [1.7,3.0] <0.001 
CLS with HIV-serodifferent partners (CLS-D) (N=2160)           
No 160/1809 8.8 1.0 
 
1.0   1.0   
Yes 76/351 21.7 2.4 [1.9,3.1] <0.001 2.5 [1.9,3.2] <0.001 2.2 [1.7,2.9] <0.001 
Participated in group sex (N=2118)               
No 127/1669 7.6 1.0 
 
1.0   1.0   
Yes 105/449 23.4 3.1 [2.4,3.9] <0.001 2.8 [2.2,3.6] <0.001 2.5 [1.9,3.2] <0.001 
Used the internet to find sex (N=2122) 
   
    
 
  
No 85/1335 6.4 1.0 
 
1.0   1.0   
Yes 147/787 18.7 2.9 [2.3,3.8] <0.001 2.6 [2.0,3.4] <0.001 2.3 [1.8,3.1] <0.001 
Total number of partners (N=2160)               
None 40/817 4.9 1.0 
 
1.0   1.0   
1 41/589 7.0 1.4 [0.9,2.2] 
 
1.3 [0.9,2.1]   1.3 [0.8,2.0]   
2-4 59/373 15.8 3.2 [2.2,4.7] 
 
3.0 [2.0,4.4]   2.7 [1.8,4.1]   
5-9 38/199 19.1 3.9 [2.6,5.9] 
 
3.6 [2.3,5.4]   3.2 [2.1,4.9]   
10-19 28/103 27.2 5.6 [3.6,8.6] 
 
4.6 [2.9,7.2]   4.0 [2.5,6.4]   
≥20 30/79 38.0 7.8 [5.1,11.7] <0.001(T) 6.1 [3.9,9.6] <0.001(T) 5.3 [3.3,8.6] <0.001(T) 
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n reporting 
STI/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1A: Core 
only aPR [95%CI] p-value 
Models 1B: Core 
+ drugs  aPR 
[95%CI] p-value  
Number of new sexual partners in past year (N=2039) 
 
    
 
  
No new partners 26/873 3.0 1.0 
 
1.0   1.0   
1-9 79/638 12.4 4.2 [2.7,6.4] 
 
4.4 [2.8,6.9]   4.2 [2.6,6.6]   
10-19 33/218 15.1 5.1 [3.1,8.3] 
 
5.0 [2.9,8.4]   4.5 [2.6,7.7]   
20-29 23/127 18.1 6.1 [3.6,10.3] 
 
6.1 [3.5,10.5]   5.5 [3.1,9.6]   
≥30  63/183 34.4 11.6 [7.5,17.7] <0.001(T) 10.6 [6.7,16.7] <0.001(T) 9.6 [6.0,15.4] <0.001(T) 
Three month recall unless otherwise specified; Global p-values by Wald test, test for trend (T), or Fisher's exact (F); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by 
modified Poisson regression; Models 1A: Each factor adjusted in separate model for core factors: age, ethnicity, time since HIV diagnosis, stable partner's HIV serostatus, ART status. 
Denominators vary due to missing data in each model. Models 1B: Each factor adjusted in separate model for core factors plus recreational drug use in the past three months 
(yes/no) 
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 STIs and the mutually exclusive categorical variable of sexual behaviour 8.4.3
All 2160 MSM with available STI data were classified into one of the following mutually exclusive groups 
of sexual behaviour in the past three months (as described in section 4.3.3):  
1. CLS-D (n=351)  
2. ‘CLS-C without CLS-D’ (n=474)  
3. Condom-protected sex only (n=553) 
4. No anal or vaginal sex (n=782) 
MSM who did not have sex in the past three months (group 4) were then excluded. Among 1378 
remaining MSM, the prevalence (95%CI) of self-reported STIs in the past three months was highest for 
MSM who had CLS-D (group 1: 21.6%, 17.6-26.3%), followed by those who had ‘CLS-C without CLS-D’ 
(group 2: 16.2%, 13.2-19.9%), and lowest for those who had condom-protected sex only (group 3: 9.2%, 
7.1-11.9%).  
 
Figure 8.5 shows the prevalence of any self-reported STIs in the past three months (as defined in section 
8.3.3.1) according to the three mutually exclusive categories of sexual behaviour (N=1378 reported anal 
or vaginal sex in past three months). In unadjusted analysis, MSM who had CLS-D had 2.3 times higher 
prevalence of STIs compared to MSM who had condom-protected sex. After adjustment for core factors, 
the magnitude of associations attenuated but remained strong. Additional adjustment for recreational 
drug use in the past three months (in addition to core factors) resulted in slight attenuation of 
magnitude of associations. After additional adjustment for total number of sexual partners in the past 
three months, the association of the sexual behaviour variable with STIs was considerably attenuated: 
prevalence of STIs was no longer significantly associated with reporting ‘CLS-C without CLS-D’, but 
remained significantly elevated among MSM who had CLS-D compared to those who had condom-
protected sex. 
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Figure 8.5: Unadjusted and adjusted associations of mutually exclusive categories of sexual 
behaviour and any self-reported STI diagnosis in past three months (N=1378 MSM had anal 
or vaginal sex in past three months) 
 
PR: prevalence ratios; Condom-protected sex is the reference group; Model 1: core factors only; Model 2: 
core factors and recreational drug use in past three months; Model 3: core factors, recreational drug use, 
and total number of sex partners in the past three months. 
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CLS-C without CLS-D
CLS-D
1.0 
1.8 (1.3, 2.5)
2.3 (1.7, 3.3)
1.0 
1.7 (1.2, 2.3)
2.4 (1.7, 3.3)
1.0 
1.5 (1.1, 2.2)
2.2 (1.6, 3.1)
1.0 (1.0, 1.0)
1.3 (0.9, 1.9)
1.6 (1.1, 2.3)
PR (95% CI)
0.001
<0.001
0.005
<0.001
0.015
<0.001
0.127
0.011
P-value
  
1 2 3
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 Linked clinical hepatitis C analysis 8.4.4
 Hepatitis C cohort  8.4.5
Analyses presented in this section are based on data from HIV-diagnosed MSM participating in ASTRA 
who consented to linkage of the questionnaire with routine clinical data; 1811 HIV-diagnosed MSM had 
hepatitis clinical data linked to questionnaire data, of whom 1702 had hepatitis C data (Figure 8.6).  
 
Figure 8.6: Cohort flow diagram 
 
 Cumulative prevalence of HCV  8.4.6
MSM were excluded from this analysis if HCV test results were available only after ASTRA completion 
(Figure 8.6, left panel). Hence, among 1195 MSM ASTRA participants with HCV test results, 161 had a 
chronic/prevalent HCV-positive record, resulting in cumulative HCV prevalence of 13.5% (95%CI 11.6-
15.5%). When excluding 18 MSM who reported IDU in the past three months, cumulative HCV 
prevalence was 12.4% (10.6-14.3%).  
 
A total of 188 MSM reported lifetime diagnosis of HCV on the questionnaire (see section 3.8.4); of these, 
138 (73.4%) were identified as having chronic/prevalent HCV in clinical records as well, while 50 (26.6%) 
were not. When including the 50 MSM who said they had lifetime HCV diagnosis on the questionnaire, 
the cumulative prevalence of HCV among 1195 MSM was 17.7% (15.6-19.9%, n=211). A small minority 
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(2.2%) of 161 MSM with prevalent/chronic HCV in clinical records did not report having lifetime 
diagnosis of HCV on the questionnaire.  
 Factors associated with cumulative HCV prevalence  8.4.7
8.4.7.1 Socio-demographic, psychological, HIV-related, and lifestyle factors  
In unadjusted analysis (Table 8.6), cumulative prevalence of HCV was higher for MSM who were of white 
ethnicity, had symptoms of depression, an HIV-positive stable partner, did not have evidence of alcohol 
dependency (by CAGE questionnaire), used recreational drugs, injected drugs, and used chemsex-
associated drugs; positive trends were also observed with increasing financial hardship and higher HCV 
prevalence, as well as increasing number of drugs used (p<0.10 for all factors). Of note, 30.9% of MSM 
who used chemsex-associated drugs had prevalent HCV, compared to 14.4% who used any other drug 
(but not chemsex-associated). Age, ethnicity, time since HIV diagnosis, place of birth, religion, 
employment, social support, anxiety, ART status, and higher alcohol consumption (by modified WHO-
AUDIT-C) were not associated with cumulative HCV prevalence. 
 
After adjustment for core factors, the following remained significantly associated with higher cumulative 
HCV prevalence, with little attenuation: symptoms of depression, having an HIV-positive stable partner, 
no evidence of alcohol dependency, and all recreational drug use factors (p<0.05 for all, models 1, Table 
8.6). The strong positive trends with increasing financial hardship and increasing number of drugs used 
in the past three months also remained robust.  
 
Any factor with p<0.10 at unadjusted analysis was a candidate for inclusion in a single multivariable 
model.(Model 2, Table 8.6) These were: ethnicity, financial hardship, depression symptoms, stable 
partner status, evidence of alcohol dependency, recreational drug use, number of drugs used, injection 
drug use (IDU), and type of recreational drugs used. Ethnicity was not retained in the model due to low 
prevalence of non-white ethnicity in this analysis. As all recreational variables could not be included in a 
single model, only IDU was retained. Hence, after adjustment for financial hardship, depression, stable 
partner status, alcohol dependency, and IDU, all factors, except for financial hardship, remained strongly 
associated with cumulative HCV prevalence. The prevalence of HCV was 80% higher among MSM with 
symptoms of depression compared to those without, and three-fold higher in relative terms among 
MSM who injected drugs compared to those who did not (both factors p<0.001). MSM who did not have 
evidence of alcohol dependency were more likely to have prevalent HCV compared to those with 
evidence. (p<0.001) 
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Table 8.6: Associations of socio-demographic, psychological, HIV-related, and lifestyle factors with cumulative prevalence of hepatitis C (HCV) (n/N=161/1195) 
  n prevalent 
HCV/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Age at recruitment, years (N=1175) 
    
    
 
  
<40 34/270 12.6 1.2 [0.8,1.8] 
 
1.3 [0.9,2.1]   
 
  
40-49 83/513 16.2 1.5 [1.1,2.1] 
 
1.5 [1.1,2.1]   -   
≥50 42/392 10.7 1.0 0.297(T) 1.0 0.104(T) 
 
  
Ethnicity (N=1171)                 
White  152/1082 14.0 1.0 
 
1.0   -   
All other (black, Asian, Mixed, other) 6/89 6.7 0.5 [0.2,1.1] 0.068 0.5 [0.2,1.1] 0.098     
Years since HIV diagnosis  (N=1195) 
    
    
 
  
≤10 74/565 13.1 1.0 
 
1.0   -   
>10 87/630 13.8 1.1 [0.8,1.4] 0.719(T) 1.1 [0.8,1.5] 0.399(T) 
 
  
Place of birth (N=1195)                 
UK 115/846 13.6 1.0 
 
1.0   -   
Outside the UK 46/349 13.2 0.9 [0.7,1.3] 0.850 1.1 [0.8,1.5] 0.605     
Religious (N=1174) 
    
    
 
  
Yes 65/471 13.8 1.0 
 
1.0   
 
  
No 95/703 13.5 1.0 [0.7,1.3] 0.888 0.9 [0.7,1.2] 0.499 -   
Education (N=1177)                 
University degree or above 74/517 14.3 1.0 
 
1.0   -   
No qualifications or up to A levels 86/660 13.0 1.0 [0.8,1.4] 0.524 0.9 [0.7,1.2] 0.333     
Employment (N=1177) 
    
    
 
  
Employed 91/704 12.9 1.0 
 
1.0   -   
Unemployed or other(carer, student, retired) 69/473 14.6 1.1 [0.8,1.5] 0.415 1.2 [0.9,1.6] 0.224 
 
  
Money for basic needs (N=1178)                 
Always 73/618 11.8 1.0 
 
1.0   1.0   
Mostly 48/332 14.5 1.2 [0.9,1.7] 
 
1.2 [0.9,1.7]   1.2 [0.8,1.6]   
Sometimes/never 38/228 16.7 1.4 [1.0,2.0] 0.052(T) 1.4 [1.0,2.1] 0.043(T) 1.2 [0.8,1.7] 0.348(T) 
Social support (N=1188) ‡ 
  
  
 
    
 
  
High  91/713 12.8 1.0 
 
1.0   -   
Medium/low 70/475 14.7 1.2 [0.9,1.5] 0.330(T) 1.2 [0.9,1.6] 0.240(T) 
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  n prevalent 
HCV/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Depression symptoms (N=1195) ‡                 
No 99/881 11.2 1.0 
 
1.0   1.0   
Yes 62/314 19.7 1.8 [1.3,2.3] <0.001 1.8 [1.4,2.4] <0.001 1.8 [1.3,2.4] <0.001 
Anxiety symptoms (N=1195) ‡ 
    
    
 
  
No 121/946 12.8 1.0 
 
1.0   -   
Yes 40/249 16.1 1.3 [0.9,1.7] 0.175 1.3 [0.9,1.8] 0.119 
 
  
Stable partner's HIV-serostatus (N=1195)                 
HIV-positive 63/272 23.2 1.0 
 
1.0   1.0   
HIV-negative or unknown status  31/393 7.9 0.3 [0.2,0.5] 
 
0.4 [0.2,0.5]   0.4 [0.2,0.6]   
No stable partner 67/530 12.6 0.5 [0.4,0.7] <0.001 0.5 [0.4,0.7] <0.001 0.5 [0.4,0.7] <0.001 
ART status (N=1190) 
    
    
 
  
On ART 143/1034 13.8 1.0 
 
1.0   -   
Not on ART 17/156 10.9 0.8 [0.5,1.3] 0.325 0.7 [0.5,1.2] 0.259 
 
  
ART status/self-reported VL (N=1170)* ‡                 
On ART, reports undetectable VL 116/850 13.6 1.0 
 
1.0   -   
On ART, does not report undetectable VL 22/164 13.4 1.0 [0.6,1.5] 
 
1.1 [0.7,1.6]   
 
  
Not on ART 17/156 10.9 0.8 [0.5,1.3] 0.655 0.8 [0.5,1.2] 0.508     
Study log-recorded VL (N=1188)*                 
≤50c/mL 119/912 13.1 1.0 
 
1.0   -   
>50c/mL 42/276 15.2 1.1 [0.8,1.6] 0.354 1.1 [0.8,1.6] 0.353     
Study log-recorded CD4 count (N=1188)                 
≤350cells/mm
3
 13/144 9.0 1.0 
 
1.0   -   
>350cells/mm
3
 148/1044 14.2 1.5 [0.9-2.6] 0.111 1.4 [0.8,2.4] 0.209     
Higher alcohol consumption(N=1194) ‡ 
    
    
 
  
No 136/956 14.2 1.0 
 
1.0   -   
Yes 25/238 10.5 0.7 [0.5,1.1] 0.140 0.7 [0.5,1.1] 0.122 
 
  
Evidence of alcohol dependency (N=1195) ‡                 
No 148/983 15.1 1.0 
 
1.0   1.0   
Yes 13/212 6.1 0.4 [0.2,0.7] 0.001 0.4 [0.2,0.7] 0.002 0.4 [0.2,0.7] 0.001 
Recreational drug use (N=1195) ‡ 
  
  
 
    
 
  
No 43/576 7.5 1.0 
 
1.0   -   
Yes 118/619 19.1 2.6 [1.8,3.6] <0.001 2.2 [1.6,3.1] <0.001 
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  n prevalent 
HCV/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1: aPR 
[95%CI] p-value 
Model 2: aPR 
[95%CI] p-value  
Number of recreational drugs used (N=1195)‡               
None 43/576 7.5 1.0 
 
1.0   -   
1 21/208 10.1 1.4 [0.8,2.2] 
 
1.3 [0.8,2.1]   
 
  
2-4 62/284 21.8 2.9 [2.0,4.2] 
 
2.5 [1.7,3.6]   
 
  
≥5 91/713 27.6 3.7 [2.5,5.5] <0.001 3.0 [2.0,4.6] <0.001     
Injection drug use (IDU) (N=1195) ‡ 
    
    
 
  
No  143/1157 12.4 1.0 
 
1.0   1.0   
Yes 18/38 47.4 3.8 [2.7,5.5] <0.001 3.4 [2.4,4.9] <0.001 3.0 [2.1,4.2] <0.001 
Type of recreational drug used (N=1195) ‡                 
None 43/576 7.5 1.0 
 
1.0   
 
  
Chemsex-associated drugs 54/175 30.9 4.1 [2.9,5.9] 
 
3.4 [2.3,5.0]   -   
All other (not chemsex-associated) 64/444 14.4 1.9 [1.3,2.8] <0.001 1.7 [1.2,2.5] <0.001     
Global p-values by Wald test or test for trend (T); PR: prevalence ratio; CI: confidence interval; Adjusted PRs (aPR) by modified Poisson regression; Models 1: Each factor adjusted in 
separate model for core variables: age, ethnicity, time since HIV diagnosis, stable partner's HIV serostatus, and ART status. Denominators vary due to missing data in each model. 
Model 2: Any factor with p<0.10 in unadjusted analysis included in a single model, plus clinic. (Only IDU retained in model 2 due to collinearity with recreational drug use, number 
of drugs, type of drugs used). *In both cases, model for 'ART status/self-reported VL' and model for study log-recorded VL omit variable on ART due to collinearity. Alcohol 
consumption by WHO-AUDIT-C, alcohol dependency by CAGE questionnaire.  
‡ All factors defined in section 3.8. 
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8.4.7.2 Sexual behaviours, other STIs and cumulative HCV prevalence  
In unadjusted analysis (Table 8.7), all sexual behaviours and any self-reported diagnosed STIs were 
associated with cumulative HCV prevalence. After adjustment for core factors, all sexual behaviours and 
self-reported STIs in the past three months remained significantly associated with higher HCV 
prevalence (p<0.05 for all, models 1A: Table 8.7 ). Significant positive trends were also observed with 
increasing number of partners in the past three months, as well as with increasing number of new sex 
partners in the past year (p-trend<0.001 for both).  
 
Additional adjustment for injection drug use (IDU) in the past three months (and core factors) resulted 
in attenuated, but still robust associations with cumulative HCV prevalence (models 1B: Table 8.7). MSM 
who had CLS-C had over two-fold higher prevalence of HCV compared to those who did not; similarly, 
those who had any other self-reported diagnosed STI in the past three months had 40% higher 
prevalence of HCV in relative terms compared to those without another STI.  
 Incident HCV over follow-up 8.4.8
Of the initial 1702 MSM with available HCV data, participants were excluded if they had clinically-
verified or self-reported HCV infection prior to ASTRA completion; 1137 MSM remained.(Figure 8.6, 
right panel) Over a median of 1.8 years [IQR 1.3-2.2] and 1935 person-years (PY) at risk, 6 new HCV 
cases were recorded. Incidence of HCV was 0.31 per 100 PY (95% 0.13-0.69). Conclusions drawn on the 
basis of these six incident cases are limited, but the framework of analysis demonstrates the approach 
that will be taken once greater follow-up (FU) is accrued. 
8.4.8.1 Factors associated with incident HCV  
Table 8.8 shows the associations of factors with new HCV over FU. The median time elapsed between 
clinic-recorded VL and incident HCV diagnosis date was 1.5 years (IQR 0.2-4.2) and of clinic-recorded 
CD4 count was 1.1 years (0.3-2.7). All six MSM with incident HCV had high clinic-recorded CD4 counts 
prior to HCV diagnosis (median 500, IQR 410-840 cells/mm
3
). There was an indication, despite the very 
small number of incident HCV cases, that IDU and chemsex-associated drug use in the three months 
prior to questionnaire completion conferred higher risk of incident HCV. There was some suggestion of 
elevated risk of incident HCV among MSM who had CLS, CLS-C, CLS-D, or a self-reported diagnosis of 
syphilis in the past three months, as well as among those with 10 or more new sex partners in the past 
year. However, conclusions based on the small number of incident cases are limited.  
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Table 8.7: Associations of sexual behaviours, other STIs in the past three months and cumulative prevalence of hepatitis C (HCV) (n/N=161/1195) 
  
n with 
chronic/ 
prevalent 
HCV/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1A: Core 
only  
aPR [95%CI] p-value 
Models 1B: 
Core + IDU  
aPR [95%CI] p-value  
Any anal and/or vaginal sex  (N=1195) 
   
    
 
  
No 36/430 8.4 1.0 
 
1.0   1.0   
Yes 125/765 16.3 2.0 [1.4,2.8] <0.001 1.8 [1.3,2.6] 0.001 1.7 [1.2,2.4] 0.005 
Condomless sex (CLS)  (N=1195)               
No 64/736 8.7 1.0 
 
1.0   1.0   
Yes 97/459 21.1 2.4 [1.8,3.3] <0.001 2.2 [1.6,2.9] <0.001 1.9 [1.4,2.7] <0.001 
CLS with HIV-seroconcordant partners (CLS-C) (N=1195) 
 
    
 
  
No 74/844 8.8 1.0 
 
1.0   1.0   
Yes 87/351 24.8 2.8 [2.1,3.8] <0.001 2.4 [1.7,3.3] <0.001 2.1 [1.5,2.9] <0.001 
CLS with HIV-serodifferent partners (CLS-D) (N=1195)           
No 130/1009 12.9 1.0 
 
1.0   1.0   
Yes 31/186 16.7 1.3 [0.9,1.9] 0.160 1.6 [1.1,2.2] 0.011 1.6 [1.1,2.2] 0.013 
Participated in group sex (N=1167)               
No 99/927 10.7 1.0 
 
1.0   1.0   
Yes 58/240 24.2 2.3 [1.7,3.0] <0.001 2.2 [1.7,3.0] <0.001 2.1 [1.5,2.8] <0.001 
Used the internet to find sex (N=1171) 
   
    
 
  
No 79/735 10.7 1.0 
 
1.0   1.0   
Yes 78/436 17.9 1.7 [1.2,2.2] <0.001 1.7 [1.3,2.3] <0.001 1.6 [1.2,2.1] 0.002 
Total number of partners (N=1195)               
None 38/451 8.4 1.0 
 
1.0   1.0   
1 43/336 12.8 1.5 [1.0,2.3] 
 
1.3 [0.9,2.0]   1.3 [0.8,1.9]   
2-4 63/319 19.7 2.3 [1.6,3.4] 
 
2.2 [1.5,3.2]   2.0 [1.4,3.0]   
≥5 17/89 19.1 2.3 [1.3,3.8] <0.001(T) 2.3 [1.4,3.8] <0.001(T) 2.0 [1.2,3.4] <0.001(T) 
Number of new sexual partners in past year (N=1130) 
 
    
 
  
No new partners 42/480 8.8 1.0 
 
1.0   1.0   
1-9 57/357 16.0 1.8 [1.3,2.7] 
 
1.7 [1.1,2.4]   1.6 [1.1,2.3]   
10-19 25/133 18.8 2.1 [1.4,3.4] 
 
2.4 [1.5,3.7]   2.0 [1.3,3.2]   
≥20 31/160 19.4 2.2 [1.4,3.4] <0.001(T) 2.2 [1.5,3.4] <0.001(T) 1.9 [1.3,3.0] <0.001(T) 
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n with 
chronic/ 
prevalent 
HCV/N row % 
unadjusted 
PR[95%CI] p-value 
Models 1A: Core 
only  
aPR [95%CI] p-value 
Models 1B: 
Core + IDU  
aPR [95%CI] p-value  
Any self-reported STI (N=1180)                 
No 136/1065 12.8 1.0 
 
1.0   1.0   
Yes 24/115 20.9 1.6 [1.1,2.4] 0.013 1.7 [1.1,2.5] 0.011 1.4 [1.0,2.2] 0.074 
Number of self-reported STIs (N=1195) 
   
    
 
  
None 137/1080 12.7 1.0 
 
-   -   
1 21/90 23.3 1.8 [1.2,2.8] 
 
    
 
  
≥2 3/25 12.0 0.9 [0.3,2.8] 0.014(F)     
 
  
Self-reported syphilis (N=1195)                 
No 157/1170 13.4 1.0 
 
-   -   
Yes 4/25 16.0 1.2 [0.5,3.0] 0.765(F)         
Three month recall of sexual behaviours unless otherwise specified; Global p-values by Wald test, test for trend (T), or Fisher's exact (F); PR: prevalence ratio; CI: confidence interval; 
Adjusted PRs (aPR) by modified Poisson regression; Models 1A: Each factor adjusted in separate model for core factors. Models 1B: Each factor adjusted in separate model for core 
factors and injection drug use (IDU) in the past three months. Denominators vary due to missing data in each model.  
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Table 8.8: Associations of socio-demographic, HIV-related, lifestyle characteristics, sexual 
behaviours and incident hepatitis C diagnosis (n/N=6/1137) 
  
n/PY IR/100PY [95%CI] 
unadjusted 
IRR/100 PY 
[95%CI] 
p-value 
(exact)  
Age at recruitment, years (N=1118)         
<40 3/608 0.49 [0.16-1.53] 2.5 [0.3,23.7]   
40-49 2/808 0.25 [0.06-0.99] 1.2 [0.1,13.4]   
≥50 1/485 0.21 [0.03-1.46] 1.0 0.638 
Years since HIV diagnosis  (N=1137) 
   
  
≤10 3/1023 0.29 [0.09-0.91] 1.0   
>10 3/913 0.33 [0.11-1.02] 1.1 [0.2,5.7] 0.870 
Stable partner's HIV-serostatus (N=1137)       
HIV-positive 2/435 0.46 [0.12-1.84] 1.0   
HIV-negative or unknown status  2/653 0.31 [0.08-1.23] 0.6 [0.1,4.6]   
No stable partner 2/848 0.24 [0.06-0.94] 0.5 [0.1,3.5] 0.777 
ART status (N=1132) 
   
  
On ART 4/1598 0.25 [0.09-0.67] 1.0   
Not on ART 2/329 0.61 [0.15-2.43] 2.2 [0.4,12.1] 0.361 
Clinic-recorded VL (N=1130)*         
≤50c/mL 2/1219 0.16 [0.04-0.66] 1.0   
>50c/mL 4/707 0.57 [0.21-1.51] 3.5 [0.6, 18.6] 0.156 
Clinic-recorded CD4 count (N=1133)* 
  
  
<350cells/mm3 0/349 - - - 
≥350cells/mm3 6/1581 0.38 [0.17-0.84] 
 
  
Higher alcohol consumption(N=1137) ‡       
No 5/1576 0.32 [0.13-0.76] 1.0   
Yes 1/359 0.28 [0.04-1.98] 0.9 [0.1,7.6] 0.918 
Recreational drug use (N=1137) ‡ 
   
  
No 0/933 - 
 
  
Yes 6/1002 0.6 [0.27-1.33] - - 
Number of recreational drugs used (N=1137)‡       
1-3 4/682 0.59 [0.22-1.56] 1.0   
≥4 2/320 0.63 [0.16-2.5] 1.1 [0.2,6.1] 0.901 
Injection drug use (IDU) (N=1137) ‡ 
   
  
No  5/1892 0.26 [0.11-0.63] 1.0   
Yes 1/43 2.31 [0.33-16.39] 10.4 [1.2,89.4] 0.033 
Chemsex-associated drug use (N=1137) ‡       
No 3/1633 0.18 [0.06-0.57] 1.0   
Yes 3/303 0.99 [0.32-3.07] 4.8 [1.0,24.0] 0.054 
Any anal and/or vaginal sex  (N=1137) 
  
  
No 1/659 0.15 [0.02-1.08] 1.0   
Yes 5/1276 0.39 [0.16-0.94] 2.6 [0.3,22.4] 0.380 
Condomless sex (CLS)  (N=1137)         
No 1/1168 0.09 [0.01-0.61] 1.0   
Yes 5/767 0.65 [0.27-1.57] 7.5 [0.9,63.9] 0.067 
CLS with HIV-seroconcordant partners (CLS-C) (N=1137) 
 
  
No 2/1351 0.15 [0.04-0.59] 1.0   
Yes 4/584 0.68 [0.26-1.82] 4.6 [0.8,25.0] 0.080 
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n/PY IR/100PY [95%CI] 
unadjusted 
IRR/100 PY 
[95%CI] 
p-value 
(exact)  
CLS with HIV-serodifferent partners (CLS-D) (N=1137)     
No 3/1624 0.18 [0.06-0.57] 1.0   
Yes 3/311 0.96 [0.31-2.99] 5.3 [1.1,26.0] 0.042 
Participated in group sex (N=1111) 
   
  
No 4/1460 0.27 [0.1-0.73] 1.0   
Yes 2/431 0.46 [0.12-1.86] 1.6 [0.3,8.8] 0.586 
Used the internet to find sex (N=1112)       
No 2/1172 0.17 [0.04-0.68] 1.0   
Yes 4/719 0.56 [0.21-1.48] 3.6 [0.7,19.5] 0.143 
Total number of partners (N=1137) 
   
  
0-4 4/1738 0.23 [0.09-0.61] 1.0   
≥5 2/198 1.01 [0.25-4.04] 4.2 [0.8,23.1] 0.097 
Number of new sexual partners in past year (N=1137)     
0-9 1/1353 0.07 [0.01-0.52] 1.0   
≥10 5/583 0.86 [0.36-2.06] 10.8 [1.3,92.5] 0.030 
Any other STI (N=1121)         
No 4/1669 0.24 [0.09-0.64] 1.0   
Yes 2/237 0.84 [0.21-3.37] 3.3 [0.6,17.8] 0.173 
Syphilis (N=1121) 
   
  
No 5/1887 0.26 [0.11-0.64] 1.0   
Yes 1/49 2.06 [0.29-14.61] 7.3 [0.8,62.1] 0.071 
Three month recall unless otherwise specified. p-values by exact significance test; IR: incidence rate; IRR: 
incidence rate ratio; PY: person-years; STI: sexually transmitted infection. *Clinic-recorded VL and CD4 
closest to HCV test date.  
‡ All factors defined in sections 3.8 and 6.3 
8.5 Discussion 
 Summary of findings  8.5.1
In this large study of HIV-diagnosed MSM attending for HIV care, one in 10 had a self-reported diagnosis 
of STIs (other than HIV) in the past three months. The majority of STI co-infections were bacterial, with 
chlamydia (CT), gonorrhoea (NG), and syphilis being most prevalent. STI co-infections were more 
prevalent among MSM who were younger, had an HIV-positive stable partner, were not on ART, and 
used recreational drugs in the past three months (including IDU and chemsex-associated drugs). 
Prevalence of STI co-infections was also associated with reporting any anal or vaginal sex, any CLS, CLS-
C, CLS-D, group sex, and high partner numbers, even after adjustment for socio-demographic, HIV-
related factors, and recreational drug use (including IDU). Among those who had sex in the past three 
months, those who had CLS-D had significantly higher prevalence of STI co-infections compared to those 
who had condom-protected sex. In longitudinal analysis using linked routine clinical data, the 
cumulative prevalence of any hepatitis C (HCV) diagnosis prior to ASTRA completion was 13.3%. 
Symptoms of depression, recreational drug use (and IDU), sexual behaviours (any sex, CLS, CLS-C, CLS-D, 
group sex, high partner numbers), and any other STI co-infection were strongly associated with 
prevalent HCV. Incident HCV diagnosis over almost two years of follow-up was recorded for six MSM 
ASTRA participants, yielding an incidence rate of 0.31 per 100 person years (PY). Despite the low 
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number of incident HCV infections, there was suggestion that incidence was higher among MSM who 
reported IDU, chemsex-associated drug use, and CLS-D in the past three months.  
 Prevalence of STIs in ASTRA  8.5.2
The prevalence of any STI among HIV-diagnosed MSM in this study was assessed by self-reported 
diagnosis with a three month recall period. Previous studies which recruited HIV-diagnosed MSM from 
outpatient clinics in high income countries and also used self-reported measures found prevalence 
estimates of any STI in the past 12 months ranging from 13% to 41% (see Table 8.1). The most 
commonly reported STIs in ASTRA were CT, NG, and syphilis, in line with estimates of STI surveillance 
among MSM in the UK.
471
 This pattern of STI prevalence was also observed in the Swiss HIV cohort study 
(SHCS)
546
 among 112 HIV-diagnosed MSM who reported having sex in the past year. In other studies 
that provided prevalence estimates for specific STIs (see Table 8.1), genital warts were the most 
prevalent STI in two US studies
239,298
 while syphilis was most prevalent in a German study.
316,547
  These 
differences reflect the prevalence of different STIs in different populations of HIV-diagnosed MSM 
worldwide. 
 Factors associated with prevalent self-reported diagnosed STIs  8.5.3
The factors found to be associated with self-reported diagnosis of STIs in this chapter mostly mirror 
factors that found to be associated with any CLS in the past three months in Chapter 4. As shown in 
Table 4.4, CLS was more prevalent among younger MSM. In this chapter (Table 8.4), there was also 
evidence of a consistent association of younger age and higher prevalence of any self-reported STI in the 
past three months. An earlier US study of over 200 HIV-diagnosed MSM also showed that younger age 
was predictive of incident bSTIs at follow-up; this estimate was adjusted only for repeated measures 
(but not any other factors, such as CLS).  
 
In Chapter 4, it was also shown that MSM with an HIV-positive stable partner were more likely to report 
CLS in the past three months, compared to those who had an HIV-serodifferent or no stable partner. 
(Table 4.4) Similarly, in this chapter, MSM with an HIV-positive stable partner tended to be more likely 
to have any STI in the past three months. This finding is in line with recent evidence of enteric STI 
outbreaks in the UK, in which the majority of cases were HIV-positive MSM who reported CLS with other 
HIV-positive men only.
521
 
 
In line with earlier studies
554,558,560,568
, socio-economic factors such as ethnicity, education, employment 
status, place of birth were not associated with any STI co-infection in ASTRA.  Similarly, none of these 
socio-economic factors were associated with reporting CLS in the past three months in Chapter 4, either. 
In this chapter, there was some evidence that MSM who reported financial hardship (no money for basic 
needs) were more likely to have higher prevalence of STI co-infections; financial hardship was not 
associated with reporting any CLS in Chapter 4 (Table 4.4).  
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In this analysis, MSM who were not on ART and those who had detectable VL had significantly higher 
prevalence of self-reported STIs, even after adjustment for time with HIV diagnosis. The pattern of 
higher STI prevalence among those not on ART is similar to that seen in Chapter 4, with higher 
prevalence of CLS among those not on ART. As in our study, three earlier studies also reported 
significant associations of not being on ART
548
 or having detectable HIV VL and self-reported bacterial 
STIs in the past three months.
239,547
 In contrast, a systematic review of 37 studies showed no difference 
in the prevalence of STI co-infections according to ART status in HIV-diagnosed men and women.
116
 It 
may be that previous STI co-infections may activate HIV replication leading to increased viremia. In this 
case, elevated HIV VL may be a proxy for having an STI.  
 
Recreational drug use, including IDU, has been identified as a key factor in the transmission of bSTIs and 
HCV among HIV-diagnosed MSM in the UK.
148,370,539,568,571,572
 In this study, all measures of recreational 
drug use were strongly associated with self-reported prevalent STIs; chemsex-associated drug use was 
strongly associated with higher prevalence of any STI. Drug-induced sexual disinhibition may facilitate 
CLS with multiple partners, as well as traumatic and prolonged sex practices that in turn lead to STI 
transmission. 
 
CLS and high partner numbers were, as expected, strongly associated with any self-reported STI. A small 
minority of studies reviewed in this chapter explore the factors associated with higher risk of (prevalent 
or incident) STIs, over and above the risk conferred by CLS (see section 8.2.11). In this ASTRA analysis 
(and the majority of other studies reviewed) associations with self-reported STIs paralleled associations 
with reporting CLS and high partner numbers. Specifically, when compared to MSM who had condom-
protected sex, MSM who had CLS-D were more likely to report any STI. Maintaining consistent condom 
use is likely to be challenging in the context of high partner numbers. It is also likely that accurate 
ascertainment of all partners’ HIV status is more uncertain with high partner numbers. Therefore, the 
number of sex partners reported in the past three months (or number of new partners in the past year) 
can be used as a predictor of STI risk in epidemiological studies. CLS remains the most useful marker of 
STI transmission (other than HIV) for epidemiological surveillance and STI prevention among HIV-
diagnosed MSM.  
 Hepatitis C co-infection 8.5.4
Over the past two decades, there has been increasing evidence of HCV transmission among MSM who 
do not report IDU, and of the emergence of acute HCV among HIV-diagnosed MSM in Europe and North 
America. This evidence has highlighted the importance of the sexual route in changing the pattern of 
HCV transmission among HIV-diagnosed MSM.  
8.5.4.1 Cumulative prevalence of HCV 
In ASTRA, the cumulative HCV prevalence (the proportion of MSM ever tested for anti-HCV or HCV RNA 
who had received a positive HCV test result) was 13.3% overall, 12.4% when excluding men who 
reported IDU, and 17.7% when including men with self-reported lifetime diagnosis of HCV only. A 
287 
 
systematic review (2000-2015) of 13 studies including over 9500 HIV-diagnosed MSM in high-income 
countries reported cumulative prevalence of 8.3% (95%CI 6.7-9.9%) overall and 7.1% (5.1-9.0%) when 
excluding MSM who reported IDU.
536
 Our estimates are in line with those from earlier cross-sectional 
surveys with linked clinical data (HCV prevalence ranging from 7.7% to 15.2%).  
8.5.4.2 Factors associated with prevalent HCV  
A number of socio-demographic factors were not associated with prevalent HCV in ASTRA. As observed 
in two earlier UK cross-sectional questionnaire surveys (SHARP
568
 and GMSS
560
), HCV prevalence did not 
differ significantly by participants’ age, ethnicity, educational attainment, or employment status in our 
study.  
 
In ASTRA, a strong association was observed between evidence of depressive symptoms and higher 
prevalence of chronic HCV; depression was associated with 80% higher prevalence of HCV in relative 
terms, even after adjustment for markers of lower socio-economic status, IDU, and stable partner 
status. Prevalence of depression has been shown to be significantly higher among HCV-diagnosed 
individuals compared to those without HCV.
578
 It is possible that this is still the case in HIV/HCV co-
infected individuals, but research is scarce in this area. Temporality in the association of depression and 
HCV cannot be established from ASTRA due to its cross-sectional design. However, it could be 
hypothesized that depression is a result of living with a diagnosis for a second chronic condition in 
addition to HIV, as well as of coping with treatment, complications, and morbidity related to HCV. On 
the other hand, it could also be that HIV-diagnosed people with pre-existing depression may have higher 
susceptibility to HCV infection; this could be mediated through the strong association of recreational 
drug use with CLS, as shown in Chapter 6 (see Figure 6.3). With the advent of DAAs, HCV cure rates have 
improved dramatically
579
; it will remain important to continue screening for and managing depression 
among HCV/HIV co-infected individuals.   
 
The cumulative prevalence of HCV was over two-fold higher among MSM who did not have evidence of 
alcohol dependency compared to those who did in ASTRA (based on the CAGE questionnaire
353
, a 
screening tool for alcohol abuse and dependence). Among individuals with chronic HCV, progression of 
HCV-related liver disease is increased by heavy alcohol use.
580
 Our findings could be due to MSM 
minimising consumption of alcohol as a result of HCV infection.  
 
A quarter of HIV-diagnosed MSM in ASTRA with a stable partner who was also HIV-positive had 
prevalent HCV; the association remained strong after adjustment for socio-demographic, HIV-related, 
and lifestyle factors. It could be that this finding is due to lower condom use with HIV-positive stable 
partners. All types of sex, CLS, and group sex were also strongly associated with prevalent HCV, after 
accounting for IDU and core factors. Strong positive trends were also observed of the total number of 
partners and number of new sex partners in the past year. Recreational drug use, IDU, polydrug use, 
and, specifically, use of chemsex-associated drugs in the past three months were strongly associated 
with prevalent HCV. In particular, CLS-C was associated with two-fold higher prevalence of HCV, 
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independent of IDU and other core factors. While it is encouraging that a sizeable proportion of HIV-
diagnosed MSM in ASTRA restrict CLS to HIV-positive partners only, this clearly does not eliminate the 
risk of other STIs, including HCV. Increased diagnoses of HCV, syphilis, NG, and CT among HIV-diagnosed 
MSM in the UK in the past few years have coincided with the emergence of sexually transmissible 
enteric infections (see section 8.2.8.2). These overlapping epidemics suggest that sexual networks of 
HIV-diagnosed MSM engaging in serosorting may contribute to transmission of HCV and other STIs in 
the UK. Chemsex (and associated sexual behaviours) may play a key role in the development of these 
sexual networks and in maintaining a pool of prevalent HCV infections resulting in ongoing transmission 
of HCV among HIV-diagnosed men. In addition, the practice of chemsex and ‘slamming’ (injecting drugs 
used in chemsex, particularly methamphetamine and mephedrone) should be distinguished from IDU 
involving heroin as the drugs, characteristics of users, and risks for STIs, HIV, and other blood-borne 
viruses may be different.  
 
MSM who used the internet to find sex also had 60% higher prevalence of HCV compared to those who 
did not. In recent years, the internet has facilitated finding sex partners based on HIV-serostatus and 
specific sexual interests (such as CLS-C and chemsex); geosocial networking smartphone apps may thus 
play an important role in the ongoing increase in incidence of HCV and other bSTIs among MSM in the 
UK. 
8.5.4.3 Incident HCV over follow-up 
Among HIV-diagnosed MSM in ASTRA, the incidence of HCV diagnosis was 0.31 per 100 PY based on six 
seroconversions. This estimate is in line with those from enhanced surveillance of newly acquired HCV 
among HIV-diagnosed MSM in England (0.24 per 100 PY in 2012).
544
 There is evidence of ongoing but 
declining sexual transmission of HCV among HIV-diagnosed MSM in England. On the other hand, results 
from the CASCADE collaboration showed a significant increase in the incidence of HCV among HIV-
diagnosed MSM in northern and Western Europe between 1990 and 2014 (from 0.07 to 1.8 per 
100PY).
564
  
8.5.4.4 Factors associated with incident HCV  
Conclusions drawn from this analysis are limited due to the low number of incident HCV cases. In 
unadjusted analyses there was no evidence to suggest higher incidence of HCV according to 
participants’ age or time since HIV diagnosis. In the CASCADE collaboration, HCV incidence was elevated 
among younger HIV-diagnosed MSM compared to older (incidence remained highest and stable until 
age 35 and declined thereafter) and those who were recently HIV-diagnosed.
564
 The discrepancy in 
findings may be due to regional differences in local HCV epidemics among HIV-diagnosed MSM, as 
CASCADE includes 16 cohorts across Europe, Australia, and North America.  
 
The incidence of HCV was somewhat elevated among MSM with detectable HIV VL in ASTRA, although 
there was insufficient power to detect a statistical difference. Few studies have examined the 
association of HIV VL and HCV incidence: three cohort studies of HIV-diagnosed MSM did not find any 
289 
 
association of HIV plasma VL and incident HCV
492,561,563
, although one of these
561
 included ART status in 
multivariable adjustment thus masking the true effect of VL. A more recent CASCADE collaboration 
analysis showed that higher VL (especially when log10VL≥5c/mL) was significantly associated with HCV 
incidence, while CD4 count was not.
564
 The association of higher HIV VL and incident HCV may be due to 
HIV-related activation of HCV target cells which facilitate transmission of HCV.
451,494
 
 
As expected, IDU was associated with higher HCV incidence in our study. However, as only one of six 
MSM with incident HCV reported any IDU in the three months prior to ASTRA, it was not possible to 
examine the effect of IDU in multivariable models. Chemsex-associated drug use conferred almost five-
fold higher risk of incident HCV compared to no drug use/any other drug use. CLS-D and having 10 or 
more new sex partners in the past year was associated with elevated risk of incident HCV; evidence was 
weak for the association of CLS and CLS-C with incident HCV.  
 
Prior syphilis (lifetime or acute) has been shown to be a risk factor for HCV incidence among all MSM 
(regardless of HIV serostatus).
535
 In our study, there was some suggestion of elevated risk of HCV 
seroconversion with self-reported syphilis in the three months prior to ASTRA completion. Syphilis co-
infection may increase the risk of sexual transmission of HCV among HIV-diagnosed MSM, as syphilitic 
lesions may damage genital mucosa and facilitate HCV transmission
561
; syphilis co-infection may also be 
a proxy for CLS in dense sexual networks of HIV-positive men.
535
  
 Limitations 8.5.5
A number of important limitations must be considered in interpreting the results of analyses presented 
in this chapter. Firstly, with the exception of prevalent and incident HCV, all other STI diagnoses were 
measured by self-report with a three month recall. Underreporting of prevalent STIs may have resulted 
in recall bias and thus underestimation of prevalence of self-reported STIs. It was not possible to obtain 
clinically/lab-verified STI diagnoses at questionnaire completion due to the way GUM and HIV clinical 
services are separated, making data integration of routine HIV and GUMCAD data difficult. In addition, 
as the study was conducted in 2011-2012, prior to the emergence of outbreaks of sexually transmissible 
enteric infections (e.g. Shigella, E.coli, hepatitis A, and Giardia) in the UK, these STIs were not included 
as one of the options for self-reported STIs in the past three months. However, the incidence and 
prevalence of these infections remains low in the UK (for instance, 26 new cases of any Shighella serovar 
were recorded among MSM in 2015 in England); partly because they are self-limiting and affected 
people may not seek treatment. Sexual behaviours which may lead to mucosal trauma and thus 
transmission of STIs, such as fisting with/without gloves and sharing of sex toys, were not collected in 
ASTRA.  
 
The nature of this cross-sectional study does not allow for establishing temporality of self-reported STIs; 
it is not possible to know whether other STIs were acquired before or after HIV infection, or to infer 
causality in the direction of the co-infection. MSM who were recently diagnosed (≤3 months prior to 
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questionnaire completion) were excluded from analyses; this was done in order to refine temporality, so 
that the HIV diagnosis predated the other STIs.  
 
Prospective analysis of HCV incidence is currently limited by the small number of incident cases (only 6). 
For this reason, only unadjusted analyses were presented and results examined in terms of associations 
with less focus on p-values. The aim is to repeat the analysis with longer follow-up. Although this 
analysis was underpowered, with additional accrual of follow-up (and more incident cases), ASTRA is 
unique in providing linked behavioural data from the questionnaire to new HCV diagnoses.  
 
Routine clinical data was collected prior to the first two oral DAAs becoming available for treatment of 
HCV among HIV-diagnosed individuals in 2011; by end of follow-up, in 2014, three new DAAs were 
licensed for use in Europe. Although European treatment guidelines now recommend use of DAAs for 
HIV/HCV co-infected individuals, access to these treatments is still limited due to prohibitive costs.
581
  
8.6 Conclusions and Implications 
One in 10 HIV-diagnosed MSM in this study reported having a recent diagnosed STI. Self-reported STIs 
were most prevalent among MSM who were younger, not on ART, had detectable VL, and used 
recreational drugs (including injection and chemsex-associated drugs). These associations mirror those 
observed for CLS in Chapter 4. They also emphasize the importance of STI prevention strategies that 
particularly focus on HIV-diagnosed MSM.  All types of CLS and higher partner numbers were strongly 
associated with reporting any diagnosed STI. In terms of assessing and monitoring risk of transmission of 
STIs among HIV-diagnosed MSM, ‘any condomless sex’ is likely to remain the most relevant measure. 
The number of partners reported is also a useful marker of STI transmission risk, particularly for MSM 
reporting chemsex and IDU. While condomless sex with other HIV-positive partners (CLS-C) does not 
confer risk of HIV transmission to HIV-negative partners, it does confer risk of transmission of other STIs. 
Given the increasing incidence of bacterial and viral STIs among HIV-diagnosed MSM in the UK, testing, 
control, and prevention of STIs remains a cornerstone of HIV control.  
 
While evidence on the effect of treating STIs in HIV-diagnosed people on directly reducing HIV 
infectiousness is insufficient, detection and control of STIs remains critical in this population for a 
number of reasons.
582
 First, STI co-infections may increase genital HIV VL and thus facilitate HIV 
transmission to HIV-negative partners; it is still unclear, however, whether this is still the case in the 
presence of effective ART and suppressed plasma VL. Second, co-infections may affect the natural 
history of HIV via a number of biological mechanisms thus increasing the risk of morbidity and mortality. 
Conversely, HIV-induced immunosuppression may lead to reactivation of STI-coinfections that are 
otherwise undetectable.
451
 Third, transmission of STIs is perpetuated by higher rates of partner change 
and complex sexual networks, which can lead to localised outbreaks.
583,584
 Fourth, reversing the trend of 
increasing NG diagnoses is a priority given the spread of resistance to frontline antimicrobials used in 
the treatment of NG and the depletion of effective treatment options.
432
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BHIVA recommendations emphasize the routine sexual health assessment of all HIV-diagnosed MSM (at 
least six-monthly after initial HIV diagnosis and syphilis serology 2-4 times yearly).
585
 Extra-genital 
screening (rectal, pharyngeal) for CT and NG can detect up to 80% more asymptomatic infections 
compared to urine testing.
567
 There is a need for scaling up extra-genital screening approaches in HIV 
clinics, particularly for asymptomatic MSM who report receptive or insertive condomless anal or oral sex 
and those who engage in chemsex. Although HIV-diagnosed MSM are at increased risk of anal cancer 
(associated with genital warts and HIV co-infection), anal cytology is not routinely recommended in the 
UK. Self-collected specimens have recently been shown to be a convenient and acceptable way of 
testing, and may address some of the barriers to screening in this population.
586
  
 
DAAs are highly effective, have favourable tolerability, short treatment duration, and are expected to 
increase treatment uptake and SVR rates at population level.
535
 The effect of DAAs will be modest 
without expansion of access to testing and treatment. Prevention in this case is imperative in limiting 
the possibility of HCV reinfection after SVR. Regular routine HCV screening among HIV-diagnosed MSM 
with cleared HCV or SVR and in HIV negative MSM on PrEP would be beneficial in preventing incident 
HCV infections in HIV positive MSM. The risk of hepatotoxicity and other liver-related complications (see 
section 8.2.7.4) is still relevant in the era of DAAs and highlights the need for comprehensive 
management of other risk factors beyond HIV and HCV control, particularly in populations with high 
alcohol consumption and chemsex use.
587
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9 Summary and conclusions 
The aim of this thesis was to describe the sexual behaviours of HIV-diagnosed MSM in the UK in the era 
of effective ART. The ASTRA study, due to its representative and substantive sample size, comprehensive 
data collection, and linkage to clinical data, offered enhanced understanding of sexual behaviours of 
HIV-diagnosed MSM in the UK, and of the co-factors (socio-demographic, psychological, health, lifestyle, 
HIV-related) that these may be associated with. The study’s results have important implications for 
improved care of HIV-diagnosed people and for national HIV prevention efforts. 
9.1 Rationale and background to the ASTRA study  
The introduction of antiretroviral therapy (ART) in 1996 was accompanied by reported increases in 
prevalence of ‘high-risk sexual behaviours’ (mainly condomless sex, CLS) among all MSM (HIV-negative 
and HIV-diagnosed/HIV-positive) in Europe and North America.
93–97
 This raised concern about a possible 
causal effect, whereby HIV optimism may prompt complacency around ‘safe sex’ practices, and thus 
lead to increases in ‘risky’ sexual behaviours. A number of studies carried out over the next five to ten 
years provided evidence that ART use was not associated with sexual behaviours perceived to confer 
risk of HIV transmission (specifically, condomless sex with HIV-discordant status partners, CLS-
D).
100,103,108,110–112,114,115
 However, the late 2000’s saw fundamental changes in the awareness and 
understanding of HIV transmission risk.
118
 Evidence from observational studies of heterosexual HIV-
serodifferent couples accumulated, showing the profound protective effect of virological suppression on 
ART on reducing an HIV-positive individual’s infectiousness to an HIV-negative sexual partner.
7,242
 
Following the “Swiss statement” in 2008, it was hypothesized that the prevalence and patterns of ‘risky’ 
sexual behaviours among HIV-positive people could change as a result of raised awareness of the Swiss 
Statement.
124
 In this context, a programme of work including the ASTRA study was designed as a 
comprehensive assessment of the preventive role of ART on HIV transmission. There was concern that 
increased awareness of the protective effect of suppressed viral load (VL) on HIV infectiousness may 
adversely impact on levels of CLS among MSM with HIV, which may in turn undermine the full potential 
impact of early treatment in reducing transmission. The ASTRA study aimed to understand the 
association between use of ART, perceived (self-reported) VL suppression, and sexual behaviours, in 
order to inform assessment of the public health impact of a possible strategy of early ART initiation.
89
 
The secondary aims of ASTRA were to investigate sexual behaviours and attitudes among key 
demographic subgroups, and to examine the association of a range of co-factors (socio-demographic, 
psychological, HIV-, ART-, health-related, and lifestyle) with specific sexual behaviour measures, in order 
to inform HIV clinical care and prevention.
205
 This thesis made a contribution to these secondary aims 
and considered HIV-diagnosed MSM only.  
 
Since ASTRA was conducted, further evidence accumulated on the impact of ART on reducing 
infectiousness of people living with HIV, particularly from PARTNER
9
, a study carried out as part of the 
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same programme of work as ASTRA. Moreover, the START trial demonstrated individual clinical benefit 
of earlier treatment of HIV.
16
 On this basis, treatment policy in the UK and elsewhere changed to 
recommend immediate ART initiation for all people diagnosed with HIV.
588
  
9.2 Thesis summary and implications of main findings  
 Chapter 2: Literature review of sexual behaviour among HIV-diagnosed men 9.2.1
who have sex with men  
Chapter 2 provided a historical context to the evolving concept of sex with ‘high risk’ for HIV 
transmission among MSM living with HIV since the introduction of ART. A summary of evidence on 
factors associated with different types of CLS was provided. Evidence from a number of studies did not 
support the hypothesis that receiving ART or having undetectable viral load (VL) leads to ‘risky’ sexual 
behaviours (in particular CLS with HIV-serodifferent partners, CLS-D).
108–111
 A literature review was also 
conducted, focussing on studies of HIV-diagnosed MSM recruited from clinical settings in high-income 
countries, and examining the prevalence and correlates of various types of CLS. The review found that 
CLS is overall prevalent among HIV-diagnosed MSM recruited from clinical settings, with estimates for 
any CLS in the past three months ranging from 31% to 51%. Prevalence estimates of CLS were higher in 
samples recruiting men from community settings and online. The prevalence of CLS-D ranged from 15% 
to 27% and of CLS with perceived HIV-seroconcordant partners (CLS-C) overall from 14% to 
24%.
103,113,114,131,150–152,156,157,159
 While evidence from earlier UK studies of HIV-diagnosed MSM suggested 
an overall observed increase in the prevalence of CLS between 2000 and 2008, this may have been 
explained by the concurrent reduction in prevalence of CLS-D and the increase in prevalence of CLS-C 
during that period.
94,99,115,126,140
  
 
Studies which examined associations of individual-level factors with prevalence of various types of CLS 
among HIV-diagnosed MSM were also reviewed. Certain co-factors were identified as related to higher 
prevalence of any CLS, including younger age and having HIV-positive partners, but results varied 
according to study type, recruitment location, covariates included, measurement of different types of 
‘risky sex’, varying recall periods, adjustment for confounders, and sample sizes. There remain gaps in 
evidence on patterns of sexual behaviours according to: time living with diagnosed HIV, personal 
perceptions of virological status, measures of psychological wellbeing (symptoms of depression and 
anxiety, perceived social support), and type of relationship with a partner (casual or main/stable). Since 
2008, there have been very few studies examining sexual behaviour of HIV-diagnosed people in the UK. 
As a result, evidence on the prevalence of CLS, CLS-D, CLS-C, and other sexual behaviours among HIV-
diagnosed MSM in the UK has been lacking. 
 Chapter 3: Data and methodology 9.2.2
Chapter 3 described the methodology of the thesis. The thesis aims were addressed using data from 
ASTRA, an observational, cross-sectional, self-administered questionnaire study of HIV outpatients 
attending one of eight UK NHS clinics from February 2011 to December 2012, with an additional 
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longitudinal component based on routine linked clinic data. Details of recruitment and confidentiality 
procedures were provided, along with a description of the ASTRA questionnaire. My involvement in the 
study started after ASTRA was designed and data was collated; I performed extensive data cleaning, 
management, and derivation of variables. The rationale and derivation of all variables used in the thesis 
were explained in detail. A discussion of statistical methods used was also provided, with emphasis on 
the reasoning behind the use of modified Poisson regression over logistic regression throughout the 
thesis. 
 
The strengths of the ASTRA study in addressing the aims of the thesis include the large sample size, the 
confidential, self-reported detailed information on recent sexual behaviour, attitudes, and potential co-
factors (such as recreational drug use), and the collection of both subject-reported and clinic-recorded 
VL level. The overall ASTRA response rate (64% of eligible patients approached) was reasonably high and 
comparable to earlier UK studies of people attending for HIV care.
131,133,153,589
 To assess the 
generalisability of the ASTRA sample in relation to the population of HIV-diagnosed men and women 
living in the UK as of the end of recruitment (2012), ASTRA respondents were compared to individuals 
included in the Survey of Prevalent HIV Infections Diagnosed (SOPHID) during the same period. A lower 
proportion of younger men (<25 years) and a lower proportion of women and black African individuals 
were represented in ASTRA, but prevalence of ART use was similar in ASTRA and SOPHID. The patients 
approached to participate in ASTRA (eligible) accounted for approximately 7% of the national HIV-
diagnosed population; the 2248 MSM included in analyses in this thesis comprised approximately 6.5% 
of all MSM in SOPHID. 
 Chapter 4: Condomless sex among HIV-diagnosed MSM: prevalence and co-9.2.3
factors  
Chapter 4 examined, among HIV-diagnosed MSM participating in ASTRA, the prevalence of and factors 
associated with recent CLS, including CLS overall, CLS-D, and CLS-C. The co-factors examined included 
socio-demographic, psychological, HIV and ART-related. The chapter also examined the association of 
different types of CLS with other sexual behaviours.  
 
The majority of men reported having anal or vaginal sex in the previous three months (64%). Prevalence 
of any CLS in the previous three months was relatively high (38%): 29% reported CLS-C overall and 15% 
reported CLS-D. Among those who had CLS-D, there was some evidence of potential HIV risk reduction 
practices taking place, such as only being the receptive partner (40%), or only being the insertive partner 
without ejaculation (29%). Among MSM who reported having anal or vaginal sex, the majority of men 
had less than five sex partners in the past three months and over a quarter had 10 or more new sex 
partners in the past year. When classifying all MSM into mutually exclusive categories of recent sexual 
behaviour, over a third of men did not report any anal or vaginal sex, a quarter reported condom-
protected sex only, a fifth reported ‘CLS-C without CLS-D’ (which could indicate HIV-serosorting), and a 
sixth reported CLS-D.  
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Prevalence of CLS was higher among younger MSM (<30 years); it was lower soon after HIV diagnosis 
(up to 2 years), then increased (at 2-5 years), and steadily decreased thereafter to lowest levels (at >15 
years post-diagnosis), but not independently of participant’s age. MSM were more likely to report CLS 
with an HIV-positive stable partner than with an HIV-serodifferent stable partner. In addition, 
prevalence of CLS was higher among MSM who were on ART with self-reported undetectable VL 
(compared to on ART without undetectable VL or not on ART). No association was observed of 
socioeconomic factors, psychological symptoms, ART adherence, or clinic-recorded VL, with reporting 
CLS (versus not reporting CLS, which also included those who did not have any sex or those who had 
condom-protected sex in the past three months).  
 
The pattern of associations was broadly similar for CLS-D. Younger age and having an HIV-serodifferent 
stable partner were associated with CLS-D. There was some suggestion that prevalence of CLS-D was 
lower among MSM on ART (compared to those not on ART); among MSM on ART  CLS-D prevalence was 
higher among those with self-reported undetectable VL (compared to self-reported not undetectable 
VL). 
 
The four mutually exclusive categories of sexual behaviour in the past three months revealed more 
complex underlying patterns. Compared to the three sexually active groups (CLS-D, ‘CLS-C without CLS-
D’, and condom-protected sex), MSM who did not have sex in the previous three months were 
significantly different on almost all factors. This group tended to be older, diagnosed with HIV for longer, 
have lower socio-economic status, low social support, and symptoms of depression and anxiety. In 
terms of HIV-related factors, men who did not have sex were more likely to be on ART, adherent, and 
virally suppressed. There were few significant differences in socio-demographic factors between the 
three sexually active groups, except for age; MSM who had ‘CLS-C without CLS-D’ were slightly younger 
than MSM who had CLS-D or condom-protected sex. In addition, MSM who had CLS-D were significantly 
more likely to report higher financial hardship after adjustment for core socio-demographic and HIV-
related variables, compared to those who had ‘CLS-C without CLS-D’ or condom-protected sex.. 
Although men who had ‘CLS-C without CLS-D’ had the highest prevalence of detectable study log VL 
(27%) followed by those who had CLS-D (25%), and condom-protected sex (17%), there were no 
significant differences in the distribution of ART use, ART adherence, or VL non-suppression between 
the three sexually active groups. In fact, MSM on ART with self-reported detectable VL were more likely 
to report having condom-protected sex compared to any CLS, even after adjustment for socio-
demographic and other factors. Low social support, symptoms of depression and anxiety followed a 
similar pattern, with prevalence being higher in the CLS-D group, followed by ‘CLS-C without CLS-D’, and 
lowest for the condom-protected group.  
 
When examining factors associated with having ‘CLS-C without CLS-D’ or CLS-D relative to condom-
protected sex, it was shown that MSM who had any CLS (CLS-D or ‘CLS-C without CLS-D’) were more 
likely to have symptoms of depression. Additionally, relative to those who had condom-protected sex, 
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MSM who knew their personal VL were less likely to have CLS-D (versus those who did not know their 
personal VL).  
 
Among MSM who had anal or vaginal sex, those who had CLS-D tended to be more likely than those 
who had ‘CLS-C without CLS-D’ to report high partner numbers, recent STI diagnoses, group sex, and low 
condom self-efficacy; both groups had much higher prevalence of these factors than men reporting 
condom-protected sex. There was a striking association of the number of new sex partners in the past 
year and prevalence of any CLS in the past three months, particularly for CLS-D. MSM who had ‘CLS-C 
without CLS-D’ had the highest prevalence of self-reported lifetime diagnosis of hepatitis C (HCV). 
 
Results presented in this chapter show prevalence estimates of CLS and CLS-D consistent to those shown 
in earlier UK clinic-based studies (2000-2010). This finding lends support to our ability to reliably and 
repeatedly measure such sexual behaviours and capture trends. Based on these findings, the prevalence 
of CLS-D among HIV-diagnosed MSM in the UK attending for care has remained fairly stable since 2008. 
Use of the mutually exclusive categories of sexual behaviour added specific strengths to this thesis, as it 
allowed for: (i) examination of the prevalence of ‘CLS-C without CLS-D’ (as a measure which may 
indicate active HIV-serosorting), (ii) separation of the condom-protected sex group from the no sex 
group, (iii) investigation of the differing associations of various co-factors with different types of sexual 
behaviours. This was particularly important in examining differing effects of psychological factors and 
knowledge of personal VL, which were not apparent using a binary classification for CLS or CLS-D. Future 
epidemiological studies examining factors associated with CLS and CLS-D could thus benefit from using 
such mutually exclusive categorisations of sexual behaviour. The high prevalence of CLS-C overall may 
suggest actual or perceived serosorting taking place. In order to capture actual serosorting, however, 
future studies should ascertain intentional CLS with partners of the same HIV-serostatus, as well as the 
motivations behind it.  
 Chapter 5: Characterising CLS-D with higher HIV transmission risk  9.2.4
For HIV-diagnosed individuals, CLS-D was the main marker of ‘risky’ sex for HIV transmission before 
studies demonstrated the profound positive impact of ART use on HIV transmission. There is no 
consensus yet on a definition of CLS-D with risk of HIV transmission in epidemiological research. Very 
few studies have examined prevalence of CLS-D with higher risk of HIV transmission among HIV-
diagnosed MSM, and none have done so in the UK. This chapter presented a literature review of studies 
that incorporate clinic-recorded VL level into the definition of higher HIV transmission risk CLS-D, which 
emerged two years after ASTRA concluded recruitment (2014). These studies used various definitions 
for ‘high HIV transmission risk’ sexual behaviour, incorporating factors in addition to CLS-D, such as: VL 
level, seropositioning, ART status, proportion of CLS acts, and other STI co-infections. As a result, the 
prevalence of higher HIV risk CLS-D among HIV-diagnosed MSM ranged from 4% to 45%, reflecting 
differing definitions and variation in study design and methodology, timing of VL measurements, VL cut-
offs, method of survey administration, recall period, and potential genuine differences across 
populations and demographic groups.   
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This chapter aimed to assess the prevalence of sex with an appreciable risk of HIV transmission among 
people with diagnosed HIV, by better reflecting the reduction in HIV transmission risk when the HIV-
diagnosed person is on virally suppressive ART.
24,242
 The main definition of CLS-D with higher HIV 
transmission risk required reporting CLS-D in the previous three months and not being on ART at the 
time of the questionnaire or having latest study log-recorded VL>50c/mL. For over 60% of MSM, the VL 
value was from a test done during the three month period prior to questionnaire completion, which 
coincided with the recall period for sexual behaviours (including CLS-D). Various supplementary 
definitions for CLS-D with an appreciable risk of HIV transmission were examined among all ASTRA 
MSM. In addition to the main definition, the following criteria (which may indicate increased risk of 
infectiousness even in the presence of a single suppressed VL on ART) were included: having started ART 
<9 months ago, reporting recent and substantial non-adherence to ART, or having a self-reported recent 
diagnosis of another STI. The prevalence of higher HIV risk CLS-D in the previous three months ranged 
from 4.2% to 7.5%, depending on criteria included. Compared to prevalence of CLS-D in the past three 
months, prevalence of higher HIV risk CLS-D was lower by 50-70% in relative terms. Participants 
reporting higher HIV risk CLS-D were similar to those reporting other CLS-D in terms of socio-
demographic, psychological, lifestyle characteristics and sexual behaviours. Use of the linked routine 
clinical data allowed assessment of the effect on prevalence if fulfilment of the detectable VL criteria 
was widened to include any detectable VL within six months prior to questionnaire completion. Such 
definitions had a small effect on prevalence of higher HIV risk CLS-D. The main definition of higher HIV 
risk CLS-D developed in this chapter was subsequently used in Chapters 6 and 7.  
 
There remain challenges in defining CLS-D with higher HIV transmission risk, both in epidemiological 
studies and clinical settings. In order for behavioural studies on HIV transmission to be representative of 
developments in HIV prevention, there is a need to move away from the concept of ‘unsafe’ and ‘risky’ 
sex defined as CLS-D only. Instead, there is a need to examine other measures of CLS-D which have a 
greater potential for HIV transmission. Accounting for VL level and ART status concurrent to CLS-D is one 
of the ways forward in adapting research to contemporary evidence and in standardising definitions for 
use in epidemiological surveillance. Additional longer-term follow-up from the PARTNER study
9
 will also 
be crucial in providing more precise estimates of HIV transmission risk among MSM in the context of 
effective ART. Such information is important in refining current guidelines and in helping HIV-diagnosed 
individuals and their partners make informed decisions on having CLS-D safely. There is a major 
difference in implications relating to the prevalence of any CLS and of CLS-D with higher HIV 
transmission risk (38% vs 4% respectively); among HIV-diagnosed people, measures of CLS overall 
remain most relevant measure for transmission of other (non-HIV) STIs, but measures of CLS-D that 
account for VL will be the most relevant measures of HIV transmission risk sex.  
 
In future research, the main definition of higher HIV risk CLS-D used in this thesis could also be 
incorporated as a fifth category into the mutually exclusive sexual behaviour classification (so that the 
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groupings are: higher HIV risk CLS-D, other CLS-D, ‘CLS-C without CLS-D’, condom-protected sex, no anal 
or vaginal sex). This was done in the published paper based on this Chapter (see Appendix VII), in which I 
separated the two categories of CLS-D and further examined differences in socio-demographic, lifestyle, 
HIV-related factors, and other sexual behaviours.
590
 
 Chapter 6: Recreational drug use and condomless sex 9.2.5
Research conducted over the past twenty years has demonstrated that a higher proportion of MSM in 
the UK and abroad use recreational drugs compared to age-comparable non-MSM populations,
278–282
 
and that drug use is more prevalent among HIV-positive compared to HIV-negative MSM.
282,287,294–299
 
Few studies have been conducted on drug use among large representative samples of HIV-diagnosed 
MSM in the UK. Since 2013, health care services and community organisations in the UK have been 
reporting shifting trends in popularity and use of specific drugs among MSM,
345,346
 suggesting, firstly, an 
increase in prevalence of ‘club drug’ use overall, and secondly, the emergence of ‘chemsex’. In this 
context, Chapter 6 aimed to examine the prevalence, patterns, and factors associated with recreational 
drug use, as well as the association of recreational drug use with CLS and other sexual behaviours 
among HIV-diagnosed MSM. A secondary aim was to examine the association of drug use and 
problematic alcohol consumption with ART outcomes (non-adherence and VL non-suppression). 
 
The prevalence of any recreational drug use in ASTRA was high (51% in the past three months); almost 
25% used at least three types of drugs during that time period (polydrug use) and 15% reported 
chemsex-associated drug use. Injection drug use (IDU) was reported by a minority of MSM (3%). There 
were extremely strong and consistent associations between increasing numbers of drugs used and 
increasing prevalence of all types of CLS (including CLS-C, CLS-D, and higher HIV transmission risk CLS-D), 
group sex, higher number of sexual partners, and low condom self-efficacy. Use of the mutually 
exclusive sexual behaviour categorisation demonstrated differing patterns of drug use according to type 
of CLS. Compared to condom-protected sex, polydrug use was prevalent both among men who had CLS-
D and those who had ‘CLS-C without CLS-D’. However, polydrug use and chemsex-associated drug use 
were most prevalent in the ‘CLS-C without CLS-D’ group. Use of nitrites was most prevalent among those 
who had CLS-D.  
 
Higher alcohol consumption was associated with higher prevalence of CLS-D and of higher HIV risk CLS-
D, independently of recreational drug use. While drug and polydrug use, higher alcohol consumption, 
and evidence of alcohol dependency were significantly associated with non-adherence to ART, there 
was no significant association with VL non-suppression. This may reflect, to some extent, the ability of 
current ART regimens to achieve and sustain viral suppression, despite suboptimal adherence 
(‘forgiveness’). 
 
Ours was the first study since the 2003 ‘London Gyms’ study
289,312
 to describe the prevalence and 
patters of drug use among HIV-diagnosed MSM in the UK, and the first study to report on prevalence of 
mephedrone use in this population. At the time results from this chapter were published
591
(see 
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Appendix VI), the phenomenon of chemsex was beginning to emerge. There are still no published 
quantitative studies describing the motivations, prevalence, patterns, and harms of chemsex use among 
MSM in the UK (regardless of HIV-serostatus). As a result, a number of important questions remain 
unanswered. Future studies of chemsex will benefit from explicitly defining the concept, enquiring 
about use of specific drugs before and during sex , further specifying whether chemsex was condomless 
or condom-protected, the HIV-serostatus of sexual partners. There is also need for research in the 
determinants as well as the psychological and physical effects of chemsex in a way that aims to minimise 
harm. 
 
Since ASTRA concluded recruitment (2012), a small number of ‘club drug’ clinics have been established 
in London, bridging the gap between HIV treatment and substance misuse services.
592,593
 This is a 
welcome advancement in provision of judgment-free harm reduction advice and support, which must 
nevertheless continue to expand within and outside of London. The confluence of drugs, condomless 
anal sex, HIV, and gay men is one that can easily be sensationalised in research and the media. This 
would be detrimental to efforts to reduce stigma and marginalisation of MSM living with HIV, and may 
also prevent individuals from seeking advice and support on safer chemsex use. All HIV-diagnosed MSM, 
and particularly younger men, may benefit from support and awareness of the side-effects of drug use, 
particularly when combined with multiple other drugs, alcohol, or with ART regimens. National STI/HIV 
prevention strategies, in collaboration with community organisations, will need to develop and 
incorporate evidence-based toolkits for the clinical management of recreational drug and chemsex users 
on ART. 
 Chapter 7: Non-disclosure of HIV serostatus and condomless sex  9.2.6
In the era of suppressive ART, the role of HIV-serostatus disclosure to sexual partners remains unclear. 
Studies of HIV-diagnosed MSM in high income countries have reported varying prevalence estimates of 
non-disclosure, due to the different populations sampled and diverse definitions of non-disclosure used; 
non-disclosure to anyone in the social circle ranged from 2% to 33%, to a stable partner from 4% to 53%, 
and to new/casual sex partners from 9% to 66%. Evidence on the association of non-disclosure to casual 
sex partners with CLS is also mixed. This chapter investigated, among HIV-diagnosed MSM from ASTRA, 
the prevalence of non-disclosure of HIV serostatus to the social network (friends, family, co-workers) 
and to a stable partner, and attitudes to non-disclosure to new sexual partners. The chapter also 
examined factors associated with non-disclosure to a stable partner and to new sexual partners, and the 
association of non-disclosure measures and sexual behaviours.  
 
A small minority of ASTRA MSM had not disclosed their HIV-serostatus to anyone (<5%), including to a 
stable partner. These estimates were comparable to those observed in earlier UK studies using similar 
constructs of non-disclosure.
114,133,394
 One of the strongest associations with non-disclosure to a stable 
partner was ethnicity, with non-disclosure being higher among MSM of black, Asian, mixed, or other 
(non-white) ethnicities, which may reflect cultural barriers. Non-disclosure was highest among MSM 
recently diagnosed with HIV and declined steadily with longer time since diagnosis, suggesting that 
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disclosure may be a gradual process. Non-disclosure to a stable partner was independently associated 
with the current partner’s unknown HIV serostatus, consistent with earlier studies of HIV clinic 
attendees. No associations were observed of socio-economic factors (age, religion, education, and 
employment), psychological symptoms, relationship-related factors, and non-disclosure to a stable 
partner. 
 
Among MSM who reported having sex in the past three months, lower sexual disclosure (lower intent to 
disclose to new sex partners) was prevalent (44%) and associated with markers of higher socio-
economic status and having an HIV-serodifferent or no stable partner. MSM who were on ART with self-
reported suppressed VL had lower sexual disclosure than those who were on ART without self-reported 
suppressed VL and those not on ART. This finding may suggest that HIV-diagnosed MSM with perceived 
undetectable VL were more likely to think of HIV-serostatus disclosure as not necessary due to their low 
HIV infectiousness. This may also provide some evidence that knowledge of personal VL status may 
influence sexual attitudes and behaviours; this effect may become more widespread with increasing 
awareness of the positive impact of ART on HIV infectiousness. Recreational drug and alcohol use were 
not associated with lower sexual disclosure. Lower sexual disclosure was independently associated with 
CLS, CLS-D, CLS-C, group sex, using the internet to have sex, and high partner numbers in the past year. 
Use of the mutually exclusive categories of sexual behaviour demonstrated that levels of non-disclosure 
were similar among MSM who had condom-protected sex and those who had CLS-D; however, sexual 
disclosure was higher among those who had ‘CLS-C without CLS-D’, compared to condom-protected sex. 
This finding may suggest that HIV transmission risk reduction may be in place, in the form of mutual 
disclosure with HIV-positive partners and HIV-serosorting. Of note, over 90% those who had CLS-D and 
lower sexual disclosure were on ART with undetectable VL. 
 
HIV status disclosure has been seen as an important step towards enhancing mental health through 
increased social support. In this chapter there was no evidence that low functional social support, 
depression, or anxiety symptoms were associated with higher prevalence of non-disclosure to a stable 
partner. A detailed analysis based on this chapter has been published
594
 (see Appendix VI), examining 
the effect of non-disclosure to anyone in the social circle with prevalence of low social support, 
psychological symptoms, non-adherence to ART, and VL non-suppression on ART.   
 
Groups with highest non-disclosure may need a supportive context as soon as possible after HIV 
diagnosis; health facilities must assist individuals in building communication skills, coping strategies, and 
in mobilizing support for those who need it. Disclosure does not necessarily lead to ‘safer’ sexual 
behaviour but could inform choice in type of sex within and outside of a stable relationship. Couples’ 
HIV testing and counselling can facilitate mutual serostatus disclosure and is associated with lower 
prevalence of condomless sex overall and with reduction in the number of concurrent casual sex 
partners.
427
 Emphasis on HIV-serostatus disclosure to sexual partners places the majority of 
responsibility of reducing HIV transmission risk on HIV-diagnosed individuals, who may already 
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experience perceived or enacted stigma.
408
 HIV-diagnosed MSM may not disclose to sex partners but 
still practice some form of HIV risk reduction, be it having CLS-D while being on suppressive ART, or 
having HIV-seroconcordant partners only. Discussion and agreement on condom use or non-use and 
acceptable levels of risk for both partners may be more relevant in the context of reducing HIV 
transmission risk.
381,414
 Prevention efforts could benefit from assisting HIV-diagnosed people in 
effectively communicating and negotiating acceptable sexual behaviours with sex partners, and in 
providing a supportive context for those who choose not to disclose their HIV-serostatus. 
 Chapter 8: Hepatitis C co-infection, other sexually transmitted infections, and 9.2.7
condomless sex 
HIV and other sexually transmitted infections (STIs) have epidemiological synergy, sharing transmission 
routes, biological interactions, and common risk factors. HIV-diagnosed MSM in the UK remain 
disproportionally affected by STI co-infections, characterised by: continuing and rapid rise of diagnoses 
of gonorrhoea, syphilis, and genital herpes; ongoing outbreaks of sexually transmissible enteric 
infections; and outbreaks of sexually transmitted hepatitis C virus (HCV), not associated with injection 
drug use (IDU). This chapter examined, among HIV-diagnosed MSM, the prevalence and factors 
associated with bacterial and viral STI co-infections, the prevalence and incidence of HCV over follow-up, 
and factors associated with both prevalent and incident HCV.  
 
One in 10 HIV-diagnosed MSM in ASTRA reported having any diagnosed STI (other than HIV) in the 
previous three months, with the majority of STIs reported being bacterial; chlamydia, gonorrhoea, and 
syphilis were most prevalent, in line with UK surveillance data.
471,521
 Self-reported STIs were most 
prevalent among MSM who were younger (<30 years), not on ART, had detectable VL, and used 
recreational drugs (including injection and chemsex-associated drugs). These associations mirror those 
observed for CLS in Chapter 4. They also emphasize the importance of STI prevention strategies that 
particularly focus on HIV-diagnosed MSM. All types of CLS and higher partner numbers were strongly 
associated with reporting any diagnosed STI. Compared to MSM who had condom-protected sex, MSM 
who had CLS-D were significantly more likely to have an STI; this was independent of socio-demographic 
factors, drug use, and partner numbers.  
 
The second part of this chapter focussed on HCV, using data from HIV-diagnosed MSM participating in 
ASTRA who consented to linkage of the questionnaire with routine clinical data. The cumulative 
prevalence of (chronic/prevalent) HCV was 13% (and 12% when excluding MSM reporting IDU). A strong 
association was observed between evidence of depressive symptoms and higher prevalence of chronic 
HCV. While temporality in this association cannot be ascertained due to the cross-sectional nature of 
our data, these results suggest that screening for and managing depression among HIV-diagnosed 
individuals may be important. In prospective analysis, the incidence of HCV over follow-up was 0.3 per 
100 person years based on 6 HCV seroconversions. Despite the very small number of incident HCV cases, 
initial results suggested that injection and chemsex-associated drug use, CLS-D, and high partner 
numbers were predictive of incident HCV.  
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In terms of assessing and monitoring risk of transmission of STIs among HIV-diagnosed MSM, ‘any CLS’ is 
likely to be the most relevant measure in research and surveillance. STIs were assessed by self-report, 
which may have led to recall bias and underreporting; future studies of HIV-diagnosed MSM would 
benefit from STI screening at study recruitment.  
 
Detection and control of STIs remains critical among HIV-diagnosed MSM; scaling up of routine sexual 
health assessment with extra-genital screening is important. Barriers to accessing STI testing (concerns 
about stigma and confidentiality, embarrassment, limited clinic opening hours) could be addressed with 
development of accurate, rapid smartphone-enabled diagnostic self-testing kits for multiple STIs, linked 
to online clinical management pathways.
595
 While bacterial STIs are mostly curable, managing the 
spread of antimicrobial resistant gonorrhoea is a public health priority. With the advent of DAAs, HCV 
cure rates have improved dramatically.
579
 It will remain key to expand access to HCV treatment. Routine 
HCV screening of HIV-diagnosed MSM, in particular those who report high partner numbers, chemsex 
use, and traumatic sex practices, will be beneficial in preventing incident HCV infections. There is 
emerging evidence among HIV-negative MSM enrolled in PrEP trials that on demand antibiotic post-
exposure prophylaxis (PEP) for STIs reduces the incidence of bacterial STIs
596
; the long term efficacy of 
this strategy and its impact on antibiotic resistance remains to be assessed.  
9.3 Limitations  
Interpretation of findings from this thesis requires careful consideration of bias, in addition to 
confounding and chance, and considerations relating to causality. Bias in the estimate of the causal 
effect of the exposure on the dependent variable is mainly categorised into selection and measurement 
(information) bias.  
 Selection bias 9.3.1
Selection bias arises from the procedures by which study participants are selected from the source 
population, or self-selected by consenting to participate; it occurs when there is a difference between 
characteristics of people selected and those not selected for the study, arising when the sample selected 
is not random. In ASTRA, the recruitment strategy may have been biased and led to over-recruitment of 
particular social groups. For example, health-conscious patients may have been more frequent clinic 
attendees and therefore more likely to be invited to participate during the recruitment period. 
Individuals interested in sexual behaviour research may have been more likely to participate and may 
not necessarily be representative of the clinic population as a whole. However, an effort was made to 
account for this by having long recruitment periods in each participating clinic (mean of 8.2 months, see 
Table 3.4). This would have ensured that even infrequent attendees would be approached to participate 
in the study. Selection bias may also have occurred during the process of approaching and inviting 
patients to participate and in terms of which patients were approached by the recruiters. However, 
recruiters were encouraged to approach consecutive patients during the specific clinical sessions in 
which ASTRA recruitment was taking place.   
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Another component of selection bias is non-response bias. Thirty-six percent of those invited to 
participate in ASTRA did not complete a questionnaire. Non-responders could have differed from 
responders in terms of sexual behaviour, as it was clear from the information sheet that the study 
included questions on sex. Two possible groups of non-responders would emerge in this case: MSM who 
had ‘higher risk’ sex and are reluctant to admit it and MSM to whom this section would not be relevant 
(perhaps because they do not have sex). In addition, non-responders could also differ in terms of factors 
associated with sexual behaviours, such as age and recreational drugs use. While selection bias in this 
case can result in biased estimates of the prevalence of factors, it would be expected to have less of an 
impact on the association between factors. It was not possible to compare responders and non-
responders in ASTRA, but respondents could be compared with the group who consented to participate 
but did not return a questionnaire with respect to selected key factors, such as CD4 count and viral load. 
There were no significant differences in these factors compared between the two groups. This provides 
some reassurance that the respondents were broadly representative of all HIV-diagnosed individuals 
who initially agreed to participate but did not complete the questionnaire. Among MSM, the vast 
majority of participants consented to data linkage and there were few significant differences between 
those who provided consent to linkage and those who did not.  
 
Comparison of ASTRA MSM participants to the HIV-diagnosed MSM population receiving care in the UK 
(SOPHID) in 2011-2012 showed differences in the distribution of age and area of residence, but broadly 
similar distribution of ethnicity, ART status, and CD4 count. (section 9.2.2). As ASTRA may under-
represent younger HIV-diagnosed MSM, it may be that results underestimate the prevalence of factors 
that are associated with younger age, such as CLS, recreational drug use, and STI co-infections. The 
study is limited in not recruiting participants in other areas of England (Midlands, South West) as well as 
other UK countries, and this has implications for the representativeness of findings.  
 Information bias 9.3.2
Information bias results from misclassification of study participants with respect to the information 
collected about them. Differential misclassification occurs when the probability of misclassification of 
the dependent (outcome) variable is reliant on exposure status. For example, MSM who were recently 
diagnosed with HIV in ASTRA (≤3 months prior to questionnaire completion) may have been more likely 
to report CLS (one of the dependent variables under study), which may have resulted in a spurious 
association between time since HIV diagnosis and CLS. Thus, MSM who were recently diagnosed were 
excluded from analyses.  
 
Self-completed questionnaires may be subject to information bias due to missing responses or 
inaccurate recall or reporting. In addition, participants may provide inaccurate answers on sensitive or 
stigmatising behaviours (such as depression or CLS) in order to present more favourable or socially 
‘acceptable’ attitudes and behaviours, referred to as social desirability bias.  To limit social desirability 
bias, the questionnaire was self-administered in a private space and participants were reminded that 
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their answers would not be viewed by clinic staff. In addition, to minimise misclassification of exposure 
variables at the study design stage, pre-validated instruments and standard questionnaires were 
selected for inclusion in the questionnaire where possible, which have been shown to have high validity 
(such as the CAGE, WHO-AUDIT-C, PHQ-9, and GAD-7). At the data management stage, extensive data 
checks were done to ensure consistency between variables and within subsections of questions. Where 
applicable, for a limited number of variables, missing information on the questionnaire was completed 
using information from linked clinical records. While it is possible that the prevalence of sexual 
behaviour measures may be underestimated due to social desirability bias and missing data, there is 
likely to be less bias in the examination of associations between sexual behaviour and other factors.  
 Lack of qualitative data 9.3.3
As this thesis used data from a quantitative cross-sectional study, it lacks insight from qualitative data. 
Qualitative studies are valuable in exploring subjective experiences of sexual behaviour and enhancing 
contextual understanding of behaviours that cannot be easily accessed in quantitative studies.
597
 Semi-
structured and in-depth interviews are particularly suited to the study of sexual attitudes and 
behaviours, as well as in examining lifestyle issues (e.g. recreational drug use). For instance, a qualitative 
study of 30 chemsex-using MSM in South London used semi structured interviews to examine the 
motivations for engaging in chemsex in 2013-2014.
598
 This study was the first to describe the 
phenomenon formally in London, and highlighted the motivations (increasing libido) and capabilities of 
chemsex drugs (reducing inhibitions and increasing confidence and stamina) for MSM to engage in the 
kind of sexual behaviour they value.
598
 In 2017, a narrative review drew on worldwide literature to 
synthesise evidence on use and impacts of drug use among all MSM (regardless of HIV-serostatus).
599
 
The review highlighted that the cultural norms and social context for recreational drug and alcohol use 
are particularly pervasive among MSM, especially among young men; that MSM may use drugs as a 
coping strategy in managing “internal conflict about sexuality and its concealment, or the stigma 
experienced upon disclosure, [or] to avoid thoughts about personal risk for HIV acquisition”. Further, 
qualitative research is beneficial in uncovering the positive motivations for drug (and chemsex use), 
which could in turn increase understanding of the social and cultural context of drug use. Such findings, 
combined with those from quantitative studies such as ASTRA, can allow for planning of culturally 
sensitive health promotion interventions that are acceptable and effective (discussed further in section 
9.5.2.3). 
9.4 Strengths of the ASTRA study 
ASTRA was the largest and questionnaire study of HIV-diagnosed people in the UK at the time, giving 
enough power to detect modest differences between groups. Over 48% of new infections among MSM 
are diagnosed annually in London, and over 67% of MSM in ASTRA were recruited in London, 
representing 10% of all HIV-diagnosed MSM accessing NHS care in London during 2011-2012.
600
The 
overall ASTRA response rate (64% of eligible patients approached) was satisfactorily high and 
comparable to earlier UK studies of people attending for HIV care.
131,133,153,589
 Other studies recruiting 
convenience samples of HIV-diagnosed individuals (using time and location sampling of gay bars, saunas, 
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gay Pride events etc.) are harder to compare to, as the number of participants eligible cannot be directly 
determined; the range of questionnaire response rates from such UK studies (as a percentage of 
estimated MSM attending these venues at specific times) also ranges from 50% to 70%.
97,105,142,143
 
ASTRA is also unique in that patients’ routine clinical HIV data is linked to questionnaire data. A very 
high proportion (92%) of respondents agreed to linkage of clinical with questionnaire data. Although 
linkage was not complete for all clinics by late 2016, data provided were sufficient to conduct 
longitudinal analyses examining unadjusted trends. 
 
ASTRA collected comprehensive information recreational drug use, sexual behaviours, attitudes, and 
sexual health, enabling detailed examination of the number of male (and female) sexual partners, 
including recent, new, long-term, and CLS partners, as well as recent and lifetime STIs, and other 
behaviours (group sex, seropositioning). Detailed HIV-related information on VL and CD4 counts was 
collected from multiple sources (the study log, routine clinic data, and self-report), which allowed for 
examination of markers of engagement in HIV care (such as level of disagreement between self-
reported and clinic recorded viral load) and their relationship to sexual behaviour outcomes. Ours was 
the first study in the UK to date to report on prevalence of higher HIV risk CLS-D based on clinic-
recorded VL. 
9.5 Implications  
This section summarises the main implications for HIV treatment and clinical care, HIV prevention, and 
future epidemiological studies of sexual behaviour of HIV-diagnosed MSM that arose from this thesis.  
 Implications for HIV treatment and clinical care  9.5.1
9.5.1.1 Early ART initiation 
Results from Chapters 4, 5, 6, 7, and 8 show that the prevalence of condomless sex and other STIs (and 
especially with HIV-serodifferent partners) tended to be higher among MSM who were not on ART. This 
supports the strategy of early ART initiation for all individuals with diagnosed HIV, regardless of CD4 
count or clinical staging for preventing HIV transmission. As of 2015, the WHO and BHIVA recommend 
early ART initiation not only for the net clinical benefit of the patient but also for the public health 
benefit of decreasing HIV transmission.
17,601
  
 
However, the benefits of early ART cannot be realised fully without linkage to clinical HIV care. 
Addressing barriers to access and retention in HIV care is thus important. For MSM, these barriers can 
include perceived or enacted homophobia and stigma associated with attending an HIV clinic, lack of a 
supportive network, fears of breach in confidentiality, beliefs in alternative therapies as more effective 
than ART, chaotic lifestyles linked to drug use, among others. Community support (in the form of 
ongoing post-test counselling by community health workers) has been shown to have an overall positive 
impact on retention to care, ART adherence, and virological outcomes.
602
 For this reason, strengthening 
the role of community support is a good investment in the care of HIV-diagnosed people and in 
subsequent prevention of HIV transmission.  
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9.5.1.2 Prevention and management of sexually transmitted co-infections 
Results from Chapters 6 and 8 show the relatively high prevalence of condomless sex and STI co-
infections, associated with high partner numbers and chemsex-associated drug use in this population of 
HIV-diagnosed MSM. These findings highlight the need for continued focus on STI prevention among 
HIV-diagnosed MSM. In the UK, HIV-diagnosed MSM are disproportionally affected by acute bacterial 
STIs and hepatitis C (compared to HIV-negative MSM), which suggests that STI transmission is occurring 
in sexual networks of HIV-positive MSM. The continuing risk of syphilis among MSM, particularly in 
London, is also of concern, and has been shown to be associated with condomless sex between HIV-
positive partners.
603
 Therefore, screening, diagnosis, treatment of STIs and contact tracing should 
continue to be offered routinely as part of open access comprehensive HIV prevention and care for all 
MSM. Promotion of condom use and of awareness of STIs should continue (where available) and expand 
through sexual health campaigns targeted at MSM.  
9.5.1.3 Harm reduction for HIV-diagnosed MSM who use drugs 
Chapters 6, 7, and 8 highlight the high prevalence of recreational drug, chemsex, and polydrug use and 
extremely strong associations with measures of condomless sex, non-disclosure of HIV-serostatus, STIs, 
and HCV co-infection among HIV-diagnosed MSM in ASTRA. 
 
There is a need for expansion of integrated sexual health and drug services for all MSM (regardless of 
HIV serostatus in regions where recreational drug use is most common. MSM who inject drugs (for 
example as part of chemsex) should have access to sterile injecting equipment. A London sexual health 
clinic now provides free “slamming packs” for men engaging in chemsex, containing colour-coded 
syringes and needles, dosing syringes for measuring GHB safely, sterilised spoons for mixing drugs, a 
thermometer, and a sharps bin.
604
 This clinic sets an example for health promotion and harm reduction 
that is grounded in innovative thinking and prompt action, which should be extended throughout areas 
of the UK in which chemsex occurs.  
 
Providing achievable goals in chemsex use can help to define and structure progress. Qualitative studies 
show that among MSM who wish to make changes around their chemsex use, healthcare providers and 
peer-workers can help identify achievable goals.
605,606
 While certain men may wish to abstain from 
chemsex entirely, others may have more short-term goals, such as reducing use, managing sexual risk-
taking and boundaries more effectively during chemsex, safer drug-dosing, or abstaining for a specific 
period of time, among other goals. In MSM who may not wish to make changes, it is important that a 
risk assessment is made, both to the health and wellbeing of the chemsex user and of their sexual 
partners. 
 
Psychosocial support should also be available to MSM who experience mental health issues as a result 
of their chemsex use. This can include psychological and physical dependence on chemsex drugs, 
withdrawal symptoms, depression, anxiety, and paranoia, as well as post-traumatic stress disorder 
induced by non-consensual sex or sexual assault occurring during chemsex-induced “black outs”.  
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The possibility of recreational drug and ART interactions should also be stressed, particularly given that 
over half of HIV-diagnosed MSM on ART in ASTRA had used recreational drugs in the past three months. 
The potential for drug-drug interactions (DDIs) is highest between ritonavir-boosted PI regimens and 
EDDs, benzodiazepines, ketamine, and chemsex drugs.
320
 Hence, clinicians need to not only expand their 
knowledge and understanding of DDIs, but also need to be aware of all recreational and prescribed 
substances their HIV-diagnosed patients are using. National HIV treatment guidelines could benefit from 
inclusion of potential DDIs with specific recreational drugs and guidance on choice of regimen, dosage 
adjustment, monitoring, and provision of information to patients.  
9.5.1.4 Mental health and wellbeing 
In Chapter 4 it was shown that the prevalence of symptoms of depression and anxiety was significantly 
higher among HIV-diagnosed MSM who did not have sex and was also high among MSM who had CLS-D. 
In Chapter 8 symptoms of depression were also prospectively associated with incident hepatitis C 
among HIV-diagnosed MSM, although findings were based on a very small number of HCV 
seroconversions. Nevertheless, provision of routine screening and management of depression in HIV-
diagnosed MSM remains an important part of integrated routine HIV care.  
 Implications for HIV prevention  9.5.2
To respond effectively to HIV among MSM, a comprehensive package of interventions is needed to 
assist with programming for HIV prevention.  
9.5.2.1 Reducing the prevalence of undiagnosed HIV infection 
As discussed in section 1.3, the majority of HIV transmissions in the UK are estimated to derive from 
HIV-undiagnosed MSM. Hence, a reduction in the prevalence of undiagnosed HIV in this population 
(currently estimated to be 12%), will be key in decreasing the number of new HIV diagnoses. This can be 
achieved by increasing HIV testing availability and uptake (including self-sampling and self-testing 
options). Voluntary HIV testing and counselling should be routinely offered to all MSM in community 
and clinical settings, and by a variety of providers, including community outreach workers and general 
practitioner surgeries. In community-based testing, it is important that linkages are in place, to care and 
treatment services for those who test positive as well as to prevention services for those who test 
negative. In addition to testing, pre- and post-test counselling provides a unique opportunity for health 
promotion and behavioural interventions. Pre-test counselling should provide accurate information 
about the test and the implications of each respective result; post-test counselling should provide a 
supportive discussion of personal choices on disclosure of HIV-serostatus, risk reduction for HIV and 
other STI transmission, and personalised treatment choices.   
9.5.2.2 Strategies for reducing HIV transmission 
9.5.2.2.1 Condom use  
A quarter of HIV-diagnosed MSM in ASTRA reported always using condoms during anal sex in the past 
three months. This sizeable proportion shows that the correct and consistent use of condoms remains 
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an important message in preventing sexual transmission of HIV and of other STIs. Increasing the 
availability, affordability, and accessibility of condoms and condom-compatible lubricants not only in 
sexual health clinics but also through targeted distribution programmes (e.g. in sex-on premises venues, 
chemsex parties, nightclubs) remains an essential component of the HIV response. Promotional 
campaigns can not only increase awareness but also promote the acceptability of using condoms, as a 
way to overcome personal and social barriers to their use. As shown in Chapter 4, 7% of ASTRA HIV-
diagnosed MSM reported low condom self-efficacy and almost 16% reported difficulty negotiating 
condom use, which may contribute to the high prevalence of condomless sex overall in this population. 
Hence, along with promotion and supply of condoms, health providers and community groups should 
develop programmes offering skills-building in negotiating condom use in those who need it.  
9.5.2.2.2 Pre-Exposure Prophylaxis (PrEP) 
In the last five years, the field of primary HIV prevention research has made dramatic achievements, 
particularly with the use of antiretroviral medications by HIV-uninfected individuals to prevent HIV 
acquisition (PrEP). As discussed in section 1.3.5.2, a number of large, well-conducted randomised trials 
have demonstrated the substantial protective effect conferred by oral PrEP in reducing the risk of HIV 
acquisition across genders, types of sexual exposure, regimens, and dosing schemes.
607
 There is, so far, 
no evidence of increased adverse safety events with PrEP use.
607
 The risk of PrEP drug resistance is also 
low, and must be weighed against the overall benefits. However, the effect of large-scale PrEP 
implementation on resistance levels overall, remains unknown. A meta-analysis of 18 studies found no 
evidence that PrEP led to behavioural risk compensation, meaning a reduction in condom use or 
increases in numbers of sexual partners. However, recent results from real-world PrEP implementation 
in the USA show a relatively high incidence of other STIs along with a 41% decrease in reported condom 
use among a subset of PrEP users.
608
  
 
Therefore, oral PrEP should be an additional prevention choice for MSM at higher risk of HIV infection, 
as part of combination HIV prevention. A number of PrEP modelling and implementation studies in high-
income countries have evaluated the impact of PrEP on HIV diagnoses among MSM since 2010 (with 
time horizons from 10 to 40 years). A review of six of these studies showed that PrEP alone will not be 
able to reduce HIV diagnoses to zero, regardless of the time horizon.
609
 The UNAIDS goal of eliminating 
HIV by 2030 can be achieved with a combination of PrEP uptake and regular HIV testing in HIV-negative 
individuals, early ART initiation in HIV-diagnosed individuals, and promotion of condom use.
609
 This 
message is now promoted in the local authority-supported ‘Do It London’ sexual health initiative 
(http://doitlondon.org/), which aims to increase HIV testing and to promote more prevention choices to 
people in London. Expansion of such campaigns outside London would be beneficial. 
 
The overall observed decreases in the number of potentially infectious HIV-positive MSM seen in the 
UK, coupled with increased use of PrEP among HIV-negative MSM, may translate to potential population 
increases in condomless sex. This is a concern for the detrimental spread and impact of antimicrobial 
resistant gonorrhoea, which is no longer susceptible to most available therapies.
432
 MSM who report 
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condomless sex, chemsex, high partner turnover (regardless of HIV-serostatus) should have prioritised 
access to prevention measures such as PrEP and regular STI screening (or re-testing in cases of a prior 
STI diagnosis).
610,611
 
9.5.2.3 The role of qualitative studies  
Findings from qualitative studies are able to bring forth the challenges and opportunities of developing 
strategies for reducing HIV transmission. Evidence from focus groups of HIV-diagnosed MSM attending 
for HIV care in the UK and the USA shows that sexual risk reduction interventions are more appealing 
when they address the broader life context of living with HIV, including psychosocial stressors, stigma, 
and disclosure, as well as community beliefs regarding HIV treatment and normalisation.
597,612
 
Qualitative work is especially useful in informing the formulation of hypotheses and data collection 
procedures for the development of sexual risk assessment tools (such as the indicator of higher HIV risk 
CLS-D developed in Chapter 5) to be used in sexual health care settings.
605
 A pertinent example is that of 
the Fenway Study group (USA), which used semi-structured interviews among HIV-negative men who 
use chemsex drugs; this study identified acceptable strategies for use of PrEP while ‘high’ on drugs, 
detailing men’s dosing and regimen preferences according to level of drug use.
606
  
 
In addition, qualitative studies have highlighted inequalities in HIV literacy, which could be barriers to 
effective use of ART as prevention.
613,614
 For instance, a recent qualitative study (interview and focus 
groups) of HIV-diagnosed MSM receiving care in the USA found that only a small minority of men 
perceived that ART reduced infectivity; this study showed that interventions need to be specifically 
tailored to populations’ needs.
615
 Among HIV-negative men, a Scottish focus group and in-depth 
interview study explored men’s understandings of PrEP effectiveness, finding that concerns about 
maintaining PrEP adherence and low perception of HIV risk were barriers to potential PrEP uptake.
616
 
Findings from this study draw attention to how PrEP rollout must include diverse communication 
methods given differences in HIV literacy.  
 
Mixed methods exploratory approaches from the UK also underscore the acceptability of and barriers to 
implementation of prevention approaches among MSM and healthcare providers.
617,618
 For example, 
combination of focus group thematic analysis and cross-sectional questionnaires among MSM in 
Scotland showed that self-testing awareness was prevalent, but associated with specific socio-
demographic factors, and that willingness to self-test was high and associated with finding sex online.
619
 
Lastly, evidence-based health promotion benefits greatly from the contributions of qualitative methods 
in assessing delivery of interventions. As an instance, the SELPHI RCT examines whether free HIV self-
testing leads to increased rates of HIV diagnosis in England and Wales (2017-2020); the trial embedded a 
qualitative feasibility study and process evaluation, which captured the perspectives of MSM in relation 
to HIV self-testing, and specifically how the trial components impacted on acceptability to self-test for 
HIV.
617
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 Implications for future epidemiological studies  9.5.3
The thesis results have implications for definitions of variables in research studies that aim to capture 
risk behaviour in relation to HIV and STI transmission.  
9.5.3.1 Mutual classification of sexual behaviour 
Firstly, findings from Chapters 4, 6, and 7 show that adoption of the mutually exclusive classification of 
sexual behaviours is beneficial as it captures different types of condomless sex, CLS, (with HIV-
serodifferent or other HIV-positive partners only) and allows for separate analysis of condom-protected 
sex versus no sex. This classification brings insights into serosorting and associated factors, and leads to 
better evaluation of complex associations between socio-demographic, health, and lifestyle factors with 
different types of sexual behaviour.  
9.5.3.2 Higher HIV risk CLS-D indicator 
Secondly, epidemiological studies of sexual behaviour among HIV-diagnosed MSM would benefit from 
further refining the concept of CLS-D with a higher risk of HIV transmission, incorporating VL level. 
Results from Chapter 5 were the first to formally examine higher HIV risk CLS-D in the UK, at a time 
when HIV transmissions were high and ongoing among MSM, and ‘any CLS’ was used in research as a 
marker of HIV transmission risk. While the concept of ‘any CLS’ remains the most appropriate indicator 
for measuring risk of transmission of other (non-HIV) STIs, it is no longer the most useful measure of HIV 
transmission risk sex. The landscape of HIV has changed substantially during the course of this study, 
which has implications for the use of the ‘higher HIV risk CLS-D’ indicator in studies and surveillance of 
sexual behaviours. For the first time ever, the UK saw an 18% decline in newly-diagnosed HIV between 
2015 and 2016, particularly among MSM in London.
620
 PrEP use has expanded among HIV-negative men 
since 2012 (when ASTRA completed recruitment), and treatment guidelines changed in 2015 to 
recommend initiation of ART at HIV diagnosis. As a result, the proportion of HIV-diagnosed MSM likely 
to contribute to HIV transmission in the current era of the epidemic is likely to be small, and to continue 
declining as more men achieve virological suppression on ART. As PrEP use further expands, studies and 
surveillance systems will need to address ways to incorporate preventative measures taken by HIV-
negative partners, too. For example, while 4.5% of ASTRA MSM had higher HIV risk CLS-D, the 
proportion of HIV-negative partners on PrEP is unknown. The proportion of men who had higher HIV risk 
CLS-D accounting for PrEP may thus be much lower, and will continue to decline. In the context of new 
HIV prevention methods, a broader range of sexual risk indicators is needed. Future studies of HIV-
diagnosed men will still benefit from using the indicator proposed in this thesis, but they could also 
enquire about HIV-negative partners’ use of PrEP; a new indicator could thus measure CLS-D with 
detectable viral load and no reported PrEP use. 
9.5.3.3 Self-perceived viral load  
In Chapters 4 and 7 there was some evidence that men who were on ART with self-reported 
undetectable VL (versus without self-reported undetectable VL) tended to report more CLS-D and were 
less likely to disclose their HIV serostatus to new sex partners. This may be due to increased awareness 
of the extremely low risk of HIV transmission when the HIV-diagnosed partner is on effective ART, and 
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thus overall lower condom use. Although the results presented are reassuring in showing that any effect 
of perceived undetectable viral load on sexual behaviour of HIV-diagnosed MSM would not impact 
adversely on HIV or STI transmission risk, it will be important to continue monitoring these associations 
as ART use expands. 
9.6 Concluding remarks 
The ’90-90-90’ targets set by UNAIDS reflect key points in the continuum of HIV care, with respect to HIV 
testing, treatment, and viral load suppression.
621
 The UK has made significant progress towards these 
goals, having already reached the second and third ‘90’ targets among MSM, with 94% of HIV-diagnosed 
MSM being on ART, and 96% of those having suppressed viral load. For the first time ever in 2016, there 
was an observed decline in new HIV diagnoses in the UK. This exciting development must be met with 
consolidated combination prevention, consisting of innovations in scaling up of HIV testing and access to 
early ART across the UK for all individuals at highest risk of HIV.
85
 As ART use expands among the HIV-
diagnosed population, it will be crucial to continue promoting sustained high ART adherence, regular VL 
monitoring, and ongoing awareness of personal VL level among people with diagnosed HIV.
182
 Reaching 
all three ‘90’ targets in the UK would undoubtedly deliver immense benefits to people living with HIV; it 
is also important in increasing population-level HIV VL suppression and thus reducing onward 
transmission of HIV. However, the ‘90-90-90’ strategy does not provide a target for ensuring good 
health-related quality of life among HIV-diagnosed MSM, both in terms of co-morbidities and of self-
perceived quality of life, including sexual wellbeing. Hence, apart from reducing HIV transmission and 
related morbidity, treatment, policy, and research will need to address a comprehensive set of issues in 
virally suppressed MSM living with HIV including: psychological and sexual well-being, harm reduction in 
recreational drug use, and comprehensive management of co-morbidities and STI co-infections.  
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Appendix I. ASTRA study documents  
ASTRA INFORMATION SHEET 
Version 2.0  07/01/2011 
This information sheet and the other study documents are also available in French. Just ask the 
clinic nurse if you would prefer a French copy. 
 
ASTRA Questionnaire Study  
We would like to invite you to take part in a research study. Please take some time to read this 
information about the study and decide whether or not to take part. Please ask the person who 
invited you to take part if anything is unclear or if you have any other questions.  
 
What is the study about? 
This is a questionnaire study, looking at how HIV and HIV treatment (antiretroviral treatment) 
affects people’s lives, including their health, quality of life, and lifestyle. In particular, the study 
will investigate the link between HIV treatment and sexual lifestyles. The results will be used to 
help decide what the effects would be of offering immediate treatment to all people in the UK 
who are diagnosed with HIV. 
 
Who is taking part? 
This study is being conducted at five HIV clinics in the UK. Everyone coming to each of these 
clinics is eligible to take part. This includes people who are not taking HIV treatment as well as 
those who are on treatment. We would like as many people as possible to participate, and so 
your contribution is important.  
 
What will I have to do? 
If you agree to take part, you will be asked to complete a questionnaire about your health and 
well-being, your lifestyle, your experience of having HIV, and your views on HIV treatment. The 
questionnaire includes some personal questions about your sex life. You can complete the 
questionnaire on your own. It should take 15 to 30 minutes to complete.   
 
When will I complete the questionnaire? 
We would like you to complete the questionnaire today, while you are here in the clinic, either 
before or after seeing the doctor. There is a private space available for you to complete your 
questionnaire, if you would prefer this. The study nurse will make sure you don’t miss your 
appointment with the doctor.  
 
Will my questionnaire responses be confidential? 
Yes, completely. Your name or clinic number will NOT be written on the questionnaire. Your 
answers will NOT be seen by the doctors and nurses in the clinic, and your answers will NEVER 
be recorded in your clinic notes. Your completed questionnaire can be placed in a sealed 
envelope which will not be opened by the clinic staff. 
 
What clinical information will be recorded? 
If you agree to take part in the study, we will record your latest viral load and CD4 count as part 
of the study data.  
 
Will any other information about me be gathered? 
You will be asked if you agree to us adding your routine HIV clinical information (from this clinic 
only) to the questionnaire information. This is so we can see how peoples’ questionnaire 
responses relate to their current and future situation. The HIV clinical information would be: 
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 Your laboratory test results (e.g. viral load and CD4 count) 
 Your HIV treatment details 
 Other routine information on your HIV care (e.g. any illnesses or hospital admissions) 
This is a standard procedure for research studies. The clinical information is added in such a 
way that your questionnaire responses remain completely confidential, and are NEVER put 
together with your name or clinic number. You do not have to agree to this, and you can still 
participate in the study if you do not agree. If you do agree, the clinical information will be 
collected once when everyone has completed the questionnaire, and on several more 
occasions over the next few years.  
 
What will happen to the information? 
Your anonymised responses will be added to everyone else’s responses, and analysed by 
computer. The data will only be analysed for groups and not for individuals. The findings will be 
submitted to medical journals and national and international health conferences. Details of 
publications from this study will be made available on the ASTRA study website  
(www.astra-study.org).  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you may keep 
this information sheet and you will be asked to sign the consent form. If you agree to take part 
you can still change your mind and decide not to complete and submit the questionnaire. If you 
choose not to take part in the study, this will not affect the standard of care you receive. 
 
Are there any risks in taking part? 
There is no risk to you in taking part in the study. If you find the questionnaire raises issues that 
concern you, or that you would like to discuss further, please ask the nurse to arrange for you to 
speak to [insert appropriate clinic/local health professional…………………………………….. ] 
 
Who is leading this research? 
A team of HIV specialists and researchers from the UK is leading this study. The study is being 
coordinated by the Research Department of Infection and Population Health, University College 
London, and is funded by the National Institute for Health Research (NIHR). This study has 
been reviewed and approved by a research ethics committee. 
 
Site lead …………………………………………….. 
Site…………………………………………………… 
 
Dr Fiona Lampe 
Research Department of Infection and Population Health, University College London. 
http://www.ucl.ac.uk/iph/    f.lampe@ucl.ac.uk 
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Please 
initial 
box 
 
NO, I 
do not 
agree 
 
YES, I 
agree 
 
CONSENT FORM for ASTRA Questionnaire Study 
Version 2.1  21/01/2011 
 
Clinical centre: ………………………………………………….. 
ASTRA Study ID: __________________          
Clinic Number: __________________ 
 
1. I confirm that I have read and understand the information sheet 
(version 2.0, dated 07/01/2011) for this study. I have had the 
opportunity to consider the information, ask questions, and have 
had these answered satisfactorily. 
 
2. I agree to take part in this study. 
 
 
 
3. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
4.  I agree / do not agree that information from this clinic on my 
laboratory test results, HIV treatment and clinical care can be 
added to my questionnaire responses. 
 
 
 
 
 
     
 
 
________________________       __ __ /__ __ / __ __ __ __         
__________________ 
Name of patient                     Date                                    Signature 
 
________________________       __ __ /__ __ / __ __ __ __         
__________________ 
 
Name of person taking consent     Date                                    Signature 
 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes   
Please initial 
one box only 
 
Please 
initial 
box 
 
Please 
initial 
box 
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348 
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351 
 
352 
 
353 
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355 
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Appendix II. Search strategy used in MEDLINE and EMBASE for 
systematic literature review of condomless sex among HIV-
diagnosed MSM in high-income countries (1995-2016) 
 
 
#  Search terms  Number retrieved  
1 HIV/ or HIV infections/ or HIV seropositivity/ or HIV-
positive/ or "HIV positive"/ or HIV-infected/ or "HIV 
infected"/ [Title/Abstract] 
189884 
2 Sexual Behaviour.mp. or exp Sexual Behavior/ or 
Unprotected/ or Risk/ or Unsafe Sex/ or “unprotected 
anal intercourse”.mp. 
199676 
3 risk reduction behavior/ or HIV serosorting/ or safe 
sex/ or condomless sex/ [Title/Abstract] 
12115 
4 Homosexuality, Male/ or Homosexuality/ or gay/ or 
MSM/ or “men who have sex with men”.mp. 
26475 
5 2 or 3 208319 
6 1 and 5 24211 
7 6 and 4 9253 
8 Great Britain/ or UK or Scotland.mp. or United States/ 
or America/ or Canada/ or Western europe.mp. or 
Europe/ or Australia/ 
1349429 
9 7 and 8 1989 
10 Limit 9 to English language and publication range 
1996-2016 
1664 
11 Limit 10 to journal articles only (excludes newspaper 
articles, editorials) 
1426 
12 Limit 11 to exclude literature reviews or opinion 
papers 
449 
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Appendix III. Results of literature search on EMBASE and MEDLINE  
1
st 
Author Database Country / Title Source / Included in literature review? Reasoning if not 
Aghaizu A Ovid 
MEDLINE(R) 
UK Sexual behaviours, HIV testing, and the proportion of men at risk of transmitting and acquiring 
HIV in London, UK, 2000-13: a serial cross-sectional study. 
The Lancet. HIV. 3(9):e431-40, 2016 
Sep. 
Yes 
Beer L Ovid 
MEDLINE(R) 
USA Disparities in HIV transmission risk among HIV-infected black and white men who have sex with 
men, United States, 2009. 
AIDS. 28(1):105-14, 2014 Jan 2. Yes 
Bolding G Ovid 
MEDLINE(R) 
UK Gay men who look for sex on the Internet: is there more HIV/STI risk with online partners?. AIDS. 19(9):961-8, 2005 Jun 10. Yes 
Bouhnik 
A-D 
Ovid 
MEDLINE(R) 
FR Unprotected sex in regular partnerships among homosexual men living with HIV: a comparison 
between sero-nonconcordant and seroconcordant couples (ANRS-EN12-VESPA Study).  
AIDS 2007; 21 Suppl 1: S43–8. Yes 
Bourne A SigmaResearc
h website 
UK Relative safety II: risk and unprotected anal intercourse among gay men with diagnosed HIV.  London, UK; 2009.    
Bruce D Ovid 
MEDLINE(R) 
USA Sexual risk behavior and risk reduction beliefs among HIV-positive young men who have sex 
with men. 
AIDS & Behavior. 17(4):1515-23, 
2013 May. 
Yes 
Colfax GN Ovid 
MEDLINE(R) 
USA Sexual risk behaviors and implications for secondary HIV transmission during and after HIV 
seroconversion. 
AIDS 2002; 16: 1529–35. Yes 
Dodds JP Embase UK Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample 
of homosexual men. 
Sex Transm Infect 2004; 80: 236–40. Yes 
Dodds JP Embase UK A tale of three cities: persisting high HIV prevalence, risk behaviour and undiagnosed infection 
in community samples of men who have sex with men.  
Sex Transm Infect 2007; 83: 392–6. Yes 
Durham 
MD 
Ovid 
MEDLINE(R) 
USA Sexual risk behavior and viremia among men who have sex with men in the HIV Outpatient 
Study, United States, 2007-2010. 
Journal of Acquired Immune 
Deficiency Syndromes: JAIDS. 
63(3):372-8, 2013 Jul 1. 
Yes 
Elford J Embase UK Peer led HIV prevention among homosexual men in Britain.  Sex Transm Infect 2002; 78: 158–9. Yes 
Elford J Embase UK High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is 
the role of HIV optimism? 
AIDS 2002; 16: 1537–44. Yes 
Elford J Embase UK HIV treatment optimism and high-risk sexual behaviour among gay men: the attributable 
population risk 
AIDS 2004; 18: 2216–7. Yes 
Elford J Embase UK Sexual behaviour of people living with HIV in London: implications for HIV transmission. AIDS 2007; 21 Suppl 1: S63–70. Yes 
Elford J Embase UK High-risk sexual behaviour among London gay men: no longer increasing. AIDS 2005; 19: 2171–4. Yes 
Elford J Embase UK HAART, viral load and sexual risk behaviour.  AIDS 2005; 19: 205–7. Yes 
Elford J Ovid UK HIV in East London: ethnicity, gender and risk. Design and methods. BMC Public Health. 6:150, 2006.   
360 
 
1
st 
Author Database Country / Title Source / Included in literature review? Reasoning if not 
MEDLINE(R) 
Elford J Ovid 
MEDLINE(R) 
UK Barebacking among HIV-positive gay men in London.  Sex Transm Dis 2007; 34: 93–8. Yes 
Elford J Ovid 
MEDLINE(R) 
UK The Internet and HIV study: design and methods. BMC Public Health. 4:39, 2004 Sep 1. No: protocol paper 
Elford J Ovid 
MEDLINE(R) 
UK Sexual health of ethnic minority MSM in Britain (MESH project): design and methods. BMC Public Health. 10:419, 2010. No: protocol paper 
Diamond 
C 
Ovid 
MEDLINE(R) 
USA Use of and adherence to antiretroviral therapy is associated with decreased sexual risk 
behavior in HIV clinic patients.  
J Acquir Immune Defic Syndr. 2005 
Jun 1;39(2):211–8.  
Yes: in factors 
section 
Glass TR Embase SW  Is unsafe sexual behaviour increasing among HIV-infected individuals? AIDS 2004; 18: 1707–14. Yes 
Golin C Ovid 
MEDLINE(R) 
USA Psychosocial characteristics and sexual behaviors of people in care for HIV infection: an 
examination of men who have sex with men, heterosexual men and women. 
AIDS & Behavior. 13(6):1129-42, 
2009 Dec. 
Yes 
Gorbach 
P.M. 
Ovid 
MEDLINE(R) 
USA Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: 
Effects of drug use and partner types. 
Journal of Acquired Immune 
Deficiency Syndromes. 56 (2) (pp 
176-182), 2011. Date of Publication: 
01 Feb 2011. 
Yes 
Halkitis 
PN 
Ovid 
MEDLINE(R) 
USA Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men.  AIDS. 2005 Apr;19 Suppl 1:S77-86.  
Halkitis 
PN 
Ovid 
MEDLINE(R) 
USA Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, 
and behavioral correlates.  
AIDS. 2005 Apr;19 Suppl 1:S27-35.  
Hart GJ Ovid 
MEDLINE(R) 
UK Sexual risk behaviour of men who have sex with men: emerging patterns and new challenges. Curr Opin Infect Dis 2010; 23: 39–44. Yes 
Hickson F SigmaResearc
h website 
UK HIV testing and HIV serostatus-specific sexual risk behaviour among men who have sex with 
men living in England and recruited through the internet in 2001 and 2008.  
Sex Res Soc Policy 2013; 10: 15–23. Yes 
Hickson F SigmaResearc
h website 
UK State of Play: findings from the England Gay Men’s Sex Survey 2014.  Sigma Research London, 2016. Yes 
Hickson F SigmaResearc
h website 
UK Tactical dangers: findings from the United Kingdom Gay Men’s Sex survey 2008.  London, UK; 2010.    
Hickson F SigmaResearc
h website 
UK HIV, sexual risk, and ethnicity among men in England who have sex with men.  Sex Transm Infect. 2004 Dec;80(6):443–50.  
Hirshfield 
S 
Ovid 
MEDLINE(R) 
USA Social media use and HIV transmission risk behavior among ethnically diverse HIV-positive gay 
men: results of an online study in three U.S. states. 
Archives of Sexual Behavior. 
44(7):1969-78, 2015 Oct. 
Yes: in factors 
section 
Holt M Ovid 
MEDLINE(R) 
AUS Brief Report: HIV Prevention by AUSn Gay and Bisexual Men With Casual Partners: The 
Emergence of Undetectable Viral Load as One of a Range of Risk Reduction Strategies. 
Journal of Acquired Immune 
Deficiency Syndromes: JAIDS. 
70(5):545-8, 2015 Dec 15. 
Yes 
Khosropo Embase USA Trends in serosorting and the association with HIV/STI risk over time among men who have sex Journal of Acquired Immune Yes 
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1
st 
Author Database Country / Title Source / Included in literature review? Reasoning if not 
ur C.M. with men. Deficiency Syndromes. 72 (2) (pp 
189-197), 2016. Date of Publication: 
01 Jun 2016. 
Kozal MJ Ovid 
MEDLINE(R) 
USA Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in 
clinical care.  
AIDS 2004; 18: 2185–9. Yes 
Kramer 
SC 
Embase EU Factors associated with unprotected anal sex with multiple non-steady partners in the past 12 
months: results from the European Men-Who-Have-Sex-With-Men Internet Survey (EMIS 
2010). 
BMC Public Health. 16:47, 2016. No - no info on 
HIV+ UK MSM 
Kouyos 
RD 
Ovid 
MEDLINE(R) 
SW Increases in Condomless Sex in the Swiss HIV Cohort Study.  Open forum Infect Dis. 2015 
Apr;2(2):ofv077.  
Yes 
Kravcik S Ovid 
MEDLINE(R) 
CA Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the 
need for safer sexual practices. 
J Acquir Immune Defic Syndr Hum 
Retrovirol 1998; 19: 124–9. 
Yes 
Lattimore 
S 
Ovid 
MEDLINE(R) 
UK Changing patterns of sexual risk behavior among London gay men: 1998-2008.  Sex Transm Dis 2011; 38: 221–9. Yes 
Magidson 
JF 
Ovid 
MEDLINE(R) 
INTL Engagement in HIV care and sexual transmission risk behavior among men who have sex with 
men using online social/sexual networking in Latin America. 
AIDS Care 2015; 27: 1055–62. Yes 
Magidson 
JF 
Embase INTL Antiretroviral Medication Adherence and Amplified HIV Transmission Risk Among Sexually 
Active HIV-Infected Individuals in Three Diverse International Settings. 
AIDS Behav 2016; 20: 699–709. Yes 
Margolis 
AD 
Ovid 
MEDLINE(R) 
USA Anal intercourse without condoms among HIV-positive men who have sex with men recruited 
from a sexual networking web site, United States. 
Sexually Transmitted Diseases. 
41(12):749-55, 2014 Dec. 
Yes 
Mattson 
CL 
Embase USA Sexual risk behaviour and viral suppression among HIV-infected adults receiving medical care in 
the United States.  
AIDS 2014; 28: 1203–11 Yes 
Mayer KH Embase USA Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-
infected patients in primary care: implications for prevention interventions. 
Sexually Transmitted Diseases. 
39(1):1-7, 2012 Jan. 
Yes 
Mayer KH Ovid 
MEDLINE(R) 
USA Factors associated with amplified HIV transmission behavior among American men who have 
sex with men engaged in care: implications for clinical providers.  
Ann Behav Med 2014; 47: 165–71. Yes 
Mitchell 
KR 
Ovid 
MEDLINE(R) 
UK Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and 
Lifestyles (Natsal-3).  
Lancet 2013; 382: 1817–29. Yes 
Nardone 
A 
Ovid 
MEDLINE(R) 
UK A comparison of high-risk sexual behaviour and HIV testing amongst a bar-going sample of 
homosexual men in London and Edinburgh. 
European Journal of Public Health. 
11(2):185-9, 2001 Jun. 
Yes 
Nardone 
A 
Ovid 
MEDLINE(R) 
UK Active surveillance of sexual behaviour among homosexual men in London.  Commun Dis Public Health 1998; 1: 
197–201. 
Yes 
Ostrow 
DE 
Ovid 
MEDLINE(R) 
USA Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking 
among HIV-infected and uninfected homosexual men.  
AIDS. 2002;16(5):775-780. Yes 
Parsons 
JT 
Embase USA Correlates of sexual risk behaviors among HIV-positive men who have sex with men.  AIDS Educ Prev 2003; 15: 383–400. Yes 
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Parsons 
JT 
Ovid 
MEDLINE(R) 
USA Sexual harm reduction practices of HIV-seropositive gay and bisexual men: serosorting, 
strategic positioning, and withdrawal before ejaculation.  
AIDS 2005; 19 Suppl 1: S13–25. Yes 
Paz-Bailey 
G. 
Ovid 
MEDLINE(R) 
USA Trends in condom use among MSM in the United States: The role of antiretroviral therapy and 
seroadaptive strategies. 
AIDS. 30 (12) (pp 1985-1990), 2016. 
Date of Publication: 31 Jul 2016. 
Yes 
Prestage 
G 
Ovid 
MEDLINE(R) 
AUS Use of viral load to negotiate condom use among gay men in Sydney, AUS. AIDS & Behavior. 13(4):645-51, 2009 
Aug. 
Yes 
Prestage 
G 
Ovid 
MEDLINE(R) 
AUS How has the sexual behaviour of gay men changed since the onset of AIDS: 1986-2003. Aust N Z J Public Health 2005; 29: 
530–5. 
Yes 
Remien 
RH 
Ovid 
MEDLINE(R) 
USA Risk Perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy.  AIDS Behav 2005; 9: 167–76. Yes 
Remien 
RH 
Ovid 
MEDLINE(R) 
USA The association between poor antiretroviral adherence and unsafe sex: differences by gender 
and sexual orientation and implications for scale-up of treatment as prevention. 
AIDS & Behavior. 18(8):1541-7, 2014 
Aug. 
Yes: in factors 
section 
Rodger AJ Ovid 
MEDLINE(R) 
EU Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of 
AntiRetroviral Treatment (START) trial. 
HIV Medicine. 16 Suppl 1:64-76, 2015 
Apr. 
Yes 
Semple 
S.J. 
Ovid 
MEDLINE(R) 
USA Factors associated with sex in the context of methamphetamine use in different sexual venues 
among HIV-positive men who have sex with men. 
BMC public health. 10 (pp 178), 2010. Date of Publication: 
2010. 
Sherr L Ovid 
MEDLINE(R) 
UK Successive switching of antiretroviral therapy is associated with high psychological and physical 
burden. 
Int J STD AIDS 2007; 18: 700–4. Yes 
Sherr L Ovid 
MEDLINE(R) 
UK Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity.  AIDS Care. 2008 Apr;20(4):442–8.  Yes 
Siegler 
A.J. 
Embase USA The role of intent in serosorting behaviors among men Who have sex with men sexual 
partnerships. 
Journal of Acquired Immune 
Deficiency Syndromes. 64 (3) (pp 
307-314), 2013. Date of Publication: 
01 Nov 2013. 
Yes 
Stephens
on JM 
Ovid 
MEDLINE(R) 
UK Is use of antiretroviral therapy among homosexual men associated with increased risk of 
transmission of HIV infection?  
Sex Transm Infect 2003; 79: 7–10. Yes 
Suzan-
Monti M 
Ovid 
MEDLINE(R) 
FR The burden of HIV experience and care among MSM having an HIV-positive seroconcordant 
steady partner: a possible research hypothesis. Results from the French VESPA ANRS EN-12 
study.  
Sex Transm Infect. 2011 
Aug;87(5):396–8.  
Yes 
Suzan-
Monti M 
Embase FR Sexual risk behaviour among people living with HIV according to the biomedical risk of 
transmission: results from the ANRS-VESPA2 survey.  
J Int AIDS Soc 2016; 19: 20095. Yes 
Suzan-
Monti M 
Embase FR Sexual Behavior with Serodiscordant Partners Among HIV-Positive Men Who Have Sex with 
Men Followed Up in Hospitals Between 2003 and 2011 in France: Results from a Repeated 
National Representative Survey (ANRS VESPA and VESPA2). 
 AIDS Patient Care STDS. 2016 
May;30(5):193–6.  
Yes 
The EMIS 
Network 
SigmaResearc
h website 
EU  EMIS 2010: The European Men-Who-Have-Sex-With-Men Internet Survey. Findings from 38 
Countries.  
Stockholm:The European Centre for 
Disease Prevention and Control. 
No: UK data not 
presented by HIV-
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MEDLINE(R) 
AUS Sexual practices in a broad cross-sectional sample of Sydney gay men. AUSn & New Zealand Journal of 
Public Health. 21(7):762-6, 1997 Dec. 
Yes 
Van de 
Ven P 
Ovid 
MEDLINE(R) 
AUS Sexual risk behaviour increases and is associted with HIV optimism among HIV-negative and 
HIV-positive gay men in Sydney over the 4 year period to February 2000. 
AIDS. 14(18):2951-3, 2000 Dec 22. Yes 
Van de 
Ven P 
Ovid 
MEDLINE(R) 
AUS In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk 
reduction rather than unbridled sex. 
AIDS Care 2002; 14: 471–80. Yes 
Vanable 
PA 
Embase USA  Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive 
and HIV-negative gay and bisexual men. 
Health Psychol 2000; 19: 134–45. Yes 
Velter A Embase FR Sexual and prevention practices in men who have sex with men in the era of combination HIV 
prevention: results from the Presse Gays et Lesbiennes survey, France, 2011.  
Euro Surveill. 2015 Jan;20(14).    
Wallace 
LA 
Embase UK HIV prevalence and undiagnosed infection among a community sample of gay and bisexual 
men in Scotland, 2005-2011: implications for HIV testing policy and prevention. 
PLoS One 2014; 9: e90805. Yes 
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UK  “What Do You Need?”: Findings from a national survey of people with diagnosed HIV.  London, UK; 2009.  Yes 
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EU The European Men-Who-Have-Sex-With-Men Internet Survey (EMIS): Design and Methods.  Sex Res Soc Policy. Springer US; 2013 Dec 7;10(4):243–57.  
Williamso
n LM 
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UK Sexual risk behaviour and knowledge of HIV status among community samples of gay men in 
the UK. 
AIDS. 22(9):1063-70, 2008 May 31. Yes 
Wilson 
P.A. 
Ovid 
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USA Fluctuations in depression and well-being are associated with sexual risk episodes among HIV-
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Health Psychology. 33 (7) (pp 681-
685), 2014. Date of Publication: July 
2014. 
Yes: in factors 
section 
Wilson PA Embase USA Sexual Risk Behavior Among Virologically Detectable Human Immunodeficiency Virus-Infected 
Young Men Who Have Sex With Men. 
JAMA Pediatrics. 170(2):125-31, 2016 
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Yes 
Wolitski 
RJ 
Embase USA The Emergence of Barebacking Among Gay and Bisexual Men in the United States: A Public 
Health Perspective 
 J Gay Lesbian Psychother 2005; 9: 9–
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Yes 
Wolitski 
RJ 
Embase USA Prevention with gay and bisexual men living with HIV: rationale and methods of the 
Seropositive Urban Men’s Intervention Trial (SUMIT).  
AIDS. 2005 Apr;19 Suppl 1:S1-11.  Yes 
Xia Q Embase USA Knowledge of sexual partner’s HIV serostatus and serosorting practices in a California 
population-based sample of men who have sex with men.  
AIDS. 2006 Oct 24;20(16):2081–9.  Yes 
Zablotska 
IB 
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AUS Behavioural surveillance among gay men in AUS: methods, findings and policy implications for 
the prevention of HIV and other sexually transmissible infections. 
Sexual Health. 8(3):272-9, 2011 Sep. Yes 
Allen VC 
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MEDLINE(R) 
  The Association Between Alcohol Consumption and Condom Use: Considering Correlates of HIV 
Risk Among Black Men Who Have Sex with Men. [Review] 
AIDS & Behavior. 19(9):1689-700, 
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No: review 
Bachman Ovid   Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV- AIDS Education & Prevention. No: not relevant 
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n LH MEDLINE(R) positive men who have sex with men (MSM) in a primary care setting. 25(2):87-101, 2013 Apr. 
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MEDLINE(R) 
  Unprotected anal intercourse in HIV-positive and HIV-negative gay men: the relevance of 
sexual arousability, mood, sensation seeking, and erectile problems.[Erratum appears in Arch 
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Archives of Sexual Behavior. 
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Ovid 
MEDLINE(R) 
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PLoS ONE [Electronic Resource]. 
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Bavinton 
BR 
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Bavinton 
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prevention research.  
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Current HIV Research. 6(6):579-84, 
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  Factors associated with unprotected anal intercourse between HIV-positive men and regular 
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size (<40) 
Bocour A. Embase   Differences in risk behaviors and partnership patterns between younger and older men who 
have sex with men in New York City. 
Journal of Acquired Immune 
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417-423), 2011. Date of Publication: 
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No: no CLS 
estimates  
Bogowicz 
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  HIV testing behaviour and use of risk reduction strategies by HIV risk category among MSM in 
Vancouver. 
International Journal of STD & AIDS. 
27(4):281-7, 2016 Mar. 
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Bonell CP Ovid 
MEDLINE(R) 
  Methamphetamine use among gay men across the UK. International Journal of Drug Policy. 
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No: results not by 
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Bourne A Ovid 
MEDLINE(R) 
  Problems with sex among gay and bisexual men with diagnosed HIV in the United Kingdom. BMC Public Health. 12:916, 2012. No: no CLS 
estimates  
Brennan 
DJ 
Ovid 
MEDLINE(R) 
  HIV treatment optimism and unsafe anal intercourse among HIV-positive men who have sex 
with men: findings from the positive connections study. 
AIDS Education & Prevention. 
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Breskin A Ovid 
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  Factors Associated With Hepatitis C Infection Among HIV-Infected Men Who Have Sex With 
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Sexually Transmitted Diseases. 
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estimates  
Burnham 
KE 
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AIDS Care. 28(3):347-53, 2016. No: no CLS 
estimates  
Carballo-
Dieguez A 
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  Sexual negotiation, HIV-status disclosure, and sexual risk behavior among Latino men who use 
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Carvalho 
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Embase   HIV testing among Portuguese men who have sex with men - results from the European MSM 
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HIV Medicine. 14 (SUPPL.3) (pp 15-
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No: results not by 
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meta-analysis. 
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Danta M Ovid 
MEDLINE(R) 
  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to 
high-risk sexual behaviours. 
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Denning 
PH 
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MEDLINE(R) 
  Unprotected anal intercourse among HIV-positive men who have a steady male sex partner 
with negative or unknown HIV serostatus. 
American Journal of Public Health. 
95(1):152-8, 2005 Jan. 
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Doerner R Ovid 
MEDLINE(R) 
  Circumcision and HIV infection among men who have sex with men in Britain: the insertive 
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Archives of Sexual Behavior. 
42(7):1319-26, 2013 Oct. 
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Dukers 
NH 
Embase   Sexual risk behaviour relates to the virological and immunological improvements during highly 
active antiretroviral therapy in HIV-1 infection.  
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estimates  
Evans AR Ovid   Central and east European migrant men who have sex with men: an exploration of sexual risk Sexually Transmitted Infections. No: data not by HIV 
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Ferrer L Embase   Undiagnosed HIV infection in a population of MSM from six European cities: results from the 
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European Journal of Public Health. 
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American men who have sex with men. 
American journal of public health. 
103 (5) (pp 875-880), 2013. Date of 
Publication: May 2013. 
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Estimates from the Medical Monitoring Project. 
Sexually Transmitted Diseases. 42 (4) 
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No: not relevant 
Forney JC Embase   Risk and protective factors related to HIV-risk behavior: a comparison between HIV-positive 
and HIV-negative young men who have sex with men. 
AIDS Care. 24(5):544-52, 2012. No: Young MSM 
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Grov C Embase   HIV risk and substance use in men who have sex with men surveyed in bathhouses, bars/clubs, 
and on Craigslist.org: venue of recruitment matters. 
AIDS & Behavior. 16(4):807-17, 2012 
May. 
No: no CLS 
estimates, results 
not by HIV 
serostatus  
Grov C Ovid 
MEDLINE(R) 
  Characteristics of men who have sex with men (MSM) who attend sex parties: results from a 
national online sample in the USA. 
Sexually Transmitted Infections. 
90(1):26-32, 2014 Feb. 
No: no CLS 
estimates, results 
not by HIV 
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Grov C Ovid 
MEDLINE(R) 
  HIV Serosorting, Status Disclosure, and Strategic Positioning Among Highly Sexually Active Gay 
and Bisexual Men.  
AIDS Patient Care STDS. 2015 Oct;29(10):559–68.  
Grulich 
AE 
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MEDLINE(R) 
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AE 
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MEDLINE(R) 
  HIV Transmission in Male Serodiscordant Couples in AUS, Thailand and Brazil. Conference on Retroviruses and 
Opportunistic Infections. Seattle, 
WA, 2015: Abstract number: 1019LB. 
No: interim results 
from HIV-
serodifferent 
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discussed 
throughout thesis) 
Gullette 
DL 
Ovid 
MEDLINE(R) 
  Stages of change and condom use among an Internet sample of gay and bisexual men. Journal of the Association of Nurses 
in AIDS Care. 15(2):27-37, 2004 Mar-
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No: not relevant 
Hall HI Ovid 
MEDLINE(R) 
  HIV transmission in the United States: considerations of viral load, risk behavior, and health 
disparities. 
AIDS & Behavior. 17(5):1632-6, 2013 
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Harawa 
NT 
Ovid 
MEDLINE(R) 
  Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young 
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Journal of Acquired Immune 
Deficiency Syndromes: JAIDS. 
No: HIV-negative 
only 
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  Homosexual men's HIV related sexual risk behaviour in Scotland. Sexually Transmitted Infections. 
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Hasse B Ovid 
MEDLINE(R) 
  Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV 
cohort study.  
Clin Infect Dis 2010; 51: 1314–22. No: CLS as % of 
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Hatfield 
LA 
Ovid 
MEDLINE(R) 
  Comparison of substance use and risky sexual behavior among a diverse sample of urban, HIV-
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Journal of Addictive Diseases. 
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reviewed in drugs 
chapter  
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  Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among 
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  Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the 
combination antiretroviral therapy era compared with the pre-combination antiretroviral 
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Hirshfield 
S 
Ovid 
MEDLINE(R) 
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Journal of Medical Internet Research. 
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  The prevalence and correlates of undiagnosed HIV among AUSn gay and bisexual men: results 
of a national, community-based, bio-behavioural survey.[Erratum appears in J Int AIDS Soc. 
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Journal of the International AIDS 
Society. 18:20526, 2015. 
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Holt M Ovid 
MEDLINE(R) 
  The converging and diverging characteristics of HIV-positive and HIV-negative gay men in the 
AUSn Gay Community Periodic Surveys, 2000-2009. 
AIDS Care. 25(1):28-37, 2013. No: Comparison 
between HIV+ and 
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Horvath 
KJ 
Ovid 
MEDLINE(R) 
  Discussions of viral load in negotiating sexual episodes with primary and casual partners among 
men who have sex with men. 
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  Lymphogranuloma venereum diagnoses among men who have sex with men in the U.K.: 
interpreting a cross-sectional study using an epidemic phase-specific framework. 
Sexually Transmitted Infections. 
89(7):542-7, 2013 Nov. 
No: in STI chapter 
Jin F Ovid 
MEDLINE(R) 
  Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a 
cohort of homosexual men.  
AIDS. 2009 Jan 14;23(2):243–52.  No: seroconversion 
cohort  
Jin F Ovid 
MEDLINE(R) 
  Anal sexually transmitted infections and risk of HIV infection in homosexual men. Journal of Acquired Immune 
Deficiency Syndromes: JAIDS. 
53(1):144-9, 2010 Jan. 
No: HIV-negative 
only 
Joseph 
Davey DL 
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MEDLINE(R) 
  Sexual behavior during acute HIV infection among men who have sex with men in Los Angeles, 
California.  
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Kahler Ovid   Daily associations between alcohol use and unprotected anal sex among heavy drinking HIV- AIDS & Behavior. 19(3):422-30, 2015 No: review 
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  HIV treatment adherence and unprotected sex practices in people receiving antiretroviral 
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Khan 
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  Social and behavioral correlates of sexually transmitted infection- and HIV-discordant sexual 
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Knight KR Embase   Sexual transmission risk behavior reported among behaviorally bisexual HIV-positive injection 
drug-using men. 
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Knussen 
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2013.  
LGBT Heal. 2015 Sep;2(3):200–20.  No: meta-analysis 
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Publication: 01 Aug 2013. 
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Appendix IV. Comparison of MSM who had CLS without specifying partners' HIV-serostatus ('CLS-
unspecified') to MSM who had ‘CLS-C without CLS-D’ or CLS-D (N=836) 
  
CLS-unspecified 
(N=31) 
CLS-C without CLS-D 
(N=479) 
CLS-D (N=326) 
Total 
(N=836) 
  n col % n col % p-value◊ n col % p-value† row n 
Age at recruitment, years (N=829)                   
<30 1 3.2 32 6.7 
 
23 7.1   56 
30-39 8 25.8 150 31.4 
 
75 23.3   233 
40-49 15 48.4 195 40.9 
 
144 44.7   354 
50-59 7 22.6 85 17.8 
 
62 19.3   154 
≥60 0 - 15 3.1 0.799 (F) 18 5.6 0.753 (F) 33 
Time since HIV diagnosis (N=829)     
   
  
 
    
3 months-2 years 3 9.7 40 8.4 
 
29 9.0   72 
2-5 years 6 19.4 94 19.7 
 
57 17.6   157 
5-15 years 9 29.0 234 49.1 
 
165 50.9   408 
>15 years 13 41.9 109 22.9 0.070 (F) 73 22.5 0.057 (F) 195 
Recreational drug use (N=835)‡                   
No 10 32.3 146 30.5 
 
103 31.6   259 
Yes 21 67.7 333 69.5 0.835 223 68.4 0.940 577 
Use of chemsex-related drugs* (N=835)‡     
   
  
 
    
No 22 71.0 316 66.0 
 
253 77.6   591 
Yes 9 29.0 163 34.0 0.568 73 22.4 0.401 245 
Number of recreational drugs used (N=576)‡                   
1 3 14.3 65 19.5 
 
51 22.9   119 
2-4 12 57.1 150 45.0 
 
114 51.1   276 
≥5 6 28.6 118 35.4 0.635 (F) 58 26.0 0.723 (F) 182 
Participant's HIV-negative sexual partner(s) took PEP or PrEP (N=835)‡     
   
  
 
    
No/missing 31 100.0 473 98.7 
 
312 95.7   816 
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CLS-unspecified 
(N=31) 
CLS-C without CLS-D 
(N=479) 
CLS-D (N=326) 
Total 
(N=836) 
  n col % n col % p-value◊ n col % p-value† row n 
Yes 0 - 6 1.3 - 14 4.3 - 20 
Harmful/hazardous alcohol consumption (N=835)                   
No 27 87.1 406 84.8 
 
251 77.0   684 
Yes 4 12.9 73 15.2 0.743 (F) 75 23.0 0.195 (F) 152 
Stable partner's HIV-serostatus (n=835)     
   
  
 
    
HIV-positive 9 29.0 253 52.8 
 
47 14.4   309 
HIV negative or HIV-unknown (incl.missing partner status) 5 16.1 54 11.3 
 
143 43.9   202 
No stable partner 17 54.8 172 35.9 0.037 136 41.7 0.006 325 
Sexually transmitted infection (STI) (N=824)‡                   
No 28 90.3 397 83.8 
 
247 77.2   672 
Yes 3 9.7 77 16.2 0.449 (F) 73 22.8 0.110 (F) 153 
Lifetime hepatitis C diagnosis (N=814)     
   
  
 
    
No 27 87.1 359 77.4 
 
256 80.0   642 
Yes 4 12.9 105 22.6 0.265 (F) 64 20.0 0.476(F) 173 
Current STI symptoms (N=835)                   
No/missing 26 83.9 420 87.7 
 
273 83.7   719 
Yes 5 16.1 59 12.3 0.573 (F)  53 16.3 0.985 (F) 117 
Group sex (N=820)‡     
   
  
 
    
No 20 69.0 305 64.1 
 
169 53.5   494 
Yes 9 31.0 171 35.9 0.593 147 46.5 0.109 327 
Used internet to find sex (N=820)‡                   
No 13 44.8 203 42.6 
 
113 35.8   329 
Yes 16 55.2 273 57.4 0.818 203 64.2 0.332 492 
Transactional sex (N=827)‡     
   
  
 
    
No 29 100.0 470 98.3 
 
317 98.8   816 
Yes 0 - 8 1.7 N/A 4 1.2 - 12 
"I feel confident that I can make sure a condom is used with any partner, in any situation" (N=820) 
Strongly/tend to agree or undecided 25 83.3 435 91.8 
 
276 87.1   736 
Tend to/strongly disagree 5 16.7 39 8.2 0.169 (F) 41 12.9 0.572 (F) 85 
HIV transmission risk beliefs (N=819)     
   
  
 
    
Most conservative 13 43.3 190 40.3 
 
85 26.6   288 
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CLS-unspecified 
(N=31) 
CLS-C without CLS-D 
(N=479) 
CLS-D (N=326) 
Total 
(N=836) 
  n col % n col % p-value◊ n col % p-value† row n 
Moderately conservative 15 50.0 254 53.9 
 
200 62.7   469 
Least conservative 2 6.7 27 5.7 0.780 (F) 34 10.7 0.180 (F) 63 
Viral load agreement (N=694 on ART)                   
Agreement 23 82.1 355 90.8 
 
251 91.3   629 
Disagreement 5 17.9 36 9.2 0.176 (F) 24 8.7 0.166 (F) 65 
"I find it difficult to discuss condom use with a new sexual partner" (N=822)     
   
  
 
    
Tend to/strongly disagree or undecided 25 83.3 408 85.7 
 
234 73.8   667 
Strongly/tend to agree 5 16.7 68 14.3 0.788 (F) 83 26.2 0.379 (F) 156 
"I am less likely to use a condom with a casual partner" (N=816)                   
Tend to/strongly disagree or undecided 19 65.5 383 81.0 
 
185 58.7   587 
Strongly/tend to agree 10 34.5 90 19.0 0.043 130 41.3 0.566 (F) 230 
"I am worried I could have infected someone else with HIV in the past few months " (N=815) 
Tend to/strongly disagree or undecided 23 79.3 461 97.5 
 
257 81.6   741 
Strongly/tend to agree 6 20.7 12 2.5 <0.001 58 18.4 0.803 76 
Number of sexual partners (N=820)‡                   
1 11 39.3 193 41.0 
 
78 24.2   282 
2-4 8 25.0 133 28.4 
 
93 28.9   234 
5-9 2 7.1 71 15.2 
 
56 17.4   129 
10-19 2 7.1 45 9.6 
 
41 12.7   88 
≥20 6 17.9 20 4.3 
 
44 13.7   70 
>1 but exact number missing 1 3.6 7 1.5 0.025 (F) 10 3.1 0.386 (F) 18 
10 or more new partners in past 12 months (N=835)     
   
  
 
    
No/missing 14 45.2 193 40.3 
 
176 54.0   383 
Yes or >1 but exact number missing 31 100.0 479 100.0 0.593 326 100.0 0.347 836 
P-values by chi-squared test, chi-squared test for linear trend (T), or Fisher's exact test (F); col %: column percentage; row n: total number by row; ‡ Three month recall period; ◊ p-value comparing CLS-
unspecified with CLS-D group; †p-value comparing CLS-unspecified with CLS-C only group; * GHB/GBL, mephedrone, crystal methamphetamine 
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Appendix V. Natural history of HIV  
Beginning of the HIV epidemic 
In 1981 a formerly unknown disease was described in previously healthy gay men in the United States. It 
was characterised by high incidence of rare opportunistic infections, such as fungal pneumonia and the 
cancer Kaposi’s Sarcoma.
622,623
 Surveillance reports of an expanding epidemic continued to rise across 
the USA during 1982, and new cases were also described among intravenous drug users and recipients 
of blood transfusions.
624,625
 The epidemic was characterised by extremely high mortality rates (85% died 
within five years of initial diagnosis) and underlying acquired immune deficiency.
626–628
 As the epidemic 
was mostly described among clusters of epidemiologically linked gay men, the emerging hypothesis on 
the cause of the disease was that of a sexually transmitted infectious agent.
629
 By 1983 the etiologic 
agent had been isolated and identified as a novel human retrovirus, phylogenetically similar to 
lentiviruses, which were known to cause chronic infections in animals.
630,631
 Due to its detrimental effect 
on human immunity, the virus was named human immunodeficiency virus (HIV). In 1985, serologic 
assays were developed for the detection of anti-HIV antibodies in blood of asymptomatic individuals; 
this was catalytic in screening blood donations and paved the way to discovery of therapies.
632,633
 The 
first therapy that became available in 1987 was azidothymidine (AZT, or zidovudine), an antiviral agent 
found to lower short-term incidence of mortality, and opportunistic infections, and to slow the 
progression of HIV-related complications among patients with advanced HIV infection.
634
 AZT was also 
found to reduce mother-to-child transmission of HIV (MTCT) among pregnant women from 25.5% to 
8.3%.
635
 Early treatment of individuals with asymptomatic HIV infection with AZT monotherapy, 
however, had profound side effects and did not improve overall prognosis.
636
 In the early to mid-1990’s 
greater understanding of viral dynamics and of additional drug discovery targets lead to the synthesis of 
new antiviral drugs (protease inhibitors, PIs).
637,638
 Randomised controlled trials among asymptomatic 
people with HIV also showed that a two-drug combination therapy was superior to monotherapy.
639,640
 
Landmark studies in 1995-96 demonstrated that triple combination therapy (termed highly active 
antiretroviral therapy, HAART) was superior to two-drug therapy in reducing both mortality
641
 and the 
amount of HIV found in blood serum (plasma viral load, VL).
642,643
 At the same time, VL laboratory assays 
were developed and paved the way for the discovery of the critical role of low viral load in predicting 
progression to AIDS and death.
644
 HAART became the standard of care in the USA and Western Europe 
and by 1998 surveillance data showed marked reduction in AIDS morbidity and mortality in countries 
offering HAART.
645
 Since the beginning of the epidemic, a total of 78 million individuals (95%CI 71-87 
million) have acquired HIV, and 39 million (35-43) have died of AIDS-related diseases.
1
 Thirty-five years 
after the isolation of HIV, antiretroviral drug therapy, technological and research advances in the 
understanding of transmission dynamics and determinants have transformed HIV from a ‘death 
sentence’ to a treatable chronic condition. 
2
 
 
Origins and strains of HIV 
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Two types of HIV circulate in human populations. The majority of infections globally are caused by HIV-
1; a minority of infections in individuals resident in or native to West Africa are caused by HIV-2. Both 
viruses originated from lentiviruses circulating in African primates (simian immunodeficiency viruses, 
SIV); HIV-1 originated from SIV in different subspecies of chimpanzees in West-Central Africa, while HIV-
2 derived from SIV in mangabey monkeys in West Africa.
626
 There is evidence that HIV crossed species 
between 1885 and 1925 and has been detected in blood samples as far back as 1959.
626
  
 
HIV has enormous genetic diversity and numerous subtypes are distributed across the globe. Three 
groups of HIV-1 exist: ‘M’ (‘main’), ‘O’ (‘outlier’), and ‘N’ (‘new’), which are all further subdivided into 
smaller subtypes according to geographical region of endemicity. The first type of HIV recognised during 
the 1981 outbreak and the majority (90%) of today’s HIV-1 infections in North America and Europe are 
due to group ‘M’, and specifically subtype ‘B’, whereas subtype ‘C’ is more prevalent in Southern Africa, 
and others (‘A’ and ‘D’) are prevalent in sub-Saharan Africa.
626
  
 
Description of the virus  
HIV is a retrovirus with two identical copies of single-stranded ribonucleic acid (RNA) genomes within 
one virion (infectious particle.)
626
 The virion is comprised of a protective protein shell, or capsid, which 
in turn consists of thousands of copies of the viral p24 protein (antigen). HIV preferentially infects 
immune cells, such as helper T-lymphocytes and macrophages, which carry a CD4+ cell surface antigen 
(receptor). In order for HIV to replicate, it must bind onto the host cell via surface membrane co-
receptors (chemokine receptors CCR5 or CXCR4), fuse into the surface, and penetrate the host cell.
646
 
Following fusion, the virion’s core is uncoated and the two strands of RNA are transcribed into a double-
stranded DNA copy of the RNA genome (the ‘provirus’) by the enzyme reverse transcriptase. The 
provirus is transported to the host cell’s nucleus and integrated into the host’s genomic DNA by the viral 
enzyme integrase. Subsequent provirus transcription leads to expression of new viral RNA for synthesis 
of viral proteins and assembly of new virions, which exit the host cell by budding through the cell 
membrane.
636,647
 Once viral DNA has integrated into the host genome as a provirus, it can remain 
dormant and thus go undetected by the immune system for many years. Latently infected CD4 cells 
have a dormant integrated provirus and are thus not able to produce new virions. This property explains 
the presence of viral reservoirs (cell types or anatomical sites of accumulated latently infected T-cells) 
outside of blood, such as lymphoid tissues, the central nervous system, and genital mucosal 
membranes.
648
 Once latently infected CD4 cells are activated, transcription of the provirus genome 
starts anew and immature virus particles bud from the host cell membrane.
649
 Following expulsion, new 
virions undergo maturation by the enzyme protease, and are able to infect other cells.
650
 The rate of HIV 
replication is extremely rapid; 10
12 
virions are estimated to be produced daily and a similar number of 
millions of CD4+ lymphocytes being destroyed.
626,636
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Detection of HIV  
Testing blood plasma for HIV is undertaken by laboratory assays, classified into those that detect HIV-
specific antibodies (for screening and confirmation of a new HIV infection), those that identify HIV-
specific proteins (antigens), and those which detect or monitor viral nucleic acid (HIV RNA or HIV 
proteins). In the UK, universal free HIV testing is offered in genitourinary medicine (GUM)/sexual health 
clinics, antenatal services, and healthcare services for those diagnosed with tuberculosis, hepatitis B or 
C; as of 2008, testing is also recommended in primary care practices and general medical admissions 
where diagnosed HIV prevalence is greater than 2 in 1,000 population.
651
 
 
Antibody testing 
Antibodies are proteins secreted by white blood cells which identify, bind to, and attempt to neutralise 
pathogens called antigens (such as p24). Blood plasma concentrations of these biomarkers vary by days 
since exposure to HIV. (Figure V1)  
Following the isolation of HIV-1 in 1983, blood-screening antibody tests (immunoassays) became 
available for HIV detection. Since then, there have been four successive generations of these tests used 
for screening and diagnosis.
652
 Each new generation of assays achieved a reduction in the window 
period, improving detection of early infection. (Figure V1) The first-generation test (enzyme-linked 
immunosorbent assay, ELISA) indicated the presence or absence of the virus within 12 weeks of 
infection, but suffered from low specificity. The window period was reduced to a mean of six weeks with 
second-generation immunoassays (introduced in 1987), and further yet to three weeks with third 
generation assays, (introduced in the early 1990s).
652
 Fourth-generation screening assays, introduced in 
1997, test blood plasma for anti-HIV antibodies and p24 antigen simultaneously, reducing the window 
period even further to two weeks.
651,653
 They have excellent sensitivity (99.8-100%) and specificity (99.5-
99.3%).
654
 In the case of a reactive sample (where HIV antibodies are detected), testing of a second 
sample and three additional confirmatory laboratory assays are required (Western Blot or Immunoblot) 
to verify infection and differentiate between HIV types (1 or 2) and major groups (‘M’,’O’, and ‘N’).
651,655
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Figure V1: Evolution of viral and immunological markers following HIV infection656 
 
Rapid Tests 
Assays that can detect specific HIV-antibodies or p24 in thirty minutes or less are referred to as rapid or 
point-of-care tests (POCT). POCTs are designed to detect biomarkers in serum, plasma, whole blood 
(from fingerprick), or oral fluid (from a mouth swab), but tend to have lower sensitivity compared to 
established immunoassays (e.g. fourth-generation ELISA).
657,658
 The prevalence of false negatives in 
POCTs during primary HIV infection makes rapid tests problematic in detecting acute infection.
659
 POCTs 
that use oral fluid have lower sensitivity (81-91%) compared to those which use fingerprick whole blood 
samples (92-98%).
660
 Nevertheless, POCTs facilitate access to testing and are routinely used in GUM 
clinics in the UK.
651,661
 
Detecting recent HIV infection 
Since 2009, the Recent Infection Testing Algorithm (RITA) has been used in UK routine surveillance data 
to distinguish recently acquired from long-standing HIV infections.
662
 RITA is based on a modified version 
of ELISA, called enzyme immunoassay (EIA), which measures the strength in the bond between HIV 
antibody and antigen (also known as ‘avidity index’), which tends to be weaker at the initial stages of 
infection.
663
 RITA also incorporates information on CD4 count, ART status, and AIDS-defining illnesses. 
Hence, samples with low antibody avidity index (<80%) demonstrate a positive RITA result, meaning a 
likely recent HIV acquisition (approximately six months prior to HIV diagnosis). 
Natural history of HIV  
CD4 count 
Depletion of CD4 lymphocyte cells is quantified by flow cytometry, a laboratory test used to count the 
number of CD4 cells in a cubic millimetre of blood (mm
3
), referred to as CD4 count;
664
 this is a marker of 
Image removed for copyright reasons 
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immunological status and allows for staging of HIV disease. Normal ranges are between 500 and 
1200cells/mm
3
, with opportunistic infections most prevalent below 200cells/mm
3
.  
Viral load quantification  
The amount of virions circulating in blood plasma (viral load, VL) is considered the single best marker of 
long-term clinical progression (up to 10 years) to AIDS and death.
665–667
 Viral load is measured as copies 
of virion per millilitre of blood plasma (c/mL) and is usually considered on a log scale. Therefore a 
change in VL is reported as a log change (in powers of 10, log10). Viral load is used as a marker of the 
total replication activity of the virus in an individual.
668
 A higher VL is associated with a faster rate of CD4 
cell decline than a lower VL.  
 
Viral load became quantifiable with the development of nucleic acid-based molecular diagnostic assays 
in the latter half of the 1990’s.
643,669,670
 The development of quantitative polymerase chain reaction 
(PCR) has led to significant improvement in the sensitivity of laboratory techniques to estimate and 
monitor HIV-1 VL. PCR is now widely used and can have a lower quantification limit of 40c/mL.
650,651
 HIV-
1 RNA becomes detectable in blood plasma approximately 11 days after exposure to the virus.(Figure 
V1)
671
 In cases of suspected very recent infection (< 15 days), when patients may have early symptoms, 
fourth generation assays may be negative. In this case only, UK guidelines on testing (2012) recommend 
viral load testing performed with specialist input.
585
  
 
Immune response to HIV 
HIV replication leads to sustained immune activation, which in turn leads to severe immune 
deficiency.
647,672
 Persistent immune activation is characterised by enhanced production of activation 
markers on CD4 cells and B-lymphocytes as well as by high concentrations of inflammatory cytokines; 
these proteins promote inflammation in lymphoid tissues by expressing adhesion molecules which trap 
lymphocytes.
673
 During high-level viremia, CD4 responses to HIV antigens are impaired leading to 
dysregulated immune responses to other opportunistic pathogens. CD4 cell activation induces complete 
cell cycles, ending in accelerated cellular death, and thus leads to depletion of T-cells and destruction of 
peripheral lymphoid tissues. With advancing HIV disease, production of other immune system cells 
(macrophages and natural killer cells) is halted and severe immune deficiency ensues.
672
 
 
Clinical stages of HIV infection 
The course of HIV progression varies significantly by individual, but is overall characterised by 
progressive loss of immune system function.
636
 The World Health Organization (WHO) and the Centers 
for Disease Control (CDC) have developed classification systems for the natural history of HIV disease 
according to laboratory findings and clinical manifestations, which are mainly used in resource limited 
settings.
674,675
(Table V1) The 2007 WHO staging system relies on clinical presentations of various 
diseases, conditions, and infections, and it is intended to be used globally across resource settings. The 
2008 CDC classification system relies on monitoring of CD4 counts; the lowest CD4 count or the 
presence of an AIDS-defining condition is used to determine the stage of infection. 
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Table V1: Classification of HIV disease stages according to the WHO and the CDC674,675 
WHO stage
676
 Clinical manifestation CDC 
stage
674
 
AIDS-
defining 
condition 
Laboratory-
confirmed 
CD4 count 
Clinical stage1    Stage 0 
(early HIV 
infection) 
- - 
Asymptomatic No symptoms reported or upon 
examination 
    
Persistent 
generalised 
lymphadenopathy 
Enlarged lymph nodes for 3 months or 
longer 
      
Clinical stage 2 Unexplained weight loss (<10% of body 
weight), recurrent upper respiratory 
tract infections, herpes zoster, oral 
ulceration, papular pruritic lesions, 
seborrhoeic dermatitis, fungal nail 
infections  
Stage 1 None ≥500 
cells/mm
3
 
Clinical stage 3 Unexplained weight loss (>10% of body 
weight), unexplained chronic diarrhoea 
and persistent fever, persistent oral 
candidiasis, pulmonary TB, severe 
bacterial infection (e.g. pneumonia, 
meningitis), acute necrotising gingivitis 
or periodontitis, unexplained anaemia, 
neutropaenia, or chronic 
thrombocytopaenia  
Stage 2 None 200-499 
cells/mm
3
 
Clinical stage 4 HIV wasting syndrome, Pneumonia, 
Chronic herpes simplex virus infection, 
Extrapulmonary TB, Kaposi sarcoma, HIV 
encephalopathy 
Stage 3 
(AIDS) 
Yes <200 
cells/mm
3
 
 
Primary HIV infection (PHI) 
PHI describes the first stage of the disease, from infection with HIV until immune system function 
achieves balance with viral replication.
677
 Seroconversion, the period of time during which HIV-specific 
antibodies are produced and become detectable in blood plasma tests, begins two to six weeks after 
infection and lasts five to ten days on average. In over 80% of cases seroconversion is accompanied by 
flu-like symptoms (fever, fatigue, headache, pharyngitis, lymphadenopathy, and maculopapular skin 
rash) which resolve over two to four weeks.
636
  
 
PHI is characterised by active viral replication and CD4 cell depletion.
678
 The virus continuously replicates 
in lymphoreticular tissues (lymph nodes, spleen, gut-associated lymphoid cells, and macrophages) and 
preferentially infects CD4+ T lymphocytes initially in the genital/rectal membranes, spreading via the 
blood to lymph nodes and lymphoid tissues in the gut.
679
 Rapid replication leads to exponentially 
increasing plasma viremia, with up to millions of virus copies per millimetre of plasma (c/mL) produced. 
At this point the viral population doubles every six to ten hours.
678
 Diagnostic tests using antibody 
reactivity may be indeterminate or negative during this stage, as anti-HIV antibodies are generated (and 
thus detectable) two to six weeks after the onset of seroconversion symptoms. Plasma viral load and 
p24 antigen assays however, are positive from the onset of symptoms.
636
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Clinical latency 
Clinical latency describes the asymptomatic phase between PHI and the development of AIDS. Viral 
replication, CD4 cell loss, and destruction of lymphoid tissue in the gut are continuous throughout 
infection, but HIV-infected individuals generally remain free from serious illnesses for a number of 
years.
678
 Within four to six months of seroconversion the host’s immune system is able to respond to 
HIV, which leads to a decrease in VL to a plateau (‘set point’) that varies between individuals.
636
  
 
AIDS 
AIDS refers to the point in disease progression when CD4+ T cell counts decline to critical levels (<200 
cells/mm
3
) resulting in opportunistic infections and clinical immunodeficiency. The 2015 UK guidelines 
follow CDC classification systems of AIDS-defining illnesses to define progression to AIDS.
17
(Table V2) In 
the absence of ART, an individual’s higher viral ‘set point’ correlates with faster rate of disease 
progression to AIDS; the average period of time between infection and AIDS is 10 years, but some 
individuals develop AIDS within two years. Median survival post-AIDS diagnosis in the absence of ART 
ranges from one to two years.
636
 There is strong evidence from meta-analyses that prior to the 
widespread use of ART, time since and age at seroconversion were the major determinants of risk of 
AIDS and death among people with HIV in Europe, North America, and Australia.
680
  
Table V2: CDC classification of Stage 3 AIDS-defining conditions674 
AIDS-defining conditions: 
Bacterial infections, multiple or recurrent 
Candidiasis of bronchi, trachea, or lungs 
Candidiasis of esophagus 
Cervical cancer, invasive 
Coccidioidomycosis, disseminated or extrapulmonary 
Cryptococcosis, extrapulmonary 
Cryptosporidiosis, chronic intestinal (>1 month's duration) 
Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month 
Cytomegalovirus retinitis (with loss of vision) 
Encephalopathy, HIV related 
Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or esophagitis (onset at 
age >1 month) 
Histoplasmosis, disseminated or extrapulmonary 
Isosporiasis, chronic intestinal (>1 month's duration) 
Kaposi sarcoma 
Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex 
Lymphoma, Burkitt (or equivalent term) 
Lymphoma, immunoblastic (or equivalent term) 
Lymphoma, primary, of brain 
Mycobacterium avium complex or Mycobacterium kansasii, disseminated or extrapulmonary 
Mycobacterium tuberculosis of any site, pulmonary, disseminated,or extrapulmonary 
Mycobacterium, other species or unidentified species, disseminated or extrapulmonary 
Pneumocystis jirovecii pneumonia 
Pneumonia, recurrent 
Progressive multifocal leukoencephalopathy 
Salmonella septicemia, recurrent 
Toxoplasmosis of brain, onset at age >1 month 
Wasting syndrome attributed to HIV 
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Appendix VI. Background on STI aetiology among males  
Table VI.1: Natural history, transmission, clinical manifestation, diagnosis, and treatment of common bacterial STIs among males 442–452  
STI Aetiology Sexual 
transmission 
Natural history (untreated) Clinical features  Diagnostic methods Treatment/management ‡ 
Chlamydia 
(CT) 
Bacterial 
(C.trachomatis) 
serovars D-K  
Direct 
inoculation of 
infected 
secretions from 
mucous 
membranes 
Incubation period 7-21 days. 
Spontaneous resolution 12 
months from diagnosis in 50%. 
Complications (rare): 
epididymitis, sterility, prostatitis, 
reactive arthritis  
Urethral discharge and/or 
dysuria (50%). Remainder 
asymptomatic. Rectal infection 
asymptomatic (>60%) but may 
cause anal discharge/pain. 
Positive NAAT on urine or 
urethral/rectal swab. 
POCT using EIA.  
•Twice daily doxycycline for 7 days 
or single dose azithromycin. 
•Avoidance of sex incl. with 
condoms until treatment and 
symptoms resolved. 
• All sexual contacts should be 
notified (within 2 weeks prior to 
symptom onset or last 3 months if 
asymptomatic) and offered 
testing/treatment.  
Gonorrho
ea (NG) 
Bacterial 
(N.gonorrhoeae) 
Direct 
inoculation of 
infected 
secretions from 
mucous 
membranes 
Incubation period 1-14 days. 
Spontaneous symptom 
resolution within 6 months 
untreated (95%). Complications 
(rare) as in CT. 
Urethral/anal discharge (80%), 
dysuria (50%) within 5 days of 
exposure. Pharyngeal symptoms 
in 10-25%. Asymptomatic in 5-
10%. Mild fever, skin rash 
Positive NAAT on urine or 
urethral/rectal/pharyngea
l swab, or positive culture 
from any site 
• Single dose intramuscular 
ceftriaxone plus single dose oral 
azithromycin 
• Avoidance of sex including with 
condoms until treatment and 
symptoms resolved 
• Sexual contact tracing as per CT 
• High levels of multi-drug 
resistance require alternative 
regimens 
Lymphogr
anuloma 
venereum 
(LGV)  
Bacterial 
(C.trachomatis) - 
serovars L1-L3  
Penetration of 
skin through  
lacerations, 
abrasions  
•Primary lesion: painless genital 
or perianal papule or ulcer and 
proctitis, 3-12 days after 
exposure. Occurs in 3-53% and 
heals rapidly. 
Genital lesion/ulcer/bubo and 
inflammatory proctitis (>90%): 
rectal pain, bleeding, discharge, 
constipation. Ulcers in pharynx. 
Positive NAAT on urine, 
bubo pus, or 
genital/rectal/pharyngeal 
swabs 
• Twice daily doxycycline for 21 
days 
• Contact tracing for all sexual 
contacts since and during 4 weeks 
prior to symptom onset 
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STI Aetiology Sexual 
transmission 
Natural history (untreated) Clinical features  Diagnostic methods Treatment/management ‡ 
•Secondary stage: 
Lyphadenopathy after 10-30 
days, painful anogenital bubo, 
which may ulcerate (in ~33%) or 
disappear.  
Non-
gonococca
l urethritis 
(NGU)/ 
Non-
specific 
urethritis 
(NSU) 
•Bacterial: CT 
(30-50% of 
cases), 
M.genitalium (6-
50%), 
U.urealyticum(1
1-26%) 
•Viral: 
Adenovirus (2-
4%), HSV-1/HSV-
2 (2-3%) 
• Parasite: 
T.vaginalis (1-
20%) 
Sexual (not 
always) 
Incubation period 1-5 weeks. 
Overall self-limiting. 
Complications (rare): 
epididymitis (<2% of untreated), 
reactive arthritis (% unknown) 
Urethral discharge, dysuria, 
penile irritation. Asymptomatic 
in up to 25%. 
For symptomatic patients 
only: Confirmed 
microscopy of urethral 
smear or urine specimen.  
• Twice daily doxycycline for 7 
days or single dose azithromycin 
(or multiple doses for 4 days if 
M.genitalium-positive) 
• Avoidance of sex including with 
condoms until treatment and 
symptoms resolved 
• Partner notification within past 4 
weeks (symptomatic) or up to past 
6 months (asymptomatic) 
Syphilis Bacterial 
(T.pallidum) 
Direct lesion 
contact: sexual 
(only from early 
syphilis), blood-
borne 
• Early (infectious) syphilis: 
- Primary:
 
9-90 days after 
infection resolving within 2-8 
weeks  
- Secondary: 6 weeks-6 months 
after infection with persisting 
primary lesion (in 33%) 
- Early latent: within 2 years of 
infection 
• Late syphilis: 
- Late latent: >2 years of 
infection 
- Late benign can appear 
• Early (infectious) syphilis: 
-Primary: painless ulcerative 
lesion where direct contact with 
infected lesion occurred 
(genitals,extra-genital) 
-Secondary: malaise, fever, skin 
lesions, lymphadenopathy, 
musculoskeletal, renal, 
neurological symptoms 
-Early latent: no signs/symptoms 
• Late syphilis: 
- Late latent: no signs/symptoms 
gumma formation (benign 
Positive serology 4 weeks 
after infection (can take 
up to 12 weeks to 
develop). 
• Early: single injection of penicillin 
(or other oral antibiotics for 10 
days) and serological review 
monthly for 3 months 
• Late or unknown duration latent: 
weekly injections of penicillin for 3 
doses (or other oral antibiotics for 
17 days) and serological review 
until negative  
• All sexual contacts within past 3 
months should be notified (extend 
to past 2 years if secondary/early 
latent syphilis) 
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STI Aetiology Sexual 
transmission 
Natural history (untreated) Clinical features  Diagnostic methods Treatment/management ‡ 
between 10-15 years, 
musculoskeletal or CVD after 15-
20 years (10-30%), 
meningovascular or neurological 
disease after 2-25 years (5-12%) 
granulation tissue) on skin, 
bones, oral cavities 
- CVD, disease associated with 
early and late neurosyphilis  
• Avoidance of sex including with 
condoms until early lesions fully 
healed and until 2 weeks following 
treatment  
Trichomo
nas (TV) 
Parasitic 
(T.vaginalis) 
Direct genital 
contact  
Incubation period range 3-9 
days. Overall self-limiting. 
Spontaneous resolution in 20-
25% 
NGU. Asymptomatic in up to 
50%.  
NAATs, culture, or direct 
microscopy of urethral 
smear/urine specimen  
• Twice daily metronidazole for 7 
days or single dose 
• Simultaneous treatment of sex 
partners within past 4 weeks 
• Avoidance of sex for ≤1 week 
until patient and partner(s) 
completed treatment 
Not showing details for presentation of STIs in women, focus is on men only. CVD: cardiovascular disease; EIA; Enzyme-linked immunosorbent assay (see chapter 1); NAAT: nucleic 
acid amplification test;. ‡ Treatment as per UK national guidelines for each STI.  
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Table VI.2: Aetiology, transmission, natural history, clinical features, and management of genital herpes and genital warts among males450,451,453,454  
STI Aetiology Sexual 
transmission 
pathway 
Natural history  Clinical features  Diagnostic 
methods 
Management ‡ 
Genital 
herpes 
Herpes 
simplex virus 
(HSV) type 1 
and 2 
Direct skin 
contact with 
infected oral 
mucosa (HSV-
1) or genital 
mucosa (HSV-
2)  
Symptoms at acquisition of HSV-2 
in up to 33%: incubation among 
them ranges 2 days-2 weeks.  
• Primary: 1st infection without 
pre-existing antibodies. Latency 
established in local sensory 
ganglia.  
• Recurrent: intermittent 
reactivation of latent virus with 
lesions (4-15 days) or 
asymptomatic shedding (18-55% 
of HSV-2, 10-29% of HSV-1). 
Significant morbidity if left 
untreated. 
• Primary: Asymptomatic in 
>60%. Fever, malaise, myalgia 
within first week (50%). Painful 
blistering, ulcerative lesions in 
ano-, orogenital membranes. 
Urethral discharge/disuria 
(33%). Can also cause 
neurological involvement. 
• Recurring within first year in 
90% of those with HSV-2, 60% 
HSV-1. Prodrome (skin tingling, 
nerve pain) up to 48 hours prior 
to lesion appearance (50%). 
Lesions confined to affected 
anogenital site. 
• Clinical 
presentation 
• NAATS or PCR 
of genital  
lesion or rectal  
swab  
• Serology  
• Virus typing 
• Primary: general advice, analgesics, 
antiviral management within 5 days of 
onset for 5 days. 
• Recurrent: typically mild and self-
limiting, antiviral treatment can partially 
control symptoms and antiviral 
prophylaxis reduces recurrences. General 
advice and support. 
• Avoidance of sex during lesion 
recurrence or prodromes. Advice: 
transmission may occur with 
asymptomatic shedding; condom use may 
not completely prevent transmission. 
Disclosure encouraged. 
Genital 
warts* 
Human 
papillomavirus 
(HPV) - 
anogenital 
lesions caused 
by HPV types 
6,11 
Direct skin 
contact  
Incubation period 3 weeks to 8 
months for development of 
anogenital warts (benign 
epithelial skin tumours). 
Spontaneous clearance within 6 
months (30%). Persistent 
infection with ≥1 high-risk HPV 
type can cause high grade 
dysplasia and progression to 
anogenital/oropharyngeal 
cancers. 
• Majority asymptomatic.  
• New lumps/growths in 
anogenital area, local irritation, 
bleeding, discomfort, perianal 
lesions.  
• Clinical 
presentation 
• Topical cream/gel for 1 week (or up to 
16 weeks depending on wart clearance 
rate) 
• Physical ablation (excision, cryotherapy, 
electrosurgery, laser treatment) 
• Consistent condom use advised  
• Prophylactic HPV vaccine  
Not showing details for presentation of STIs in women, focus is on males only. * Does not include oral warts. NAATs: nucleic acid amplification tests; PCR: polymerase chain 
reaction; ‡ Management as per UK national guidelines for each STI.  
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